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Résumé 
Plusieurs arguments de la littérature suggèrent l’importance de l’alimentation dans le 
développement tumoral et l’efficacité des traitements anti-cancereux. Dans différents modèles 
animaux, la restriction calorique (CR) supprime la prolifération des cellules tumorales et les 
sensibilise aux thérapies ciblées. Par conséquent, des approches non-pharmacologiques comme la 
restriction calorique ont un intérêt grandissant en clinique. 
Considérant l’addiction des cellules tumorales aux nutriments, nous nous sommes demandé quels 
macronutriments pouvaient avoir des propriétés anticancéreuses. A partir d’un modèle murin de 
lymphomes B (modèle transgénique Eµ-Myc) nous avons testé l’impact de deux régimes 
alimentaires : l’un pauvre en glucides (Low CHO, 25% de réduction en glucides) et l’autre pauvre 
en protéines (Low PROT, 25% de réduction en protéines). Des souris syngéniques C57BL/6 ont 
été injectées par voie intraveineuse avec des cellules primaires Eμ-Myc. Malgré un apport 
alimentaire équivalent entre les groupes, nous avons observé que le régime pauvre en protéines 
augmente la survie globale des souris C57BL/6 développant un lymphome B Eµ-Myc. De manière 
intéressante, nous avons démontré que cet effet pro-survie est dépendant du système immunitaire. 
En effet, la déplétion des cellules T CD8+ ou l’utilisation d’un modèle murin immunodéficient NSG 
(NOD-SCID il2rγ), empêche l’effet bénéfique du régime pauvre en protéines sur le développement 
tumoral. Nous avons reproduit et étendu nos observations en utilisant des lignées modèles de 
cancéreuses colorectaux (CT26) et de mélanome (B16) injectée dans des souris syngéniques, 
immunocompétente. 
Les cellules tumorales étant fortement dépendantes des nutriments, nous avons émis l’hypothèse 
qu’un régime pauvre en protéines pourrait induire un stress du réticulum endoplasmique (RE) dans 
ces dernières. En effet, nous avons observé une augmentation des protéines impliquées dans la 
signalisation du RE : CHOP et sXBP1. Par conséquent, nous avons traité les souris nourries en 
régime pauvre en protéines avec deux inhibiteurs du stress du RE : TUDCA, inhibiteur générique 
et MKC4485 qui cible l’activité ribonucléase d’IRE1. Dans les deux cas, ces inhibiteurs ont bloqué 
l’effet du régime faible en protéines sur le développement tumoral et l’infiltration des T CD8+ au 
sein de la tumeur. Pour s’affranchir, des potentiels effets secondaires des inhibiteurs chimiques, 
nous avons invalidé IRE1 dans la lignée CT26 et nous avons obtenus des résultats similaires, 
démontrant que la voie IRE1 dans les cellules tumorales est une voie centrale dans la réponse 
immunitaire anticancéreuse induite par un régime pauvre en protéines. En outre, nous avons 
découvert que l’activation de RIG-I est un événement en aval de l’activation d’IRE1 et que, par 
analyse bio-informatique nous avons pu corréler une signature IRE1 à une infiltration immunitaire 
élevée et à une immunogénicité accrue du cancer chez les patients atteints de mélanome, 
glioblastome et cancer colorectal. De ce fait, nous avons démontré que la réponse du système 
immunitaire induite par un régime pauvre en protéines est une conséquence de l’activation accrue 
de IRE1 dans les cellules cancéreuses. 
Mots clés : IRE1, RIG-I, réponse immunitaire, stress du réticulum endoplasmique, cancer. 
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SUMMARY 
Several arguments from the literature suggested the importance of diets in cancer development and 
in the efficacy of anti-cancer therapies. Calorie restriction (CR) suppresses cancer growth in 
various animal models and sensitizes tumor cells to targeted therapies (Meynet & Ricci, 2014). 
Thus, non-pharmacologic approaches such as CR have a growing interest in the clinic. 
Considering the nutrient addiction of cancer cells, we wondered which specific macronutrients 
contribute the most to anti-cancer effects. Therefore, we tested the reduction in specific 
macronutrient without decrease in general calorie intake on tumor development. We used two diets: 
reduced in carbohydrates (Low CHO, -25% carbohydrates) and diet reduced in protein (Low 
PROT, -25% proteins) on the Eµ-Myc transgenic mouse model of B-cell lymphoma. Syngeneic 
C57BL/6 mice were intravenously injected with primary Eμ-Myc cells. We observed that low 
PROT-diet, in spite of equal calorie intake among the groups, resulted in increase of the overall 
survival of Eµ-Myc-bearing C57BL/6 mice. Very importantly, we established that this pro-survival 
effect is immune system-dependent as both depletion of CD8+ T cells and use of immunodeficient 
NSG (NOD-SCID il2rγ) mouse model prevented the beneficial effect of the low PROT-diet on the 
tumor development. We reproduced and further extended our observations using subcutaneous 
injection of CT26 colorectal cancer cells in syngeneic immunocompetent BALB/c mice and B16 
melanoma in C57BL/6 mice.  
As tumor cells are highly dependent on nutrients, we speculated that low PROT diet could induce 
ER stress in tumor cells. Indeed, we observed increase in proteins implicated in ER stress signaling 
– CHOP and sXBP1. Therefore, we treated low PROT-diet fed mice with two ER stress inhibitors,
the general inhibitor TUDCA or MKC4485, which targets IRE1 RNAse activity. In both cases, 
inhibitors significantly prevented the effect of the Low PROT-diet on tumor development and on 
intratumoral number of CD8+ T cells. To eliminate any side effects of chemical inhibitors, we 
invalidated IRE1 in CT26 cells and obtained similar results, demonstrating that IRE1 signaling in 
tumor cells is a central event in the low PROT-diet induced anti-cancer immune response. In 
addition, we have uncovered RIG-I activation as a downstream event of IRE1 activation and by 
bioinformatic analysis correlated high-IRE1 signature with high immune infiltration and enhanced 
immunogenicity of cancer in patients bearing melanoma, glioblastoma and colorectal cancer. 
Hence, we have shown that the immune system response elicited under a Low PROT diet is a 
consequence of increased IRE1 activation in cancer cells. 
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INTRODUCTION 
Cancer has probably accompanied multicellular organisms since the very early beginning of their 
evolutionary development. Archeo-biologists have found fossils of dinosaurs already affected by 
tumor (Dumbrava et al., 2016; Rothschild, Witzke, & Hershkovitz, 1999). Similarly, our direct 
Neanderthal ancestors 150 000 years ago already had incidents of cancer (Monge et al., 2013). 
Multiple malignant tumors have been found in Egyptian mummies, and even more interestingly, 
first written description of breast cancer comes from 2500 BC, noting at the end no treatment 
options available for this disease (Tauxe, 2015; Zink et al., 1999). Therefore, it would be not an 
overstatement to say that if cancer has accompanied us throughout our evolutionarily development, 
the anti-cancer protective mechanisms likely have occurred and evolved alongside.  
As live organisms are the products of Darwinian evolution, cancer is believed to be the product of 
the same process, just in the microscale and vastly accelerated. In a similar fashion as “The Selfish 
Gene” hypothesis, proposed by Richard Dawkins in his famous book from 1976, cancer 
development can be seen as the effect of a “selfish cell” – meaningless “replicator”. Evolutionary 
selective advantage can be defined by the genetical fitness, which is the degree of the species/cell 
capabilities to succeed in the certain environment. Upon shifts in the environment, the fitness of a 
species changes, pushing for more evolutionary adaptations. Cancer cells do not only adapt to the 
environment they evolve within, they actively shape it in their own favour. Hence, the more time 
they have, the worst for the host. Every day healthy tissues are exposed to damage caused by 
external stressors (UV, toxins) but also internal - as the result of their own metabolism and cell bio-
machinery. If the cell is unable to fix the damage, it must be eliminated for the sake and benefit of 
the whole organism. Using specialised self-defence mechanisms like immune system, hundreds of 
dangerous, pre-malignant cells, are being efficiently eliminated before they pose any threat to the 
well-being of the body.  
Just from these basic rules of biology we can imagine the optimal anti-cancer strategy – reduce the 
toxic exposure, strengthen your body defence, keep your organism environment hostile for 
malignant cells, and if it occurs, the sooner you find it the highest chances you have to stop it. 
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I. Diet 
Diet is arguably one of the most influential environmental factor in human health and well-being. 
Moreover, it has profound cultural and psychological impact on people’s life, emerging from the 
inevitable dependency of human existence on the food supply during centuries. Despite the 
enormous complexity of the relation between food and health, people very early noticed that what 
they are eating impacts their body. Hence, throughout time dietary “common knowledge’’ has been 
shaped and evolved alongside human civilization. Nowadays, scientists involved in nutrition 
research have an uneasy task to put aside these common beliefs and accurately investigate the 
relation between food and health, followed by reasonable interpretation and hopefully practical 
implications of obtained results. 
1. Environment is the primary factor in cancer prevention 
For a long period of time, mainly because of the excitement surrounding genetic code discovery, 
the scientific interest in studying the impact of environmental factors on human cancer diseases 
was put aside. Indeed, there have been many studies investigating the familial genetic components 
and the susceptibility of developing particular type of cancers, with spectacular cases of specific 
gene(s) identification that was primarily responsible, like the famous onco-suppressor Breast 
Cancer 1 gene (BRCA1) which when found mutated indicates higher chances of developing breast 
and ovarian cancer (J. M. Hall et al., 1990; Miki et al., 1994). Despite this initial success, very soon 
it become clear that a majority of cancer cases cannot be attributed to genetic variations, and the 
biology is much more complex than it was assumed. 
 
First scientific proofs of the dominant role of the environment in cancer incidents came from 
observational studies investigating the health of the people that migrated from their country of 
origin to another country, with different environment and different risk of development of 
particular disease. With time and generations, immigrants acquired similar cancer incidents rates 
as the endogenous population they shared the new environment with. For example, Japanese people 
that are characterised by relatively high stomach and low prostate cancer incidents, after migrating 
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to Hawaii started to exhibit higher rates of prostate cancer and lower rates of stomach cancer, 
statistically resembling the native Hawaiian population (Stemmermann, Nomura, Chyou, Kato, & 
Kuroishi, 1991). Another evidence come from studies on monozygotic and dizygotic twins, where 
monozygotic twins shares 100% of genetic material, and dizygotic twins are sharing statistically 
50%, which allows with the statistical power to distinguish the contribution of genes and the 
environment to the physical and health outcome. In that case it was also concluded that the 
overwhelming contributor of cancer development was the environment (Lichtenstein et al., 2000). 
It is now commonly accepted that as few as 5-10% of all cancers can be linked to the heritable 
genetic background (Anand et al., 2008; Lichtenstein et al., 2000). 
2. Environmental contributors in cancer development
A. Epidemiological approach of diet and cancer connection 
The environment consists of many interconnected elements, including exposure to air, sun, natural 
radiation, infections – that might not be easily modifiable, and the factors that are to some extend 
the result of the personal choice – diet, physical activity, alcohol consumption, social interactions. 
Scientific interest in the diet and health connection appeared in the 19th century, but real evaluation 
had to wait until any reliable populational data were collected to perform the analysis. Exploring 
the history from the beginning of the twentieth century, it has been said at the foundation of 
American Cancer Society in 1913 by Frederick Hoffmann that “nutritional influences on the 
induction of cancer [have to] be analysed’’ (Campbell, 2017). 
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overnutrition (being obese and overweight) from the “pure’’ dietary impact, statistically 
disconnecting these two elements. In addition, it is very difficult to separate the impact of the early 
life nutrition (prenatal and early postnatal) which can have long lasting effects on the individual 
health (Song & Giovannucci, 2015b). 
Taken together, in spite of exponential increase in the number of publications in the field of cancer 
epidemiology, the initial findings and estimations of Doll and Peto remain largely valid and 
inspired many clinicians and researchers to investigate the impact of nutrition on cancer 
development in the followed years (Campbell, 2017). 
B. Modern methods of evaluating diet-cancer relation 
The scientific evidence comes from various types of research, stretched on the spectrum from 
retrospective epidemiology studies (mainly correlation studies) and more accurate clinical dietary 
trials that are much more difficult to conduct and possess serious limitations (i.e. sample size and 
number of factors being evaluated at the same time). In laboratory research, numerous animals and 
cell culture models have been developed and tested in promise to generate accurate biological 
hypothesis and then translate them into more complex experimental setups. Regardless the fact that 
in a majority of cases conclusions based on these models cannot be directly translated to the human 
dietary recommendations, they have been very helpful in process of understanding the basic cell 
biology and metabolism. They have also been an inspiration to pursue many hypothesis grounded 
on their initial results in more complex and clinically more relevant experiments and trials, which 
provided further understanding and ideas on the studied subject. 
Combining studies across those different levels of scientific research allows to formulate 
reasonable scientific-based dietary recommendations for the general population, with 
acknowledged degree of certainty based on existing evidence concerning each recommendation in 
relation to specific cancer type (Figure 2). This requires a tremendous amount of work combining 
the results from various types of research, composed of various scientific approach and 
heterogenous sample size. The scientific accuracy of the results from each study has to be assessed 
by the independent panel of experts to adjust the weight of the evidence in relation to all other 
studies. This process is to be repeated and the conclusions updated as every new research brings 
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more data. One of the biggest and systematically revised evaluations comes from The Continuous 
Update Project (CUP), established by the effort of The American Institute for Cancer Research and 
The World Cancer Research Fund International (AICR/WCRF) in 2008 (Bandera et al., 2016). As 
part of the CUP, all scientific research currently available is collated and added to a database and 
systematically reviewed by a team at Imperial College of London, evaluated by an independent 
panel of experts who ultimately interprets the evidence to make conclusions based on the existing 
body of scientific evidence.  
As a result of this simultaneous comparative analysis of various datasets, it is now evident that 
different cancer types are differentially associated with dietary patterns, with some of them more 
prone to have diet-modifiable outcomes than the others. Hence, colorectal cancer incidence and 
progression appears stronger affected by dietary factors than the other cancer types, which is very 
logical taking into consideration the direct contact that colon tissue has with the digestion of food. 
There are very few recommendations that have been shown to affect personal risk of particular 
cancer development with strong scientific evidence (Figure 2). For example, processed meats and 
alcohol consumption increase risk of developing colorectal cancer, whereas consumption of whole 
grains, dietary fibre containing foods and dairy products decreases that risk (Gonzalez & Riboli, 
2010; Vieira et al., 2017). 
On the other hand, positive impact of any of the food group impacting cancer risk cannot be easily 
attributed to some specific nutrients of this food and replaced by supplementation. For example, 
consumption of foods rich in carotenoids that has been convincingly shown to have an anticancer 
effects and thought to be cancer protective, did not turn out to have beneficial effect on lung cancer 
prevention and progression in the form of beta-carotene supplementation. Instead, beta-carotene 
supplementation resulted in increased risk of developing lung cancer in current and former smokers 
(Druesne-Pecollo et al., 2010). The other interesting observation coming from extensive effect of 
research on milk products is that dairy consumption increases prostate cancer risk, but at the same 
time decreases breast and colorectal cancer risk (Aune et al., 2015; Gonzalez & Riboli, 2010; Vieira 
et al., 2017; M. Yang et al., 2015).  
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Yet, epidemiological studies cannot provide the evidence that isolated nutrients (like vitamins, 
minerals and phyto-compounds) can represent an independent factors for cancer risk (Baena Ruiz 
& Salinas Hernandez, 2014). 
The dietary guideline recommendations are designed for the healthy adult population, and any 
single conclusion within them does not represent a recommendation on its own, but forms a part 
of the overall “body of evidence”. Because it is already difficult to draw decisive conclusions 
regarding healthy individuals, it is even more challenging to design recommendations for patients 
that have been already diagnosed with cancer. There is limited amount of evidence on the dietary 
impact and it is very much affected by the type of cancer and received treatment combined with 
side effects (Robien, Demark-Wahnefried, & Rock, 2011). It is very likely that with the 
improvement in the experimental methods for gathering and analysing dietary patterns and disease 
our knowledge on the subject of nutrition will improve substantially in the near future, especially 
with the introduction of new technologies. In addition, the use of “big data” from large patient 
databases and human samples collection coupled with multivariant statistical analysis will allow 
the researchers to more accurately point out the cause and effect, and reduce the impact of unrelated 
factors. Therefore, the experimental results and dietary regimens described in the follow up 
chapters will be based entirely on experimental studies done on animal and in vitro cell 
culture models, hence the hypothesis and any conclusions draw from these studies cannot be 
extended and are not directly applicable for human nutrition. 
Even though the official recommendations are scientifically cautious, modest and designed to be 
“achievable” by the majority of the population, a surprisingly low number of people follows even 
the minimal requirements for healthy lifestyle (Krebs-Smith, Guenther, Subar, Kirkpatrick, & 
Dodd, 2010; Moore et al., 2015). For example, despite the numerous advertisement and political 
campaigns promoting fruits and vegetables consumption, most American fails to meet national 
recommendations, and only 8% of the population consume enough amounts of vegetables and 14% 
enough amounts of fruits. This low adherence to the healthy lifestyle is very likely one of the 
reasons why estimated 50-80% of cancer could be entirely avoided, and although this statistics 
sounds very miserable, it should be rather taken us a strong incentive and the motivation for change, 
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as there is evidently a big room for improvement (Anand et al., 2008; Colditz, Wolin, & Gehlert, 
2012; Song & Giovannucci, 2015a). 
C. Laboratory approaches investigating nutrition 
In laboratory studies macro- and micro-nutrient/s modulation has been shown to affect key 
biological cell processes, for instance regulating the metabolism and cell growth by energy sensing 
AMPK (Hardie, 2007) pathway or nutrient sensing mTOR (Schmelzle & Hall, 2000). 
One of the biggest and most comprehensive dietary study, The European Prospective Investigation 
into Cancer and Nutrition, found significant associations between serum levels of molecules 
(markers) involved in key carcinogenesis pathways and risk of developing different forms of cancer 
(Gonzalez & Riboli, 2010). For instance, high serum concentration of IGF-1, major anabolic 
hormone produced generally by the liver, was associated with increased risk of prostate cancer, 
which agrees with the previous experimental studies implying the importance of insulin/IGF-1 
pathway in carcinogenesis and tumor progression (Culig et al., 1994; Harvey, Lashinger, Otto, 
Nunez, & Hursting, 2013; Levine et al., 2014). This and many other biomarkers have been used as 
substitute to assess and compare the dietary and pharmacological interventions performed in 
rigours laboratory conditions with the outcomes that we observe in the more complex real life 
environment. In the following section the most comprehensive studies of regimens found to affect 
tumor development will be described. 
3. Dietary regimens in cancer progression 
Even though the first study assessing the effect of diet on cancer was published over 100 years ago, 
the notion of dietary regimen as health promoting practices has been observed and included in 
various religious and traditional practices over the history. Although different in details, commonly 
these practices can be divided and characterised by; 1 - restricted consumption of all food over 
certain period (fasting regimens); 2- restriction of the specific type of foods (i.e. pork, meat or dairy 
products); or 3 - requiring specific method of food preparation (i.e. halal, kosher). Some of these 
dietary practices have been proposed to impact on health issues, including cancer incidence, and 
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metabolic biomarkers, hence studies have been conducted to test various beliefs with the scientific 
rigor and in the scientific fashion. 
A. Calorie restriction 
Caloric restriction (CR) is the reduction of caloric intake generally by 10-40% without the 
induction of malnutrition. CR is currently the most robust dietary intervention known to increase 
healthy life (fewer diseases) and prolong lifespan across a spectrum of living organisms, from yeast 
to mice and primates, and has been under investigation for almost a century (McCay, Crowell, & 
Maynard, 1989; Meynet & Ricci, 2014; Tannenbaum & Silverstone, 1953). More importantly, CR 
has increasing amount of evidence supporting its role in inhibiting tumor development, with the 
first experimental studies described over 50 years ago (Tannenbaum & Silverstone, 1953). In fact, 
its antitumor effects have been proved to be substantial and spans across various types of 
spontaneous and inducible cancer models summarised in (Figure 3) (Pallavi, Giorgio, & Pelicci, 
2012): mammary (Kharazi et al., 1994; H. W. Li, Zhao, & Sarkar, 1994), leukemia (Yoshida, 
Hirabayashi, Watanabe, Sado, & Inoue, 2006; Yoshida et al., 1997), liver (Ploeger, Manivel, 
Boatner, & Mashek, 2017), pancreatic (Lashinger et al., 2011; Roebuck, Baumgartner, & 
MacMillan, 1993), colon (Dirx, van den Brandt, Goldbohm, & Lumey, 2003; Mai et al., 2003), 
breast (Phoenix, Vumbaca, Fox, Evans, & Claffey, 2010), and prostate (Bonorden et al., 2009). 
Furthermore, when tested, the highest degree of restriction was associated with the highest level of 
protection (Figure 3) (Kumar, Roy, Tokumo, & Reddy, 1990; Ruggeri, Klurfeld, Kritchevsky, & 
Furlanetto, 1989). The effect of CR has been largely attributed to the modulation of 
phosphoinositide 3-kinase (PI3K) and Protein kinase B (PKB), also known as AKT pathway, since 
tumors carrying a mutation in either PI3K or PTEN (negative regulator of PI3K) genes failed to 
respond to calorie restricted diets (Kalaany & Sabatini, 2009), hence the modulation of AKT 
activity seems to be a crucial factor in CR antitumor effects (Curry et al., 2013) ( Figure 4). 
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Insulin like growth factor I (IGF-1) is primarily synthesised and secreted by the liver upon growth 
hormone (GH) stimulation. Circulating levels of IGF-1 and IGF-1 binding proteins have been 
strongly correlated with risk of developing various cancers (Anisimov & Bartke, 2013; Cao et al., 
2012; Crowe et al., 2009; Endogenous et al., 2010). Striking evidence of IGF-1 role in cancer 
induction comes from individuals who carry inheritable mutations in the growth hormone receptor 
(GHR) gene, which disables liver centred production and secretion of IGF-1 (Guevara-Aguirre et 
al., 2011). Compared to their non-mutation bearing relatives, these individuals are almost 
completely protected against development and death from cancer. 
On the basis of the above findings, the scientific rush to discover signaling molecules and 
compounds mimicking CR has started (Figure 4 and Table 1). In the context of cancer, main 
interest focused on mammalian Target of Rapamycin (mTOR), AMP-activated protein kinase 
(AMPK), family of sirtuins and more recently autophagy pathways.  
 mTOR 
The central hub of metabolic cell processes coordination and nutrient availability is focused on 
mTOR pathway. The history of mTOR discovery is one of the example how the broad range of 
clinical and observational insights could lead to the most scrupulous experimental investigations 
in very simple yeast organisms, and then it extended its importance throughout all of the 
phylogenetical kingdoms (Manning, 2017; Sabatini, 2017).  
mTOR owes its name to the natural inhibitor of its activity found in the bacteria isolated from soil 
on pacific islands the Rapa Nui in 1972, known more widely as the Easter Islands. The isolated 
bacteria strain Streptomyces hygroscopicus has been found to be a source of variety of biologically 
relevant molecules like Sirolimus (another name for rapamycin), ascomycin (immunosuppressant), 
nigericin (antibiotic), milbemycin (antiparasitic agent). Sirolimus has been clinically used for many 
years as an immunosuppressive drug, even before knowing its actual mechanism of action. 
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produces distinct effects on T cell signaling, the existence of another target of rapamycin was 
speculated and finally described (Heitman, Movva, & Hall, 1991). 
Now we know of existence of two functional complexes mTORC1 and mTORC2 in mammals, 
with mTORC1 being the main target of rapamycin and currently is much more extensively studied 
compared to mTORC2. Therefore, mTORC1 will be referred as mTOR from now on. 
mTOR in known as a master growth and metabolism regulator that senses and integrates diverse 
nutritional and environmental cues such as growth factors, cellular energy levels, stress and amino 
acids availability. It exert its actions through control of main cell anabolic and catabolic processes 
including mRNA translation, lipid synthesis and autophagy (Yecies & Manning, 2011). 
The small GTPase Ras homolog enriched in brain Rheb (GTP-bound form) is a major activator of 
mTOR. Rheb is negatively regulated by the tuberous sclerosis heterodimer TSC1/2, which converts 
Rheb to its GDP-bound form. Most upstream signals are channelled through AKT and TSC1/2 to 
regulate the GDP/GTP state of Rheb (Huang & Manning, 2009). In contrast, amino acids can 
activate mTOR independently of TSC1/2 or AKT axis, acting by the spatial translocation of 
mTORC1 to the lysosomal surface where it is activated upon interaction with Rheb (Sancak et al., 
2010). 
Recently, mTORC1 has been shown to be responsive to changes in purine nucleotides pool in a 
similar manner to its sensing of amino acid pool (Hoxhaj et al., 2017). In comparison, amino-acid 
sensing is orchestrated by the GATOR1-Rag branch and intracellular nucleotide levels seems to be 
dependent on the TSC-Rheb axis (Emmanuel et al., 2017; Hoxhaj et al., 2017). This recently 
described nucleotide sensing property of mTOR is already under investigation as metabolic target 
in cancer treatment and has been shown to provide vulnerabilities of cancer cells to further therapy, 
such as use of nucleotide synthesis IMPDH1/2 enzyme inhibition (Valvezan et al., 2017). mTOR 
driven nucleotide biosynthesis has been found as an important factor in cancer development, as 
tumor cells requires significantly more pyrimidines than can be supplied by extracellular import 
(Howell, Ricoult, Ben-Sahra, & Manning, 2013; Moyer, Oliver, & Handschumacher, 1981). Thus, 
based on these findings we can expect novel strategies to target metabolic vulnerabilities in cancer 
treatment. 
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Cellular stress or energy deficiency can inhibit mTOR activity. AMPK activation in response to 
low energy levels can lead to TSC2 phosphorylation and mTOR inhibition. In addition, AMPK 
seems to directly exert its action on mTOR activity by phosphorylation of protein Raptor, one of 
the members of the mTORC1 complex (Gwinn et al., 2008). 
The approved uses and ongoing testing of various mTOR inhibitors (sirolimus and Rapalogues, 
rapamycin derivatives) in the clinic for diseases such as tuberous sclerosis complex (TSC mutated 
genetic disorder, characterized by disseminated growth of benign tumors), illustrate the importance 
of mTORC1 signaling in cancer growth. 
Since its discovery, the modulation of mTOR activity has been believed to hold the promise to 
slow down and/or improve many negative outcomes attributed to aging process, for example 
reducing the risk of age-related disorders, which will be discussed further in the next sections 
(Johnson, Rabinovitch, & Kaeberlein, 2013).  
 AMPK 
5' adenosine monophosphate-activated protein kinase (AMPK) is a cell energy sensor responsible 
to maintain ATP levels stable over energy crisis, signed by drop in the ratio of AMP/ATP, exerting 
its action through shutting down anabolic processes and promoting catabolic machinery. For 
example, AMPK can inhibit energetically demanding protein synthesis by activation of eukaryotic 
elongation factor 2 kinase (eEF2K) (Leprivier et al., 2013).  
As in the case of many others, AMPK signaling evolved mechanisms to protect cells from stress 
and enable survival over periods of energetical scarcity. The activation of AMPK leads to inhibition 
of mTOR, therefore under some conditions it slows down growth and tumor progression, but at the 
same time it can lead to tumor cell survival by induction of protective autophagy during 
metabolic/oxidative stress, potentially interfering with some of the chemotherapeutical treatments 
(Faubert et al., 2013; Jeon, Chandel, & Hay, 2012). Hence, the duration and magnitude of AMPK 
activity, as well as the timing of therapeutic intervention targeting AMPK pathways seem to be 
crucial in harnessing its antitumor effects. 
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In syngeneic mouse model of MYC-driven lymphoma activation of AMPK by low-carbohydrate 
diet feeding resulted in sensitization of cancer cells to ABT-737-induced cell death and extended 
mice survival. Mechanistically, low-carbohydrate diet reduced serum glycemia, which in turn 
activated AMPK and inhibited mTOR activity, leading to downregulation of myeloid cell 
leukemia-1 protein (MCL-1), key anti-apoptotic protein contributing to ABT-737 resistance 
(Rubio-Patino et al., 2016). 
There are several compounds found to directly or indirectly activate AMPK, and many of them 
have been investigated as dietary restriction mimetic, like metformin, resveratrol, quercetin, 
genistein, berberine, curcumin- indirect, and AICAR and salicylate as direct AMPK inhibitors (J. 
Kim, Yang, Kim, Kim, & Ha, 2016). 
 Sirtuins 
Sirtuins are a family of NAD+-dependent enzymes that modulate the metabolic status of cells 
through targeting and modifying activity of proteins involved in a wide range of cellular processes, 
having a key roles in physiology of healthy and malignant cells (Chalkiadaki & Guarente, 2015). 
In mammals seven sirtuins have been described so far, exhibiting range of functions and cellular 
localisations (Guarente, 2013). It has been proposed that sirtuins ca serves as sensors of cellular 
nutrient availability, and their activity modulation can mimic the effects of CR on carcinogenesis 
(Chalkiadaki & Guarente, 2015). In mammals, CR leads to SIRT1 activation in diverse cells and 
tissues, that is attenuated by IGF-1 (Cohen et al., 2004). In addition, transgenic mice with SIRT1 
overexpression phenotypically mimic mice under CR: they are leaner; with improved glucose 
tolerance; decreased blood cholesterol and insulin levels; reduced incidence of spontaneous 
carcinomas/sarcomas, and protection against colon cancer (Bordone et al., 2007; Firestein et al., 
2008; Herranz et al., 2010). Despite such promising metabolic effects, SIRT1 induction alone or 
combined with CR appears to have limited role in cancer protection and do not bring additional 
benefits, possibly owing to its differential tissue-specific expression and regulation (Boutant et al., 
2016; Herranz, Iglesias, Munoz-Martin, & Serrano, 2011). 
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B. Fasting 
Fasting is the practice of withdrawal consumption of any food or its dramatic restriction for a 
certain period (not particularly defined and specie-dependent). Historically, it might be the oldest 
and most widely adapted way of dietary regimen among human race, commonly having a religious 
purpose. Despite existence of anecdotal evidence attributing fasting anti-cancer properties, 
scientific investigation of the use of fasting-based regimens in cancer prevention and treatment are 
relatively recent. 
Fasting and CR are simultaneously similar in some features but profoundly different in others, and 
they cannot be treated as the same regimen but with different magnitude. Exercise training could 
serve as an analogy in order to compare the different outcomes that these two dietary regimens 
could displayed. As it is commonly known acute/intense high load exercise (fasting) produces 
differential metabolic and physiological response compared to chronic/low intensity training (CR), 
which results in gain of higher overall body endurance. As such, CR and fasting can result in 
different stress response of the organism. Additionally, fasting leads to depletion of glycogen 
storages and utilisation of ketone bodies as a source of energy, metabolic processes which have not 
been reported in CR. 
The first days of fasting display high rate of gluconeogenesis and amino acids being catabolized 
and used as the source of energy, especially alanine coming probably from muscles. Insulin is 
decreased, as oppose to increase in glucagon. As fasting continues, the body starts to use its fat 
deposits for energy production which results in progressive ketosis, which means the increase of 
ketone bodies produced by the liver and utilized by peripheral tissues as a fuel, including 
acetoacetate and β-hydroxybutyrate (Kerndt, Naughton, Driscoll, & Loxterkamp, 1982). Ketosis, 
state previously known mainly from its induction in diabetic individuals as an effect of insulin 
insensitivity or abrogated production, is a natural condition that the body resorts to survive such 
nutrient starvation. 
Mechanistically, fasting results in the inactivation of mTOR and Ras-PKA and activation of 
Rim15, a key enzyme indispensable for some of the fasting related beneficial outcomes. The last 
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event produces increased expression of proteotoxic and oxidative stress response genes, 
participating in the induction of the fasting-protective effects (Wei et al., 2008). T 
The protective cellular effects have also been attributed to the decrease in body general 
inflammation under CR or food deprivation. Interestingly it has been reported that level of β-
hydroxybutyrate specifically (one of the ketone bodies) could be responsible for inhibition of 
inflammasome by suppression of NLRP3-dependent inflammasome activation (Youm et al., 2015). 
Very interesting phenomena associated with fasting are Differential-Stress-Resistance (DSR) and 
Differential-Stress-Sensitization (DSS) (Buono & Longo, 2018). Those refer to the differential 
effect of fasting-induced stress between healthy and malignant cells, leading to higher and lower 
resistance respectively to additional stressors (like chemotherapy) (Figure 5). This surprising 
effect could simultaneously lead to higher cytotoxicity of anti-cancer targeting cancer cells, at the 
same time having lower side-effects and toxicity towards healthy tissues at the same time. For 
example, 48-72h period of fasting protects mice from otherwise deadly doses of doxorubicin and 
etoposide (C. Lee et al., 2010). In addition, 72h fasting period mice had lost roughly 20% of their 
initial body weight, reduced glucose levels by 41% and IGF-1 levels by 70%. This protection was 
lost under restoration of circulating IGF-1 levels with simultaneous injection during the fasting 
period. In contrast, malignant cells are being more prone to cytotoxic effect under fasting 
conditions (D'Aronzo et al., 2015; C. Lee et al., 2012; Shi et al., 2012). For example, 24h fasting 
synergistically potentiated gemcitabine effectiveness in a pancreatic cancer xenograft model 
(D'Aronzo et al., 2015). The explanation of this paradoxical phenomenon may lay on the constant 
activation of oncogenes in tumor cells, that not able to be switched off pushes the cell to grow and 
proliferate even against the worsening of extracellular conditions, inherently making them more 
susceptible to anti-cancer treatment. On the other hand, healthy cells are able to sense nutrient 
scarcity by responding to extracellular signals (GH, IGF-1), shut down metabolism and prepare 
their survival mechanisms in order to thrive. 
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Currently, it has been shown in a pilot study that 48h fasting prior to chemotherapy is safe and 
might provide beneficial effects reducing DNA damage in healthy cells such as lymphocytes and 
myeloid cells (Bauersfeld et al., 2018; de Groot et al., 2015). 
Interestingly, in a recent study evaluating the benefits of CR and fasting in male C57BL/6J mice, a 
single daily meal (12-13h fasting) and 30% CR resulted in higher mouse survival, lower insulin 
resistant and fasting blood glucose levels; and delayed onset of liver pathologies as compared with 
ab libitum diet regardless diet composition (Mitchell et al., 2018). These authors tested two 
different diets, one of them with higher fructose (but equal percentage of carbohydrates) and lower 
protein. Modulation of macronutrients in both diets did not make any difference in the positive 
effects of CR and fasting which points out that feeding regimens could have a higher impact on 
health and lifespan than diet composition per se. Importantly, fasting for 12-13h apart of mimicking 
CR outcomes, did not lead to body weight loss, advantage that should be considered in cancer 
research. 
Nevertheless, the pre-clinical trials of this type of regimens are being currently evaluated 
worldwide, and likely to shed some light on the potential benefits and limitations. Some of the 
particularly interested are listed below. 
The safety and metabolic outcomes in cancer patients receiving fasting mimicking diet (FMD) - a 
plant-based, calorie-restricted, low carbohydrate, low-protein, is being evaluated (NCT03340935).  
Effects of fasting (36h before and 24h after chemotherapy) on patients with advanced metastatic 
prostate cancer are also under investigation (NCT02710721). The long term 21-day fasting-like 
diet (providing only 5% of baseline calories) will examine the changes of disease-associated 
metabolic biomarkers (NCT03193177). 
C. Macronutrient modulation 
Caloric restriction in experimental setup relies on restricting 20-40% of general food intake in the 
treated group as compared to the control. As the food in the control group (not CR group) consists 
of the complex distribution of macronutrients (fat, carbohydrates and protein) and micronutrients 
(minerals, vitamins, phytocompounds etc.) with different ratio of these nutrients across the 
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scientific literature, this adds another level of complexity in order to compare results from different 
studies and define which nutrient restriction exactly (of the above-mentioned) could be responsible 
for the CR effect. This problem has been acknowledged at the very beginning of the experimental 
CR studies at the first half of twentieth century and since it has been debated and generates 
scientific confusion (Speakman, Mitchell, & Mazidi, 2016). 
The nutritional requirement of the organism on each nutrient depends on variety of factors, 
including stage of body development, age, energy expenditures, genetics, and obviously the species 
the experiment is based on. Firstly, it is evident that different species will have differential nutrient 
requirements. Secondly, the nutrient requirements greatly differ along the lifespan, and the body 
response to macronutrient modulation is different in young than in adult and advanced aged 
animals. Finally, due to interactions occurring between nutrients and other dietary constituents as 
well as the non-linearity of responses to many nutrients it creates complexity of the impossible to 
resolve scale. For example, some vitamins are known as being important in mineral absorption in 
the guts, therefore their availability can in long-terms manifest as mineral deficiency. As the CR 
studies have been restricting all of the above nutrients at once, it is rational to assume that the 
availability of some could fall under nutritional requirement threshold whereas the amount of the 
other nutrients would still be sufficient, hence the observed effect could be not due to calorie 
restriction per se, but to some nutrients being restricted. For example, 40% CR leads to reduction 
of 40% calories coming equally from carbohydrates, proteins and fats, but the restriction of one of 
them can have stronger impact than the others. Therefore, the same nutrient modification can have 
very different effect on health, longevity and carcinogenesis. 
The question of what is the limiting element that CR regimen utilises, either calories or any of the 
macro/micro-nutrient components, is still under investigation. It is actually very likely that CR acts 
simultaneously through multiple pathways, thus it results in so vast effects on multiple organism 
levels and diseases, and it will be unlikely to identify one mechanism that explains them all 
(Speakman et al., 2016). 
Recently, the new approach called Geometric Framework (GF), emerged from the progress in 
mathematical modelling and statistical analysis could help to assess the impact of single factor 
among the fluctuations in multiple overlapping factors and become a big step forward in our 
33 
 
understanding of nutrition (Simpson et al., 2017). As oppose to the traditional nutritional 
experiments with “one variable at a time”, where focus is on the modulation of the single dietary 
component, GF-based experiments rely on the cross modulation of multi-variables simultaneously 
(nutrients). The effect of single nutrient modulation can be therefore represented graphically as a 
point over a given time period or as a moving trajectory within an n-dimensional space, where each 
dimension is a nutrient. The value of such approach proofed its value first in the model of 
Drosophila (K. P. Lee et al., 2008) and subsequently in mice (Solon-Biet et al., 2014). 
Researchers from Sydney undertook a meticulous work testing the effect of 25 diets fed ad libitum, 
varying in dietary energy density, protein, fat, and carbohydrate. The researchers measured the 
impact of each diet on food intake, cardiometabolic phenotype, and longevity in 858 C57BL/6 male 
and female mice, in particularly measuring glucose tolerance, blood pressure, plasma levels of 
insulin, leptin and amino acids, blood lipid and liver function markers. The diets differed greatly 
in the content of protein (5%–60%), fat (16%–75%), carbohydrate (16%–75%), and energy density 
(8, 13, or 17 kJ/g). The study primary goals were to determine what drives CR longevity extension 
by measuring the lifespan and physiological mechanisms of aging, particularly focusing on the 
activity of mTOR and amino acid modulations. When they have compared the groups of the highest 
calorie intake to the group of the lowest (30% CR), the last one accounting for the effect of the 
other macronutrient modulation (like compensatory overfeeding), they have not found the 
previously reported lifespan extension. Instead, when mis-matched with all the other factors, 
reduction in protein intake was clearly positively and dose-dependent correlated with mouse 
lifespan extension, increasing it by approximately 30% as the protein:carbohydrate ratio decreased 
(Solon-Biet et al., 2014). Inversely, when the ratio increases hepatic mTOR shows activation, 
which is associated with the elevated levels of circulating branched chain amino acids. Of note, the 
low protein high carbohydrates diet was strongly associated with improved glucose tolerance, 
lower body fat and low blood triglycerides and insulin levels (Solon-Biet et al., 2014; Solon-Biet 
et al., 2015). The researchers confirmed some of their initial results in the follow-up study 
investigating the metabolic outcomes of 8-week dietary modifications, where the protein restriction 
generated the metabolic benefits of CR, at the same time not providing additional advantage when 
the mice where already under low-protein diets (Solon-Biet et al., 2015). It would be of utmost 
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importance and interest to test and statistically measure the effect of such spectrum of dietary 
modulation in a similar study on tumor progression and cancer incidence. 
The additional data highlighting the benefits of lower protein consumption comes from the 
corroborative work where researchers collated the result of populational human study using 
nutritional survey substantiated with IGF-1 serum levels measurements with cellular in vitro and 
in vivo mouse models (Levine et al., 2014). The low protein consumption appears to have a 
protective effect against all-cause and cancer mortality prior to age 66 and correlates with lower 
circulating IGF-1 levels in humans. In mice, low protein diet (4% of total protein) resulted in slower 
cancer growth of subcutaneously injected B16 melanoma cells in C57BL/6 mice as compared to 
high protein diet (18% from total protein), which was correlated with lower free circulating IGF-1 
and higher mIGFBP-1. To test the hypothesis that the modulation of IGF-1 serves as the driving 
force of tumor growth inhibition, the researchers used GHRKO mouse model, where the 
invalidation of growth hormone receptor disrupts the Growth Hormone/IGF-1 axis. In GHRKO 
mice tumor growth of B16 wild type (WT) melanoma cells was slower as compared to the WT 
C57BL/6 mice, indicating that circulating levels of hormones dictates the tumor progression rates. 
Of note, the 4% content of protein diet resulted in weight loss and growth retardation in mice 
BALB/c model, which indicates the high magnitude of the above dietary intervention, which might 
not be successfully achieved and result in negative health effect over long-term in other models or 
aged mice. In accord with these observation, the effect of low protein diet was beneficial for young 
mice (3-4 months old) but not necessarily in older mice (10 months old) which reproduced the 
observation in human population (Levine et al., 2014).  
Of note, studies in Caenorhabditis elegans and rats indicate that the proteostasis in endoplasmic 
reticulum is drastically reduced during aging (Ben-Zvi, Miller, & Morimoto, 2009; Gavilan et al., 
2009; Naidoo, Ferber, Master, Zhu, & Pack, 2008; Taylor & Dillin, 2013). It would be interesting 
to investigate whether such physiological modulation is not connected with different outcomes of 
nutritional intervention between young and older animals. The relation between proteostasis and 
aging is further discussed in the chapter describing the unfolded protein response (UPR). 
In summary, the latest research appears to point toward protein as the main contributor of long- 
appreciated CR in general health and aging, linking the protein consumption to its effects on 
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regulation of mTOR and IGF-1 axis. Whether the low-protein dietary regimens could affect cancer 
progression and occurrence has to be investigated in the future studies. 
D. Diet in the pill - CR mimetics 
Based on the findings and impact of CR and dietary related nutritional studies, the promise of 
developing the pharmacological approach instead of food intervention inspired many scientists to 
look for molecules that could affect the same pathway as CR does. CR mimetics (CRm) are the 
group of compounds that phenocopies one or several effects of CR regimen. It was proposed  that 
CRm treatment should phenocopy metabolic, hormonal, and physiological effects of CR, activates 
stress response pathways observed in CR and enhances stress protection, extent longevity and 
reduce overall aging and age-related diseases (Handschin, 2016; Ingram & Roth, 2011, 2015; 
Madeo, Pietrocola, Eisenberg, & Kroemer, 2014). Another proposed definition of CRm is the 
reduction in overall protein acetylation, which in turn would promote cytoprotective autophagy 
that would be beneficial for cellular and organ function (Madeo et al., 2014). 
The screening of CRm is based on the molecule ability to reproduce one or several intermediate 
physiological effects that have been observed in the CR studies, such as reduction in glucose, 
insulin and triglyceride circulating levels. Results of ongoing studies identifying potential CRm are 
published by the NIA Interventions Testing Program, which every year start evaluation of several 
compounds for their CRm activity, including among the others aspirin, nitroflurbiprofen, 4-OH-
alpha-phenyl-N-tert-butyl nitrone (4-OH-PBN), nordihydroguiaretic acid (NDGA) and rapamycin. 
Several compounds have been recognised as CR mimetics, which are listed and shortly 
characterised in Table 1 but only few of them have been demonstrated to impact cancer 
progression, and here we will discuss only some of them. 
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Table 1: Calorie restriction mimetics. 
Name Characteristic Mechanism of action Ref. 
2-Deoxy-D-
glucose 
Glucose analog, decreases body weight, 
insulin levels and body temperature. 
Cardiotoxic 
Glycolysis inhibitor (Ingram & Roth, 2011) 
Metformin 
Biguanide, anti-diabetic drug, extends 
lifespan, reduces incidence of age-related 
diseases (cancer, cardiovascular disease, 
and chronic kidney disease). Risk of lactic 
acidosis 
Mitochondrial complex I inhibitor 
and indirect AMPK activator. 
Enhances sensitivity of insulin 
receptors, activates genes reducing 
glucose synthesis and reduces gene 
expression of enzymes that increase 
oxidation of fatty acids 
(Kawashima et al., 
2013; D. L. Smith, Jr. 
et al., 2010) 
Rapamycin 
Antibiotic with pro-longevity effect, 
reduces pathological Amyloid β levels in 
animal models of neurodegenerative 
disorders. Immunosuppresor 
mTOR inhibitor, upregulation of 
autophagy to remove damaged or 
misfolded proteins 
(Ingram & Roth, 2011; 
Nikolai, Pallauf, 
Huebbe, & Rimbach, 
2015) 
Resveratrol 
Plant polyphenol (grapes) with lifespan-
enhancing effect, prevents age-related 
diseases, increases insulin sensibility, 
lowers body weight. Anti-tumor actions 
Deacetylase (sirtuins) activator, 
autophagy induction. Inhibition of 
phosphoinositide 3-kinase (PI3K) 
(J. Li, Zhang, Liu, 
Chen, & Chen, 2017; 
Nikolai et al., 2015) 
Oxaloacetate Intermediate of the TCA cycle, increases lifespan, lowers fasting glucose levels 
Activation of AMPK via an 
increase in the NAD+/NADH ratio 
(Ingram & Roth, 
2015) 
Lipoic acid 
Antioxidant scavenging ROS and 
recycling of other antioxidants, 
counteracts age-related disorders 
Induction of Uncoupling Protein 
(UCP) expression leading to 
decrease of ROS produced by the 
mitochondrial electron chain 
(Nikolai et al., 2015) 
Rimonabant 
Anti-obesity drug, improves insulin 
sensibility, lipid profile, and decreases 
visceral fat accumulation. High levels of 
psychiatric side effects 
Endocannabinoid-1 receptor 
blocker 
(Horn, Bohme, 
Dietrich, & Koch, 
2018) 
Hydroxycitrate Anti-obesity agent, increases autophagic flux, anti-cancer effects 
Competitive inhibitor of the ATP 
citrate lyase (AcCoA depletion), 
autophagy induction 
(Pietrocola et al., 
2016) 
Spermidine 
Natural polyamine, anti-cardiac aging 
effects, reduces arteriosclerosis, anti-
aging effects 
Acetyltransferase (EP300) 
inhibitor, autophagy induction 
(Eisenberg et al., 
2009; Marino, 
Pietrocola, Madeo, & 
Kroemer, 2014; 
Pietrocola, Castoldi, 
Markaki, et al., 2018) 
N-Glucosamine 
Natural amino sugar and dietary 
supplement, extends life span, lowers 
blood glucose levels 
Glycolysis inhibitor, indirect  
AMPK activator (Weimer et al., 2014) 
Quercetin 
Plant polyphenol, expands lifespan, anti-
tumor actions, synergism with other 
autophagy-inducing plant metabolites 
(resveratrol) 
Sirtuin activation, autophagy 
induction 
(Pallauf & Rimbach, 
2013) 
Genistein 
Plant polyphenol (soybeans), extends 
lifespan, protects against age-associated 
degenerative disorders, lowers blood 
pressure 
AMPK activation, autophagy 
induction (E. B. Lee et al., 2015) 
Curcumin 
Plant polyphenol (tumeric), anti-
inflammatory, anti-oxidant and cell death-
inducing properties, improves obesity-
associated comorbidities, anti-cancer 
properties 
Histone acetyltransferase inhibitor, 
autophagy induction. Modulation of 
Akt and Erk pathways 
(Marcu et al., 2006; 
Pallauf & Rimbach, 
2013; Sarker et al., 
2015) 
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Name Characteristic Mechanism of action Ref. 
AICAR 
Analog of AMP, prevents fat gain, 
restores muscle mass by preventing 
inflammation-associated cachectic muscle 
wasting 
AMPK activator 
(D. T. Hall et al., 
2018; Ruegsegger, 
Sevage, Childs, 
Grigsby, & Booth, 
2017) 
Salicylate 
Plant hydroxybenzoic acid, anti-
inflammatory properties, prolongs health 
span and lifespan, reverses high-fat diet-
induced insulin resistance, anti-
arteriosclerotic and cancer-preventive 
effects 
Inhibitor of the acetyltransferase 
EP300 (autophagy induction in 
heart and liver), NF-kB inhibitor, 
AMPK activator 
(Pietrocola, Castoldi, 
Markaki, et al., 2018) 
 2-Deoxy-D-glucose  
2-Deoxy-D-glucose (2DG) is a chemical analog of glucose, structurally similar enough to be up-
taken by the cells as glucose sharing by the same membrane transporter as glucose and then 
converted by hexokinase to 2-Deoxy-D-glucose-6-phosphate. Because the latter cannot be further 
metabolised, its being accumulated within the cell and subsequently result in the block of 
glycolysis. Cancer cells in general have higher requirements for glucose, as well as they have 
elevated levels of glucose transporters and hexokinase, hence they are more sensitive to 2DG 
treatment than non-cancerous cells. 
2DG was one of the first proposed CRm, resulting in reduced circulating insulin levels and lowered 
body temperature, two physiological markers strongly predicting longevity, but producing at the 
same time detrimental cardiotoxicity in rats (Ingram & Roth, 2011; Minor et al., 2010; D. L. Smith, 
Jr. et al., 2010). 
In addition to its glycolytic-inhibitory capacity, 2DG was found to induce endoplasmic reticulum 
stress (ER stress) through competition with mannose in the initial steps of N-linked protein 
glycosylation. Protein glycosylation begins in ER and is considered as a post-translational 
modification. The "N" in the name of this type of glycosylation indicate that the glycans are 
covalently attached to Asparagine (Asn or N) I am not sure about this, I thought that N is due to 
linking to nitrogen instead of oxigen, since there are also O-glycoproteins. It is the most common 
type of protein glycosylation - 90% of glycoproteins are N-glycosylated. Changes in surface protein 
glycosylation have been observed in the development of cancer and could serve as 
immunostimulatory signal (Stowell, Ju, & Cummings, 2015; Wolfert & Boons, 2013). In fact, it 
has been observed that 2DG treatment can affect T-cell and NK cell-tumor cell recognition and 
38 
 
activation in vitro, having opposite effects probably dependent on the dose of 2DG administered, 
enhancing cancer recognition upon low dose (0.5 mM) and decreasing it when the dose was 
relatively high (20 mM) (Andresen et al., 2012; Beneteau et al., 2012). In the second case, the 
inhibition of cancer recognition by NK cells was attributed to abrogation of NKG2D ligands 
expression on the cell surface, the mechanism that will be described further in the discussion. 
 Metformin 
Metformin, blood glucose lowering drug from the family of biguanides has been for long time the 
first-line medication for type 2-diabetes mellitus patients. Its primary mechanism of action is the 
ability to reduce hepatic gluconeogenesis and increase glucose turnover in muscles and adipose 
tissue in hyper-glycemic patients, which is primarily driven by AMPK activation (Pernicova & 
Korbonits, 2014). Mechanistically, metformin inhibits the mitochondrial respiratory complex I, 
leading to activation of AMPK, followed by enhanced insulin sensitivity and lowered cAMP levels. 
Metformin also has AMPK-independent effects on the liver that may include inhibition of fructose-
1,6-bisphosphatase by AMP (Martin-Montalvo et al., 2013; Rena, Hardie, & Pearson, 2017; D. L. 
Smith, Jr. et al., 2010). In addition, in some context it can efficiently inhibit mTORC1 signaling 
independently of its action on AMPK, by which some of its physiological effects can be explained 
(Ben Sahra et al., 2011). 
Metformin caught attention as cancer modulating treatment, due to emerging reports of lower 
incidents of tumor formation in diabetic patients receiving metformin, as well as lower mortality 
rates among those who already developed cancer (Landman et al., 2010). Even more interestingly, 
this effect turned out to be immune system dependent, since metformin treatment in 
immunodeficient mice did not delay either cancer growth or survival (Eikawa et al., 2015).  
 Rapamycin 
As already mentioned, rapamycin is the inhibitor of mTORC1, central hub of nutrient sensing in 
the cell. Its administration profoundly mimic the CR phenotype, including whole organism 
metabolism, gene expression and serum bio-profiling, leading to increased longevity in various 
animal models (Ingram & Roth, 2015). Unfortunately, the negative effect of rapamycin on 
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mTORC2 and side negative metabolic outcome render this CR mimetic as of very limited use (Fang 
et al., 2013; Lamming et al., 2012). Interesting observation is the upregulation of autophagy due to 
mTOR inhibition by rapamycin, which could promote removal of damaged and misfolded proteins 
(Fig 4). 
 Aspirin 
Another recently proposed CRm is the well known drug acetylsalicylic acid (Aspirin). It belongs 
to the non-steroid anti-inflammatory (NSAID) group reducing fever, pain and inflammatory 
response. For the discovery of the mechanism by which aspirin reduces inflammation, a Noble 
prize was awarded in 1982. Primary mechanism of aspirin is the suppression in the production of 
prostaglandins and thromboxanes by inhibition of cyclooxygenases COX-1 and COX-2, required 
for prostaglandin and thromboxane synthesis. Additional mechanisms of action include uncoupling 
of oxidative phosphorylation (Norman, Howell, Millar, Whelan, & Day, 2004), NO free radicals 
formation (Paul-Clark, Van Cao, Moradi-Bidhendi, Cooper, & Gilroy, 2004) and NF-κB signaling 
modulation (McCarty & Block, 2006). 
Another important effect of aspirin molecular mechanism is the prevention of blood clot formation 
and blood thinning. By interfering with thromboxane production, it is reduces the platelets ability 
to form aggregates, thus hampering wound formation and healing. 
It has been shown that low-dose aspirin treatment can mimic CR by stimulating autophagy through 
the inhibition of acetyltransferase EP300 by direct competition with acetyl coenzyme A to bind 
EP300 enzyme catalytic domain (Pietrocola, Castoldi, Maiuri, & Kroemer, 2018; Pietrocola, 
Castoldi, Markaki, et al., 2018). Unfortunately these promising results have to be taken with 
caution, as long-term aspirin administration risk can overshadow the potential benefits, and chronic 
administration of aspirin has been unexpectedly found to increase the cancer-related cell death risk 
(McNeil et al., 2018). 
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II. CANCER 
1. Cancer – common denominator of many diseases 
Cancer is not a single disease, but a group of malignancies caused by uncontrolled 
proliferation of heterogenous cell mass, sharing some common features which are known as 
hallmarks of cancer (Hanahan & Weinberg, 2000, 2011). The hallmark list initially included six 
features: proliferative signaling; growth suppression evasion; metastasis; replicative immortality; 
angiogenesis and cell death evasion; which was later expanded by additional four: immune escape, 
inflammation, metabolism deregulation and genome instability. Thus, obtaining the above-
mentioned malicious character, the initially healthy cell must undergo a series of steps, reshaping 
its inner biological machinery, simultaneously evading recognition to be killed (by immune system 
in higher organisms) or to commit a suicide (by its own self-destruction machinery initiated by the 
defects caused by malignant transformation and stress). 
It is not an easy path, that is why majority of pre-cancerous cells are detected and efficiently 
removed from the organism by its own surveillance system (Afshar-Sterle et al., 2014; Marcus et 
al., 2014). For the cell to succeed and evade all of the obstacles (internal and external) it can take 
years for the disease to manifest and be detected by the current methods (Valastyan & Weinberg, 
2011). The time before cancer initiation and detection is called latency period. This latency period, 
estimated to be years (even decades) is the time where it is believed natural selection in the 
microscale is taking place for precancerous cells, followed by exponential growth and deadly 
metastatic processes when the tumor is finally detectable and reaches certain malignancy stage 
(Greaves & Maley, 2012). The dormant, slowly dividing pre-cancerous cells that do not yet have 
the potential and resources to overcome natural barriers and defences of the organism are much 
more prone to be targeted and removed at this early stage than later in time, when they are so much 
more heterogeneous and resistant. That is one of the rational for early cancer detection methods as 
a very important step in cancer elimination and treatment. Yet, as it was mentioned, years can pass 
without any visible symptoms of the emerging disease, and likely that is the exact time that all the 
prevention measures have the highest impact on stopping cancer progression. Hence, here we will 
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focus on couple critical steps in cancer developmental evolution – escaping cell death, escaping 
anti-cancer immune recognition, and reshaping cell metabolism to support growth and expansion. 
2. Cancer - Avoiding death 
In higher evolved organisms, removal of particular cells during certain developmental stage is 
natural and necessary, thus this process is precisely regulated on many steps. In cancer 
development, a premalignant cell has to deregulate death pathways to avoid cell suicide as a result 
of gene and protein damage accumulation. Therefore, tumor evolves two main mechanisms to 
progress: avoiding cell death in first place; and if that is not possible, uses apoptotic machinery to 
die in an immunological silent way, so the host organism will not be alarmed and respond towards 
malignant cells. Herein, the importance and character of apoptosis will be shortly described in the 
context of cancer and immune response, and the recent concept “immunogenic cell death” will be 
presented.  
A. Apoptosis – programmed cell death 
Apoptotic process is necessary for proper development of multicellular organisms, and as it has to 
take place in physiological conditions, without disrupting the normal growth and function of the 
tissue, death of the cell happens in a “silent” mode – no unnecessary damages to the bystanders. 
This type of death, a physiological self-destruction, was named apoptosis, and is characterised by 
a multi-step programmed process leading to decomposition of the cell structures and re-absorption 
by the neighbouring cells and professional phagocytic cells, without rendering stress and leaving 
trace of its existence, as opposed to cell necrosis, which was initially defined as a passive or 
accidental cell membrane disruption, leading to inner cytosol leakage and inflammation. In recent 
years, multiple cell death types have been discovered and this list is likely to be expanded and 
characterised more deeply in the near future (Galluzzi et al., 2018). From the cancer perspective, 
avoiding cell death is one of the first barriers to overcome. 
Various stresses (extrinsic and intrinsic) are known to trigger the apoptotic program. Even the sole 
process of tumorigenesis can be internally exhausting and challenging enough to activate proteins 
and pathways governing self-destruction cell mode: elevated oncogene signaling, DNA damage 
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and acute cellular energetic deficiencies, for instance. Yet, those tumors that succeed in progression 
and resistance to the therapy managed to efficiently block activation of pro-apoptotic pathways 
(Fulda, 2010). 
The apoptotic machinery can be triggered by sensing an intracellular signal (intrinsic program) or 
by receiving extracellular signal “to die” involving for instance, Fas receptor activation (extrinsic 
apoptotic program). Both programs culminate in activation of caspases, caspase 8 for extrinsic and 
caspase 9 for intrinsic program, which in turn activates downstream effector caspases family-3,-6, 
and -7 (Figure 6). The apoptotic process is characterized by: 
- mitochondrial outer membrane permeabilization and cytochrome C release 
- phosphatidylserine relocalization from inner to outer side of the cell membrane 
- DNA fragmentation 
- cell shrinkage and fragmentation 
- ATP-dependence 
- immunologically silencing – no inflammation  
The intrinsic apoptotic program is more widely implicated as a barrier to tumorigenesis, but there 
is an increased interest of extrinsic cell death ligands use as a manner to induce cancer cell death 
in pre-clinical treatments. 
The extrinsic apoptotic pathway begins when membrane receptors containing Death Domain (DD) 
such as TNFα receptor 1, FAS receptor or TRAIL receptor binds to its specific ligand, here TNFα, 
FAS-ligand or TRAIL, respectively. Receptor-ligand binding triggers the recruitment of proteins 
to the DD region in the cytosolic part of the receptor, forming the death-inducing-signaling-
complex (DISC), initiating the apoptotic machinery, resulting in pro-caspase 8 activation via 
dimerization in so called induced proximity mechanism. Main function of activated caspase 8 is 
initiate cell death (type II extrinsic pathway). Thus, caspase 8 can cross-react with intrinsic 
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The intrinsic apoptotic pathway involves mitochondrial protein machinery, and it is responsible for 
majority of physiological cell death in higher organisms. In a non-physiological context 
(pathological), intrinsic apoptosis pathway triggers are: DNA damage, heat shock, UV, irradiation, 
oxidative stress, chemotherapy and ER stress among others. Briefly, the cell stress(-ors) can impact 
on the family of proteins governing the apoptotic machinery localized in the mitochondria, where 
the signal is integrated. The ratio between the anti- (i.e. Bcl-2 family, Bcl-xL, Mcl-1) and pro-
apoptotic proteins (i.e. Bad, Bax, Bok, Bid, Bim) dictates the cell fate by regulating the integrity 
of mitochondrial outer membrane (MOM). When pro-apoptotic proteins prevail, MOM 
permeabilization (MOMP) leads to release of apoptosis proteins and cell death. Cytochrome c, an 
essential component of oxidative respiration that transfers electrons between Complexes III and IV 
in the inner membrane and is found exclusively within mitochondria under physiological condition, 
upon MOMP binds to APAF-1 and caspase-9 forming the apoptosome, activating caspase-9 and 
then executor caspases -3, -6 and -7 (Cotter, 2009). Apoptosome formation can be hampered by 
overexpression of proteins belonging to heat shock protein (HSP) family, mechanism which is 
widely utilized in cancer cells due to their higher than normal exposure to stress, and it is one of 
the cell death escape mechanisms acquired by some cancers (Beere et al., 2000; Bruey et al., 2000). 
Following apoptotic cell self-disintegration, cells secrete and expose a variety of molecules that 
serve as the “eat me” signals, allowing to be recognized as well as to be eliminated, and “find me” 
signal, attracting the specialised phagocytic cells. These primary signals are present during the 
immunologically silent apoptotic cell death as they are in the necrotic death, and it is the co-existing 
secondary signals (cytokine and DAMPs) that eventually determine the immune response. 
One of the major regulator shaping the character of the cell death, either pro- or anti-immunogenic, 
is the endoplasmic reticulum (ER) and pathway implicated in its stress response, further described 
in the following chapters. 
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B. ICD inducing chemotherapies 
Immunogenic cell death (ICD) is a form of cell death which can induce an effective anti-tumor 
immune response (Krysko et al., 2012). Majority of ICD inducers, elicit danger signaling through 
ER stress/UPR signaling caused by some cytostatic agents such as anthracyclines doxorubicin 
(Doxo) and mitoxantrone (MTX), oxaliplatin, bortezomib, or physical stressors including 
radiotherapy and photodynamic therapy (Galluzzi, Buque, Kepp, Zitvogel, & Kroemer, 2017a; 
Garg & Agostinis, 2014; Krysko et al., 2012). The majority of commonly used chemotherapeutics 
fails to induce ICD. Chemotherapies that can induce canonical ICD through calreticulin (CRT) 
exposure turned out to have an immunogenic effect that is dependent on the ER stress-mediated 
induction of the PERK/eIF2α pathway which regulates the surface exposure of CRT (Obeid et al., 
2007; Panaretakis et al., 2009).  
Anthracyclines have been long used in the treatment of leukemia, lymphoma, uterine, ovarian, 
sarcoma, and breast malignancies. The most commonly used anthracycline is doxorubicin due to 
its low toxicity and potent antitumor activity that depends on CD8+ T cells and IFN-γ, which in 
turn correlate with the response to the treatment (Mattarollo et al., 2011). In fact, the response of 
cancer cells to anthracyclines has found to partially mimic those induced by viral infection, as both 
induces an Type I IFN (IFN-I) response through Toll like receptor 3 (TLR3) activation. IFN-I 
antagonist is IFNAR1, which upon binding will trigger the release of CXCL10. In this sense, it has 
been shown that anthracycline efficacy can be reduced by neutralizing the IFN-I receptors 
(IFNAR1) and the CXCL10 receptors (CXCR3) (Sistigu et al., 2014). This could partially explain 
the enhanced response to chemotherapy of tumors growing in syngeneic immunocompetent mice 
rather than in immunodeficient mice. 
Another example of an anticancer therapy that has been shown to have immunogenic activity is 
bortezomib (market name: Velcade). This proteasome inhibitor triggers damaged protein 
accumulation, inducing chronic ER stress through the activation of the PERK/CHOP pathway, 
which may sensitize cells to BOK-dependent apoptosis (Carpio et al., 2015; Llambi et al., 2016). 
It renders tumor cells immunogenic by upregulating HSP60 and HSP90 on the cell surface, 
improving dendritic cell (DC) function and inducing an CD8 T cell-mediated immune response 
(Chang et al., 2012; Spisek et al., 2007). 
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Interestingly, new experimental drugs with the capacity to induce ICD are being continuously 
discovered, like Epothilone B. This microtubular inhibitor cause polyploidy, induces ICD and 
results in anticancer immunosurveillance. It is being investigated for the treatment of ovarian 
cancer, lung cancer, brain cancer, breast cancer, and gastric cancer (Senovilla et al., 2012). 
Additionally, drugs with therapeutic uses other than cancer treatment are also starting to be 
discovered as ICD inducers with potential anticancer properties. This is the case of Digoxin and 
Digitoxin, which are cardiac glycosides used to treat heart failure. These cardiac glycosides induce 
the accumulation of cellular Ca2+, which is beneficial to cardiocytes but ultimately leads to 
cytotoxic ER stress in cancer cells (Menger et al., 2012). 
In the same way, chemotherapeutic treatments that do not induce danger-associated molecular 
patterns (DAMPs) exposure are unable to induce ICD. Cisplatin, for example, fails to induce ICD 
unless it is combined with ER stress inducers (i.e. thapsigargin, tunicamycin) (Martins et al., 2011) 
or with compounds that in combination will increase ER stress (i.e. pyridoxines) (Aranda et al., 
2015). This was also the case when lymphomas were treated in vivo with a combination of 
Etoposide and 2-Deoxy-D-glucose (2DG). Etoposide alone did not induce an immune response 
unless combined with low doses of 2DG, which is a well-known inducer of ER stress (Beneteau et 
al., 2012). 
Targeting the UPR in cancer treatment is an interesting and growing area of research. Nevertheless, 
these approaches may also alter the development and function of tumor infiltrating immune cells, 
affecting immunosurveillance and favoring immune escape mechanisms, for example increasing 
pro-tumoral cytokine-driven inflammation. For these reasons the combination of UPR-targeting 
drugs with chemotherapies should be carefully evaluated. Recent studies have demonstrated that 
induction of immune response along with non-immunogenic therapies can result in additional 
benefit and improved treatment response. This is the case of CR that was shown to induce the 
autophagic stress response when combined with non-immunogenic chemotherapies, resulting in an 
anticancer immune response (Pietrocola et al., 2016). 
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3. Metabolism of cancer cells 
While the observation that cancer metabolism is abnormal in comparison to the healthy tissue was 
done almost a century ago by the famous Noble Prize winner Dr Otto Warburg, the metabolic 
modulation as an effective anti-cancer therapy has just started to deliver promising results. Dr 
Warburg noticed markedly increased glucose consumption by tumors, the cancer feature that is 
used routinely nowadays in cancer diagnosis by positron emission tomography (PET) imaging with 
radioactive labelled glucose analogues. 
Just a quick glimpse at the simplified metabolism signaling pathway map could answer the question 
why so many people failed to harness its therapeutic potential – the complexity and sophistication 
of multiple intertwined circuits within a cell make it look particularly difficult to target. Metabolic 
treatment-induced modulation should be lethal towards malignant cells while sparing non-
malignant cells. At a time, the genetic approach seemed much more attainable, and was holding a 
great promise to stop cancer at the very beginning. Unfortunately, cancer genetic landscape is much 
more complex than it was expected, and gene-based therapies are still in majority the promise of 
the future. Genomic landscape consists of deregulation and mutation of multiple genes, and 
probably much more of cross-gene interaction plus non-coding genome regions that are known/or 
very likely are affecting all the paths to tumorigenesis, not mentioning the constant micro-evolution 
happening within the heterogenous tumor tissue. On the other hand, cell metabolism analysis 
reveals limited number of ways that the cell can use to produce energy and building blocks. 
The major two ways of ATP production by cells is glycolysis and oxidative phosphorylation 
(OxPhos) (Figure 7). It was often considered that proliferative cells rely mostly on glycolysis and 
differentiated cells use oxidative phosphorylation as the main source of energy. 
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Glycolysis is a less efficient way of glucose utilisation in terms of ATP production- it gives merely 
2 mol of ATP per 1 mol of glucose, whereas oxidative phosphorylation provides 36 mol/1 mol of 
glucose, but on the other hand glycolysis flux is significantly more rapid than OxPhos, partially 
compensating for its low ATP yield. Additionally, pyruvate, the end product of glycolysis, is 
subsequently converted into lactate using NADH as a source of proton, thus, replenishing the pool 
of free NAD+ required for glycolysis to continue. Lactate is then removed extracellularly, not only 
being lost as a source of carbon but also creating a toxic environment. Surprisingly, Dr Warburg 
noticed that cancer cells are using glycolysis over oxidative phosphorylation even with unlimited 
access to oxygen (Figure 8) (Liberti & Locasale, 2016; Vander Heiden, Cantley, & Thompson, 
2009). Although he proposed at that time that this could be the result of defects in mitochondrial 
functioning that would disrupt proper electron transport chain to function, nowadays we know that 
majority of tested malignant cells have perfectly functional mitochondria, implicating that 
glycolysis provides some advantage for rapidly proliferating cells over OxPhos. As it was later 
shown, healthy cells also preferentially use glycolysis under high proliferation demands, as for 
example rapidly expanding pool of T lymphocytes.  
The explanation of this phenomena (preferential use of less energetically efficient glycolysis during 
proliferation) could be the much higher increase in demand of other nutrients (nucleotides, amino 
acids and lipids) for the proliferative cells, whereas the ATP demand changes just slightly. As it 
turns out, the energy might not be the limiting factor for highly dividing cells, but the building 
blocks and macromolecules as nucleotides and amino acids might be of much higher importance 
(Figure 8) (Vander Heiden et al., 2009). It is also the reason for high cancer glutamine dependency 
– as this amino acid is the direct precursor and anaplerotic supplier of the tricarboxylic acid cycle 
(TCA) for all of the above macromolecules. The important feature of cancer development is the 
fact that, at least in the initial phase, tumor cells are not limited by energy supply in form of glucose 
– as it is constantly delivered by circulation. In fact, the host ability to keep the constant levels of 
circulating blood sugars is enormous, even after prolonged food deprivation and starvation, ranging 
between 80 to 110 mg/dL, and rarely dropping under 70 mg/dL. 
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Cancer cells exhibit an additional feature – their growth is independent from external signaling 
factors. As opposed to unicellular organisms, multicellular life evolved specialised interdependent 
tissues, whose particular development and growth is tightly regulated. Every tissue and organ has 
its own specialisation and function, making the organism as a whole unit more efficient, but also 
making every part dependent on the rest. Thus, cells growth and division is limited and occur only 
in response to extracellular growth signals, even though the cell is constantly supplied with 
nutrients, energy and oxygen. Hence, many cancer mutations lead to abnormalities in growth 
signaling, and pushes cell division in their absence, or even against the anti-proliferative signals.  
A. Glucose 
Cancer cells have a markedly increased consumption of glucose as compared to normal tissue. 
However, this overconsumption is used mainly in the de novo synthesis of lipids, nucleotides and 
amino-acids, instead of energy. Owing the necessity of malignant cells for glycolysis in order to 
produce sufficient amount of energy in parallel with an increased de novo synthesis, an important 
question arises: why and how tumor cells import so much extracellular glucose? Higher organisms 
evolved tight regulation of nutrient uptake via growth factor signals (Thompson, 2011). Deprived 
these signals, healthy cells do not survive in vitro, not able to import required nutrient even in an 
enriched nutritive environment (Aaronson, 1991; Talapatra & Thompson, 2001). Oncogenes that 
result in activation of PI3K/AKT signaling pathway enable to circumvent the need of external 
growth stimuli, thus enabling malignant cell survival (Aaronson, 1991; Edinger & Thompson, 
2002). Such oncogenes act as master regulators of glucose uptake, inducing expression of glucose 
membrane shuttle GLUT1 and enhancing the activity of glycolytic enzymes hexokinase (HK) and 
Phosphofructokinase-1 (PFK) (Edinger, 2005; Pavlova & Thompson, 2016). 
Based on this increased glucose consumption some therapeutic treatments like 2DG (discussed in 
chapter describing CR mimetics) have been tested, but unfortunately with low efficacy or with 
unfavourable side effects. Nevertheless, 2DG in combination with other chemotherapeutic drugs 
can result in additional synergistic benefits, for example sensitizing the tumor cells to the primary 
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therapy (Cheong et al., 2011; Meynet et al., 2012; Reyes, Wani, Ghoshal, Jacob, & Motiwala, 
2017). 
B. Glutamine – carbon source for lipid and nucleotide synthesis under 
hypoxia 
Glutamine, a non-essential amino acid that is found at the highest concentration in the human 
bloodstream among other amino acids, similar to glucose it is tightly regulated and maintained at 
roughly 0.5 mM through the common effort of dietary uptake, de novo production and, if needed, 
muscle protein catabolism. In fact, rather than incorporating glutamine into protein synthesis, 
tumor cells use it as a source of nitrogen for de novo synthesis of nucleic acids and as a carbon 
source in anaplerotic fuelling of TCA cycle. Glutamine can be a precursor of multiple essential 
metabolites by their de novo synthesis (Figure 9). 
Glutamine enhanced import and utilization is profoundly induced by transcription factor c-Myc. Its 
targets include glutamine transporters (ASCT2, SN2), glutamine to glutamate conversion enzyme 
(GLS1), as well as crucial enzymes in nucleotide biosynthesis - Ribose-phosphate diphosphokinase 
(PRPS2) and Carbamoyl phosphate synthetase II (CAD), thymidylate synthase (TS) and inosine 
monophosphate dehydrogenase 1/2 (IMPHD1/2) (J. Zhang, Pavlova, & Thompson, 2017) (Figure 
7). All of the above-mentioned proteins promote the high metabolic flux and utilization of 
glutamine. In addition, the product of GLS1 reaction results in glutamate, a cell membrane 
impermeable metabolite, whose accumulation in turn serves as the exchange substrate for cysteine 
import by glutamate/cystine xCT/slc7A11 antiporter, supplying gluthatione synthesis and 
antioxidant response (Shin et al., 2017). On the other hand, invalidation of xCT protein improves 
cancer cell viability under glucose deprivation via preservation of intracellular glutamate to 
maintain mitochondrial respiration (Sayin et al., 2017; Shin et al., 2017). 
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In contrast to healthy cells generally importing exogenous fatty acids, many cancer types exhibit 
high rates of de novo lipid synthesis. Multiple oncogene-related pathways can impact on lipid 
biosynthesis (mTOR, AKT, IGF-1 to mention only few of them), partially by induction of lipogenic 
enzymes such as fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1). It has been 
shown that tumor cells are highly depended on these rate limiting enzymes, and their inhibition can 
slow down progression of various tumors in mice (Ackerman & Simon, 2014; Currie, Schulze, 
Zechner, Walther, & Farese, 2013; Fritz et al., 2010). 
Currently, a knowledge gap exists on tumor (geno-)types and their micro- and macro-nutrient 
requirements. There are numerous difficulties in studying metabolic alterations and their 
implications for tumor development. Additionally, cancer cells can have profoundly different 
metabolism in vitro versus in vivo. For example, KRAS-driven lung cancer is known to rely heavily 
of glutamine in vitro, but in vivo despite its presence, KRAS-driven malignant cells prefer to use 
mitochondrial metabolism of pyruvate entering the TCA cycle coming from glucose metabolism 
rather that through glutamine derived α-ketoglutarate (Davidson et al., 2016). 
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continue to acquire previously described cancer hallmarks, namely replicative immortality and 
abnormal metabolism, and will transit in the stage of cancer promotion. Here again, additional 
immune stimulatory triggers emerged from continued inflammatory processes will urge body 
defence mechanisms to fight, inducing local inflammation and increasing Tumor Infiltrating 
Lymphocytes (TILs), at which step many tumors can be rejected or suppressed and develop into 
benign tumors, no threatening life. Unfortunately, at this stage cancer cells also undergo negative 
immune-selection, eliminating highly immunogenic cells and favouring progression of the cells 
that developed low-immunogenic phenotypes. If the cancer cells find favourable circumstances 
and escape immune pressure, they will enter the last stages – escape and metastasis. The complete 
immune escape by tumor cells renders TILs entirely useless and exhausted, and the previous 
mechanisms of inflammation and cytokine secretion do not only lose their potential to suppress 
tumor growth, but they can even accelerate it. 
Both innate and adaptive immune mechanisms play a role in tumor development, although T cells 
are found to be present within tumors three times more often (70%) than innate immune cells in 
human colorectal carcinoma (CRC) (Angelova et al., 2015).  
Both innate and adaptive immunities play important role in anti-cancer response (Figure 11), and 
invalidation by genetic means either one of them cripple cancer cells elimination in a manner 
surprisingly reassembling pathogen elimination (Figure 12) (Klinke, 2012) as shown by 
O’Sullivan et al (O'Sullivan et al., 2012) in one of the pioneering studies investigating the theory 
of cancer immunoediting and dissecting the role of both arms of immune system in this mechanism. 
According to the immunoediting paradigm, the immune system recognizes and eliminates 
immunogenic malignant cells (capable of triggering an immune response), while omitting those 
that escaped that recognition. Cancer immunoediting is classically divided into 3 phases, 
elimination, equilibrium, and escape, starting with high immunogenic tumor sequentially 
progressing into last stage characterized by very low immunogenic cancer cells (Figure 10). 
Without immune system engagement, for example in the case of immunodeficient mouse models, 
immunoediting does not take place and cancer cells exhibit continuously highly immunogenic 
phenotype. Thus, immune system plays active and complex role along whole cancer development. 
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pro-inflammatory cytokine secretion (S. Lee & Margolin, 2011). In other words, it could be argued 
that the ineffectiveness of the transition from innate to adaptive immune response could result in 
tumor growth acceleration, as prolonged chronic inflammation, a hallmark of the innate immune 
system activity, in general promotes tumor growth and metastasis (Shalapour & Karin, 2015). 
A. Dendritic cells 
Dendritic cells (DCs) are specialised antigen-presenting cells (APCs) bridging innate and adaptive 
immunity. DCs are physiologically and functionally adapted to patrol crucial immunologically 
sensitive area of mammalian body - intestine, lung, skin (where they are called Langerhans cells). 
DCs are actively acquiring extracellular micro- and macromolecules, at the same time using the 
Toll-like receptors to detect any danger signals coming from pathogens or malignant cells 
(Nowarski, Gagliani, Huber, & Flavell, 2013). They are classically divided into conventional 
(cDC) and plasmacytoid (p) DCs. cDC are equipped with TLR2 and TLR4, sensing accordingly 
lipid-containing pathogen associated molecular patterns (PAMPs) (i.e. lipoteichoic acid and 
lipopolysaccharide, LPS) (Goubau, Deddouche, & Reis e Sousa, 2013); Y. Wang, Swiecki, 
McCartney, and Colonna (2011). Once activated, cDC secrete massive amount of IL12 which 
favours T cell growth, IFNγ and TNFα production and induces cytotoxicity of CD8+ T lymphocytes 
and NK cells. IL10 within TME has been shown to counteract functionality and activity of DCs in 
the tumor context. 
pDC are a smaller subclass of DC equipped with TLR7 and TLR9, recognizing single stranded 
RNA and pathogenic unmethylated CpG DNA, respectively. Upon activation, pDC produces type 
I interferons (IFN-I), IFNα and IFNβ (Goubau et al., 2013; Y. Wang et al., 2011). 
B. Macrophages 
Macrophages are highly specialised phagocytic cells actively scavenging and digesting cellular 
debris, foreign macromolecules, microbes, cancer cells, and any entities that do not express self-
cellular surface markers. Macrophages are present in the TME at all stages of tumor development, 
and owing to their rich repertoire of mechanism and secretome they actively shape the TME and 
contribute to many aspects of cancer progression: inflammation, angiogenesis, metastasis, 
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immunosuppression, and in particular cases response to chemotherapy (Noy & Pollard, 2014). 
Experimental and clinical studies indicate that (at least in established tumors) macrophages 
generally favour tumor growth and act as immune system suppressors (Condeelis & Pollard, 2006; 
Kimura et al., 2007; Noy & Pollard, 2014). Hence, tumor-associated macrophage (TAM) depletion 
or reprogramming is of a high interest and an area of intense investigation. Two main macrophage 
phenotypes with antagonistic phenotypes have been described: M1 phenotype driven by IFNγ and 
LPS is pro-inflammatory and has anti-tumoral activity; and M2 phenotype driven by IL-4 and IL-
10 with anti-inflammatory properties, associated with tumor progression and anti-tumor immune 
suppression (Figure 11) (Yuan et al., 2015). 
TAM depletion with specific anti-CSF-1R antibody (binding and disrupting extracellular survival 
signal which leads to cell death) proved to effectively inhibit cancer progression in a mouse model 
of MC38 colorectal adenocarcinoma and MCA1 fibrosarcoma. Efficient depletion of TAM lead to 
increase in cytotoxic CD8+ T lymphocytes and reduction in FoxP3 regulatory T cells (Tregs), 
resulting in decreased tumor growth and longer survival. Importantly, patients with metastatic 
primary pleural mesothelioma, endometrial carcinoma, and colorectal cancer receiving anti-CDF-
1R therapy experienced partial response and exhibited CD8+ T cell increase similar to experimental 
studies (Ries et al., 2014). 
Important feature of this approach is the specificity of anti-CSF-1R treatment towards M2 
macrophages (Cannarile et al., 2017). Furthermore, CSF-1R expression is detected on other 
myeloid cells within the TME, including DCs and MDSCs, however the effect of CSF-1R targeted 
therapy on these populations is still unclear (Cannarile et al., 2017). 
Currently CSF-1R is under investigation in phase I/II for melanoma patients with a BRAF V600E 
or BRAF V600K mutation (NCT03101254). 
Recently dietary protein restriction (21% protein in Ctr versus 7% in protein restricted diet) has 
been shown to slow down tumor progression in two independent syngeneic mouse models of 
prostate cancer RP-B6-Myc and kidney renal adenocarcinoma (RENCA) upon combination with 
anti-PD-1 therapy (Orillion et al., 2018). Protein-reduction diet did not alter the overall TAM 
infiltration, but increased the number of M1 macrophages in parallel with a decrease in M2 
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macrophages in human xenograft prostate cancer LuCaP23.1 SCID mouse model. These results 
are in accord with previous findings where low protein diet reduced tumor growth in these model, 
which was linked to decreased tumor proliferation and mTOR activity of cancer cells (Fontana et 
al., 2013). In addition, upon low protein diet combined with anti-PD-1 treatment, TME has 
increased ration of M1/M2 macrophages. Based on this promising result, a pilot clinical study was 
launched where patients receiving immunomodulatory treatment of prostate cancer vaccine for 
castration resistant form of prostate cancer will receive either 10% or 20% protein-containing diet 
during the treatment period, after which immune system will be evaluated by flow cytometry 
(Orillion et al., 2018). 
3. Adaptive anti-cancer immune response 
Unlike innate immunity, adaptive immunity is much more specific towards pathogens or stressors, 
but it needs time and diverse inter-cellular cooperation to properly develop. Importantly, it provides 
so called immunological memory, entrusted in long-lived resting T cells with the high potential to 
be re-activated upon antigen recognition and elicit an effective immune response. It is heavily 
based on recognition of short amino-acid segments (antigen) in the context of the major 
histocompatibility complex (MHC) class I through T-cell receptor (TCR). In the context of cancer, 
it has been shown that there are many of so-called neo-antigens, the products of defective protein 
synthesis caused by DNA mutations and alternative splicing. Specialized APCs are participating 
in effective education of T cells by active up-take of circulating antigens/proteins, degradation, 
processing and loading onto MHC class II complexes in order to present them to CD4+ T cells 
which will elicit B-T cell cooperation for antibody production against the antigens. The alternative 
mechanism that is recognizable as of high importance in tumor immune response is the ability of 
APC to load acquired foreign antigens on the class I MHC (instead of MHC class II)  complexes 
and cross-present them to CD8+ T cells directly. 
A. T lymphocytes 
Bone marrow derived, thymus matured and selected T lymphocytes are present in the majority of 
solid tumors and are critical for an effective immune response and long-term tumor-free survival. 
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They express a range of surface receptors regulating their ability to engage, recognise and eliminate 
dysfunctional cells. Importantly, T cells can undergo a selection process in the peripheral lymph 
nodes, where with the cooperation of DCs and helper CD4+ T cells they can gain potent and specific 
cytotoxic functions. But even then, inhibitory signals can overpower the cytotoxic signaling and 
render them ineffective in the tumor context, even though they retain most of their functional and 
proliferative abilities and cytotoxicity when tested ex vivo (Daud et al., 2016; Mahnke et al., 2012; 
Williams et al., 2017). 
Cytotoxic T cells express T-cell receptors that after selection and maturation with the help of APC 
and CD4+ T cells can recognize a specific antigen in the context of class I MHC molecules, 
normally present on the surface of all body cells. Upon positive recognition, T cell launches its 
killing machinery in the form of cytotoxic proteins perforins and granzymes which enters the 
targeted cell and initiate its programmed cell death. Another way to induce cell death is via surface 
interaction of FAS ligand and FAS receptor, which initiates the DISC recruitment and subsequent 
death machinery as described in chapter “Apoptosis – programmed cell death”. 
In general, higher percentage of TILs is correlated and predicts a better clinical outcome, longer 
survival and higher chances of tumor-free survival (Naito et al., 1998; Pages et al., 2005; L. Zhang 
et al., 2003). However, other studies have demonstrated that some of the immune cell subsets are 
associated with worse prognosis, seeming to promote tumorigenesis. For example, Tregs can 
potently inhibit immune activity in TME, and paralyze CD8+ T lymphocytes cytotoxicity. 
Implication of CD8+ in anti-cancer immune response will be further described in following 
chapters. 
B. MDSCs and Tregs 
Myeloid derived suppressor cells (MDSCs) can also hampered anti-cancer immune response 
through secretion of multiple immunoinhibitory signals, more specifically by secreting arginase I. 
Arginase I can extracellularly deplete arginine levels, making it less available for T cells, thus 
lowering their effectivity (Rodriguez et al., 2004). 
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Additionally, MDSCs have been shown to drive apoptosis of CD8+ T cells, limiting their ability to 
immunosurveillance and respond to immunotherapy. Mechanistically, increased IFNγ levels within 
TME induced the pro-apoptotic FAS ligand expressed on MDSCs. Disruption of this FASL/FAS 
interaction let to enhanced immune response and synergistically with checkpoint blockade slowed 
down the growth of induced melanomas in mice (Horton & Gajewski, 2018; Horton, Williams, 
Cabanov, Spranger, & Gajewski, 2018). 
 
Tregs, MDSCs and cancer cells by themselves supress effective immune response launched by 
TILs. TME promotes TILs apoptosis and poison immune effector cells through the release of 
factors like nitric oxide (NO), reactive oxygen species (ROS), IL-10, IL-6, arginase-I (ARG1), 
Vascular Endothelial Growth Factor (VEGF), indoleamine 2, 3-dioxygenase (IDO), and TGF-β 
(Figure 13) (Lippens et al., 2016; Monu & Frey, 2012; Zhai et al., 2018; Zhao et al., 2016). The 
cross-talk between immune cells population involving specific sub-population of DCs and Tregs 
is another layer of complexity, participating in the fine tuning and self-tolerance activation. 
By secretion of IDO, pDCs promote Tregs immunosuppressive functions, ultimately halting 
immune response (Lippens et al., 2016). The current knowledge about development and regulation 
of cancer immunity, especially the immunosuppression by TME, is still incomplete and is likely to 
vastly expand in the coming years. Complexity and entanglement of various cells, cytokines and 
mechanisms involved in shaping immune response is probably one of the most challenging and 
promising area of investigation in order to improve and develop new strategies in cancer therapies. 
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markedly different TME and TILs compared to patients lacking clinical response. The main 
characteristic of the high responder group is the high presence of CD8+ T cells coupled with type 
I interferon (IFN-α/β) signature (Joyce & Fearon, 2015; Spranger, 2016). Based on that, cancer 
patients started to be sub-grouped into T-cell-inflamed and non-T-cell-inflamed patients Table 2. 
Table 2: T-cell inflamed versus T cell-non inflamed tumor phenotype 
TME Phenotype T-cell-inflamed non-T-cell-inflamed 
T cell infiltration high low 
PD-L1 / PD1 signaling high low 
tumoral IDO expression high low 
Tregs recruitment high low 
surface antigen expression (i.e. 
MHCI) low high 
CXCL9/CXCL10 high low 
PTEN status mostly active lost 
innate immune recognition present non detectable 
P53 signaling present lost 
Beta- catenin signaling low high 
CCL2/CCL4 expression high low 
response to immunotherapy good responders bad responders 
 
 
T-cell-inflamed tumors are characterized by the upregulation of immune inhibitory mechanisms, 
such as induction of immune inhibitory checkpoint on their surface, which makes them prone to 
immune checkpoint targeted therapies, in contrast to non-T-cell-inflamed tumors. Immune 
checkpoints are surface regulators of the immune system activation. Under normal circumstances, 
their action is crucial for developing self-tolerance. Some of them have been recognised as of high 
importance in anti-tumor immunity and are clinically targeted by specific monoclonal antibodies 
in order to re-activate anti-tumor response. CTLA-4 (expressed on Treg and activated T cells), PD-
1 (expressed on T cells) and LAG3 (expressed on activated T cells, NK, B cells and pDCs) are the 
most common known inhibitory checkpoints. Various tumors upregulate ligands for immune 
checkpoint inhibitors, such as PD-L1 and CD80 in order to suppress anti-cancer immunity (Juneja 
et al., 2017; Lim et al., 2017). 
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Unfortunately, exclusion of anti-tumor specific TILs represents even more a therapeutically 
challenging mechanism of immune escape. Importantly, there is increasing amount of evidence 
that TME and stress sensing pathways can effectively modulate the transition between these two 
distinct tumor phenotypes. It is the area of ICD and secretory pathway modulation (chemokines 
and DAMPS) that will be extensively discussed in the following chapters. Nevertheless, these two 
major phenotypes of TME, CD8+ T and CD8- T cells require significantly different approaches in 
order to maximize therapeutic effects. 
5. Cytokines in cancer progression 
William Coley, famously named “father of immunotherapy”, at the end of the XIX century made 
the striking observation that tumors can underwent spontaneous regression in patients infected by 
pathogen. By brilliant insightful idea, Coley attributed the cancer regression to the activation of the 
organism immunity, that was triggered by concomitant pathogen invader. Unfortunately, against 
intense efforts of its inventor, the clinical benefit of such discovery appeared way before scientific 
understanding and techniques could support the pursuit of effective and safe use of that 
observation. 
Now we know that some of the response that Coley was observing was attributed to acute 
inflammation caused by infection, and as this may be initially successful in cancer therapy, very 
often tumors survive and even evolve the ability to feed on sustained inflammation as a way to 
promote their own growth. This is one of the reason by which pro-inflammatory agents has to be 
used with caution in patients suffering from cancer, but on the other hand, knowing why some 
cancer can be stopped by inflammation and why others thrive on it is critical to decide how to treat 
cancers effectively with immunotherapeutic-based approaches. 
Interestingly, IFN-I production can be driven by retinoic acid-inducible gene I (RIG-I). An increase 
in IFN-I was found to favour anti-cancer T cell response resulting in spontaneous tumor rejection 
in some cases (Burnette et al., 2011; Diamond et al., 2011; Fuertes et al., 2011). In fact, both DCs 
and CD8+ T cells have been found to rely on IFN-I to establish responses against tumor cells. In 
addition, it has been also demonstrated that IFN-β is an indispensable element of effective anti-
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tumor response to immunomodulatory therapy in vivo by increasing DCs cross-presentation and 
drastically improving anti-PD-L1 treatment (X. Yang et al., 2014).  
Inactivation of IFNα receptor in melanoma and colorectal cancer cells resulted in accelerated tumor 
growth in mice xenograft models and low expression of IFNAR predicted poorer prognosis in 
human CRC patients (Katlinskaya et al., 2016; Katlinski et al., 2017). This detrimental effect was 
mediated by generation of immune excluded (non-T-cell inflamed) tumors and attenuated anti-
cancer immune response. 
6. Nutrient competition within TME 
Highly proliferating and hypovascularized solid tumors suffer from nutrient scarcity, creating 
hostile and competitive survival environment. Variations in extracellular nutrients can shape the 
metabolism and efficacy of immune cells occupying TME. In addition, the by-products of tumor 
metabolism can serve as signals for immune cells, modulating their response. High consumption 
of glutamine by enhanced glutaminolysis in tumor cells could result in its scarcity for TILs (Jin, 
Alesi, & Kang, 2016; Perez-Escuredo et al., 2016). Glutamine serves as an important factor in T 
cell function and self-renewal, and its extracellular level is indispensable for tumor suppressor 
metabolite S-2-hydroxyglutarate production in CD8+ T cells (Sinclair et al., 2013; Swamy et al., 
2016; Tyrakis et al., 2016). 
TILs suppression can also be an effect of essential amino acid degradation by overexpression of 
indoleamine-2,3-dioxygenase (IDO), enzyme converting tryptophan to kynurenines (Rodriguez et 
al., 2004; Sinclair et al., 2013; Uyttenhove et al., 2003). More studies have investigated the critical 
role of various amino acid levels on T cell anti-tumor efficacy, but there is still a huge gap in our 
understanding of TME and its metabolic fluctuations. It is thought important to take amino acid 
impact on the immune cell population under consideration before proceeding with metabolic 
targeted therapies in cancer treatment. For example, serine deprivation slows down Myc-driven 
tumor growth, partially by making cancer cells less fitness to sustain environmental stressors, thus 
serine metabolism and bioavailability recently caught attention as promising therapeutic metabolic 
target (Maddocks et al., 2017; Sullivan & Vander Heiden, 2017). However, at the same time serine 
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seems to be particularly an essential metabolite for T cell effector expansion, hence likely affecting 
anti-tumor immune response (E. H. Ma et al., 2017). 
Oxidized lipids, lipid metabolism and cholesterol levels are also important factors in TILs function. 
There is enormous amount of evidence that obesity, high fat diet, accumulation of excess fatty 
acids and its metabolism are strongly linked to cancer development. The surprising observation 
linking statin use and lower cancer incidents are gaining more attention (Demierre, Higgins, 
Gruber, Hawk, & Lippman, 2005; Gronich & Rennert, 2013). Lipid accumulation can impair DCs 
ability to effectively present and activate T cells (Cubillos-Ruiz et al., 2015; Ramakrishnan et al., 
2014). In addition, to hampering T cell directly, oxidized lipids seem to fuel tumoral MDSC, further 
attenuating effective immune response (Al-Khami et al., 2017; Condamine et al., 2016). 
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IV. Endoplasmic reticulum, ER stress and UPR 
1. Protein synthesis and ER stress 
Protein synthesis is the most energetically demanding process in the cell, which consumes up to 
75% of the overall cell energy expenditure (Lane & Martin, 2010). Yet, a significant amount of 
newly synthesized proteins does not fulfill the quality control standards and need to be eliminated 
or recycled. The damaged proteins, in addition to be energetically expensive, pose threats for cell 
physiology and homeostasis especially under the harsh environmental conditions of the tumor 
microenvironment (TME) (Hetz, Chevet, & Oakes, 2015).  
Tumors are a non-homogenous mass of malignant and non-malignant cells residing within the 
TME, characterized by hypoxia, nutrient deprivation, lower pH and rich cell-to-cell interactions 
(Cubillos-Ruiz, Bettigole, & Glimcher, 2017). In order to progress and spread, the tumor need 
constant adaptation to changing conditions, which requires, among other things, enhanced protein 
production for various purposes. On the other hand, non-cancer cells are forced to modulate their 
metabolism either to adapt to current environmental circumstances, or to produce molecules 
intended to fight tumor expansion. In both cases, mechanisms altering cell proteostasis (proper 
protein homeostasis) are initiated to satisfy higher than physiological demand on protein 
production, and if these mechanisms are not sufficient, cells will experience endoplasmic reticulum 
stress (ER stress) as a result of the accumulation of misfolded protein within the endoplasmic 
reticulum (ER) (Ackerman & Simon, 2014; Cubillos-Ruiz et al., 2017). 
The ER is a highly organized organelle with diverse functions, including lipid production, calcium 
homeostasis, and drug detoxification, but its main function is synthesis of roughly one third of all 
proteins (Hetz, Chevet, & Harding, 2013; Hur et al., 2012). For that reason, the ER is equipped 
with the biochemical machinery designated to promote proper protein maturation and folding, 
assess protein quality and direct defective proteins to repair or degradation pathways (Hetz et al., 
2015). Protein modifications occurring in the ER are also one of the first steps of the secretory 
pathway, which includes protein glycosylation and trafficking of proteins expressed on the cell 
surface or delivered to the extracellular milieu (Dejeans et al., 2014; Galluzzi et al., 2017a). 
70 
 
2. Unfolded Protein Response 
The unfolded protein response (UPR) is controlled by three ER stress sensors, all localized in the 
ER transmembrane: Activating Transcription Factor 6 (ATF6), Inositol Requiring Enzyme 1 
(IRE1α) and PKR-like endoplasmic reticulum kinase (PERK) (Fig. 14). Under stress-free 
conditions, they are kept in their inactive form by the ER chaperone GRP78 (also known as BiP), 
which dissociates in the presence of misfolded protein accumulation in the ER, freeing the sensors 
and allowing the subsequent activation of the UPR signaling (Hetz et al., 2015). IRE1 is the first 
discovered and evolutionarily the most conserved UPR sensor, possessing both a serine/threonine 
kinase domain and an endoribonuclease domain. IRE1 is located in the ER membrane and when 
released from GRP78 repression, undergoes di/oligomeryzation and autophosphorylation, enabling 
its enzymatic activity. Subsequently, endoribonuclease activity of IRE1 catalyzes XBP1 mRNA 
alternative splicing, cutting out an intron of 26 nucleotides, which results in an open reading frame 
shift. The translational product of this alternatively spliced XBP1 (XBP1s) is a potent transcription 
factor, which targets genes encoding proteins participating in protein folding, in the ER-associated 
degradation and ubiquitin–proteasome pathways (ERAD), in protein trafficking, and in lipid 
biosynthesis (H. Kim, Bhattacharya, & Qi, 2015). 
Additionally, the endoribonuclease domain of IRE1α has the activity to cleave and degrade various 
mRNA in a process named regulated IRE1-dependent decay (RIDD), thus reducing the overall 
synthesis load on the ER, but paradoxically it can also cleave genes encoding chaperone proteins, 
favoring apoptosis (Han et al., 2009). 
Another branch of the UPR pathways is driven by PERK, a Ser/Thr kinase whose oligomeryzation 
state followed by autophosphorylation induces concomitant activation, reducing protein translation 
via phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α). Simultaneously, accumulation 
of peIF2α triggers the selective translation of ATF4, which is a transcription factor that can induce 
CHOP and GADD34, proteins engaged in apoptosis induction and peIF2α dephosphorylation, 
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The last UPR sensor to be mentioned is ATF6, which unlike the former two ER sensors does not 
undergo oligomeryzation, and instead is translocated to the Golgi apparatus upon GRP78 release, 
where it is cleaved by site-1 and site-2 proteases (S1P and S2P). The released part of this cleaved 
protein is a potent transcription factor which migrates to the nucleus triggering the expression of 
genes encoding chaperones, components of the ERAD machinery and proteins involved in lipid 
biochemistry (Hetz et al., 2015; I. Kim et al., 2008). 
Therefore, the UPR appears to be one of a range of crucial mechanisms that is modified by cancer 
cells for their successful growth and spreading.  
In the following chapter dualistic role of UPR activation and interactions between tumor and its 
microenvironment including immune involvement will be discussed. But first, we will look into 
some intriguing connection between UPR and aging, as many of the dietary regimens that suppress 
cancer growth have also been effective in delaying aging and increasing longevity, and their effect 
was proposed to be mechanistically obtained at least partially by enhanced proteostasis and UPR 
activity. 
3. UPR and Aging 
With age, tissues gradually lose the capacity to produce properly folded proteins, partially as a 
result of lower UPR activity and XBP1 in the most (Taylor & Dillin, 2013). Whole tissue over-
expression of sXBP1 in C. elegans does not extend lifespan, despite increasing ER stress 
resistance. 
Tissue specific sXBP1 expression revealed antagonistic effects on longevity, shortening the C. 
elegans lifespan when sXBP1 was overexpressed in muscle tissue, but extending it when 
overexpressed in neuronal or intestinal tissue (Taylor & Dillin, 2013). Thus, UPR modulation has 
positive effects on some tissues, while at the same time having negative effects on others. 
Interestingly, the neuronal activation of sXBP1 per se was physiologically irrelevant, suggesting 
that the nervous system adjusts the proteostasis machinery in the global, whole-organism manner, 
while the anti-aging effectors operate in the periphery, highlighting the intestine.  
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Protein misfolding is tightly connected with aging. In general, the older the animal is, the more 
damaged and misfolded peptide it accumulates. Thus, it could be a consequence of reduced UPR 
activity also observed in aged animal tissues. As UPR induces proteostasis i.e. via chaperone 
production, it has been proposed and shown that single heat shock protein (HSP) overexpression 
can extend lifespan in experimental model of C. Elegans, and multiple HSPs proved to have higher 
effect than single HSP induction (Swindell, 2009; Walker et al., 2001). That results point to 
hampered proteostasis as major factor in aging. Moreover, simpler organisms like yeast happen to 
express only one discovered ER stress sensor – IRE1, and it is a crucial protein in yeast lifespan 
extension triggered by CR (Choi, Kwon, & Lee, 2013; Labunskyy et al., 2014). Genetic approach 
experiments confirmed the effect of enhanced UPR and lifespan extension, as the reverse, where 
sXBP1 ablation reduced expected lifespan in C. elegans (Cui et al., 2015; Henis-Korenblit et al., 
2010). More recently, essential vitamin D3 has been shown to reduce proteotoxicity in an aged C. 
elegans model, that resulted in extended lifespan, and was dependent on UPR components. More 
precisely, vitamin D3 treatment was able to specifically induce IRE1 activity (Mark et al., 2016). 
4. UPR in Cancer 
Cell types and tissues display very distinctive ER protein folding capacities, depending on their 
protein production demand and stress state. For example, during cancer transformation from 
healthy to malignant cells, there are many critical steps where internal (oncogene-driven protein 
synthesis) or external (nutrient shortages, hypoxia) factors impose high demand on protein 
synthesis and quality assessment in the ER (Cubillos-Ruiz et al., 2017; Hart et al., 2012). When the 
ER folding capacity is not sufficient to meet proper protein synthesis it results in ER stress and 
triggers a cascade of adaptive mechanisms named the UPR that is meant to restore proteostasis. 
Hence, the UPR will inhibit protein translation to halt the accumulation of misfolded protein, 
increase the production of proteins such as chaperones and foldases that assist in proper protein 
folding, and promote the degradation and elimination of misfolded proteins to limit their negative 
impact on cell physiology. The UPR induction serves as a cyto-protective and pro-survival 
mechanism, but when the ER stress cannot be restored and it prolongs, the same pathways that 
were initially engaged in cell survival, will lead to cell death, typically by apoptosis (M. Wang & 
Kaufman, 2014). 
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A. Persistent activation of UPR in cancer 
In the TME cells encounter harsh conditions that are known to trigger cellular stress, such as low 
availability of oxygen and various nutrient, oxidative stress, tissue acidification, and improper lipid 
homeostasis (Cubillos-Ruiz et al., 2017). Deprivation of particular amino acids such as proline 
(Sahu et al., 2016) and glutamine (Shanware et al., 2014) has been shown to induce ER stress-
dependent tumor growth inhibition and stimulates cytokine secretion, respectively. Finally, a high-
caloric feeding before tumor onset induced unresolved ER stress in a KRAS-driven lung tumor 
model, leading to reduced tumor growth (Ramadori et al., 2015). These studies show that there is 
a direct connection between dietary, therefore metabolic modulation and the induction of the UPR. 
In addition, tumoral cells display considerably higher demand of protein synthesis at every step of 
cancer development, making them prone to chronic ER stress (Dejeans, Barroso, Fernandez-
Zapico, Samali, & Chevet, 2015). As a matter of fact, spontaneous mouse and human lymphomas 
show higher levels of UPR activation when compared with normal tissues. In this context, it was 
shown that the oncogenes c-Myc and N-Myc activate the PERK/eIF2α/ATF4 pathway, which leads 
to cytoprotective-autophagy induction and decreased survival (Hart et al., 2012). In addition, the 
loss of tumor suppressor genes like p53 during transformation can induce the synthesis of proteins 
that were previously repressed, leading to ER stress induction (Namba et al., 2015). 
The first description of the role of ER stress in cancer progression and sensitivity to 
chemotherapeutic agents was proposed almost 15 years ago (Y. Ma & Hendershot, 2004), and up 
to date many clinical studies have observed elevated expression of UPR actors such as IRE1α, 
XBP1, PERK and ATF6 in different types of cancers (Obacz et al., 2017). Importantly, the ER 
stress sensor GRP78 which serves as the key modulator of the UPR response has been found to 
facilitate cancer migration and its expression is positively correlated with the progression from 
early to advanced cancer stages (Niu et al., 2015; Tang et al., 2012; L. Zhang et al., 2017). GRP78 
was also shown to control fatty acid oxidation and silencing of GRP78 resulted in increased drug 
sensitivity by modulation of lipid metabolism (Cook et al., 2016). Interestingly, an antibody 
targeting GRP78 has been shown to improve the efficacy of ionizing radiation therapy in human 
glioblastoma and non-small cell lung cancer cell lines in vitro and in athymic mice models (Dadey 
et al., 2017). 
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It is now clear that ER stress induction and consequent UPR activation are tightly linked and 
orchestrate many important features in cancer development and prognosis. How UPR regulation 
impacts on the different cancer types is still a subject of extensive research as the pathways 
involved in ER stress and their effect on the TME vary largely from one cancer type to another 
(Cubillos-Ruiz et al., 2017). 
B. UPR and cancer hallmarks 
The hallmarks of cancer proposed by Hanahan and Weinberg have been briefly discussed in chapter 
“Cancer – common denominator of many diseases”, and here the particular focus on these 
hallmarks modulation and UPR will be presented (Hanahan & Weinberg, 2011). This list includes: 
resisting cell death, sustaining proliferative signaling, activating invasion and metastasis, enabling 
replicative immortality and inducing angiogenesis. Additionally, these traits are driven by cell 
genome instability, gene mutations and local inflammation, accompanied by modulation of 
metabolism and evasion of immune surveillance. Importantly, the UPR machinery regulates most 
if not all of these features. 
 Proliferative signaling 
Proliferation is usually halted upon UPR induction, as the adaptive UPR reduces protein synthesis 
(M. Wang & Kaufman, 2014). Indeed, XBP1 loss in intestinal stem cells increases their number in 
vivo and promotes tumor formation in the APCmin polyposis mice in an IRE1α-dependent manner 
(Niederreiter et al., 2013). Other studies have shown that induced ER stress impacts on a number 
of growth-promoting signaling pathways: p38 MAPK, PI3K, AKT/mTOR and Raf/MEK/ERK 
pathways (Garg, Maes, van Vliet, & Agostinis, 2015), and depending on the context, these 
pathways could promote or suppress cancer development (Darling & Cook, 2014). 
 Cell death evasion 
In order to evade death signals cancer cells can selectively induce the PERK/eIF2α/ATF4 arm of 
the UPR, which leads to increased cell survival by the induction of cytoprotective autophagy in 
Myc-induced tumor transformation (Hart et al., 2012). Autophagy is an intracellular degradation 
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process via delivery of cytoplasmic entities to the lysosomes, where macromolecules are lysed and 
their components recycled. Generally it is believed that defects in the autophagy machinery favors 
cancer initiation, while later on, the restoration of autophagic responses serve cancer cells as 
support for survival, proliferation and growth in the presence of harsh microenvironmental 
conditions (Galluzzi, Pietrocola, et al., 2015). Autophagy is induced in response to virus infection 
by the ATF6 and PERK branches of the UPR (M. Wang & Kaufman, 2014). Finally, the blockage 
of autophagy by knock-down of its regulator beclin 1 results in sensitization to tamoxifen upon 
sXBP1 overexpression (R. Hu et al., 2015). 
 Immortality 
Replicative immortality is obtained by cancer cells through activation of telomerase, 
ribonucleoprotein providing the main mechanism by which cells lengthen their telomeres that are 
shortened during cell division. It has been reported that telomerase undergoes activation due to the 
ER-stress dependent increased expression of the catalytic component of telomerase (TERT) (Zhou 
et al., 2014). That could be explained by upregulation of its transcriptional regulator β-catenin, 
which is induced by the UPR via the IRE1 branch (X. X. Li et al., 2017), but the direct link is still 
missing. 
 Genome instability 
Genome stability is affected by the similar threats that induce ER stress: ROS accumulation, 
hypoxia and heat stress as the first examples.  Indeed, tunicamycin-induced ER stress and glucose 
deprivation affects the induction of the mechanisms of DNA repair via proteasomal degradation of 
Rad51, the protein engaged in DNA double strand break reparation (Yamamori, Meike, Nagane, 
Yasui, & Inanami, 2013). Additionally, there is reason to believe that hypoxia can lead to aberrant 
DNA repair, genomic instability, and results in cellular cancer transformation (Bristow & Hill, 
2008). Finally, increased GRP78 transcription from ER stress can also facilitate DNA damage 
repair through recruitment of arginine histone methyltransferase PRMT1, and ER stress could favor 
histone H4 acetylation, known to be involved in the chromatin structure regulation and 
transcription factor recruitment (Baumeister et al., 2005). 
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 Metastasis 
Metastatic outgrowth refers to cancer cell migration from its primary tumor site and colonization 
of secondary tissues, very often distant and having a substantially different microenvironment. 
Clinically, metastasis is a very negative prognostic indicator, correlated with high mortality. The 
UPR contributes to this process by facilitating extracellular matrix protein production to enable 
cell migration and invasion. Firstly, the PERK branch of the UPR facilitates cancer cell survival in 
response to the loss of cell-to-cell contact, as it is required to perform epithelial-to-mesenchymal 
transition (Dey et al., 2015; Feng et al., 2014). Secondly, silencing the PERK/ATF4 pathway by 
chemical inhibition reduces metastasis in vivo in NOD/SCID models of breast cancer metastasis 
(Dey et al., 2015; Feng et al., 2014), possibly by blocking the upregulation of LAMP3, protein 
involved in enhanced cell migration and metastatic abilities (Mujcic et al., 2013). Finally, tumor 
dormancy, a critical step for invasive cancer cells to implant in a pre-metastatic niche, has been 
shown to be dependent on p38 activation which drives GRP78 upregulation and PERK 
phosphorylation (Ranganathan, Zhang, Adam, & Aguirre-Ghiso, 2006) as well as ATF6 activation 
(Cubillos-Ruiz et al., 2017; Schewe & Aguirre-Ghiso, 2008). UPR components can control cell 
cycle and proliferation rates by IRE1 and PERK, thus contributing to tumor dormancy and 
chemotherapy resistance (Urra, Dufey, Avril, Chevet, & Hetz, 2016). This ability of anti-
proliferative dormancy enables cancer cells to survive the initial phase of establishment in foreign 
environments and to become proliferatively active when they adapt to new conditions, hence 
promoting cancer recurrence. 
 Metabolism deregulation 
Deregulated cellular energetics can be also shaped by UPR. The mitochondrial-associated 
membrane (MAM) and the ER can spatially interact, modulating apoptosis and mitochondrial 
fission/fussion dynamics (Hetz et al., 2015). These interactions are possible as least partially by 
mitofusin 2 (Mfn2), a GTPase protein localized in the MAM. It has been shown that Mfn2 
physically interacts with PERK, regulating mitochondrial–ER interactions, thus impacting on 
metabolism, calcium signaling and apoptosis (Munoz et al., 2013). Mfn2 ablation leads to a potent 
ER stress response, at the same time reducing apoptosis and autophagy (W. Wang et al., 2015). In 
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addition, sXBP1 was found to drive phospholipid biosynthesis and secretory pathway gene 
expression, supporting ER expansion (Sriburi et al., 2007). 
As described above, by inducing a specific sub-lethal manner of the UPR machinery cancer cells 
obtain multiple benefits, enabling them to outcompete healthy cells, escape intrinsic and extrinsic 
anti-tumoral mechanisms and colonize new physiological niches where they can thrive and 
progress. Many of these adaptations result from close links of ER stress with UPR-derived 
autophagy and mitochondrial crosstalk. Understanding how and in which manner cancer cells 
hijack UPR machinery could open new perspectives and improved and effective anti-cancer 
therapies. 
C. UPR and cell death regulation  
The UPR serves to restore proteostasis, but if unresolved, the same pathways that were initially 
used for survival are leading to cell death, primarily by apoptosis (Figure 15). For example, under 
acute ER stress the PERK/eIF2α/ATF4 pathway leads to the inhibition of protein translation 
resulting in cell survival. However, prolonged PERK activation induces signals leading to the 
translation of ATF4 that regulates CHOP induction and results in apoptosis (Pytel, Majsterek, & 
Diehl, 2016). 
Perturbation of calcium homeostasis in the ER is central in UPR death pathways signaling. ER 
stressors brefeldin A and tunicamycin lead to cytosolic calcium ions accumulation, which triggers 
cell death through caspase-12-dependent apoptosis in neuronal cells. Interestingly, 
pharmacological activation of SK2 channels protects against cell death induced by these 
compounds, pointing towards calcium homeostasis as the critical event in cell death induction upon 
ER stress (Richter et al., 2016).  Moreover, calcium homeostasis regulates cell fate through the 
BCL-2 family of proteins, many of which reside within the ER. The UPR directly regulates the 
activity of these pro- and anti-apoptotic proteins by modulating their ratio. Interestingly, the anti-
apoptotic proteins BCL-2 and BCL-XL physically associate with the inositol trisphosphate receptor 
and alter its ability to release calcium ions lowering the ER calcium basal levels (Vervliet, Parys, 
& Bultynck, 2016), whereas the pro-apoptotic protein BAX has the opposite effect (R. G. Jones et 
al., 2007). Another example of how the UPR controls BCL-2 family members is the activation of 
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IRE1α, which leads to the inhibition of BCL-2 and induces the phosphorylation of the pro-apoptotic 
protein BIM via binding to JNK and TNF receptor-associated factor 2 (TRAF2), favoring apoptosis 
induction (M. Wang & Kaufman, 2014). Moreover, the pro-apoptotic proteins PUMA and BIM are 
transcriptionally induced by CHOP in response to ER stress  (Ghosh, Klocke, Ballestas, & Roth, 
2012; Puthalakath et al., 2007), whereas CHOP represses BCL-2 expression (M. Wang & 
Kaufman, 2014). Finally, CHOP and ATF4 mRNAs and proteins have short half-lives explaining 
why sustained activation of the UPR pathways is necessary to induce cell death (M. Wang & 
Kaufman, 2014).  
Even though BIM has been found to be essential to induce ER stress-mediated apoptosis in a range 
of cell types both in vitro and in vivo (Puthalakath et al., 2007), the other BH3-only proteins such 
as BID, NOXA and PUMA appear to have only partial effect (Hetz et al., 2015). BOK (BCL-2 
Ovarian Killer) has been recently described to be a unique regulator of apoptosis activation under 
ER-stress conditions, independently of BAX and BAK expression, connecting apoptotic signals at 
the ER membrane to apoptotic induction in the mitochondria (Carpio et al., 2015). 
More interestingly, BOK is not activated by the BH3-only proteins or inhibited by the antiapoptotic 
proteins. In fact, BOK is constitutively degraded via the ERAD pathways, being stabilized when 
the proteasome is inhibited (Llambi et al., 2016). Additionally, the UPR-mediated inhibition of 
protein translation decreases Mcl-1 protein levels, important antiapoptotic member of the BCL-2 
family protein, therefore sensitizing resistant myeloma cells to apoptosis induced by thapsigargin 
(Gomez-Bougie, Halliez, Moreau, Pellat-Deceunynck, & Amiot, 2016). 
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and to activate the endoribonuclease activity by an alternate mode that enforces XBP1 splicing and 
limits mRNA decay and apoptosis (Han et al., 2009). In vivo IRE1α facilitates tumor growth by 
promoting the expression of the tumorigenesis driver β-catenin, and IRE1α chemical inhibition or 
genetic knock-down inhibited colonic tumorigenesis in an immunodeficient mouse model, 
confirming its pro-survival role (X. X. Li et al., 2017). Altogether, the activation of IRE1α and its 
effect on cancer cell death or survival seems to be highly dependent on its oligomeryzation state 
which modulates its endoribonuclease and kinase activities. 
ATF6 activation through ER-stress induction leads to the increased expression of genes involved 
in UPR and ERAD: XBP1, GRP78, chaperones and oxidoreductases, among others. Its role in the 
UPR is majorly cytoprotective, and its activation contributes to fine-tuning of the IRE1α and PERK 
signaling, eliciting pro-survival properties in vitro and in vivo (Cubillos-Ruiz et al., 2017; I. Kim 
et al., 2008; Schewe & Aguirre-Ghiso, 2008). ATF6 activation has been linked to increased tumor 
dormancy and increased tumor resistance to chemotherapy, interestingly by AKT-independent 
activation of mTOR signaling (Schewe & Aguirre-Ghiso, 2008). 
Apoptosis is known as a tolerogenic type of cell death because, up to date, it was believed that it 
did not induce an immune response. However, some forms of cell death produced by certain ER 
stress-inducing stimuli lead to the release of danger signals by the dying cell, indicating that cell 
death signaling under ER stress could be even more complex and cell type-/context- dependent 
(discussed below) (Galluzzi et al., 2017a). 
Taken together, cancer cells undergoing ER stress will induce the UPR, which in a context and 
time dependent manner will favor pro-survival or pro-death pathways resulting in enhanced or 
decreased tumor progression. 
5. Endoplasmic reticulum and immunogenic cell death 
There is growing evidence that the UPR can control the anti-tumor immune response by modulating 
the character of cancer cell death. The UPR can regulate the release DAMPs it was already defined, 
which are classical “find me” and “eat me” signals. In brief, DAMPs are intracellular molecules, 
usually ubiquitous and tightly regulated, that are hidden from the immune system’s recognition 
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under normal conditions. However, upon acute stress or death induction, cells can induce an 
immunogenic-driver response by the expression of DAMPs on the cell surface (e.g. CRT and 
HSPs) or by their extracellular release (e.g. ATP and High Mobility Group Box 1 - HMGB1) 
(Galluzzi et al., 2017a; Grootjans, Kaser, Kaufman, & Blumberg, 2016). This type of cell death is 
known as Immunogenic Cell Death (ICD)  (Figure 16). Interestingly, ICD must be preceded by 
the ER stress and UPR in order to induce CRT and HSPs surface exposure. In the case of CRT 
exposure it has been suggested that this event depends on activation of the PERK/eIF2α pathway 
(Panaretakis et al., 2009). Furthermore, ATP release depends on induction of pre-mortem 
autophagy (Galluzzi et al., 2017a). The importance of ATP and HMGB1 release can be appreciated 
in the Ripk3−/− or Mlkl−/− TC-1 syngeneic mouse lung cancer cells, which are impaired in secretion 
of these two DAMPs under canonical ICD inducer Mitoxantrone. As opposite to their WT 
counterparts, Ripk3−/− or Mlkl−/− TC-1 fails to induce immune response, which can be rescued by 
local administration of ATPases plus a synthetic TLR4 ligand, where the by APCs and CD8+ T 
cells intra-tumoral infiltration is restored (H. Yang et al., 2016). 
CRT binds CD91, ATP binds purinergic receptors (P2Y2 or P2X7) and HMGB1 binds TLR4, 
respectively (Galluzzi et al., 2017a). These receptors are found on DCs and promote engulfment 
of dying cells, attraction of dendritic cells into the tumor bed, production of IL-1β and tumor 
antigen presentation, respectively. In the case of CRT, it is a highly conserved calcium-binding ER 
chaperone that has important functions in the immune response. For example, CRT is a chaperone 
for MHC class I molecules, regulating antigen presentation hence affecting recognition by CD8+ T 
cells (Raghavan, Wijeyesakere, Peters, & Del Cid, 2013). It is also associated with the increased 
expression of CD86, CD80 and MHC class II in the cell surface of DCs, leading to an efficient 
anti-cancer CD8+ T cell response (Grootjans et al., 2016). CRT exposure also plays an important 
role in the immunosurveillance mechanism induced by cells 
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surface activation markers and MHC class II expression. These events resulted in the decrease of 
T cell proliferation and differentiation affecting the activation of T cells in ex vivo co-cultures 
(Grootjans et al., 2016). In more recent studies, increased expression of HMGB1, HMGN1, XBP1 
and p-eIF2α was correlated with a high amount of tumor infiltrating lymphocytes in triple negative 
breast cancer (TNBC) patients (Park et al., 2016).  
Besides DAMPs, there are also “don’t eat me” signals that will help cancer cells avoid the immune 
system’s recognition. ER stress regulated proteins also control these signals. For example, GRP78 
inhibition in BALB/c and athymic tumor-bearing mice increased Monocyte Chemoattractant 
Protein-1 (MCP-1) serum levels and regulated CD47, a glycoprotein of the immunoglobulin 
superfamily critical in self-recognition. Non-malignant tissue increased the CD47 “don’t eat me” 
signal in response to GRP78 inhibition, while the tumoral tissue decreased its expression. In this 
way, GRP78 inhibition stimulated macrophage infiltration and reduction of estrogen receptor–
positive breast cancers (Cook et al., 2016). 
In summary, the UPR has a very important role in ICD induction and constitutes a promising target 
for the development of anti-cancer strategies. This is the case for checkpoint blockade 
immunotherapies that can only benefit patients with tumors that have TILs previous to the 
treatment. Tumors that do not have TILs can be sensitized to checkpoint blockade immunotherapies 
when combined with ICD-inducing drugs (Pfirschke et al., 2016). In this sense, the co-
administration of chemotherapies that do not induce ICD with immunogenic chemotherapies 
capable of inducing the UPR should be considered as a promising anti-cancer strategy.  
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6. UPR cross-talk and immune regulation 
A. NFκB 
The UPR can crosstalk with different signaling pathways in order to regulate tumor-host 
interactions. Interestingly, the three branches of the UPR have been shown to induce the pro-
inflammatory NF-κB pathway. IRE1 interacts with TRAF2, recruiting IκB kinase (IKK) and 
inducing the phosphorylation and degradation of IκB, which allows NFκB to translocate to the 
nucleus and regulate the transcription of its target genes. IκB has a shorter half-life than NFκB and 
for this reason, changes in protein translation under ER stress stimuli that activate the PERK 
pathway, will induce the NFκB pathway by affecting the IκB:NFκB ratio. Finally, ATF6 can induce 
NFκB through the activating phosphorylation of AKT (Grootjans et al., 2016). 
B. Hypoxia 
Under low oxygen availability, the UPR can interact with the hypoxia HIF-1α pathway, which can 
promote vascularization, glycolysis, and survival. When hypoxic conditions are combined with ER 
stress inducers the HIF1α pathway and the UPR synergize to activate downstream targets, 
including VEGF (Pereira, Frudd, Awad, & Hendershot, 2014). An example of this synergy is when 
HIF1α, which is hyperactivated in TNBC, heterodimerizes with sXBP1 under hypoxic conditions, 
correlating with poor patient prognosis. They will both function as co-regulators and regulate the 
transcription of HIF-1α transcriptional targets (i.e. VEGF-A, PDK1, GLUT1 and DDIT4) (Chen et 
al., 2014). Control of mRNA translation is an important cellular response to both ER stress and 
hypoxia. Hypoxia activates the PERK/eIF2α/ATF4 pathway leading to the inhibition of global 
mRNA translation. The translation of ATF4 will still take place in a HIF1α-independent but 
PERK/eIF2α/ATF4-dependent manner, most likely through Siah proteins.  Siah1 and Siah2 are 
proteins that stabilize HIF1α and ATF4, through prolyl hydroxylase 1 (PHD1) downregulation. 
The PERK/ATF4 and IRE1α/xBP1 pathways can also induce Siah2. The fact that Siah2 has sXBP1 
responsive elements in its promoter raises the possibility of a direct control of the PERK/ATF4 
pathway by the IRE1 pathway. This could be the first step in the response to stress conditions as 
Siah1 and Siah2 can stabilize HIF1α and then it is possible that HIF1α could replace sXBP1 in the 
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Siah promoter, as their response elements overlap (Scortegagna et al., 2014). The 
PERK/eIF2α/ATF4 branch of the UPR has been shown to have a pro-survival effect on tumor cells 
under hypoxic conditions. This occurs through the UPR-mediated activation of pro-survival 
autophagy and its inhibition increases cell death (M. Wang & Kaufman, 2014).  
C. Response to pathogen 
The similarities between the antigen-specific immune response triggered by ICD and the one 
induced by pathogen infection have led scientists to investigate these pathways commonalities, in 
hope to apply this knowledge in cancer research. This is the case of TLRs, which are pattern 
recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs). 
Activation of TLRs and the IRE1α/sXBP1 pathway are interconnected and result in the induction 
of the innate immune surveillance in response to pathogen infection. In macrophages, TLR 
activation will induce a ROS-dependent specific activation of the IRE1α/sXBP1 pathway, but not 
of the other arms of the UPR. Then, sXBP1 will induce IL-6 and IFN-β cytokine production 
(Martinon, Chen, Lee, & Glimcher, 2010).  This kind of response is not restricted to TLRs, as there 
is a clear link between the UPR and Retinoic acid-inducible gene-I (RIG-I)-like Receptors (RLRs). 
RLRs are RNA helicases that sense pathogenic RNA and initiate antiviral immunity. Recent studies 
have linked IRE1α with the RIG-I pathway upon pathogen infection (Cho et al., 2013) and 
pathological conditions (Eckard et al., 2014). Upon the activation of IRE1α’s endonuclease 
activity, the cleavage of endogenous RNA through its downstream pathway RIDD (Regulated 
IRE1-Dependent Decay) may produce fragments that resemble those of pathogens as they lack 5’-
caps or 3’-polyA-tails that mark mRNA as “self”.  These fragments will activate RIG-I that will 
induce an innate immune response. 
D. Endogenous RNA sensing 
In the context of cancer, endogenous RNAs that are not shielded by RNA binding proteins have 
already been shown to act as DAMPs for PRRs. It was observed that in primary human breast 
cancers, activated stromal cells present unshielded RNA in exosomes in order to propagate anti-
viral signaling to the tumor microenvironment. These unshielded RNAs in stromal exosomes result 
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in an inflammatory response when transferred to immune cells and in tumor growth and invasion 
when transferred to breast cancer cells (Nabet et al., 2017). These studies were performed in vitro 
and in athymic mice, but other studies performed in immunocompetent mice demonstrated that 
RIG-I activation induced the secretion of extracellular vesicles by melanoma cells that act as 
immune activating agents favoring the anticancer immune response (Dassler-Plenker et al., 2016). 
Studies in immunocompetent mice demonstrated that the administration of a siRNA designed to 
silence Bcl-2 and activate RIG-I efficiently inhibited tumor growth through an antitumor immune 
response. This antitumor response involved the activation of myeloid and plasmacytoid DCs, NK 
cells, CD4+ and CD8+ T cells and was associated with the secretion of type I cytokines (IFNα, IL-
12p40 and IFNγ) (Poeck et al., 2008). Furthermore, RIG-I has been proposed as a tumor suppressor 
in HCC as RIG-I deficiency promotes hepatocellular carcinoma (HCC) carcinogenesis (Hou et al., 
2014). Other studies in highly immunodeficient mice have suggested that RIG-I can inhibit tumor 
growth by inducing apoptosis through the regulation of BH3-only proteins (Besch et al., 2009). 
Additionally, it was described that pancreatic cancer cells treated with RIG-I–like helicase ligands 
die through immunogenic cell death (ICD). This ICD occurred through the translocation of CRT 
to the cell surface and the posterior release of HMGB1 that activated DCs and cytotoxic CD8+ T 
cells (Duewell et al., 2014).
E. Proinflammatory cytokines and interferons 
The link between UPR and IFNI was not clear, as UPR inducing agents (tunicamycin and 
thapsigargin) have not been found to trigger any production or secretion of type I IFNs (J. A. Smith 
et al., 2008). However, combined with LPS or poly I:C (agonists of TLR4 and TLR3) the increase 
in IFNI was massively induced as compared to PRR agonist alone (F. Hu et al., 2011; J. A. Smith 
et al., 2008). In addition, other pro-inflammatory cytokines including IL-6 and TNFα have been 
induced as well, revealing more general UPR control over cytokine secretion (Martinon et al., 
2010; J. A. Smith et al., 2008). 
IRE1 RNase chemical inhibition was recently shown to sensitize breast cancer tumors to paclitaxel 
treatment and prolong survival of TNBC tumor-bearing immunodeficient mice (Logue et al., 
2018). Mechanistically, IRE1 promoted secretion of pro-inflammatory cytokines (such as CXCL1, 
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IL-6 and IL-8) which in turn enhanced cell proliferation and growth. This result suggest that IRE1 
activity would accelerate tumor growth, which was not the case when tested in vivo upon IRE1 
RNase chemical inhibition. Nevertheless, this finding strengthen the idea of IRE1 functions as the 
master regulator of cell the secretome. Although, as cell secretome varies from one to another cell 
type it is rational to assume that depending on cell type where IRE1 is modulated one can expect 
different, possibly even contradictive outcomes of that regulation. 
The pro-tumorigenic or antitumorigenic effects of individual cytokines are context dependent and 
heavily influenced by synergisms in the complex cytokine milieu. UPR, as central actor in the cell 
secretome control, plays crucial part in cytokine modulation, and here we discuss some of the 
cytokine possibly affected by UPR and implicated in tumor development. 
Altogether, these studies highlight the importance of studying the regulation of the UPR in the 
context of cancer in order to understand immunogenicity and to improve the antitumor immune 
responses and therapies.  
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SUMMARY
Dietary restriction (DR) was shown to impact on
tumor growth with very variable effects depending
on the cancer type. However, how DR limits cancer
progression remains largely unknown. Here, we
demonstrate that feeding mice a low-protein (Low
PROT) isocaloric diet but not a low-carbohydrate
(Low CHO) diet reduced tumor growth in three inde-
pendent mouse cancer models. Surprisingly, this ef-
fect relies on anticancer immunosurveillance, as
depleting CD8+ T cells, antigen-presenting cells
(APCs), or using immunodeficient mice prevented
the beneficial effect of the diet. Mechanistically, we
established that a Low PROT diet induces the
unfolded protein response (UPR) in tumor cells
through the activation of IRE1a and RIG1 signaling,
thereby resulting in cytokine production and
mounting an efficient anticancer immune response.
Collectively, our data suggest that a Low PROT diet
induces an IRE1a-dependent UPR in cancer cells,
enhancing a CD8-mediated T cell response against
tumors.
INTRODUCTION
Dietary restriction (DR) without malnutrition, which includes
caloric restriction (CR) and fasting, is well recognized as one of
the most reliable methods to enhance life span and reduce the
incidence of a wide variety of diseases, including human cancers
(Fontana and Partridge, 2015). DR has a beneficial impact on
health and life span, affects cancer development (Longo and
Mattson, 2014; Lu et al., 2017; Meynet and Ricci, 2014), and
sensitizes tumor cells to chemotherapy (Meynet et al., 2013; Ru-
bio-Patin˜o et al., 2016), notably by increasing tumor immunosur-
veillance (Di Biase et al., 2016). The identification of new
methods to induce immunosurveillance has become crucial for
the development of effective therapeutic protocols against can-
cers, the inhibition of tumor development and progression, and
the enhancement of long-term protection. However, using DR in-
terventions, such as acute fasting or prolonged CR, to reduce
tumor growth can be very difficult to tolerate for most cancer pa-
tients receiving treatment due to the development of cachexia
and DR-related weight loss (Porporato, 2016). Therefore, devel-
oping alternative methods to benefit from DR-mediated reduc-
tion in tumor growth without impacting total caloric intake is an
area of intense research (Be´ne´teau et al., 2012; Pietrocola
et al., 2016). Indeed, it has been suggested that macronutrient
modulation rather than calorie intake determines the effect of
DR on health and aging (Levine et al., 2014; Solon-Biet et al.,
2014). Interestingly, several studies have demonstrated that
the balance of protein in the diet is especially important for these
effects, as a low-protein (Low PROT) diet produces beneficial
metabolic effects similar to DR, such as reductions in insulin-
like growth factor 1 (IGF-1) and cancer incidence and an increase
in longevity (Fontana et al., 2013; Levine et al., 2014; Solon-Biet
et al., 2014, 2015).
Macronutrient modulation might also impact protein homeo-
stasis, which is also referred to as proteostasis, and in particular
endoplasmic reticulum (ER) functions (Cubillos-Ruiz et al., 2017).
Consequently, the adaptive unfolded protein response (UPR) is
stimulated when ER proteostasis is disturbed. Accumulating
evidence indicates that chronic activation of the UPR supports
themain hallmarks of cancer by favoring cancer cell autonomous
and non-autonomous processes, which ultimately condition the
immunosuppressive and pro-tumorigenic microenvironment
(Cubillos-Ruiz et al., 2017). However, certain forms of ER stress
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(environmentally or therapy-induced) can elicit immunogenic
cancer cell death (ICD), which enables the release of key immu-
nostimulatory (such as interferon g [INFg]) and danger signals,
eventually driving efficient antitumor immunity (Galluzzi et al.,
2015; Garg et al., 2015).
The UPR is controlled by three main ER resident sensors:
Inositol Requiring Enzyme 1a (IRE1a), Activating Transcription
Factor 6a (ATF6a), and PKR-like endoplasmic reticulum kinase
(PERK) (Hetz et al., 2015). Upon ER stress, IRE1a oligomerizes
and auto-transphosphorylates, thus activating the endoribonu-
clease domain that subsequently catalyzes the non-conven-
tional splicing of X-box binding protein 1 (XBP1) (Calfon et al.,
2002; Lee et al., 2002) together with the tRNA ligase RtcB (Lu
et al., 2014). Spliced XBP1 (sXBP1) is an active transcription fac-
tor that regulates the expression of genes encoding proteins
involved in protein folding and quality control, ER-associated
degradation, and phospholipid synthesis. IRE1a RNase activity
is also involved in regulated IRE1-dependent decay (RIDD) of
mRNA, rRNA, and microRNAs (Maurel et al., 2014). Interestingly,
in response to ER stress, RIDD-mediated RNA cleavage into sin-
gle-strand fragments lacking markers of self was shown to acti-
vate RIG1 (Retinoic Acid Inducible Gene 1). This RIDD-RIG1
pathway affects in turn adaptive immunity in humans (Eckard
et al., 2014). Similar to IRE1a, on ER stress, PERK dimerizes
and trans-autophosphorylates, thus leading to the phosphoryla-
tion of the translation initiation factor eIF2a and global protein
synthesis attenuation. This also leads to translational activation
of ATF4, a transcription factor that controls the expression of
genes whose products are involved in amino acid transport,
autophagy, and redox control (Pakos-Zebrucka et al., 2016).
Finally, ER stress induces ATF6 export from the ER and its trans-
membrane cleavage by Site-1 protease (S1P) and Site-2 prote-
ase (S2P), two Golgi resident proteases. The released cytosolic
ATF6 fragment acts as an active transcription factor (Hetz
et al., 2015).
Based on these premises, we analyzed the mechanism by
which macronutrient modulation can mimic the antitumoral
properties of DR by feeding mice ad libitum with isocaloric
custom diets. Our results demonstrate that an isocaloric Low
PROT diet but not a low-carbohydrate (Low CHO) diet can
induce an IRE1a/RIG1-dependent increase in immunosurveil-
lance, suggesting that such a diet can represent a clinically inter-
esting alternative to DR interventions in the context of cancer
development, tumor immunity, and treatment.
RESULTS
A Low-Protein Diet Limits Tumor Development through
the Induction of Immunosurveillance
To analyze the effect of macronutrient modulation on tumor
development, we fed mice bearing myc-driven lymphoma iso-
lated from Em-Myc mice (Adams et al., 1985) custom engineered
isocaloric diets containing either 25% less proteins (Low PROT)
or 25% less carbohydrates (LowCHO) comparedwith the control
diet. Mice were fed ad libitum with the different diets, and the
regimens’ impact on mouse survival was monitored over time
(Figure 1A). We established that only Low PROT diet increased
mouse survival, whereas global food intake and mouse weight
were equivalent for all diets (Figures S1A and S1B). The increase
in survival observed under the Low PROT diet was associated
with a reduction of spleen weight compared with the other
groups, thus indicating reduced lymphoma development (Fig-
ure 1B). Moreover, lymphoma-bearing lymph nodes from immu-
nocompetent mice fed with a Low PROT diet presented an
increase in IFNg expression (Figure S1C). Given that IFNg is a
key cytokine for innate and adaptive immunity, we hypothesized
that the Low PROT-dependent increase in survival could, at least
in part, be due to an enhanced anticancer immune response. To
test this hypothesis, we depleted cytotoxic CD8+ T cells using an
anti-CD8-specific antibody (Figures S1D and S1I). Strikingly, the
impairment of the cytotoxic immune response prevented the
beneficial effect induced by the Low PROT diet, suggesting a
central role for CD8+ T cells (Figure 1A).
To further confirm the role of LowPROT diet-induced immuno-
surveillance, we transplanted primary lymphoma cells isolated
from Em-Myc mice into immunodeficient NOD-Scid gamma
c/ (NSG) mice. As shown in Figure 1A, a Low CHO diet did
not impact mouse survival compared with the control diet (Fig-
ure 1C). Conversely, a LowPROT diet led to a dramatic decrease
in mouse survival compared with the control diet (Figure 1D).
Importantly, the co-injection of C57BL/6 splenocytes (containing
mainly T and B cells syngeneic with the Em-Myc lymphoma cells
injected) resulted in an increase in mouse survival under a Low
PROT diet (Figure 1D). These findings further confirm the key
role of the immune system in the beneficial effect of the Low
PROT diet on tumor development.
We extended our observations in vivo using two
additional mouse models: a murine colorectal carcinoma
(CRC) cell line (CT26) subcutaneously injected into syngeneic
Figure 1. A Low PROT Diet Affects Tumor Development in a CD8-Dependent Manner
(A) Survival curve of syngeneic C57BL/6mice that were intravenously injectedwith Em-Myc lymphoma cells. Mice were fed ad libitumwith Ctl, LowCHO, and Low
PROT diets and were intraperitoneally injected with PBS or aCD8 antibody (Ctl, n = 8; Low CHO, n = 9; Low PROT, n = 10; Low PROT aCD8, n = 6).
(B) Spleen weight of C57BL/6 mice intravenously injected with Em-Myc lymphoma cells and fed ad libitum with Ctl, Low CHO and Low PROT diets (4 mice
per group).
(C and D) Survival curve of NSG mice that were intravenously injected with Em-Myc lymphoma cells with or without splenocytes and fed ad libitum with Ctl, Low
CHO and Low PROT diets (Ctl, n = 5; Low CHO, n = 5; Low PROT, n = 5; Ctl + Splenocytes, n = 3; Low PROT + Splenocytes, n = 3).
(E) Tumor growth curve of syngeneic BALB/c mice that were subcutaneously injected with CT26 colorectal carcinoma cells. Mice were fed ad libitumwith Ctl and
Low PROT (12.5%, 25%, and 40%) diets (Ctl, n = 7; Low PROT 12,5%, n = 7; Low PROT 25%, n = 8; Low PROT 40%, n = 8).
(F) Tumor volume at day 14 of data shown in (E).
(G) Tumor growth curve of syngeneic BALB/c mice that were subcutaneously injected with CT26 colorectal carcinoma cells. Mice were fed ad libitumwith Ctl and
Low PROT diets and were intraperitoneally injected with PBS or aCD8 antibody (Ctl, n = 11; Low PROT, n = 10; Ctl aCD8, n = 8; Low PROT aCD8, n = 8).
(H) Tumor volume at day 12 of data shown in (G).
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM. Comparisons of every group versus Ctl group, except where specified otherwise. When not
mentioned, differences are not significant. All experiments are representative of two performed. See also Figure S1.
830 Cell Metabolism 27, 828–842, April 3, 2018
A B
C
D E
Figure 2. A Low PROT Diet Increases CD8 Tumor-Infiltrating Lymphocytes
(A and B) BALB/c mice were subcutaneously injected with CT26 colorectal carcinoma cells and were fed ad libitumwith Ctl and Low PROT diets. Upon sacrifice,
CD3+ cells were isolated from spleens and incubated with (A) live CT26 cells or (B) B16 cells for 4 hr. The ability of T cells to kill tumor cells was determined by flow
cytometry. Cell death of CT26 and B16 cells was determined by DAPI staining (at least seven mice per group).
(legend continued on next page)
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immunocompetent BALB/c mice and a murine melanoma cell
line (B16) subcutaneously injected into syngeneic immunocom-
petent C57BL/6 mice. Given that a Low CHO diet did not have
any effect on mouse survival using the Em-Myc model (Figures
1A and 1B), we focused our attention on the Low PROT diet.
We first tested the impact of diet-protein content on tumor
growth in the CT26-BALB/c model by generating isocaloric diets
presenting a reduction of 12.5%, 25% (as in Figures 1A–1D), or
40% of protein content. The global food intake and mouse
weight were equivalent for all diets (Figures S1E and S1F).
While 12.5% and 25% protein diets resulted in similar tumor
growth reduction, the 40% diet did not show any beneficial
effect (Figures 1E and 1F). We therefore decided to use
the 25% Low PROT diet (named Low PROT diet) for the rest
of the study. Then, using the CT26-BALB/c model (Figures 1G
and 1H) and the B16-C57BL/6 model (Figures S1G and S1H),
we established that a Low PROT diet attenuated tumor develop-
ment in an immune-dependent manner, as the depletion of
CD8+ T cells (shown in Figure S1I) prevented the beneficial
effects mediated by the Low PROT diet (Figures 1G, 1H, S1G,
and S1H). Importantly, we verified that food intake or mouse
body weight were not affected by the different diets in both
models (Figures S1J–S1M). We also verified that glycemia was
not affected by the Low PROT diet (Figure S1N).
Altogether, we established using three independent and
different mouse cancer models that a Low PROT diet attenuates
tumor growth through the induction of an anticancer immune
response.
To directly address whether a Low PROT diet can induce an
efficient and specific anticancer immune response, we isolated
T cells from the spleens of BALB/c mice previously injected
with CT26 cells and fed with a control or a Low PROT diet and
from C57BL/6 mice previously injected with Em-Myc cells and
fed a control, Low CHO, or Low PROT diet. We then tested the
ability of isolated cytotoxic T cells to kill tumor cells ex vivo. In
both models, T cells isolated from the spleens of Low PROT-
fed mice were more efficient in killing syngeneic tumor cells
compared with T cells isolated from control and Low CHO
diet-fed mice (Figures 2A, S2A, and S2B). To test whether cyto-
toxic activity of T cells was specific for the syngeneic tumor cells,
we incubated ex vivo the T cells isolated from the CT26-BALB/c
model with B16 melanoma cells. T cells isolated from the CT26-
BALB/c model fed with a Low PROT diet, while efficiently killing
CT26 cells (Figure 2A), were unable to kill B16 cells (Figure 2B),
thus suggesting that a Low PROT diet leads to the expansion
of tumor antigen-specific T cells. Although the percentage of tu-
mor-infiltrating T regulatory cells (Treg, CD3+CD4+CD25+
CD127) did not vary in CT26 tumors, intratumoral natural killer
cells (NK, CD3 NK1.1+) and CD3+/CD8+ T lymphocytes were
increased (Figure 2C). Importantly, this beneficial effect of the
Low PROT diet was confirmed and correlated with an increase
in CD8+ tumor-infiltrating lymphocytes (TILs) that were visualized
by immunofluorescence on tumor sections of BALB/c bearing
CT26 tumors (Figures 2D and 2E). The increase in CD8+ TILs
was associated with an increase in the mRNA levels of IFNg
and its target CXCL10 in tumors in vivo (Figures S2C and S2D).
We demonstrated that a Low PROT diet can limit tumor devel-
opment not by affecting tumor cell proliferation capacity or by
inducing tumor cell death directly but rather through the increase
in TILs that results in the induction of an efficient and specific
anticancer immune response.
Low-Protein-Diet-Induced Immunosurveillance
Requires APCs and Involves INFg Production by
Tumor Cells
Antigen-presenting cells (APCs), like dendritic cells (DCs) or
macrophages, are central for antigen presentation (Joffre et al.,
2009; Kroemer et al., 2013). We therefore investigated their
involvement in vivo by depleting phagocytic cells from the
myeloid lineage (DCs and macrophages) using liposome clodro-
nate (Van Rooijen and Sanders, 1994) (Figures S3A and S3B).
Interestingly, the Low PROT diet-mediated protective effect
was lost upon APC depletion (Figures 3A and 3B).
To further support our conclusions, we neutralized CD86, a
co-stimulatory protein expressed on APCs that is required for
T cell activation, using a blocking antibody in vivo (Figure S3C).
As for APCs depletion, CD86 blockade in vivo prevented the ef-
fect of the Low PROT diet on tumor growth (Figures 3C and 3D).
Cytokine production by tumor cells, including INFg, plays a key
role in ICD (Galluzzi et al., 2015). We established that reduction
of IFNg expression by tumor cells (Figure 3E) prevents the effects
of a Low PROT diet on tumor growth (Figure 3F.)
Collectively our data suggest that a Low PROT diet can induce
an antitumoral immune response that relies on APCs and, at
least in part, on IFNg production by tumor cells.
A Low-Protein Diet Induces IRE1a-Dependent ER Stress
Since we found that a Low PROT diet induced an antitumoral ef-
fect in three independent mouse tumor models, we then sought
to investigate the underlying molecular mechanism by moni-
toring key signaling pathways previously reported as affected
by such a regimen. We did not observe significant modulation
of the mammalian target of rapamycin (mTOR) pathway or of
GCN2 (general control nonderepressible 2) activation, two key
sensors of the amino acid content in the cells (Kim et al., 2017;
Wek et al., 1995) (Figures S4A–S4C). We also did not observe
any modulation of the Akt pathway (Figures S4A and S4B).
Moreover, recently, autophagy induction by CR mimetics was
associated with an increase in anticancer immunosurveillance
(Pietrocola et al., 2016). However, we did not observe any sign
of autophagy induction as judged by LC3 conversion in tumor
cells isolated from Low PROT-fed mice compared with the
control diet (Figures S4D and S4E). Hence, in our model of an
isocaloric, mild reduction of protein intake, the increase in immu-
nosurveillance is not mediated by the modulation of macroau-
tophagy or mTOR/GCN2/Akt pathways.
(C) Effect of Ctl and Low PROT diets on the intratumoral frequency of infiltrating Treg, NK, CD3+, and CD8+ cells in CT26 tumors as analyzed by flow cytometry (at
least three mice per group).
(D) Immunofluorescent staining of CD8+ T cells in BALB/c CT26 bearing tumors after 25 days of diet. Scale bar is equivalent to 50 mm.
(E) Corresponding quantification (three mice per group).
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM. When not mentioned, differences are not significant. See also Figure S2.
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Figure 3. Role of Macrophages and Dendritic Cells on the Antitumor Effect of a Low PROT Diet
BALB/c mice were subcutaneously injected with CT26 colorectal carcinoma cells and were fed ad libitum with Ctl and Low PROT diets.
(A) Mice were intraperitoneally injected with clodronate liposomes (Lipo Clod) or PBS liposomes (Lipo PBS) (Ctl-Lipo PBS, n = 8; Low PROT-Lipo PBS, n = 8;
Ctl-Lipo Clod, n = 6; Low PROT-Lipo Clod, n = 6).
(B) Tumor volume at day 14 of data shown in (A).
(C) Mice were intraperitoneally injected with PBS or aCD86 antibody (Ctl - PBS, n = 8; Low PROT – PBS, n = 7; Low PROT – aCD86, n = 7).
(D) Tumor volume at day 15 of data shown in (C).
(E) Knockdown in CT26 cells of IFNg using the shRNA technique. IFNg expression was analyzed by qPCR.
(F) BALB/c mice were subcutaneously injected with CT26 shRNA of interferon g colorectal carcinoma cells and were fed ad libitumwith Ctl and Low PROT diets.
Tumor volume at day 13.
*p < 0.05, **p < 0.01. Error bars represent SEM. Comparisons of every group versus Ctl group, except where specified otherwise. When not mentioned, dif-
ferences are not significant. See also Figure S3.
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We then reasoned that reducing protein intake could limit
amino acid availability in tumor cells. Knowing that alterations
in certain amino acids (such as proline) can control ER stress in-
duction (Jeon et al., 2015; Sahu et al., 2016), we monitored the
content of amino acids in tumors. We observed a decrease in
most of the amino acids present in tumors isolated from Low
PROT diet-fed mice compared with tumors isolated from the
control diet group (Figure S4F). We therefore investigated the
activation status of different UPR markers in tumors isolated
from mice fed with the control or Low PROT diets. GRP78 and
CHOP expression were increased and IRE1a phosphorylation
was detected in tumor cells isolated from mice fed a Low
PROT diet (Figures 4A and 4B), indicating that a Low PROT
diet induced the UPR in cancer cells. We did not observe any
modulation of the AFT4 and ATF6 branches of the UPR (Figures
S5A–S5C).
Given that a Low PROT diet induced the expression of cyto-
kines (IFNg and CXCL10) in tumor cells (Figures S1C, S2C, and
S2D) and that IRE1a is a central player in this phenomenon
(Martinon et al., 2010), we further investigated this pathway.
We observed an increase in sXBP1 protein levels in tumor cells
obtained from mice fed a Low PROT diet (Figures 4A and 4B).
ER stress-dependent IRE1a induction mediated by a Low
PROT diet in tumors in vivo was further supported by the
degradation of RIDD target mRNAs (Figure 4C). RIG1 (retinoic
acid inducible gene 1) senses the small RNA fragments gener-
ated by RIDD, leading to its activation (Cho et al., 2013).
We observed the induction of RIG1 protein levels within the tu-
mors isolated from Low PROT-fed mice (Figures 4D and 4E).
Importantly, the activation of IRE1a signaling, as judged by
the generation of sXBP1, was not observed in TILs nor in
DCs, thereby suggesting it is a tumor cell-specific activation
(Figure 4F).
Collectively, our data indicate that feeding tumor-bearingmice
a Low PROT diet induces an IRE1a-dependent UPR in tu-
mor cells.
IRE1a-Mediated RIG1 Activation in Tumor Cells Is
Required for a Low PROT-Induced Anticancer Immune
Response
If IRE1a signaling in tumor cells is a central event in the Low
PROT-induced anticancer immune response, we reasoned that
attenuation of ER stress should prevent the beneficial effect pro-
vided by this diet. To test this hypothesis, we first injected CT26
cells in syngeneic immunocompetent BALB/c mice fed ad libi-
tumwith the control or Low PROT diets. As observed in Figure 1,
feeding the mice a Low PROT diet decreased tumor progression
compared with mice fed with a control diet (Figures 5A and 5B).
Eleven days after subcutaneous injection of tumor cells, half of
themice in each groupwere treated either with the pan ER stress
inhibitor TUDCA or with PBS (vehicle). Strikingly, TUDCA treat-
ment prevented the antitumoral effect of the Low PROT diet,
thereby indicating that ER stress is necessary to achieve such
response. To further support this observation, we then used
the IRE1a-specific RNase inhibitor MKC4485 to block
IRE1a-downstream signaling events. Although tumor burden
was reduced by the Low PROT diet, this effect was impaired
upon treatment with MKC4485 (Figures 5C and 5D). We verified
the efficacy of both inhibitors by assessing the reduction in
CHOP (for tauroursodeoxycholic acid [TUDCA]) or sXBP1
expression (for MKC4485) (Figures 5E and 5F) in tumor cells of
mice fed with a Low PROT diet. Consistent with our hypothesis,
both inhibitors prevented CD8+ T cell infiltration in tumors (Fig-
ures 5G, S6A, and S6B), and this effect was associated with a
drastic reduction in Low PROT-induced IFNg mRNA levels in
tumors (Figure S6C). Importantly, neither the Low PROT diet
nor the inhibitors affected T cell populations in lymphoid organs
of tumor-bearing mice, suggesting a local modulation of the im-
mune cell infiltrate rather than a global impact on whole immune
cell populations (Figures S6D and S6E).
To demonstrate that the Low PROT diet-induced anticancer
immune response is controlled by the modulation of IRE1a in
cancer cells, we used CT26 cells that were stably silenced for
IRE1a (using two independent shRNA sequences, Figure 6A).
Importantly, we verified that IRE1a knockdown did not impact
on cell proliferation (Figure S7A). We again validated that a
Low PROT diet limited tumor growth (Figure 6B). Very impor-
tantly, our in vivo data also demonstrated that IRE1a knockdown
is sufficient to prevent the beneficial effect of a LowPROT diet on
tumor growth (Figures 6C, 6D, S7B, and S7C).
To further support our conclusions and to prevent any off-
target effects of both small hairpin RNA (shRNA) targeting
IRE1a, we invalidated IRE1a in CT26 cells using the CRISPR/
Cas9 technology (Figure 6E). Again, IRE1a invalidation did not
have an impact on cell proliferation in vitro (Figure S7D) but
blunted the Low PROT diet-dependent reduction in tumor
growth (Figures 6F–6H). Finally, to elucidate the role of RIG1
on the IRE1a-dependent antitumor effect of the Low PROT
diet, we invalidated RIG1 in CT26 cells using the CRISPR/Cas9
technique (Figure 6E). As for IRE1a, RIG1 invalidation did not
modulate cell proliferation in vitro (Figure S7D) but prevented
the reduction in tumor growth induced by the Low PROT diet
(Figures 6F–6H). We then confirmed that IRE1a invalidation in tu-
mor cells limited the splicing of XBP1 and RIG1 activation
induced by the Low PROT diet (Figure 6I), confirming that RIG1
activation is downstream of IRE1a activation.
Figure 4. A Low PROT Diet Causes Unresolved ER Stress in CT26 Tumors
Syngeneic BALB/c mice were subcutaneously injected with CT26 colorectal carcinoma cells and fed ad libitum with Ctl and Low PROT diets.
(A) Tumors were harvested after 25 days of diets and lysates were prepared. Expressions of proteins related to the IRE1a pathway were analyzed by western blot.
(B) Average quantification of GRP78, pIRE1a, sXBP1, and CHOP compared with ERK2 levels (used as a loading control) or the corresponding total protein.
(C) mRNA levels of RIDD targets were measured in tumors by qPCR (at least five mice per group).
(D) Expression of RIG1 in tumor tissues was analyzed by western blot.
(E) Average quantification of RIG1 compared with ERK2 levels.
(F) CD4+/CD8+ TILs were isolated fromCT26 tumors and DCswere isolated from spleens of BALB/cmice fedwith Ctl and LowPROT diets. mRNA levels of sXBP1
were determined by qPCR and normalized by uXBP1.
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM. When not mentioned, differences are not significant. See also Figures S4 and S5.
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Figure 5. Treatment with ER Stress Inhibitors Reverses the Antitumor Immune Response Induced by a Low PROT Diet
(A–D) Tumor growth curves of syngeneic BALB/c mice that were subcutaneously injected with CT26 colorectal carcinoma cells and were fed ad libitum with Ctl
and Low PROT diets. Mice were (A) intraperitoneally injected with TUDCA (five mice per group) (C) or administered MKC4485 by gavage from day 11–16 after
subcutaneous injection with CT26 cells (at least fivemice per group). Average tumor size at day 16 of mice treated with (B) TUDCA or (D) MKC4485 of data shown
in (A) and (C).
(E) Tumors were harvested after 30 days of diets and lysates were prepared. Expression of CHOP and sXBP1 were analyzed by western blot.
(F) Corresponding average quantification of CHOP and sXBP1 compared with ERK2 levels (used as a loading control).
(G) Quantification of immunofluorescent staining of CD8+ T cells in tumors shown in Sup Figure 6A (three mice per group).
*p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM. Comparisons of every group versus Ctl group, except where specified otherwise. When not
mentioned, differences are not significant. All experiments are representative of two performed. See also Figure S6.
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Altogether, these results indicate that a Low PROT diet in-
duces IRE1a-mediated RIG1 activation in tumor cells and that
this represents a central event in the Low PROT diet-induced
immunosurveillance.
Increased IRE1a Signaling Is Associated with Increased
Antitumor T Cell Response in Human Cancers
We then decided to corroborate our mouse findings to human
data. For that matter, we investigated whether tumor IRE1a ac-
tivity could be associated with signatures of antitumoral re-
sponses. Recently, a gene signature reflecting IRE1a activation
was established in glioblastoma (Lhomond et al., 2018). Using
TGCA datasets, we stratified glioblastoma (n = 523), melanoma
(n = 293), and colorectal cancers (n = 456) based on IRE1a activ-
ity and identified for each cancer type IRE1ahigh and IRE1alow
populations (Figures S7E–S7G). Then we investigated the
expression of a series of T cell markers (Figures 7A–7C) in both
populations in the three cancer types. Interestingly, in both glio-
blastoma and melanoma, high IRE1a activity correlated with
increased levels of T cell markers (Figures 7B–7D). Surprisingly,
when the same analysis was carried out in CRC, the enrichment
in T cell markers was exclusively observed in grade I tumors (Fig-
ures 7A and 7D).
These results suggested that the association between an in-
crease in IRE1a signaling and the increase in T cell recruitment
is a common feature observed in human tumors from various
origins (Figure 7).
DISCUSSION
In this study, we examined the effect of Low CHO or Low PROT
isocaloric diets on tumor growth using three independent immu-
nocompetent syngeneic mouse models: the Em-Myc-C57BL/6 B
lymphoma model, the B16-C57BL/6 melanoma model, and the
CT26-BALB/c CRCmodel. We established that a 25% reduction
in protein but not in carbohydrate intake with no change in calo-
ries resulted in amarked decrease in tumor growth. All diets used
in our study were isocaloric but had very different impacts on tu-
mor growth (Figure 1). This suggested that the class of nutrients
rather than the amount of energy present in the food is essential
to limit tumor growth. Very importantly, this effect was not related
to the inhibition of cancer cell proliferation or to the induction of
cancer cell death per se but was rather due to the induction of an
efficient antitumoral immune response. Depletion of CD8+ T cells
(Figures 1A, 1G, 1H, S1G, and S1H), the use of immunodeficient
mice (Figures 1C and 1D) or depletion/blocking of APCs (Figures
3A–3D) prevented the beneficial effect of the Low PROT diet. We
also established that feeding tumor-bearing mice with a Low
PROT diet induced a tumor-specific cytotoxic T cell response
(Figures 2, S2A, and S2B). Therefore, our data challenge the
common dogma that lowering protein in the diet limits tumor
development by decreasing tumor proliferation. Instead, we
demonstrate that a mild reduction in protein intake without a
change in total calories ingested induces an adaptive IRE1a-de-
pendent signal in the tumor cells, leading to RIG1 activation. We
have also shown that this IRE1a/RIG1-dependent anticancer im-
mune response goes in hand with cytokine production and that
this plays a role in the Low PROT diet-induced anticancer im-
mune response as shown for IFNg (Figures 3E and 3F).
Nutrients are main regulators of circulating IGF-1, the levels of
which are correlated with increased cancer risk. Consistently, di-
etary restriction-mediated reduction in IGF-1 is largely described
as preventing cancer incidence (Klement and Fink, 2016;Meynet
and Ricci, 2014). Restriction of protein intake or some amino
acids is more efficient than CR in reducing IGF-1, which conse-
quently inhibits the PI3K/mTOR pathway and therefore limits tu-
mor cell proliferation (Fontana et al., 2008, 2013; Norat et al.,
2007; Underwood et al., 1994). However, in our experiments, a
mild reduction of dietary protein content (by 25%) slightly, but
significantly, reduced the amino acid concentration within tumor
tissues but was not associated with a significant modulation of
the mTOR pathway (Figures S4A, S4B, and S4F). In addition,
we demonstrated that the Low PROT diet-dependent reduction
in tumor development was effectively abrogated upon CD8+
T cell or APC depletion (Figures 1A, 1G, 1H, 3A, and 3B) or
when using immunodeficient mice (Figures 1C and 1D). More-
over, IRE1a and RIG1 inhibition or invalidation in tumor cells
reverted the Low PROT-dependent reduction in cancer develop-
ment (Figures 5 and 6). Altogether, our results argue against a
role of circulating IGF-1 in our settings but indicate that a Low
PROT diet induces a tumor cell IRE1a-dependent activation
of anticancer-specific T cells in a PI3K/mTOR-independent
manner.
The UPR has been described as being either pro- or antitu-
moral depending on the tumor type, the intensity of the stress,
and the nature of the microenvironment (Cubillos-Ruiz et al.,
2017; Obacz et al., 2017). We made the observation that mild
dietary reduction of protein intake leads to the induction of the
UPR in tumor cells (Figure 4). We demonstrated that the benefi-
cial effect of the Low PROT diet is dependent on the endoribonu-
clease activity of IRE1a (using the MKC4485 RNase inhibitor,
Figure 5). Our data therefore suggest that IRE1a activity can
Figure 6. A Low PROT Diet Induces an Anticancer Immune Response in an IRE1a-Dependent Manner
(A) Knockdown in CT26 cells of IRE1a using two different shRNAs. IRE1a expression was analyzed by western blot.
(B and C) (B) Tumor growth curve of BALB/c mice that were subcutaneously injected with CT26 (Empty Vector) colorectal carcinoma cells (C) and with shIRE1a
CT26 colorectal carcinoma cells and were fed ad libitum with Ctl and Low PROT diets (at least eight mice per group).
(D) Picture of representative dissected tumors for each group.
(E) Invalidation in CT26 cells of IRE1a and RIG1 using the CRISPR/Cas9 technique. IRE1a and RIG1 expression was analyzed by western blot.
(F) Tumor growth curve of BALB/c mice that were subcutaneously injected with CRISPRCtl, CRISPR IRE1a and CRISPR RIG1 CT26 cells and were fed ad libitum
with Ctl and Low PROT diets (at least eight mice per group).
(G) Tumor volume at day 13 of data shown in (F).
(H) Picture of representative dissected tumors for each group.
(I) Tumors were harvested after 17 days of diets and lysates were prepared. Expressions of proteins related to the IRE1a pathway were analyzed by western blot.
*p < 0.05, **p < 0.01. Error bars represent SEM. Comparisons of every group versus Ctl group, except where specified otherwise. When not mentioned, dif-
ferences are not significant. See also Figure S7.
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selectively contribute to themodulation of tumor outcome by im-
pacting on the tumor cells themselves and/or on the nature of the
tumor microenvironment.
It was recently established that activation of XBP1 in tumor
associated DCs led to a decrease in the anticancer immune
response (Cubillos-Ruiz et al., 2015). The authors therefore
suggested that targeting ER stress responses could have
some relevance in cancer treatment. In our model of Low
PROT diet-induced immunosurveillance, we observed the acti-
vation of the IRE1a pathway in tumor cells but not in DCs or
TILs (Figure 4F). This suggests that this is a tumor cell-specific
ER stress response, probably due to the high metabolic de-
mand and sensitivity of tumor cells to ER stress and the
UPR. Moreover, this also coincides with tumor IRE1-dependent
mechanisms recently described to modulate the nature of the
tumor microenvironment (Lhomond et al., 2018). However,
our study points toward a careful use of IRE1a inhibitors for
cancer treatment.
In the context of our current observations, how IRE1a is
activated in tumor cells upon a Low PROT diet remains to be
elucidated. One possibility would be that a Low PROT diet,
leading to a decrease in specific amino acids in tumors (Fig-
ure S4F) results in IRE1a activation, as it was previously sug-
gested (Jeon et al., 2015; Sahu et al., 2016). However, which
amino acids are involved remains to be clarified. Another hy-
pothesis could be that somehow a Low PROT diet modulates
glycemia that is known to be a central regulator of the UPR (Cu-
billos-Ruiz et al., 2017). However, we did not observe a differ-
ence in glycemia between the two groups (Figure S1N). The
exact nature of how IRE1a is activated in tumor cells upon a
Low PROT diet remains to be identified, in particular the spe-
cific signaling balance between sXBP1 and RIDD. Indeed, it
was recently demonstrated that both arms of the IRE1a
signaling pathway play antagonistic roles through the remodel-
ing of tumor microenvironment. As such, one might postulate
that a Low PROT diet could condition a specific IRE1a
signaling code in tumor cells that would favor the recruitment
of cytotoxic T cells to the tumor site and prevent the generation
of protumoral stroma.
Recently, the use of caloric restriction mimetics (CRm) was
shown to induce an anticancer immune response through the in-
duction of autophagy (Pietrocola et al., 2016). However, we did
not observe anymodulation of autophagy in our settings (Figures
S4D and S4E), suggesting that CRm and Low PROT diets utilize
independent and possibly complementary pathways to increase
immunosurveillance. Here, we describe that a 25% reduction in
protein intake is sufficient to induce an efficient anticancer im-
mune response. Of note, this diet did not have a systemic impact
on the proportion of immune system populations (Figures S6D
and S6E), suggesting a local tumor microenvironment modula-
tion that results in T cell recruitment.
Limitations of Study
Limitation of our work is brought by the fact that there is no estab-
lished or consensus definition of the percentage of protein reduc-
tion that is sufficient to generate a Low PROT diet, a factor that
might be individual, tissue, and tumor dependent. Therefore, it re-
mains a challenge to compare studies using strongprotein reduc-
tionorprolonged fastingwithstudiesusingamild reduction inpro-
tein intake. Very low-protein conditions will impact body weight,
which may not be suitable for therapeutic approaches (Di Biase
et al., 2016). Importantly, in most of these studies, the role of the
immune system was not addressed, as experiments were per-
formed in immunodeficient xenograft models. We observed that
a drastic reduction in protein content (by 40%) did not lead to a
protection toward tumor growth (Figure 1E) in ourmodel, underly-
ing the notion that amild reduction in protein contentmay not only
bemoreeasily toleratedbypatients but also that amassive reduc-
tion in protein may prevent the beneficial effect of the diet.
Stimulating the ability of the immune system to fight and limit/
eradicate tumor development is among the most promising
treatment strategies. The enthusiasm for immunomodulating
therapies targeting immune checkpoints results from the suc-
cess observed in patients suffering from several types of cancer
(Callahan et al., 2016). However, this approach is restricted to
some types of cancers or some mutations within a cancer
type. Here, we describe a simple and efficient method to stimu-
late the targeted killing of cancer cells by T cells. However, given
that mice have a metabolic rate 7-fold higher compared with hu-
mans and that they appear to be more resistant to cachexia than
humans (Bozzetti and Zupec-Kania, 2016; Demetrius, 2005), the
effect of such DR interventions on improvements in immunosur-
veillance in human cancer prevention should be investigated in
future studies. Translating the relevance of our work to humans
can be hard to address, as data from cancer patients receiving
a LowPROT regimen are not available. For this reason, we inves-
tigated the link between IRE1a activation and the increase in
antitumor T cells markers (Figure 7). Importantly, regardless of
the type of tumor analyzed (CRC, melanoma, or glioblastoma),
we observed a strict correlation between a high IRE1a signature
and an increase in markers associated with immunosurveillance,
suggesting that our results could be relevant to cancer patients.
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Antibodies
FITC Anti-CD19 Miltenyi Biotec 130-102-494; RRID:AB_2661108
FITC Anti-CD45R Miltenyi Biotec 130-110-845; RRID:AB_2658273
FITC Anti-CD49B BD Biosciences 553857; RRID:AB_395093
FITC Anti-CD11b BD Biosciences 553310; RRID:AB_394774
FITC Anti-TER-119 BD Biosciences 557915; RRID:AB_396936
VioBlue Anti-CD4 BD Biosciences 558107; RRID:AB_397030
PE Anti-CD8 BD Biosciences 553032; RRID:AB_394570
PE Anti NK1.1 BD Biosciences 557391; RRID:AB_396674
PE Anti-CD11c BD Biosciences 557401; RRID:AB_396684
PECy7 Anti-CD86 BD Biosciences 560582; RRID:AB_1727518
APC Anti-CD127 BD Biosciences 564175
FITC Anti-CD3 eBioscience 11-0031-85; RRID:AB_464883
VioBlue Anti-F4/80 eBioscience 48-4801-82; RRID:AB_1548747
APCCy7 Anti-CD25 BD Biosciences 557658; RRID:AB_396773
Mouse monoclonal Anti-XBP1 Santa Cruz sc-8015; RRID:AB_628449
Mouse monoclonal Anti-ERK2 Santa Cruz sc-1647; RRID:AB_627547
Rabbit monoclonal Anti-IRE1a Cell Signaling 3294; RRID:AB_823545
Rabbit monoclonal Anti-pS6K Cell Signaling 9234; RRID:AB_2269803
Rabbit polyclonal Anti-S6K Cell Signaling 9202; RRID:AB_331676
Rabbit polyclonal Anti-pAKT Cell Signaling 9271; RRID:AB_329825
Mouse monoclonal Anti-AKT Cell Signaling 2967; RRID:AB_331160
Rabbit monoclonal Anti-LC3B Cell Signaling 3868; RRID:AB_2137707
Rabbit polyclonal Anti-eIF2a Cell Signaling 9722; RRID:AB_2230924
Rabbit polyclonal Anti-peIF2a Cell Signaling 9721; RRID:AB_330951
Rabbit monoclonal Anti-RIG1 Cell Signaling 3743; RRID:AB_2269233
Rabbit monoclonal Anti-ATF4 Cell Signaling 11815; RRID:AB_2616025
Mouse monoclonal Anti-CHOP Cell Signaling 2895; RRID:AB_2089254
Rabbit polyclonal Anti-GCN2 Cell Signaling 3302; RRID:AB_2277617
Mouse monoclonal Anti-ATF6 Novus biologicals NBP1-40256; RRID:AB_2058774
Rabbit polyclonal Anti-pIREa Novus biologicals NB100-2323; RRID:AB_10145203
Rabbit polyclonal Anti-GRP78 Abcam ab21685; RRID:AB_2119834
Rabbit monoclonal Anti-pGCN2 Abcam ab75836; RRID:AB_1310260
anti-CD8-depleting antibody (clone53-6.7) Bioxcell BE0004-1; RRID:AB_1107671
anti-CD86-blocking antibody (clone GL-1) Bioxcell BE0025; RRID:AB_1107678
Purified Anti-mouse CD8a (clone 53-6.7) Biolegend 100701; RRID:AB_312740
Alexa Fluor 594 anti-rat secondary antibody Molecular Probes A11007; RRID:AB_141374
Chemicals, Peptides, and Recombinant Proteins
jetPEI DNA transfection Reagent PolyPlus Transfection POL101-10N
Clodronate Liposomes and PBS Liposomes Liposoma B.V. PBS-02
TUDCA Sigma-Aldrich T0266
MKC4485 John B. Patterson N/A
Recombinant mouse IL-2 AbD Serotech PMP38
DAPI Sigma-Aldrich D9542
Fast Sybr Green Applied Biosystems 4385616
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Taqman Fast Universal PCR Master Mix Applied Biosystems 4352042
O.C.T. compound Tissue-Tek 4583
amino acids mixture (98 atom % 13C, 98
atom % 15N)
Sigma-Aldrich 608254
Critical Commercial Assays
Mouse Tumor Dissociation Kit Miltenyi Biotec 130-096-730
Mouse CD4/CD8 (TIL) Microbeads Miltenyi Biotec 130-116-480
Mouse CD11c Microbeads ultrapure Miltenyi Biotec 130-108-338
ECL Western Blotting Detection Reagents GE Healthcare RPN2106
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225
RNAeasy minikit Qiagen 74104
Omniscript RT kit Qiagen 205113
Experimental Models: Cell Lines
Mouse B16-F1 cells ATCC CRL-6323
Mouse CT26.WT cells ATCC CRL-2638
Human Embrionic Kidney-293T Cells ATCC CRL-1573
Experimental Models: Organisms/Strains
Mouse: Em-Myc The Jackson Laboratory 002728
Mouse: C57BL/6JOlaHsd ENVIGO N/A
Mouse: BALB/cOlaHsd ENVIGO N/A
Mouse: NOD scid gamma c-/- (NSG) The Jackson Laboratory 005557
Oligonucleotides
Atf3 (Mm00476033_m1) Applied Biosystems 4331182
Ero1lb (Mm00470754_m1) Applied Biosystems 4331182
Sars (Mm00803379_m1) Applied Biosystems 4331182
Trib3 (Mm00454879_m1) Applied Biosystems 4331182
Hsp90b1 (Mm00441926_m1) Applied Biosystems 4331182
Hyou1 (Mm00491279_m1) Applied Biosystems 4331182
Rn18s (Mm03928990_g1) Applied Biosystems 4331182
Scara3 Forward
TGCATGGATACTGACCCTGA
This paper N/A
Scara3 Reverse
GCCGTGTTACCAGCTTCTTC
This paper N/A
Blos1 Forward
CAAGGAGCTGCAGGAGAAGA
This paper N/A
Blos1 Reverse
GCCTGGTTGAAGTTCTCCAC
This paper N/A
Col6 Forward
TGCTCAACATGAAGCAGACC
This paper N/A
Col6 Reverse
TTGAGGGAGAAAGCTCTGGA
This paper N/A
IFNg Forward
TCAAGTGGCATAGATGTGGAAGAA
This paper N/A
IFNg Reverse
TGGCTCTGCAGGATTTTCATG
This paper N/A
CXCL10 Forward
GCTGATGCAGGTACAGCGT
This paper N/A
CXCL10 Reverse 50-
CACCATGAATCAAACTGCGA
This paper N/A
bactin Forward
TGGAATCCTGTGGCATCCATGAAA
This paper N/A
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Jean-Ehrland Ricci (ricci@unice.fr).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee and the
regional ethics committee (approval reference PEA-232 and PEA-233). All experiments used age-matched female littermates.
Em-Myc/wild-type (WT) mice were obtained from The Jackson Laboratory (#002728). Five-week-old WT syngeneic C57BL/6 mice
and BALB/c mice were obtained from ENVIGO. NOD scid gamma c-/- (NSG) mice were obtained from The Jackson Laboratory
(#005557) and housed in our animal facilities (C3M-Nice, France).
Mice were fed with isocaloric diets generated by ENVIGO: Control (Ctl: TD.130931), low carbohydrates (LowCHO: TD.130932) and
low protein diet (Low PROT or Low PROT -25%: TD.130933). When specified, two other low protein diets were used (Low
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
bactin Reverse
TAAAACGCAGCTCAGTAACAGTCCG
This paper N/A
sXBP1 Forward
GCTGAGTCCGCAGCAGGTG
Villeneuve et al., 2010 N/A
uXBP1 Forward
GAGTCCGCAGCACTCAGACT
Villeneuve et al., 2010 N/A
XBP1 Reverse
GTGTCAGAGTCCATGGGAAGA
Villeneuve et al., 2010 N/A
shRNA target sequence: IRE1a sh#1:
CCAAGATGCTGGAGAGATT
This paper N/A
shRNA target sequence: IRE1a sh#2:
GCTCGTGAATTGATAGAGA
This paper N/A
shControl Santa Cruz sc-108060
shIFNg Santa Cruz sc-39607-SH
Recombinant DNA
psPAX2 plasmid Addgene 12260
pSUPER Oligoengine VEC-PRT-0005/0006
MLV-Gag-Pol Els Verhoeyen N/A
CRISPR–Cas9-control plasmid Santa Cruz sc-418922
CRISPR–Cas9-IRE1a plasmid Santa Cruz sc-429758
CRISPR–Cas9-RIG1 plasmid Santa Cruz sc-432915
Software and Algorithms
Bioinfominer e-NIOS www.bioinfominer.com
GraphPad Prism 7 GraphPad software https://www.graphpad.com/scientific-
software/prism/
Image J NIH https://imagej.nih.gov/ij/
Xcalibur 2.1 Thermo Fisher Scientific N/A
Other
Control Diet ENVIGO TD.130931
Low CHO Diet ENVIGO TD.130932
Low PROT Diet -12,5% ENVIGO TD.170630
Low PROT Diet -25% ENVIGO TD.130933
Low PROT Diet -40% ENVIGO TD.170631
Dulbecco’s MEM (DMEM) w/o Amino Acids USBiological D9800-13
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PROT -12.5%: TD.170630 and Low PROT -40%: TD.170631). % energy CHO:PROT:FAT: Ctl - (70.9%:19.5%:9.6%); Low CHO -
(54%:26.9%:19.2%); Low PROT -25% - (73.7%:14.9%:11.5%); Low PROT -12.5% - (72.2%:17%:10.8%); Low PROT -40% -
(76.4%:12.2%:11.4%).
WT syngeneic C57BL/6 mice were intravenously injected with 0.1 3 106 Em-Myc cells. At day four after injection, the food was
replaced with isocaloric diets generated by ENVIGO for 2 weeks: Ctl, Low CHO or Low PROT. BALB/c and C57BL/6 mice were
fed with isocaloric Ctl and Low PROT diets (-12.5%, -25%, -40%) one week before subcutaneous injection with 0.5 x 106 CT26 cells
or 0.25 x 106 B16 cells. NOD scid gamma c-/- (NSG) mice were fed with Ctl, Low CHO or Low PROT isocaloric diets generated by
ENVIGO one week before intravenous injection with 0.13106 Em-Myc cells. For the groups with splenocyte co-injection, splenocytes
fromwild-type C57BL/6 mice were freshly isolated and washed in PBS. Then, 23106 splenocytes were co-injected with 0.13106 Em-
Myc cells.
Syngeneic C57BL/6 mice and NSG mice injected with Em-Myc cells were monitored for lymphoma development and systemic
signs of illness, including apathy, breathing problems, precipitous weight loss, and limited ability to reach food or water. Animals
were euthanized as soon as they exhibited any signs of illness. After subcutaneous B16 and CT26 tumor cell injection syngeneic
C57BL/6 and BALB/c mice were inspected daily for tumor development. Increase in tumor size was measured with a caliper. Tumor
volume was calculated as follows: (Length x width to the power of 2)/2, where L is the longer of the 2 measurements.
For antibody-mediated depletion experiments in vivo, mice were intraperitoneally injected with 100 mg of an anti-CD8-depleting
antibody (Bioxcell, clone53-6.7, #BE0004-1) or vehicle (PBS) every second day for seven doses during 2 weeks after tumor cell in-
jection. For antibody-mediated blockade experiments in vivo, mice were intraperitoneally injected with 100 mg of anti-CD86-blocking
antibody (Bioxcell, clone GL-1, #BE0025) or vehicle (PBS) every second day for seven doses during 2weeks after tumor cell injection.
For dendritic cell andmacrophage depletion in vivo,mice were injected intraperitoneally with 200 mL of a 5mg/mL clodronate-loaded
liposome suspension (Liposoma B.V., #PBS-02) every second day for seven doses during 2 weeks after tumor cell injection. Control
mice were injected with 200 mL PBS-loaded liposomes using the same schedule.
TUDCA (Sigma-Aldrich, #T0266) was intraperitoneally administered in PBS (250 mg/gram of mouse body weight). MKC4485 was
administered by oral gavage at a dose of 10 mL/kg from a 30mg/mL suspension in 1%microcrystalline cellulose in a simple sugar at
300 mg/kg daily (Provided by John B. Patterson). Both inhibitors were administered from day 11 until day 16 after subcutaneous
tumor cell injection. Then, the mice were euthanized for further analysis. When described glycemia was measured after a few hours
of fasting by using a freestyle Optium blood glucose monitoring device.
Cell Lines and Cell Culture Conditions
Lymphoma-bearing C57BL/6 Em-Mycmice were killed by cervical dislocation as soon as they presented signs of illness. A single-cell
suspension was prepared from lymph nodes by teasing them on a 70-mm nylon filter. Cells were either resuspended in DMEM
(GIBCO) supplemented with 10% fetal bovine serum (FBS), 10 mM Hepes, 0.1 mM L-asparagine, and 50 mM b-mercaptoethanol
for further ex vivo analysis or reimplantation in wild-type mice. B16 cells were obtained from the ATCC (#CRL-6323) and cultured
in DMEM (GIBCO) supplemented with 10% fetal bovine serum (FBS). CT26 cells were obtained from the ATCC (#CRL-2638) and
cultured in RPMI-1640 medium (GIBCO) supplemented with 10% FBS and 1% sodium pyruvate. When indicated CT26 cells were
cultured for 24 hr in amino acid (AA)-deprived medium (USBiological, #D9800-13). All cell lines were incubated at 37C in a 5%
CO2 atmosphere.
METHOD DETAILS
Cytotoxicity Assay
CD3+ cells were negatively sorted from mice spleens using autoMACS (Miltenyi Biotec) with FITC antibodies against CD19 (Miltenyi
Biotec, #130-102-494), CD45R (Miltenyi Biotec, #130-110-845), CD49b (BD Biosciences, #553857), CD11b (BD Biosciences,
#553310) and Ter-119 (BD Biosciences, #557915). The resulting purified cells were co-incubated with CT26 or B16 cells at a
ratio 1:5 in the presence of IL-2 (0.1 ng/mL, AbD Serotech, #PMP38) for 4 hr or 48 hr at 37 C. Flow cytometry (MACS-Quant Analyzer,
Miltenyi Biotec) was used to analyze the cell viability of CT26 and B16 cells. CD3-negative population and back gating was used to
confirm the difference in forward scatter and side scatter parameters between cells. Cell death was evaluated by looking at plasma
membrane permeabilization of CT26 and B16 cells using 4’,6-diamidino-2-phenylindole staining (DAPI, Sigma-Aldrich #D9542).
Flow Cytometry Analysis
To obtain a single-cell suspension from tumors, lymph nodes, and spleens were filtered through a 70-mm strainer, stained, and
analyzed on MACS-Quant Analyzer (Miltenyi Biotec). The following fluorochrome-conjugated anti-mouse antibodies were used:
CD4 (VioBlue, #558107), CD8 (PE, #553032), NK1.1 (PE, #557391), CD11c (PE, #557401), CD86 (PECy7, #560582), CD127
(APC, #564175), CD25 (APCCy7, #557658) (BD Biosciences). CD3 (FITC, #11-0031-85), F4/80 (VioBlue, #48-4801-82) (eBioscience).
Percentage of CD4+ and CD8+ cells are calculated within CD3+ cells. T regs were defined as the CD3+CD4+CD25+CD127- T-cell
population. NK cells were defined as CD3-NK1.1+ cells. DCs were defined as F4/80-CD11c+ cells and macrophages were defined as
F4/80+ cells. Percentage of CD86+ cells was calculated within CD11c+ cells.
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Confocal Laser Scanning Microscopy
Tumoral tissue was snap-frozen in O.C.T. compound (Tissue-Tek, #4583). Then, 5-mm cryosections were prepared and fixed in
acetone. Purified anti-mouse CD8a (Biolegend, clone 53-6.7, #100701) was used for CD8 staining and was visualized using Alexa
Fluor 594 anti-rat secondary antibody (Molecular Probes, #A11007). All sections were stained with DAPI. For each condition at least
three measurements were performed. The number of CD8-positive cells was determined in optical fields of 403 on individual sec-
tions. Samples were imaged using a Nikon A1R confocal microscope and processed with ImageJ software analysis.
Western Blot Analysis
Tissue samples were collected and lysed using a Precellys 24 (Bertin Instruments) homogenizer (3 3 30 s, 6500 3 g) in Laemmli
buffer. Proteins were immunoblotted with the indicated antibodies. Immunoblots were visualized (FUJIFILM LAS4000) using the
ECL Western Blotting Detection Reagents (GE Healthcare, #RPN2106), and quantification was performed using ImageJ software.
anti-XBP1 (#sc-8015), and anti-ERK2 (#sc-1647) antibodies were purchased from Santa Cruz Biotechnology. Anti-IRE1a (#3294),
Anti-pS6K (#9234), anti-S6K (#9202), anti-pAKT (#9271), anti-AKT (#2967), anti-LC3B (#3868), anti-eIF2a (#9722), anti-peIF2a
(#9721), anti-RIG1 (#3743), anti-ATF-4 (#11815), anti-CHOP (#2895) and GCN2 (#3302) antibodies were purchased from Cell
Signaling. Anti-ATF6 (#NBP1-40256) and anti-pIRE1a (#NB100-2323) were purchased from Novus Biologicals. Anti-GRP78
(#ab21685) and anti-pGCN2 (#ab75836) was purchased from Abcam.
Reverse Transcriptase Quantitative-PCR (RT-qPCR) Analysis
CT26 tumors were dissociated with the mouse Tumor Dissociation Kit (Miltenyi Biotec, #130-096-730) and CD4+/CD8+ TILs were
sorted from the obtained single cell suspension using mouse CD4/CD8 (TIL) MicroBeads (Miltenyi Biotec, #130-116-480) in an au-
toMACS (Miltenyi Biotec). CD11c+ DC were sorted from spleens of tumor-bearing BALB/c mice using mouse CD11c Microbeads
ultrapure in an autoMACS (Miltenyi Biotec, #130-108-338). For total tumor tissue samples were collected and lysed using a Pre-
cellys 24 (Bertin Instruments) homogenizer (33 30 s, 65003 g) and total RNA was isolated from cells and tissue using the RNAeasy
minikit (Qiagen, # 74104) according to themanufacturer’s protocol. Reverse transcription was performed using the Omniscript RT Kit
(Qiagen, #205113). Quantitative-PCR was performed with Fast SYBR Green (Applied Biosystems, Life Technologies, # 4385616) or
TaqMan Fast Universal PCR Master Mix (Applied Biosystems, #4352042) using the 7500 Fast and the Step One real-time PCR
systems (Applied Biosystems) following the manufacturers’ instructions.
The following primers were used for SYBR Green qPCR: Scara3 Forward 50-TGCATGGATACTGACCCTGA-30 and Reverse
50-GCCGTGTTACCAGCTTCTTC-30; Blos1 Forward 50-CAAGGAGCTGCAGGAGAAGA-30 and Reverse 50-GCCTGGTTGAA
GTTCTCCAC-30 Col6 Forward 50-TGCTCAACATGAAGCAGACC-30 and Reverse 50-TTGAGGGAGAAAGCTCTGGA-30 IFNg
Forward; 50-TCAAGTGGCATAGATGTGGAAGAA-30 and Reverse 50-TGGCTCTGCAGGATTTTCATG-30; CXCL10 Forward
50-GCTGATGCAGGTACAGCGT-30 and Reverse 50-CACCATGAATCAAACTGCGA-30; bactin Forward 50-TGGAATCCTGTGGCATC
CATGAAA-30 and Reverse 50-TAAAACGCAGCTCAGTAACAGTCCG-30. sXBP1 Forward 50-GCTGAGTCCGCAGCAGGTG-30;
uXBP1 Forward 50-GAGTCCGCAGCACTCAGACT-30 and XBP1 Reverse 50-GTGTCAGAGTCCATGGGAAGA-30 (Villeneuve et al.,
2010) . The housekeeping gene b-actin was used as a control for RNA quality and for normalization.
The following Taqman assay primer sets from Applied Biosystems were used: Atf3Mm00476033_m1; Ero1lb Mm00470754_m1;
SarsMm00803379_m1; Trib3Mm00454879_m1;Hsp90b1Mm00441926;Hyou1Mm00491279_m1. The housekeeping gene Rn18s
was used as a control for RNA quality, and used for normalization: Mm03928990_g1.
All analyses were performed in triplicate, andmelting curve analysis was performed for SYBRGreen to control product quality and
specificity.
Generation of shIFNg- and shIRE1a-Transduced Cells
Self-inactivating viruses were generated by transient transfection of 293T cells (ATCC, #CRL-1573) and tittered as described
previously (Frecha et al., 2011). Briefly For VSV-G preparation, 3 microgram of envelope plasmid was co-transfected using the
classical calcium phosphate method with a 8,6 microgram Gag-Pol packaging plasmid (psPAX2, Adgene, #12260) and 8,6 micro-
gram of a plasmid encoding a control shRNA plasmid (Santa Cruz, #sc-108060) and a self-inactivating mouse lentiviral shIFNg
plasmid (Santa Cruz, #sc-39607-SH). Eighteen hours after transfection, the medium was replaced by Opti-MEM supplemented
with HEPES (Invitrogen). Viral supernatants were harvested 48 hr after transfection and filtered. The vectors were concentrated at
low speed by overnight centrifugation of the viral supernatants at 3000g at 4C.
For the generation of stable CT26 with silenced IRE1a, we used the pSUPER retroviral vector with neo+GFP (Oligoengine, #VEC-
PRT-0005/0006). The target sequences were as follows: sh#1= 50-CCAAGATGCTGGAGAGATT-30and sh#2= 50-GCTCGTGAATT
GATAGAGA-30. Oligonucleotides were cloned into the pSUPER vector following the manufacturer’s protocol. Double-stranded
DNA templates encoding siRNA oligonucleotides for IRE1a were synthesized. The specific oligonucleotide sequence contained a
sense strand of 19 nucleotides followed by a short spacer (TTCAAGAGA) and the reverse complement of the sense strand. Five
thymidines were added at the end of the synthesized oligonucleotide as an RNA polymerase III transcriptional stop signal.
Oligonucleotides were annealed and ligated into the pSUPER vector digested by BglII and HindIII, and insertion was confirmed
by EcoRI–HindIII digestion via migration in an agarose gel. For VSV-G preparation, 3 microgram of envelope plasmid was co-trans-
fected using the classical calcium phosphate method with a 8,6 microgram MLV-Gag-Pol packaging plasmid and 8,6 microgram of
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the empty pSUPER plasmid or the shIRE1a containing pSUPER plasmids. CT26 cells were transduced and sorted using a SONY
sorter SH800 based on GFP expression, resulting in >95% purity.
Generation of CRISPR/Cas9 Cells
For the generation of stable CT26 with invalidated IRE1a or RIG1 cells were transfected with 3 mg of CRISPR–Cas9-expressing
knockout plasmids (control, sc-418922; IRE1a, sc-429758; RIG1, sc-432915; all from Santa Cruz) using the jetPEI DNA transfection
Reagent (PolyPlus Transfection, #POL101-10N) as described by the manufacturer. The knockout plasmids are a mixture of three
plasmids, each carrying a different guide RNA specific for the target gene, as well as the Cas- and GFP-coding regions. GFP+ cells
were selected by sorting on a SH800S Cell Sorter (Sony Biotechnology) 24 hr after transfection, and depletion of target proteins was
verified by immunoblotting.
Sampling of Intracellular Metabolites
Tumor samples were resuspended in 170 mL of ultrapure water, manually crushed with a micro potter, vortexed, and then sonicated
5 times for 10 s using a sonication probe (vibra cell, Bioblock Scientific). At this step, 20mL of each sample were withdrawn for further
determining the total protein concentration (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific, #23225). Then, we added 350 mL
of methanol to the remaining 150 mL of lysate and we sonicated again twice for 10 s each using a sonication probe. Cell debris were
then removed by centrifugation for 30 min at 4C and 20,000g. Supernatant was recovered and incubated 1h30 on ice before a sec-
ond centrifugation step for 15min at 4C and 20,000g. The resulting metabolic extracts were dried under a stream of nitrogen using a
TurboVap instrument (Thermo Fisher Scientific) and stored at 80C until analysis.
Dried extracts were dissolved using a given volume of 95 % mobile phase A / 5% mobile phase B to give in a 1000 ng/mL total
protein concentration for alanine, arginine, proline methionine, tyrosine, isoleucine, leucine, phenylalanine, and tryptophan quantifi-
cation. The extract was then diluted 2-fold for aspartic acid, glutamine, glycine, and valine quantification, while another 4-fold dilution
was performed for asparagine, serine, threonine, glutamic acid, lysine, and histidine quantification. A defined concentration* of a
labeled amino acids mixture 98 atom % 13C, 98 atom % 15N (Sigma-Aldrich, #608254) was added to each sample in
order to normalize the signals and estimate endogenous amino acid concentrations. *13C 415N -Asn , 0.21 mg/mL; *13C3,
15N-Ser, 0.27 mg/mL; *13C4,15N-Asp, 0.64 mg/mL; *13C5,15N2-Gln, 0.24 mg/mL; *13C2,15N-Gly, 0.34 mg/mL; *13C4,15N-Thr,
0.32 mg/mL; *13C5,15N-Glu, 0.58 mg/mL; *13C3,15N-Ala, 0.54 mg/mL; *13C6,15N2-Lys, 0.26 mg/mL; *13C6,15N3-His,
0.06 mg/mL; *13C6,15N4-Arg, 0.35 mg/mL; *13C5,15N-Pro, 0.2 mg/mL; *13C5,15N-Val, 0.31 mg/mL; *13C5,15N-Met, 0.12 mg/mL;
*13C9,15N-Tyr, 0.23 mg/mL; *13C6,15N-Ile, 0.26 mg/mL; *13C6,15N-Leu, 0.56 mg/mL; *13C9,15N-Phe, 0.26 mg/mL; *13C11,15N2-
Trp, 0.34 mg/mL.
Analysis of Amino Acid Residues by Liquid Chromatography Coupled to High Resolution Mass Spectrometry (LC-MS)
LC-MS experiments were performed using a Dionex Ultimate chromatographic system (Thermo Fisher Scientific) coupled to an
Exactive (Orbitrap) mass spectrometer (Thermo Fisher Scientific) fitted with an electrospray ion source. The mass spectrometer
was externally calibrated before each analysis using themanufacturer’s predefinedmethods and provided recommended calibration
mixture. Chromatographic separation was performed on a Discovery HS F5 PFPP 5 mm, 2.1 3 250 mm column (Sigma-Aldrich) at
30C. The chromatographic system was equipped with an on-line prefilter (Thermo Fisher Scientifics). Mobile phases were 100%
water (A) and 100% aceonitrile (B), both of which containing 0.1% formic acid. Chromatographic elution was achieved with a flow
rate of 250 mL/min. After sample injection (20 mL), elution started with an isocratic step of 2 min at 5% phase B, followed by a linear
gradient from 5 to 100% of phase B in 18 min. These proportions were kept constant for 4 min before returning to 5% of phase B and
letting the system equilibrate for 6 min. The column effluent was directly introduced into the electrospray source of the mass
spectrometer, and analyses were performed in the positive ion mode. Source parameters were as follows: capillary voltage set at
5 kV, capillary temperature at 300C; sheath and auxiliary gas (nitrogen) flow rates at 50 and 25 arbitrary units, respectively; mass
resolution power of the analyzer set at 50,000 at m/z 200 (full width at half maximum, FWHM) for singly charged ions. The acquisition
was achieved from m/z 50 to 250 in the positive ionization mode during the first 12 min of the run. Under these conditions, we
achieved a good chromatographic separation and detection (with an average mass accuracy better than 3ppm) of the 19 targeted
amino acids (under their [M+H]+ form). These species were readily identified and quantified by the isotope dilutionmethod using 13C,
15N-labeled homologues (see above). Corresponding extracted ion chromatograms were generated and resulting peaks integrated
using the Xcalibur software (version 2.1, Thermo Fisher Scientific) for alanine ([M+H]+ at theoretical m/z 90.05496, retention time
2.98 min), arginine (m/z 175.11895, 3.19 min), asparagine (m/z 133.06077, 2.81 min), aspartate (m/z 134.04478, 2.84 min), glutamate
(m/z 148.06043, 2.95 min), glutamine (m/z 147.07642, 2.84 min), glycine (m/z 76.03931, 2.84 min), histidine (m/z 156.07675,
3.03 min), isoleucine (m/z 132.10191, 5.73 min), leucine (m/z 132.10191, 6.37 min), lysine (m/z 147.11280, 3.00 min), methionine
(m/z 150.05833, 4.17 min), proline (m/z 116.07061, 3.22 min), phenylalanine (m/z 166.08626, 8.57 min), serine (m/z 106.04987,
2.81min), threonine (m/z 120.06552, 2.88min), tryptophan (m/z 205.09715, 10.58min), tyrosine (m/z 182.08117, 5.51min), and valine
(m/z 118.08626, 3.79 min). P-values were calculated by applying a Mann Whitney test using the GraphPad Prism Software.
Bioinformatic Analysis
Patients were clustered according to IRE1a activity based on the normalized z-score of gene expression for the BioInfoMiner
signature of 38 genes (Lhomond et al., 2018). The z-score was calculated by the equation (X - m)/s, X stands for normalized log2
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expression data of each gene in each sample; m stands for mean of expression of each gene among all samples; and s stands for
standard deviation. Raw data (*.CEL files) of the GSE27306 dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE27306) from (Pluquet et al., 2013) were processed into R/Bioconductor by using the RMA normalization and Limma
package (Ritchie et al., 2015). The deferentially expressed genes (DEGs) between DN and WT U87 cells, were selected by using a
corrected p value threshold of 0.05 and fold change threshold of jlog2(fc)j R1.5. 1051 deferentially expressed (D.E.) genes were
then introduced into the BioInfoMiner tool and gene prioritization was executed based on the biomedical ontologies of the four-
different functional and phenotype databases (GO), Reactome, MGI and HPO, separately. For the annotation process was used
the ‘‘complete’’ version (this version amplifies the annotation of each gene with the ancestors of every direct correlated ontological
term, exploiting the structure of ontological tree) and the hypergeometric pvalue threshold was set to 0.05. 227 highly prioritized
genes including their proximal interactors was the union of the BioInfoMiner output from the four databases and 38 hub-genes
were highlighted as the intersection with the IRE1a signature of 97 genes of (Pluquet et al., 2013). The BioInfoMiner signature was
composed of 19 genes; highly up-regulated in WT versus DN U87 cells (ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8,
IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2, ZNF804A), and 19 genes; highly
down-regulated in WT versus DN U87 cells (ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM,
OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3, TMEM255A).
This 38-genes signature was used to stratify 3 different types of tumors including glioblastoma multiform (GBM; TCGA and
GBMmark, Lhomond et al., 2018), melanoma (TCGA) and colorectal cancer (TCGA) into IRE1a high and IRE1a low activity tumors.
Then based on these 2 tumor groups, the expression of the following T-cell markers was evaluated in the two groups using the
transcriptome data: IFNG, IL12, TBX21, IRF1, STAT1, GZMA, GZMB, GZMH, PRF1, GNLY, NKG7, CXCL9, CXCL10, CCL5,
CX3CL1, CXCR3, CCL2, CCL4, CXCL11, MADCAM1, ICAM1, VCAM1, CD3D, CD8A, GBP1, and all the available HLAs.
Statistics
Statistical analysis was conducted using GraphPad Prism 7 software. Differences in calculated means between groups were
assessed by two-sided Student’s t tests. For experiments involving more than two groups, differences in the calculated mean values
between the groups were assessed by one-way analysis of variance (ANOVA) followed by Fisher’s exact test. Kaplan-Meier survival
analyses were performed, and survival curves were compared using log-rank tests. A P-value less than 0.05 was considered
significant. Error bars represent the means ± standard error of the mean (SEM).
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 1 
Supplemental Figure legends 1 
Figure S1. Related to Figure 1. Effect of diets on C57BL/6 and BALB/c 2 
mice injected with tumor cells. (A) Food intake and (B) mice weight of 3 
C57BL/6 mice injected with Eµ-Myc lymphoma cells and fed ad libitum with Ctl, 4 
Low CHO and Low PROT diets. (C) IFNγ mRNA levels in the lymph nodes of 5 
C57BL/6 lymphoma bearing mice (D) Flow cytometry profile showing the 6 
effective antibody-mediated depletion of CD8 T lymphocytes. (E) Food intake 7 
and (F) mice weight of syngeneic BALB/c mice that were injected with CT26 8 
colorectal carcinoma cells and were fed ad libitum with Ctl and Low PROT (-9 
12,5%, -25% and -40%) diets. (G) Tumor growth curve of syngeneic C57BL/6 10 
mice that were subcutaneously injected with B16 melanoma cells. Mice were fed 11 
ad libitum with Ctl and Low PROT diets and were intraperitoneally injected with 12 
PBS or αCD8 antibody (Ctl, n=6; Low PROT, n=8; Ctl aCD8, n=6; Low PROT 13 
aCD8, n=8). Tumor volume at day 12 (H) of data shown in (G). (I) 14 
Confirmation of antibody-mediated depletion of CD8 T lymphocytes in mice. Flow 15 
cytometry analysis of the proportion of CD4 and CD8 T cells in spleens of 16 
C57BL/6 mice injected with Eµ-Myc or B16 cells and BALB/c mice injected with 17 
CT26 cells. (J) Food intake and (K) mice weight of syngeneic C57BL/6 mice that 18 
were injected with B16 colorectal carcinoma cells. (L) Food intake and (M) mice 19 
weight of syngeneic BALB/c mice that were injected with CT26 colorectal 20 
carcinoma cells. Mice were fed ad libitum with Ctl and Low PROT diets. (N) 21 
Glycemia was measured in BALB/c mice that were injected with CT26 colorectal 22 
carcinoma cells after 21 days of Ctl and Low PROT diets. *P < 0.05, **P < 0.01. 23 
Error bars represent SEM. When not mentioned, differences are not significant.  24 
Comparisons of every group vs. Ctl group, except where specified otherwise. 25 
When not mentioned, differences are not significant. 26 
 27 
Figure S2. Related to Figure 2. A Low PROT diet induces IFNγ and 28 
CXCL10 mRNA levels in CT26 tumors. (A-B) C57BL/6 mice were 29 
intravenously injected with Eµ-Myc cells and BALB/c mice were subcutaneously 30 
injected with CT26 colorectal carcinoma cells. C57BL/6 mice were fed ad libitum 31 
with Ctl, Low CHO and Low PROT diets. BALB/c mice were fed with Ctl and Low 32 
PROT diets. Upon sacrifice, CD3+ cells were isolated from spleens and incubated 33 
 2 
with live Eµ-Myc cells or CT26 cells for 48 hours. The ability of T cells to kill 1 
tumor cells was determined by flow cytometry. Cell death of Eµ-MYC (A) and 2 
CT26 cells (B) was determined by DAPI staining (3 mice per group). (C-D) 3 
BALB/c mice that were subcutaneously injected with CT26 colorectal carcinoma 4 
cells and were fed ad libitum with Ctl and Low PROT diets. Tumors were 5 
harvested and (C) IFNγ and (D) CXCL10 mRNA levels were measured by qPCR 6 
(at least 3 mice per group). *P < 0.05, ***P < 0.001. Error bars represent SEM. 7 
Comparisons of every group vs. Ctl group, except where specified otherwise. 8 
When not mentioned, differences are not significant. 9 
 10 
Figure S3. Related to Figure 3. Effect of clodronate liposomes and CD86 11 
blockade on myeloid cells. BALB/c mice were subcutaneously injected with 12 
CT26 colorectal carcinoma cells and were fed ad libitum with Ctl and Low PROT 13 
diets. (A) Mice were intraperitoneally injected with liposomal clodronate (Lipo 14 
Clod) or PBS liposomes (Lipo PBS). Flow cytometry profile confirming Lipo Clod-15 
mediated depletion of dendritic cells (F4/80- CD11c+) and macrophages (F4/80+). 16 
(B) Flow cytometry profile showing the effective antibody-mediated blockade of 17 
CD86 on CD11c+ cells. 18 
 19 
Figure S4. Related to Figure 4. A Low PROT diet does not modulate 20 
mTOR, AKT, GCN2 or autophagy in CT26 tumors. Syngeneic BALB/c mice 21 
were subcutaneously injected with CT26 colorectal carcinoma cells and fed ad 22 
libitum with Ctl, and Low PROT diets. (A) Tumors were harvested after 25 days 23 
of diets and lysates were prepared. Expression of indicated proteins were 24 
analyzed by western blot. (B) Average quantification of pS6K and pAKT 25 
compared with the corresponding total protein levels. (C) Expression of pGCN2 26 
and the corresponding total protein was analysed by western blot. (+) 27 
corresponds to CT26 cells cultured under amino acid deprivation conditions, used 28 
as a positive control for GCN2 activation. (D) Status of LC3 autophagy related 29 
conversion was analyzed by immunoblots. (E) Average quantification of LC3II 30 
compared with ERK2 levels (used as a loading control). (F) relative amount of 31 
amino acids measured in CT26 tumors isolated from Ctl or Low PROT diet fed 32 
 3 
mice (n=8 for Ctl and n=7 for Low PROT condition). Error bars represent SEM. 1 
When not mentioned, differences are not significant.  2 
 3 
Figure S5. Related to Figure 4. A Low PROT diet does not modulate ATF6, 4 
eIF2 or ATF4 in CT26 tumors.  (A) Expression of ATF6, eIF2 and ATF4 5 
proteins were analyzed by immunoblots. (B) Average quantification of cleaved 6 
ATF6, peIF2 and ATF4 compared with ERK2 levels (used as a loading control) or 7 
the corresponding total protein. (C) mRNA levels of ATF6 and ATF4 targets were 8 
measured in tumors by qPCR (at least 3 mice per group). Error bars represent 9 
SEM. When not mentioned, differences are not significant. 10 
 11 
Figure S6. Related to Figure 5. Treatment with ER stress inhibitors 12 
affects the recruitment of CD8 Tumor Infiltrating Lymphocytes. BALB/c 13 
mice that were subcutaneously injected with CT26 cells and were fed ad libitum 14 
with Ctl and Low PROT diets. Mice were treated with TUDCA and MKC4485 from 15 
day 11 to 16 after subcutaneous injection. (A) Immunofluorescent staining of 16 
CD8 T cells in tumors, scale bar is equivalent to 50 µm (B) Flow cytometry 17 
analysis of the frequency of infiltrating CD8 T cells in CT26 tumors. (C) IFNγ 18 
mRNA levels in CT26 tumors of BALB/c mice. (D) Flow cytometry analysis of the 19 
proportion of CD4 and CD8 T cells in lymph nodes and (E) spleens of BALB/c 20 
mice. **P < 0.01, ***P < 0.005. Error bars represent SEM. Comparisons of 21 
every group vs. Ctl group, except where specified otherwise. When not 22 
mentioned, differences are not significant. 23 
 24 
Figure S7. Related to Figure 6 & 7.  Knockdown in CT26 cells of IRE1α 25 
using two different shRNAs. (A) Proliferation curves in vitro. (B) Tumor 26 
growth curve of BALB/c mice that were subcutaneously injected with sh#2 IRE1a 27 
CT26 cells and were fed ad libitum with Ctl and Low PROT diets. (C) Tumor 28 
volume at day 11 of data shown in Fig 6B-C and Sup Figure 7B. (D) Proliferation 29 
curves in vitro of CRISPR Ctl, CRISPR IRE1a and CRISPR RIG1 CT26 colorectal 30 
carcinoma cells. Hierarchical clustering of CRC (n=456; E), Melanoma (n=293; 31 
F) and Glioblastoma (n=523, G) patients (TCGA cohorts) based on high or low 32 
 4 
IRE1a activity as assessed with the median z-score of the expression pattern of 1 
the IRE1a gene signature of 38 hub-genes (Lhomond et al. 2018). Pearson 2 
correlation was used to measure the similarity between different genes and 3 
tumor cases, as well. The expression pattern of WT vs. DN has been described in 4 
detail in (Pluquet et al., 2013). Blue: low mRNA expression levels, Red: high 5 
mRNA expression levels. Error bars represent SEM. When not mentioned, 6 
differences are not significant. 7 
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2. Preliminary result 
IRE1 activation correlates with increased MHC-I expression. 
We have previously showed that low PROT diet in mice induces an anti-tumor immune response 
dependent on specific IRE1 signaling (Rubio-Patino, Bossowski et al., 2018b). Mechanistically, 
low PROT diet induced immunosurveillance by activation of an IRE1/RIG1 axis within the tumoral 
cells, concomitant with enhanced cytokine expression and CD8+ T cell-dependent anti-cancer 
cytotoxic response. Although increase in cytokine secretion is required for enhanced immune 
response, other molecular modifications that remains to be identified are required for the induction 
of specific anti-cancer immune response. As IRE1 signaling in tumor cells seems to be the core 
determinant of low PROT-induced immunosurveillance, we focused our attention on the effect that 
modulation of this pathway could have on the immunogenic phenotype of cancer cells. A main 
determinant of effective adaptive immune response and tumor immune escape mechanism is the 
modulation of surface expression of MHC-I molecules (Garrido, Aptsiauri et al., 2016). As MHC-
I is a critical determinant of cancer cell immunogenicity, we aimed to analyze the effect of IRE1 
on MHC-I surface expression. In this regard, we used CT26 cells invalidated for IRE1 by 
CRISPR/Cas9 technology. Surprisingly, we observed lower surface expression of MHC-I in IRE1-
deficient CT26 cells as compared to control cells (Fig 1A). 
We reasoned that if IRE1 deficiency leads to downregulation in MHC-I surface expression, then 
IRE1-specific induction could conversely lead to MHC-I increase. As there is no known specific 
inducer of IRE1 which is available, and the commonly used ER stress inducing agents provoke 
general UPR induction (not specific to IRE1), we decided to use BSA-conjugated palmitate 
(PA/BSA) as one of the specific IRE inducer reported so far, as some studies reported that lipid 
alterations affecting ER membrane lipidic composition could more directly induce IRE1 (Kitai, 
Ariyama et al., 2013, Lancaster, Langley et al., 2018) (see Fig. 6 for a proposed model). We chose 
100 µM dose of PA/BSA, which over 24-hour treatment did not affect cell viability (Fig. 1B) and 
was reported to induce IRE1 activation (Kitai et al., 2013, Lancaster et al., 2018). We performed a 
kinetic assay of PA/BSA treatment over 24-hour period in CT26 cells, where we analyzed UPR 
activation and MHC-I surface expression. Tunicamycin (1 µg/mL) treatment was used as a positive 
control for general ER stress induction. We observed a time-dependent increase in phosphorylation 
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of IRE1 upon PA/BSA stimulation, starting at 1hr and lasting over 24hr-period as assessed by 
western blot (Fig. 1B). In contrast, other branches of UPR were not, or only mildly affected, as 
assessed by ATF4 expression and ATF6 cleavage (Fig. 1C). To determine the induction of IRE1 
RNase activity, we measured the relative levels of spliced mRNA XBP1 both by classical PCR and 
by real time qPCR (Fig. 1 D-E). In both approaches, we observed strong time-dependent induction 
of XBP1 splicing, indicating IRE1 RNase activation. Finally, we analyzed the surface expression 
of MHC-I by flow cytometry considering only viable CT26 cells in the kinetic treatment with 
PA/BSA, where we observed a modest but consistent increase in MHC-I levels over a 24hr-period, 
contrary to cells treated with tunicamycin, where MHC-I levels potently declined (Fig. 1F). Given 
that tunicamycin also stimulated IRE1 RNase activity (Fig.1 D-E), we concluded that probably 
additional mechanisms induced by a more general ER stress leads to MHC-I decrease, whereas the 
specific IRE1 activation drives MHC-I overexpression on the cell surface. It remains to be 
determined if the PA/BSA treatment of IRE1 invalidated CT26 does not modulate MHC-I 
expression. As the effect of PA/BSA and tunicamycin on MHC-I surface expression are in strike 
contrast, we cannot exclude the participation of additional signaling pathways in this phenomenon, 
as under tunicamycin treatment we cannot distinguish between the effects of other branches of the 
UPR. Nevertheless, as UPR activation is usually reported as a negative regulator of MHC-I 
expression (Ulianich, Terrazzano et al., 2011), we consider our results linking IRE1 activity with 
positive regulation of MHC-I expression of high relevance.   
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Glutaminase inhibition induces IRE1 activation and MHC-I surface expression. 
Although it is reported that lipid modulation can induce specific IRE1 membrane clustering and 
activation (Kitai et al., 2013), and the treatment with BSA-Palmitate in vitro indeed resulted in 
such activation in CT26 cells (Fig. 1 and Fig. 6), we have no direct evidences that lipid profile 
differs among tumors isolated from CTR and low PROT diet fed-mice. Instead, we observed a 
modulation in amino acid levels among tumors isolated from mice fed CTR and low PROT diet, 
with particular decrease in the glutamate/glutamine ratio (Article 1 Fig. 6). However, we do not 
know if this glutamine/glutamate modulation is the result of altered cellular metabolism or if it is 
the result of differential extracellular glutamine uptake. There are evidences that fatty acid 
metabolism can be affected by the disruption of glutamine/glutamate conversion, which in turn 
modulates lipid composition, but this has yet to be tested in our model of low PROT diet (Biancur, 
Paulo et al., 2017, Halama, Kulinski et al., 2018). Surprisingly, the inhibition of glutaminase has 
been reported to upregulate the proteins involved in lipid and fatty acid-related processes (Biancur 
et al., 2017). Thus, the result of glutaminase inhibition on lipid-driven IRE1 modulation is not 
evident, and has to be experimentally tested. For that matter, and to more directly translate the 
conditions of glutamine/glutamate modulation that we observed in vivo, we decided to investigate 
whether glutamine metabolism could impact IRE1 activity and in turn MHC-I expression, as we 
observed with PA/BSA treatment. We treated CT26 cells with a specific glutaminase 1 inhibitor, 
CB-839, known to block the conversion of glutamine to glutamate, the first enzymatic conversion 
enabling glutamine to enter cellular metabolic pathways such as the TCA (Gross, Demo et al., 
2014). First, we established the treatment dose of 10 µM CB-839, as that level did not affect cell 
viability, but impacted in cellular stress, reflected in diminished cell proliferation (Fig. 2A). 
Subsequently, we treated CT26 cells with CB-839 for 24 hour and analyzed the surface expression 
of MHC-I. As shown in Fig. 2B, glutaminase inhibition resulted in increased MHC-I expression 
resembling PA/BSA effect, as contrary to tunicamycin treatment. To assess IRE1 activation, we 
analyzed the generation sXBP1 by qPCR (Fig. 2C) and phosphorylation of IRE1 by western blot 
(Fig. 2D), where in both cases we observed a potent IRE1 activation and RNAse-dependent 
signaling. Strikingly, CB-839 did not produced significant increase in CHOP expression, as 
compared to complete glutamine deprivation in the medium (Fig. 2E), indicating that IRE1 
activation is more specifically induced by glutaminase inhibition than by glutamine deprivation. 
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Low-PROT diet reduces immune checkpoint markers and induces IFN expression. 
Immune checkpoints are immunosuppressive markers hampering effective anti-cancer immune 
response. There is a huge interest in developing clinical treatments targeting immune checkpoints 
signaling to reactivate compromised immune response. For example, recent studies showed 
enhanced antitumor immune response with the use of the calorie restriction mimetic metformin via 
downregulation of PD-L1 expression in tumor cells (Cha, Yang et al., 2018). We therefore 
investigated expression of immune checkpoint in vivo upon low-PROT diet regimen. For that 
matter we first reproduced our findings of low PROT-driven tumor growth suppression (Fig. 3 A-
B). We observed the expected increase in TILs under low-PROT regimen (Fig. 3C). Interestingly, 
the expression of immunoinhibitory checkpoint markers PD1 and CTLA4 were significantly 
decreased in CD8+ T lymphocytes present in tumors of mice fed low-PROT diet, as compared to 
those on the control diet (Fig 3C). That decrease in immunoinhibitory signaling could contribute 
to enhanced anti-cancer immune response and tumor growth inhibition under low-PROT 
conditions. Additionally, PD-L1 decrease was specific to CD8+ sub-population, as we did not 
observe differences in PD-L1 expression within CD45+ cells, which is the pan-marker of 
lymphocytes. Moreover, we found increased gene expression of IFNα and a trend toward increased 
levels of IFNβ and IFNγ in whole tumor lysates. In conclusion, low-PROT diet reduced immune 
checkpoint surface expression on central anti-cancer cytotoxic T lymphocytes and simultaneously 
increased IFN type I signaling.  
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Low-PROT diet impacts on cancer cell immunogenic phenotype. 
To directly address the phenotype of cancer cells under low PROT diet regimen, we negatively 
sorted the tumor cell population from CT26 tumor-bearing mice shown in Figure 3. First, we 
observed modulation in surface expression of cell markers regulating the immune response: 
NKG2D ligand H60, don’t eat me marker CD47 and immune checkpoint marker PD-L1 as 
measured by flow cytometry (Fig. 4A). Importantly, tumor cells isolated from low PROT diet-fed 
mice exhibited markedly elevated MHC-I expression as compared to those in CTR diet, 
accompanied by significant increase in CD47 and PD-L1 expression. In contrast, expression of 
H60, a MHC-I-like glycoprotein which is a known as a NKG2D ligand, was reduced under low 
PROT diet, and CTLA4 expression was not modulated (Fig. 4A). These results reveal complex 
regulation of the surface immune marker composition on tumor cells under low PROT diet feeding 
as compared to CTR diet. Next, we measured the mRNA level of a panel of cytokines, chemokines 
and inflammatory-related genes in sorted tumor cells (Fig. 4B). The levels of the cytokines IFNα, 
IFNβ, CXCL1, CXCL10, CXCL11, IL-15 and GM-CSF were increased under low PROT diet, as 
well as interferon-stimulated gene 15 (ISG15) and the chemokine CCL2 (Fig. 4B). To further 
extend our observations, we measured the expression of genes implicated in MHC-I assembling 
machinery, to assess whether the modulation of MHC-I expression is driven at the transcriptional 
level (Fig. 4C). Indeed, we have found increased levels of TAP1 gene, whose protein product is 
important in MHC-I assembling (Blees, Reichel et al., 2015). Additionally, we found elevated 
TRIM69 mRNA, E3 ubiquitin ligase implicated in immune tumor control and apoptosis. We also 
investigated gene expression of known mouse NKG2D ligands, and we found that only one of 
them, RAE-I was significantly upregulated under low PROT diet (Fig. 4D). That was unexpected, 
as we have not found any sign of in vivo and in vitro surface expression of this marker by flow 
cytometry. It is possible that as soon as RAE-1 is exposed on the plasma membrane surface, the 
cell is instantly recognized and eliminated by surrounding immune cells. The other explanation 
would be that RAE-1 is mutated and even though it is transcribed, the protein is not functional. 
However, this hypothesis has to be tested in future experiments. 
Collectively, our data indicate that feeding tumor-bearing mice a low-PROT diet results in 
alteration in the cell secretome and cancer immunogenicity. Whether these two events are 
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modulation in cytokines, chemokines or surface immune markers are dependent on the IRE1-RIG-
I axis induced by low PROT diet.   
Low-PROT diet promotes Retinoblastoma protein phosphorylation 
As we observed some modulation in NKG2D ligands expression on cancer cell under different diet 
regimens, we speculated what could be the mechanism regulating such modulation. E2F family of 
proteins implicated in the control of cell cycle has been described as regulators of some NKG2D 
ligands expression (Jung, Hsiung et al., 2012). Thus, we tested the expression of E2F1 and 
phosphorylation levels of retinoblastoma (RB) protein in whole tumors by western blot analysis. 
We found no changes in E2F1 protein levels, but we observed elevated phosphorylation of RB 
under low PROT diet regimen (Fig. 5). RB protein can bind transcription factors such as members 
of the E2F family and thereby inhibit their functions. Phosphorylation of RB disrupts that this 
interaction and releases E2F transcription factors, hence promoting their activity. These data 
suggest that E2F proteins might have higher activity via lower inhibitory regulation of RB in 
tumors from Low PROT diet fed mice. Interestingly, this result is in opposition with what we might 
expect, since we observed a reduction in tumor growth under Low PROT diet, and phosphorylation 
of RB protein is associated by cell proliferation. However, if the immune response induced by low 
PROT diet is signaled via NKG2D ligands (at least partially), the observed phosphorylation of RB 
could play a role in mediating enhanced anticancer immune response. Future experiments will 
address the link between Low PROT-induced immune response and cell cycle control in tumor 
cells. 
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DISCUSSION AND PERSPECTIVES 
We have demonstrated that IRE1 expression in tumoral cells is critical in orchestrating an effective 
anti-cancer immune response induced by low-PROT diet in three independent syngeneic mouse 
models: Eµ-myc lymphoma, colorectal carcinoma and melanoma. Either genetic or chemical 
ablation of IRE1 resulted in reversion of tumor growth suppression under low-PROT regimen, 
accompanied with reduced CD8+ TILs and abrogated cytokine production (summarized in Figure 
17). In addition, retinoic acid-inducible gene-I (RIG-I) seems to participate downstream of IRE1 
by triggering IFN-I type response in tumoral cells, followed by immune recognition and response. 
The ablation of RIG-I in cancer cells phenocopied IRE1 knock-down resistance to low-PROT diet 
induced immunosurveillance. Both IRE1 or RIG-I genetic deletions did not impact on tumor 
growth under CTR diet, indicating that in the studied model the anti-tumor properties depended on 
at least two elements: external stressor (low PROT regimen) and intact immunity (syngeneic mouse 
model). Multiple implications and questions arise from this work that need to be elucidated in the 
further studies. 
1. Diet, metabolism and cancer
Diet is recognized as the major environmental factor affecting cancer risk and survival in humans. 
Unfortunately, despite the growing awareness and scientific progress in what constitutes the 
healthy diet worldwide a trend toward overweight and obesity is still on rise, accompanied by the 
prevalence of unhealthy over healthy dietary patterns (Collaboration, 2017; Imamura et al., 2015). 
The preventive impact of diet on cancer onset is well acknowledged and documented, in contrast 
to the impact of the diet on clinical outcomes in patients with diagnosed cancer. Therefore, there is 
a growing interest in researching the nutritional impact on already established tumors, aiming to 
provide additional benefits in combination with current anti-cancer therapies. 
The vast majority of experimental studies investigating diet and cancer have been done in 
immunodeficient mouse models. The obvious limitation of such approach is the lack of immune 
system and its implication in tumor development, which means that the effect of the tested 
nutritional approach is immune system independent. 
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microbiota and anti-cancer immune responses is one of the most debated subjects in the recent 
years (York, 2018; Zitvogel, Ma, Raoult, Kroemer, & Gajewski, 2018)   
Acetyl-CoA – a central metabolite cross-connecting nutrient metabolism 
Acetyl-CoA is mainly known as the activated carrier of the acetyl group for incorporation into the 
Krebs cycle to fuel mitochondrial oxidative metabolism and ATP production, but it has no less 
important function in lipid biosynthesis and as a donor of acetyl groups for protein acetylation. 
Therefore, any metabolic perturbations and stressors likely can impact or reflect in acetyl-CoA 
modulation. In addition, acetyl-CoA lays at the interface between central carbon and fatty acid 
metabolism. It has been proposed that under hypoxic conditions, for instance in case of solid tumor 
microenvironment, the glycolytic flux is impaired and redirected toward lactate production rather 
than acetyl-CoA, diminishing its availability for downstream metabolic pathways, namely fatty 
acid and ketone bodies synthesis, steroid biogenesis and protein acetylation. Thus, hypoxic stressed 
tumor cells are pushed to rely on the other acetyl precursors, mainly glutamine and acetate, but also 
on branched chain-amino acids and free-fatty acid extracellular absorption. 
Cells can obtain required fatty acids either by absorption from the environment or by de novo lipid 
biosynthesis, and cancer cells in general prefer the second way. For that, they require constant pool 
of acetyl-CoA as a main precursor of fatty acid biogenesis. It has been established that a substantial 
fraction of cytosolic acetyl-CoA does not come from glucose or glutamine in hypoxic cells. 
As mentioned, specific IRE1 activation can be the result of lipotoxicity (increase in saturated versus 
unsaturated fatty acid accumulation within the ER membrane), but simultaneously UPR has been 
implicated in modulation of lipogenesis by activation of sterol regulatory element-binding proteins 
(SREBP) (J. Y. Kim et al., 2018). More importantly, this UPR induction has been accompanied by 
increased immune cells infiltration in the mouse model of high fat diet-induced hepatitis, more 
specifically by macrophage infiltration (Nakagawa et al., 2014). It would be interesting to test by 
metabolomics whether there is a change in the lipidomic profile of tumors developed under low 
PROT diet to have an insight in the metabolic alterations leading to specific activation of IRE1. 
GCN2 is an important sensor of amino-acid availability in the cell. Upon amino acid deprivation, 
the pool of non-bound tRNA rises, which induces phosphorylation of GCN2 and triggers ATF4 
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transcriptional activation (Ye et al., 2010). Independently, GCN2 participates in the mTOR 
inhibition, possibly by the regulation of eIF2α, which once it is activated halts protein translation 
(Averous et al., 2016). Autophagy can be also induced and in some context dependent on GCN2 
activation (X. Xia et al., 2018; X. J. Xia et al., 2016). Interestingly, GCN2-ATF4 signaling under 
nutrient scarcity has been linked to increased flux of hexosamine biosynthetic pathway through 
transcriptional regulation of the step-limiting enzyme GFAT1 (Chaveroux et al., 2016). 
Hexosamine pathway is strongly implicated in the production of N-acetylglucosamine, substrate 
that is used in protein maturation to be attached to hydroxyl group of  serine or threonine amino 
acid residues in a process termed O-GlcNAcylation (Harwood & Hanover, 2014). O-
GlcNAcylation has been recognized as an important mechanism in cancer biology, development 
and progression, impacting tumor metabolism and possibly anticancer immune response (X. Yang 
& Qian, 2017). 
Under our low PROT diet we have found mild but significant reduction of many amino acids within 
the tumor microenvironment (Article 1 Fig. S4F). Despite of this decrease, we have not found any 
signs of GCN2 nor eIF2α phosphorylation in the tumors of mice under low PROT diet regimen 
(Article 1 Fig. S4C and S5A). mTOR and AKT pathways were not modulated either (Article 1 Fig. 
S4A-B). In addition, autophagy was not increased as tested by LC3 lipidation (Article 1 Fig. S4D). 
Most importantly, ATF4 was not induced under low PROT diet (Article 1 Fig. S5A-B). Hence, the 
magnitude of amino acid decrease in our model does not seem to be enough to trigger GCN2 or 
autophagy signaling. 
As we have observed differential modulation in amino acid content between tumors dissected from 
mice under control and Low PROT diets, with particular shift toward higher glutamine/glutamate 
ratio, we decided to investigate the effect of altered glutamine metabolism on the status of IRE1 
activity and MHC-I expression. That glutamine/glutamate shift could be the result of differential 
extracellular glutamine import, but as GCN2 signaling was not affected, we reasoned that it is more 
likely to be the alteration in the enzymatic conversion of glutamine to glutamate. Thus, we used 
CB-839, a specific glutaminase inhibitor, to block glutamine to glutamate conversion, which we 
expected to partially mimic the phenotype we observed in vivo. First, we established the conditions 
and dose where CB-839 had minimal impact on cells viability (Preliminary results Fig. 2A). In 
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such an experimental set-up CB-839 treatment induced IRE1 activation, as assessed by IRE1 
phosphorylation and sXBP1 levels (Preliminary results Fig. 2C and D). Interestingly, it did not 
induce general acute ER stress, as the extent of CHOP induction was minor as compared to 
glutamine deprivation (Preliminary results Fig. 2E). At the same time MHC-I surface expression 
was markedly induced (Preliminary results Fig. 2B), indicating that alterations in glutamine 
metabolism indeed can lead to modulation in cell surface MHC-I expression, simultaneously 
inducing IRE1 activity. Further studies will be needed to establish whether these pathways are 
connected at the molecular level, or whether they are independent but induced in parallel by a 
common trigger. 
In the context of GCN2 activation in tumor progression, recent findings uncovered one way by 
which GCN2 promotes cancer survival and resistance upon chemotherapeutic asparaginase therapy 
(Nakamura et al., 2018). Interestingly from our standpoint, this study also uncovers some GCN2 
independent phenotype of asparaginase treatment. As some cancers are dependent on extracellular 
asparagine, removal of this amino acid from the tumor environment by enzymatic degradation has 
been proposed as an efficient way to starve cancer cells. GCN2 activation was shown to attenuate 
asparaginase induced cell death via ATF4-driven stress response within wide range of cancer cell 
types. Interestingly, the transcriptional profiling of human leukemic lymphoblasts CCRF-CEM 
treated either with the asparaginase alone on in combination with a GCN2 inhibitor revealed 
molecular pathways that were induced by asparagine depletion independent of downstream GCN2 
signaling. Upon GCN2 inhibition, upstream bioinformatic analysis indicated activation of 
pathways under regulation of Epidermal growth factor, IFNγ and TNFα. This indicates that amino 
acid deprivation in the form of asparaginase treatment induced pro-inflammatory phenotype, but 
in an GCN2-independent manner. Thus, it surprisingly phenocopies some of the aspects of the low 
PROT diet that we described as independent of GCN2 activity. 
In summary, the mechanisms of how low PROT diet induce specific IRE1/RIG1 axis in tumor cells 
are not yet determined and can be transmitted by indirect action of various components 
(metabolites, microbiota, fatty acid biosynthesis or others not known). It will be the goal of future 
studies to establish the exact metabolic modulation within cancer cells that leads to IRE1 induction. 
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2. IRE1 and cell secretome 
As IRE1 is central in proteostasis and stress response, it is likely that IRE activation would result 
in enhanced resistance of tumor cells to death and facilitate survival in the hostile environment and 
toxicity upon chemotherapeutic treatment. Indeed, IRE1 RNase activity ablation was shown to 
sensitize breast cancer tumors to paclitaxel treatment and prolong survival of triple negative breast 
cancer (TNBC) tumor-bearing immunodeficient mice (Logue et al., 2018). In this study Logue et 
al. screened a panel of human breast cancer cell lines and observed differential expression of 
sXBP1 protein and mRNA under basal conditions, with the highest levels in TNBC cell lines and 
cell lines with hormone receptor expression (estrogen and (hormonal epithelial growth factor 
receptor 2 (HER2) receptors). They have demonstrated that in vitro secretion of pro-inflammatory 
cytokines (CXCL1, IL6 and IL8 amongst others) is partially IRE1-dependent and promote cancer 
proliferation via cytokine autocrine loop. However, this enhanced proliferation effect was not 
reproduced in vivo when IRE1 RNase inhibitor was used as a single treatment. When combined 
with the chemotherapeutic paclitaxel, IRE1 RNase inhibition resulted in tumor growth reduction. 
Mechanistically the molecular observation of Logue et al. associating cytokine production 
dependent of IRE1 activity is in agreement with our findings, as in the case of IRE1 activation we 
have observed induction of pro-inflammatory cytokines in tumor cells (Preliminary results Fig. 
4B). In addition, we have also observed acceleration of tumor progression in an immunodeficient 
mouse model (Article 1 Fig. 1 C-D), which could be explained by IRE1-dependent cytokine 
induction under low-PROT diet. In summary, in the context of immunocompetent mice IRE1 
signaling seems to exert dominantly anti-tumor effects by dominant role of immune system activity 
in tumor development, at least within the tested cancer models. 
As it also happens, TNBC cells in contrast to the other studied breast cancer cell lines heavily rely 
on extracellular glutamine levels and exhibit high expression of glutamine converting enzymes, 
which make them more sensitive to glutaminase inhibitors treatment (Gross et al., 2014; L. Zhu, 
Ploessl, Zhou, Mankoff, & Kung, 2017). As glutamine deprivation is known to induce UPR, it 
would be of high interest to investigate if the obtained differences in sXBP1 levels (that Logues et 
al. observed both in basal culture conditions and in vivo) are not due to differential glutamine 
requirements among breast cancer types. 
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UPR and low-grade inflammation – lesson from aging  
As mentioned in the chapter of aging and UPR, aging is tightly correlated with increased 
proteotoxicity as a result of damaged polypeptide, protein aggregate accumulation and decreased 
UPR functionality. In the context of longevity and increased health-span, reducing the low-grade 
body inflammation seems to be one of the most accepted and described ways. Furthermore, low-
grade chronic inflammation is also tightly connected with increased incidence of cancer. Hence, 
acute inflammation (wound healing) is positive, but prolonged inflammatory processes are 
detrimental, and in the context of cancer, it seems to be of the utmost importance to switch towards 
adaptive immunity, otherwise persistent innate inflammation would accelerate cancer progression. 
As the immune regulation is tightly controlled and regulated at many levels, the molecular switch 
between innate and adaptive immunity is likely to depend on more than a single signaling pathway 
or molecule. It is appealing to speculate that, at least partially, this switch could be dependent on 
specific tumoral cell secretome orchestrated by the UPR. More specifically, secretion of 
inflammatory factors might be dependent on the IRE1 activation, evolutionarily the most conserved 
branch and the only one existing ER stress sensor in simpler organisms. 
This area of the reciprocal regulation between tumor and immune system is still under vigorous 
scientific investigation. Future studies will reveal to what extent the proposed engagement of UPR 
in shaping the character of anti-cancer immune response is true. 
Altered lipid metabolism and IRE1 modulation 
Solid tumors have been found to alter their lipid metabolism, partially by stimulating their de novo 
lipid biosynthesis from precursors. Lipid oxidation has been tightly connected with low-grade 
inflammation and stress signaling and has been shown to play a role in both innate and adaptive 
immune responses. As it has been discussed and shown by many studies, IRE1 can be directly 
induced by lipid-membrane stress and related lipotoxicity (Ariyama, Kono, Matsuda, Inoue, & 
Arai, 2010; Covino, Hummer, & Ernst, 2018; Halbleib et al., 2017; Kitai et al., 2013; Lancaster et 
al., 2018; Volmer, van der Ploeg, & Ron, 2013). Particularly, the ratio between saturated and non-
saturated fatty acid seems to play central role in lipotoxicity and UPR activity. This could add 
another factor contributing to the UPR activation within tumor cells, as it is evident that tumor 
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tissue differs vastly in its lipidomic profile as compared to non-malignant tissue. We have observed 
that with fatty acid Palmitate in vitro stimulation in CT26 cancer cells IRE1 is being activated 
(Supplementary results Fig. 1). We have hypothesized that the observed alterations in amino-acid 
profile between tumors dissected from CTR and low PROT diet fed mice could result in differential 
fatty acid metabolism within tumor cells. The future experiments with the characterization of tumor 
lipidome and metabolome would bring more data to verify this hypothesis. 
In turn, IRE1 can participate in de novo lipid bio-synthesis as its RNase activity was indispensable 
in oncogene-induced gene expression of fatty acid synthesis enzymes such as of HMGCR1, 
HMGCS1, ACLY, ACACA, FASN and SCD (Xie et al., 2018). 
IRE1-RIG-I axis 
As described previously, a clear link exists between the UPR and RIG-I activation. RIG-I belongs 
to the retinoic-acid-inducible gene-I-like receptors (RLRs), that are RNA helicases sensing 
pathogenic RNA and initiating antiviral immunity. Studies have linked IRE1 with the RIG-I 
pathway via production of cleaved endogenous non-shielded short RNAs by IRE1 RNase RIDD 
activity. Those RIDD products could resemble pathogenic RNA as they lack 3’ poly-A tail and 5’ 
cap, normally being present in endogenous mRNA. These fragments recognised as non-self cellular 
RNAs can be sensed by RIG-I that would induce innate immune response by turning on production 
of specific cytokines, like type I-IFNs, CXCL10 and IL-6, accompanied also by MHC class I 
upregulation (K. Li, Qu, Chen, Wu, & Shi, 2017). Endogenous non-shielded RNAs have already 
been shown to play role in cancer by acting as DAMPs (K. Li et al., 2017). In immunocompetent 
mice, RIG-I induces anticancer immune response against melanoma cells by stimulating the 
secretion of extracellular vesicles carrying NKp30-ligand (BAG6) that act as immune activators 
(Dassler-Plenker et al., 2016). RIG-I-dependent antitumor immune response involves myeloid and 
plasmacytoid DCs activation, NK cells, T lymphocytes and is strongly associated with the secretion 
of IFNs-I (Besch et al., 2009; Dassler-Plenker et al., 2016; Poeck et al., 2008). Interestingly, we 
have also observed RIG-I activation in the tumors under low-PROT diet regimen, where we could 
attribute it to the activation of the IRE1 branch of UPR (Article 1 Fig. 4D-E and Fig.6I).  
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Additional observation linking RIG-I with induction of the anti-cancer immune response come 
from the study where pancreatic cancer cells were treated with RIG-I activating ligands which 
resulted in canonical ICD induction, accompanied with CLR and HMGB1 exposure (Duewell et 
al., 2014). As we did not observe impairment in tumor cell viability under low PROT diet feeding 
that would result in ICD induction, we report novel undetermined character of RIG-I signaling in 
the anti-cancer immune response activation. We characterized RIG-I as downstream hub of UPR 
activation, it is of high importance to note the recently proposed mechanism involving RIG-I 
signaling as a new paradigm of innate immunity activation which can sense viral infection via the 
UPR. Briefly, this sensing is the result of high demand on protein synthesis by viruses that hijacks 
the host protein synthesis machinery to produce vast amount of structural viral proteins necessary 
for its replication and spreading (J. A. Smith, 2014). This proposed paradigm shares some 
important features linking UPR with RIG-I and subsequent immune response, that resemble some 
of the signaling pathway that we have described under low PROT diet condition. 
In similar manner, additional data bridging viral-infected tumor phenotype with increased CD8+ T 
cell anti-tumor response come from the study where tumor-bearing mice were infected with 
replication-competent vaccinia virus. Upon virus treatment, researchers have observed immune 
system activation and anti-tumor cytotoxicity more widespread than the actual site of infection, 
providing additional protection against tumor invasion and metastasis (M. Kim et al., 2018). Thus, 
general adaptive immune response is likely to be involved in this viral-infected model in the long-
term protective anti-tumor immunity. It would be of high interest to investigate whether RIG-I 
deficient cells would provoke such immune response upon similar treatment. 
Recently RIG-I activation has been shown to induce innate antitumor activity dependent on NK 
cells. In mouse melanoma model, RIG-I stimulation induced secretion of extracellular vesicles 
expressing on its surface NKp30-ligand Bag6 that triggered NK cells activation and anti-tumor 
immune response resulting in inhibition of tumor growth (Dassler-Plenker et al., 2016). Bag6 is 
known as a quality check point protein which participates in formation of complexes directing 
ubiquitinated proteins towards proteasomal degradation (ERAD). Intriguingly, Bag6 was described 
as part of a cluster of genes located within the MHC locus and strongly induced upon IFNγ 
treatment. Thus, it is possible that in addition to its immunogenic activity, Bag6 could serve also 
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as antigen-processing regulator (Anton & Yewdell, 2014). It will be the matter of future studies to 
decipher if the above described mechanisms are present and/or significant impact on differences in 
anti-cancer immune response between CTR and low PROT diet regimen. 
3. ICD and tumor immunogenicity 
The second open question arising from our studies is how IRE1 signaling facilitate anti-cancer 
immune response (Fig. 18 marked “2?”). That link is not necessarily intuitive, because 
IRE1/sXBP1 is usually (but not always) linked to cell survival, poor patient prognosis and late 
stages of tumor development (Avril, Vauleon, & Chevet, 2017; Sakatani et al., 2017). 
Immunogenic ER-resident lectin-like chaperone calreticulin (CRT) exposure occurs through a 
phylogenetically conserved stress pathway depending on the chemokine CXCL8 (known as IL-8) 
and PERK/eIF2α activation. We have found no indication that PERK/eIF2α is activated under low 
PROT diet regimen. Therefore, the magnitude of ER stress within tumor is likely not sufficient to 
promote CRT exposure. The unaffected tumor growth under low PROT diet in CD8+ T cell-
depleted immunocompetent mice and in an immunodeficient mouse model also points to lack of 
spontaneous cell death of tumor cells under low PROT diet feeding. Mitoxantrone (MTX), one of 
the best studied ICD-inducer has been shown to facilitate IL-8 secretion in tumor cells in vitro as 
well as in mouse tumors in vivo (Sukkurwala et al., 2014). It should be noted that IRE1 silencing 
has been shown to strongly attenuate IL-8 gene expression and secretion by Logue et al., and in 
addition IRE1 activation gene signature correlates with higher IL-8 mRNA in tumor of breast 
cancer patients (Logue et al., 2018). Therefore, the immunogenicity of cancer cells, facilitated by 
CRT exposure and/or IL-8 induction, could be in some conditions at least partially dependent on 
IRE1 signaling. It has to be stated here that high expression levels of IL-8 and its receptor CXCR2 
have been associated with poor prognosis in several type of cancer (Piperi et al., 2011; Saintigny 
et al., 2013). On the other hand, that signaling would facilitate the antigen uptake by APCs and the 
subsequent presentation of antigens to T lymphocytes, which in turn would promote an anticancer 
immune response (Sukkurwala et al., 2014). It is not an isolated case when the molecular pathway 
is being attributed with enhanced immune response, yet in retrospective patient studies turns out to 
be associated with poor disease outcome.  
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The conflicting data on allowing an effective immune response with ICD and cancer progression 
between experimental animal models and clinical observation/trials are a continued area of debate 
(Galluzzi, Buque, Kepp, Zitvogel, & Kroemer, 2017b; Hou, Greten, & Xia, 2017). It has been 
correctly pointed out that some ICD inducers also significantly increase pro-inflammatory and 
tumor growth promoting signaling molecules, such as IL-1α, IL-6 and TLR-signaling cascades. As 
such, instead of slowing cancer progression through immune response, a pro-inflammatory 
environment accelerates cancer growth and shortens patient lifespan. Moreover, neoplasms that 
have already evolved either high immune suppression mechanisms or low immunogenic 
phenotypes can exhibit very high resistance to immunomodulatory therapies. Without basal anti-
cancer immunity, or in case where physiological immunity is impaired, ICD-inducing therapies 
could be unable to provide all the benefits expected by their actions. Nevertheless, it is an open 
question which percentage of cancer cases and to what extent can benefit from immune targeted 
therapies. Accumulating preclinical and clinical data support the notion that the long-term disease 
outcome is far more dependent on anti-cancer immunological memory and immunosurveillance 
(Emens et al., 2017; Galluzzi, Buque, Kepp, Zitvogel, & Kroemer, 2015; Papaioannou, Beniata, 
Vitsos, Tsitsilonis, & Samara, 2016). 
The puzzling paradox emerges from studies where UPR have been reported to promote cancer 
progression and from evidence implicating UPR in induction of an effective anti-cancer immune 
response which favours ICD. The patient survival prognosis is based on the cancer phenotype after 
cancer detection. Once cancer is diagnosed, it is very frequent that the onset of malignant 
transformation had occurred months/years before detection, allowing tumoral cells escape all 
immune barriers elicited by the organism. Thus, UPR activation at this late stage would only make 
an impact as a pro-survival, anti-proteotoxic mechanism that would promote faster tumor growth 
and cell death escape. Hence, we can predict/speculate what conditions have to be met to trigger 
an effective anti-tumor UPR-driven immune response: 
-functional immune system 
-basal immunogenicity of cancer cells 
-basal TILs infiltration 
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-specific UPR modulation, promoting an ICD-like phenotype  
Unless all of the above criteria are simultaneously present, UPR modulation and specific IRE1 
induction might not be the optimal strategy to reduce cancer progression. In fact, in that scenario, 
they are likely to promote tumor progression due to their pro-survival character and implication in 
cytokine production. It would be helpful to look at the above criteria from the perspective of clinical 
and experimental studies. In clinics, the first two of them – “functional immune system” and “basal 
immunogenicity of cancer cells” are frequently absent. In fact, the tumor growth is dependent on 
at least one out of this two components being dysfunctional. The experimental set-up making use 
of tumor transplanted into syngeneic mouse model provides many investigational benefits, but 
differs in some important aspects between the spontaneous cancer development as it occurs in 
nature, factor that has to be acknowledged as one of the limitation of such studies. Firstly, the 
transplanted tumor consists of mature cancer cells that already underwent premalignant and 
malignant cancer evolution steps. That means that the tumor-receptor organism – “naïve” mouse 
in that case – have missed the first steps of cancer development and is colonized by final stage 
cancer cells. The successful progression of this cancer has been determined in its former host and 
implies that either the cancer cells escaped immune recognition, or they efficiently paralyzed the 
immune response against them. As they have been transplanted into new syngeneic host, where the 
immune system is yet intact, the two scenarios that are not mutually exclusive are likely to take 
place: 1- the cells are immunologically non-detectable and their presence do not induce the 
activation of anti-cancer immunity, or 2- initially the immune system is actively removing 
malignant cells, but eventually immunoinhibitory signaling and/or tumor cell number prevail over 
anti-cancer immunity and cancer cells continue proliferating. In the second scenario, the immune 
system has chance to develop an effective anti-cancer response before the accumulating mass of 
malignant cells and their immunoinhibitory signaling paralyze the anti-cancer response. This is not 
what we could expect to find in the clinical settings, where anti-cancer immunity has already been 
compromised in a step-by-step process during malignant transformation over years. Therefore, we 
have to point out that the above-mentioned experimental model constitutes an important 
translational limitation of our findings. 
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In that line, important clinical observation is the correlation of sXBP1 tumor expression in patient 
prognosis. In tumor biopsies of patients with TNBC a specific XBP1 gene-expression signature 
was strongly associated with poor prognosis, progression and metastatic events (Chen et al., 2014; 
H. Li et al., 2015). The poor prognosis for patients with breast cancer is strongly associated with 
cancer immune evasion, linked to the loss of MHC-I expression. Indeed, expression levels of 
human leukocyte antigen class I molecules are significantly downregulated at transcriptional level 
in breast cancer (Liu et al., 2012; Seliger, Maeurer, & Ferrone, 2000). As the loss of MHC-I is the 
mechanism recognized as major contributor for tumor immune escape, and core part of MHC-I 
complex assembling machinery lays within ER, it is of high relevance to investigate whether ER 
perturbation could result in hampered MHC-I expression, and if so, that modulation would 
eventually shape TIL functionality and numbers. This will be further discussed below. 
Similarly, in colorectal cancer the infiltration of immune cells within the TME is an important 
factor of clinical tumor responsiveness to immunotherapy, and varies across the colorectal cancer 
stages in humans, observing high CD8+ T cells in stages I, II and III and depletion of CD8+ T cells 
in stage IV. On the contrary, Tregs are depleted in stages I and II and enriched in the last stages, 
pointing out the importance of adjusting therapeutic interventions according to the immune system 
status within the TME (Angelova et al., 2015). 
Another interesting observation is the epigenetic regulation of basal IRE1 expression levels 
mediated by Enhancer of Zeste Homolog 2 (EZH2) levels (Bujisic et al., 2017). In this article 
authors compared two main families of Diffuse Large B-cell Lymphoma (DLBCL): Germinal 
Center B-cell-like (GCB) and Activated B-cell-like (ABC). They have noticed that IRE1-XBP1 
branch is downregulated in most of the GCB-DLBCL, and sXBP1 genetic induction specifically 
in this DLBCL sub-type decreased tumor growth in an immunodeficient mouse xenograft model. 
They tested the hypothesis of EZH2 as the main epigenetic regulator of IRE1 expression using a 
chemical inhibitor of EZH2 activity, GSK343. GSK343 modified the methylation status of IRE1 
promoter, induced its transcription and restored the IRE1 protein levels. Even though the tumor 
suppressive effects of IRE1 overexpression have been attributed to the modulation of sXBP1, the 
researchers also acknowledged the possibility that other functions of IRE1, such as RIDD, could 
participate in the observed effect. Additionally, it is known that IRE1 expression is positively 
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regulated by other branches of UPR, raising the possibility of modulation in basal IRE1 levels after 
genetic overexpression of sXBP1 (Blazanin et al., 2017; Tsuru, Imai, Saito, & Kohno, 2016). 
Many of the promising immunomodulatory therapies fail because of the negative effect on immune 
system itself. For instance, histone deacetylase inhibitors (HDACi) therapy could in principle 
provide benefits by triggering an anti-tumor response. This would be through induction of 
immunogenic phenotypes of tumor cells via canonical ICD-related HMGB1 release as shown in 
B16 mouse melanoma (Booth, Roberts, Poklepovic, Kirkwood, & Dent, 2017). Unfortunately, 
HDACi can also positively modulate immune check point inhibitor molecules like PD-1 ligands, 
which hampers the anti-cancer immune response (Booth et al., 2017; Terranova-Barberio et al., 
2017; Woods et al., 2015). In that context, the combination of HDACi with immune checkpoint 
inhibitors has been found to result in a survival extension. However, some promising HDACi like 
HDAC1/2 inhibitor can elicit strong toxicity towards immune cells, especially cytotoxic T cells, 
which could greatly impair the anti-cancer response and beneficial outcomes (R. B. Jones et al., 
2014). The interesting similarities emerge between low PROT diet regimen and HDAC inhibitor 
therapy, which could result in PD-L1 upregulation and anti-cancer immune response. However, 
low PROT diet (-25% reduction) used in our studies did not lead to any negative effects on the 
immune system components, while HDAC inhibitors have shown to have risks.  
Phosphorylation of Retinoblastoma Protein 
Retinoblastoma (RB) is a tumor suppressor protein most known as inhibitor of cell cycle by 
negative regulation of E2F family of proteins. RB phosphorylative inactivation or mutation during 
tumor progression not only stimulates proliferation by promoting the cellular G1–S transition 
through de-repression of E2F transcription factors, but it also impacts on a variety of other 
malignant events. For instance, RB has been found to modulate multiple cytokines and chemokines 
as well as cancer stem cell markers (Kitajima et al., 2017). Upon RB genetic invalidation in the 
p53-null breast cancer cell line MCF-7, the transcriptional levels of IL6, CXCL1/2/3/5 have been 
drastically increased, followed by increase in stem cell markers. In addition, chemokines such as 
CCL2 and CCL5 were markedly upregulated. On the other hand, genes involved in lipid 
biosynthesis and glutamine to glutamate conversion were downregulated (PPP1R3, GLS) as well 
as PGAM1. PGAM1 is one of the first enzyme of the glycolytic pathway whose downregulation 
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can disrupt the glycolytic flux and affect the oxidative branch of the pentose phosphate pathway 
and the serine biosynthesis pathway (Chaneton & Gottlieb, 2012). Oncogene KRAS was another 
target downregulated upon RB inactivation. MHC-I assembling machinery was also upregulated 
(TAPBP, TAP1, HLA-A/J/G and most importantly ERAP1), pointing out the possible role of RB 
in immune detection and response. This idea reflects a hypothesis that has been already proposed 
in some of the researches indicating the role of pRB in interferon-modulated pathways and MHC-
II regulation (Kitajima & Takahashi, 2017; X. Zhu, Pattenden, & Bremner, 1999). Of note, 
expression of XBP1 and its target EDEM1 was attenuated under inactivation of RB, suggesting 
that this tumor suppressor may be upstream of their regulation, which would be consistent with 
previous reported studies (Brewer, Hendershot, Sherr, & Diehl, 1999). 
In our model of low PROT diet-induced tumor growth reduction we surprisingly observed 
increased phosphorylation of RB as compared to tumors dissected from mice under control diet 
(Preliminary results Fig.5). That would imply that cell cycle rates and proliferation could be 
increased in conditions of low PROT diet. Nevertheless, overall tumor growth was suppressed in 
those conditions, in contrast to the experiment performed in immunodeficient mouse model, the 
case that was already discussed in chapter “IRE1 and cell secretome”. It is reasonable to 
hypothesize that even though cancer cells received growth-promoting signals by phosphorylation 
of RB, the immune system negated this effect. Would it mean that by promoting the RB activity 
we could expect even higher tumor growth suppression under low PROT diet regimen? Unless 
experimentally tested, we can neither answer, nor rule out this question, but it is plausible that 
inactivation of RB by phosphorylation could be necessary to induce, at least partially, an effective 
immune response via regulating the immunogenicity of cancer cells. It might be possible that tumor 
cells in contrast to healthy cells metabolically fail to adapt to low PROT diet-TME conditions. This 
could lead as explained by the differential stress sensitization (DSS) phenomenon to tumor cell 
proliferation even without necessary nutrients, which might render malignant cells prone to un-
controlled death. In addition, RB is implicated in IFNγ-driven MHC class II regulation and IL-6 
production (upon RB phosphorylation), which might actually promote immune activation (Jung et 
al., 2012; Kitajima et al., 2017; X. Zhu et al., 1999). Interestingly, NKG2D ligands such as RAE-
1 (discussed below) could be also regulated through E2F transcription factors, key downstream 
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targets of RB (Jung et al., 2012). As such, pRB-driven E2F activity could lead to expression of 
immunogenic NKG2D ligands and alert immune system to eliminate malignant cells. 
MHCI and MHCI-like family of proteins 
As it is shown in preliminary results Fig. 4A, MHC class I (MHC-I) surface expression is 
significantly induced in tumor cells isolated from mice bearing CT26 colorectal carcinoma (CRC) 
cells under low PROT feeding. MHC-I molecules are present on almost all nucleated cells in 
mammals and display oligopeptides on the cell surface which are recognised by CD8+ T cell 
receptors, enabling T cell activation in the presence of secondary signals that results in T cell 
immunosurveillance and cytotoxicity. 
Importantly this low-PROT diet induced MHC-I expression was dependent on IRE1 (Preliminary 
results Fig. 1A). As cancer cells isolated from tumor bearing mice under low-PROT diet exhibited 
significant increase in MHC-I on their cell surface (Preliminary results Fig.4A), it would be of high 
interest to investigate if this phenotype is contributing to higher immune response observed in that 
group. In addition, we have found elevated mRNA levels of key MHC-I assembling machinery 
proteins such as TAP1 and TRIM69 (Preliminary results Fig. 4C). On the other hand, this 
upregulation could be the direct consequence of IFNγ signaling, which is a known potent induced 
of MHC-I expression.  
Intriguingly, ER stress has controversial role in MHC-I processing and exposure. ER stress 
induction has been linked to both decrease (de Almeida, Fleming, Azevedo, Carmo-Fonseca, & de 
Sousa, 2007; Granados et al., 2009; Ulianich et al., 2011), and increase in MHC-I expression 
(Gameiro et al., 2014; Malamas, Gameiro, Knudson, & Hodge, 2016). In our in vitro experiments, 
general induction of ER stress by treatment with a chemical blocker of N-linked glycosylation 
(Tunicamycin) indeed led to massive downregulation in MHC-I surface expression on CT26 cells 
(Preliminary results Fig. 1D). However, specific IRE1 induction by palmitic-acid treatment 
resulted in time-dependent increase in MHC-I expression (Preliminary results Fig. 1A-D). 
However, those experiments have to be reproduced in IRE1-supressed cells in order to test whether 
this induction is being dependent on its signaling or is it an effect of another mechanism. 
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The other interesting modulation found on tumoral cells under low PROT diet regimen is the 
modulation of PD-L1. PD-L1 expression on hepatocellular carcinoma (HCC) is potently induced 
by IFN-γ release from tumor-infiltrating T cells in vivo and is not observed in cell culture conditions 
(Concha-Benavente et al., 2016; Sanmamed & Chen, 2014). IFN-γ is mainly released by T cells 
upon antigen recognition and T cell activation and serves prolonged T-cell cytotoxic response and 
amplification. Thus, induction of PD-L1 by IFN-γ represents an immune self-limiting activation 
mechanism, named “adaptive immune resistance” (Dosset et al., 2018). 
The crucial importance of PD-L1/PD1 axis in inducing long-term tumor rejection has been recently 
shown in scientific works investigating immunostimulatory chemotherapies in combination with 
anti-PD1 treatment. The researchers have investigated the effect of 5-Fluorouracil (5-FU), 
Oxaliplatin (Ox) and Mitomycin C (MitoC) as single agents and the combination of 5-FU with Ox, 
named Folfox, and 5-FU plus MitoC. Whereas Ox is known as an inducer of ICD, 5-FU was shown 
to deplete myeloid-derived supressor cells (MDSCs), and MitoC is a non-ICD chemotherapeutic. 
The double treatments, Folfox and 5-FU/MitoC groups resulted in slight tumor growth retardation 
in CT26-BALBc mice, and no tumor rejection was observed in all groups. Only under the 
combination of Folfox with anti-PD1 treatment the investigators observed massive effect on mouse 
survival as 92% of the mice were alive at day 17 after beginning the treatment compared to 56% 
in Folfox alone and 0% in control group. In addition, 62% of mice underwent complete tumor 
regression and sustained long-term immunoprotection specific towards CT26 cancer cells in the 
combined therapy with Folfox and anti-PD1. More importantly, MitoC provided no additional 
effect combined with anti-PD1 treatment, indicating immune modulation and ICD as central events 
in tumor suppression and rejection. Mechanistically, Folfox treatment induced CD8+ T cell 
intratumoral infiltration, increased numbers of IFNγ positive CD8+ T cells and promoted IFNγ 
release in response to immunogenic peptide binding. On the other hand, this combined treatment 
also upregulated translational and surface expression of immune inhibitory receptors, like PD-1 
and Tim-3, making T cells susceptible to exhaustion, which was indeed observed as CD8+ T cells 
progressively lost their antitumor activity in vivo when not combined with anti-PD1 therapy. At 
the same time, in response to T cell-derived IFNγ tumor cells upregulated its PD-L1 expression, 
that further facilitated immune suppression. In accord with this result, we have observed significant 
increase in PD-L1 expression on isolated tumor cells from mice under low PROT diet regimen 
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(Preliminary results Fig. 4A). Even though this modulation of PD-L1 did not hampered low PROT 
induced immune response, it could be interesting to test whether the combination of anti-PD-L1 
therapy would result in additional beneficial response when combined with low PROT diet. 
Thus, IFNγ-driven induction of a variety of immunoinhibitory ligands on tumor cells renders 
resistance towards immunomodulatory therapies (Benci et al., 2016). It would be interesting to 
examine whether specific UPR activation, centred on IRE1, would somehow abrogate this 
immune-inhibitory potential of cancer cells, by for instance, modulation of the cell secretome and 
surface expression of immune checkpoint ligands. 
The tumor was called “wound that never heal”. In the case of a real wound, immune cells can vastly 
infiltrate it and their growth can be promoted by growth factors resulting in a beneficial effect. 
However, this inflammatory process is detrimental in the context of cancer. As summarized in 
numerous studies, many cytokines have dual roles in tumor progression. The same interleukin can 
promote or inhibit tumor growth, depending on the context. For example TGF-β produced by tumor 
cells and surrounding stromal cells, facilitates cancer invasion and metastases, but in the earlier 
phases of tumor development it acts as a tumor suppressor, inhibiting cell growth, inducing 
apoptosis and attenuating growth signals such as the proto-oncogenic c-Myc (S. Lee & Margolin, 
2011). 
Similarly, cells producing those cytokines seem to reflect the same properties, namely suppressing 
or accelerating tumor growth depending on the context. Hence, γδ T cells that are an important 
component of TILs in patients bearing different types of cancer possess a potent antitumor activity 
mediated by production of proinﬂammatory cytokines, direct cytotoxic activity and cross-talk with 
other immune populations residing within TME. The importance of γδ T cells has been highlighted 
by analysis of ~18,000 transcriptomes from 39 human tumors, where tumor-infiltrating γδ T cells 
presence was identified as the most significant favorable prognostic marker (Lo Presti et al., 2018). 
Here again, cytokine IL-17 seems to have dualistic role in tumor progression, and γδ T cells have 
been identified as main contributors of this cytokine in TME. IL-17 promote TCR  recognition and 
cytotoxic T cell response, but at the same time was found to accelerate tumor vascularization and 
growth in immunodeficient mice (S. Lee & Margolin, 2011). Of note, tumor cell recognition by γδ 
T cells is based on the natural killer receptors such as NKG2D and NKp30, which points out the 
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importance of surface expression of their ligands on cancer cells (Correia, Lopes, & Silva-Santos, 
2013). The cross-talk between immune cell populations and their cytokine secretion is a critical 
aspect in tumor development and shapes effective anti-cancer responses. Nevertheless, in our 
model the central event and one of the early steps driving immune response is activation of 
IRE1/RIG-I axis in tumor cells. Thus, in the following studies the differential phenotype of cancer 
cells and their secretome between IRE1/RIG-I functional and deficient cells have to be addressed 
in order to determine novel molecular effectors playing a role in low PROT diet induced anti-
cancer immune response. 
  
123 
Bibliography 
Aaronson SA (1991) Growth factors and cancer. Science 254: 1146-53 
Ackerman D, Simon MC (2014) Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends 
Cell Biol 24: 472-8 
Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, Rodling L, Alsop AE, Walker J, Masson F, Belz GT, Corcoran 
LM, O'Reilly LA, Strasser A, Smyth MJ, Johnstone R, Tarlinton DM, Nutt SL, Kallies A (2014) Fas ligand-mediated 
immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20: 283-90 
Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, Sanchez MD, Dean MJ, Rodriguez 
PC, Ochoa AC (2017) Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated 
myeloid-derived suppressor cells. Oncoimmunology 6: e1344804 
Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB (2008) 
Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25: 2097-116 
Andresen L, Skovbakke SL, Persson G, Hagemann-Jensen M, Hansen KA, Jensen H, Skov S (2012) 2-deoxy D-
glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J Immunol 
188: 1847-55 
Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, 
Galon J, Trajanoski Z (2015) Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals 
distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 16: 64 
Anisimov VN, Bartke A (2013) The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit 
Rev Oncol Hematol 87: 201-23 
Anton LC, Yewdell JW (2014) Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J 
Leukoc Biol 95: 551-62 
Aranda F, Bloy N, Pesquet J, Petit B, Chaba K, Sauvat A, Kepp O, Khadra N, Enot D, Pfirschke C, Pittet M, Zitvogel 
L, Kroemer G, Senovilla L (2015) Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-
cell lung cancer. Oncogene 34: 3053-62 
Ariyama H, Kono N, Matsuda S, Inoue T, Arai H (2010) Decrease in membrane phospholipid unsaturation induces 
unfolded protein response. J Biol Chem 285: 22027-35 
Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, Vatten LJ, Norat T (2015) Dairy 
products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr 
101: 87-117 
Averous J, Lambert-Langlais S, Mesclon F, Carraro V, Parry L, Jousse C, Bruhat A, Maurin AC, Pierre P, Proud CG, 
Fafournoux P (2016) GCN2 contributes to mTORC1 inhibition by leucine deprivation through an ATF4 independent 
mechanism. Sci Rep 6: 27698 
Avril T, Vauleon E, Chevet E (2017) Endoplasmic reticulum stress signaling and chemotherapy resistance in solid 
cancers. Oncogenesis 6: e373 
Baena Ruiz R, Salinas Hernandez P (2014) Diet and cancer: risk factors and epidemiological evidence. Maturitas 77: 
202-8 
124 
Bandera EV, Fay SH, Giovannucci E, Leitzmann MF, Marklew R, McTiernan A, Mullee A, Romieu I, Thune I, Uauy 
R, Wiseman MJ, World Cancer Research Fund International Continuous Update Project P (2016) The use and 
interpretation of anthropometric measures in cancer epidemiology: A perspective from the world cancer research fund 
international continuous update project. Int J Cancer 139: 2391-7 
Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, Kunz B, Bruckner B, Sehouli J, 
Michalsen A (2018) The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with 
breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer 18: 476 
Baumeister P, Luo S, Skarnes WC, Sui G, Seto E, Shi Y, Lee AS (2005) Endoplasmic reticulum stress induction of 
the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell 
Biol 25: 4529-40 
Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR 
(2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. 
Nat Cell Biol 2: 469-75 
Ben-Zvi A, Miller EA, Morimoto RI (2009) Collapse of proteostasis represents an early molecular event in 
Caenorhabditis elegans aging. Proc Natl Acad Sci U S A 106: 14914-9 
Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, 
Bost F (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. 
Cancer Res 71: 4366-72 
Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, 
Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, 
Minn AJ (2016) Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint 
Blockade. Cell 167: 1540-1554 e12 
Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE 
(2012) Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl 
Acad Sci U S A 109: 20071-6 
Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, 
Hartmann G (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent 
apoptosis in human melanoma cells. J Clin Invest 119: 2399-411 
Biancur DE, Paulo JA, Malachowska B, Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP, 
Harper JW, Fendler W, Mancias JD, Kimmelman AC (2017) Compensatory metabolic networks in pancreatic cancers 
upon perturbation of glutamine metabolism. Nat Commun 8: 15965 
Blazanin N, Son J, Craig-Lucas AB, John CL, Breech KJ, Podolsky MA, Glick AB (2017) ER stress and distinct 
outputs of the IRE1alpha RNase control proliferation and senescence in response to oncogenic Ras. Proc Natl Acad 
Sci U S A 114: 9900-9905 
Blees A, Reichel K, Trowitzsch S, Fisette O, Bock C, Abele R, Hummer G, Schafer LV, Tampe R (2015) Assembly 
of the MHC I peptide-loading complex determined by a conserved ionic lock-switch. Sci Rep 5: 17341 
Blot WJ, Tarone RE (2015) Doll and Peto's quantitative estimates of cancer risks: holding generally true for 35 years. 
J Natl Cancer Inst 107 
Bonorden MJ, Rogozina OP, Kluczny CM, Grossmann ME, Grambsch PL, Grande JP, Perkins S, Lokshin A, Cleary 
MP (2009) Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice. 
Nutr Cancer 61: 265-75 
125 
 
Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P (2017) HDAC inhibitors enhance the immunotherapy response 
of melanoma cells. Oncotarget 8: 83155-83170 
Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, Crowe H, Marmor S, Luo J, Gu W, 
Guarente L (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6: 759-67 
Boutant M, Kulkarni SS, Joffraud M, Raymond F, Metairon S, Descombes P, Canto C (2016) SIRT1 Gain of Function 
Does Not Mimic or Enhance the Adaptations to Intermittent Fasting. Cell Rep 14: 2068-2075 
Brewer JW, Hendershot LM, Sherr CJ, Diehl JA (1999) Mammalian unfolded protein response inhibits cyclin D1 
translation and cell-cycle progression. Proc Natl Acad Sci U S A 96: 8505-10 
Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 
8: 180-92 
Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, 
Solary E, Garrido C (2000) Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2: 
645-52 
Bujisic B, De Gassart A, Tallant R, Demaria O, Zaffalon L, Chelbi S, Gilliet M, Bertoni F, Martinon F (2017) 
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor 
growth. Blood 129: 2420-2428 
Buono R, Longo VD (2018) Starvation, Stress Resistance, and Cancer. Trends Endocrinol Metab 29: 271-280 
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (2011) The efficacy 
of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71: 
2488-96 
Campbell TC (2017) The Past, Present, and Future of Nutrition and Cancer: Part 1-Was A Nutritional Association 
Acknowledged a Century Ago? Nutr Cancer 69: 811-817 
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor 
(CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5: 53 
Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q, Du J (2012) Association between circulating levels of IGF-1 and 
IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One 7: e49884 
Carpio MA, Michaud M, Zhou W, Fisher JK, Walensky LD, Katz SG (2015) BCL-2 family member BOK promotes 
apoptosis in response to endoplasmic reticulum stress. Proc Natl Acad Sci U S A 112: 7201-6 
Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo 
CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK et al. (2018) Metformin Promotes 
Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell 71: 606-620 e7 
Chalkiadaki A, Guarente L (2015) The multifaceted functions of sirtuins in cancer. Nat Rev Cancer 15: 608-24 
Chaneton B, Gottlieb E (2012) PGAMgnam style: a glycolytic switch controls biosynthesis. Cancer Cell 22: 565-6 
Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC, Hung CF (2012) Immune mechanism of the antitumor 
effects generated by bortezomib. J Immunol 189: 3209-20 
126 
 
Chaveroux C, Sarcinelli C, Barbet V, Belfeki S, Barthelaix A, Ferraro-Peyret C, Lebecque S, Renno T, Bruhat A, 
Fafournoux P, Manie SN (2016) Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 
signalling pathway. Sci Rep 6: 27278 
Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, 
Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ et al. (2014) XBP1 promotes triple-
negative breast cancer by controlling the HIF1alpha pathway. Nature 508: 103-107 
Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu 
Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB (2011) Dual inhibition of tumor energy pathway by 
2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 
10: 2350-62 
Cho JA, Lee AH, Platzer B, Cross BC, Gardner BM, De Luca H, Luong P, Harding HP, Glimcher LH, Walter P, 
Fiebiger E, Ron D, Kagan JC, Lencer WI (2013) The unfolded protein response element IRE1alpha senses bacterial 
proteins invading the ER to activate RIG-I and innate immune signaling. Cell Host Microbe 13: 558-69 
Choi KM, Kwon YY, Lee CK (2013) Characterization of global gene expression during assurance of lifespan extension 
by caloric restriction in budding yeast. Exp Gerontol 48: 1455-68 
Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA 
(2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-2 
Colditz GA, Sellers TA, Trapido E (2006) Epidemiology - identifying the causes and preventability of cancer? Nat 
Rev Cancer 6: 75-83 
Colditz GA, Wolin KY, Gehlert S (2012) Applying what we know to accelerate cancer prevention. Sci Transl Med 4: 
127rv4 
Collaboration NCDRF (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 
to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and 
adults. Lancet 390: 2627-2642 
Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL (2016) 
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNgamma That Induce PD-L1 
Expression in Head and Neck Cancer. Cancer Res 76: 1031-43 
Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, 
Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda 
SM, Wang X et al. (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear 
myeloid-derived suppressor cells in cancer patients. Sci Immunol 1 
Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 
124: 263-6 
Cook KL, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Warri A, Hilakivi-Clarke L, Roberts DD, Clarke R (2016) 
Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor 
Immunity in Breast Cancer. Cancer Res 76: 5657-5670 
Correia DV, Lopes A, Silva-Santos B (2013) Tumor cell recognition by gammadelta T lymphocytes: T-cell receptor 
vs. NK-cell receptors. Oncoimmunology 2: e22892 
Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-7 
127 
 
Covino R, Hummer G, Ernst R (2018) Integrated Functions of Membrane Property Sensors and a Hidden Side of the 
Unfolded Protein Response. Mol Cell 71: 458-467 
Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad K, Gronbaek H, Tjonneland A, Halkjaer J, Dossus 
L, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Boutron-Ruault MC, De Lauzon B, Clavel-Chapelon 
F, Palli D, Berrino F et al. (2009) The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-
2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers 
Prev 18: 1333-40 
Cubillos-Ruiz JR, Bettigole SE, Glimcher LH (2017) Tumorigenic and Immunosuppressive Effects of Endoplasmic 
Reticulum Stress in Cancer. Cell 168: 692-706 
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta 
D, Holcomb K, Ellenson LH, Caputo T, Lee AH, Conejo-Garcia JR, Glimcher LH (2015) ER Stress Sensor XBP1 
Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell 161: 1527-38 
Cui HJ, Liu XG, McCormick M, Wasko BM, Zhao W, He X, Yuan Y, Fang BX, Sun XR, Kennedy BK, Suh Y, Zhou 
ZJ, Kaeberlein M, Feng WL (2015) PMT1 deficiency enhances basal UPR activity and extends replicative lifespan of 
Saccharomyces cerevisiae. Age (Dordr) 37: 9788 
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen 
receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and 
epidermal growth factor. Cancer Res 54: 5474-8 
Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. (2013) Cellular fatty acid metabolism and cancer. Cell 
Metab 18: 153-61 
Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY 
(2013) Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary 
restriction. Cancer Discov 3: 908-21 
D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V (2015) Fasting 
cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget 6: 
18545-57 
Dadey DYA, Kapoor V, Hoye K, Khudanyan A, Collins A, Thotala D, Hallahan DE (2017) Antibody Targeting GRP78 
Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non-Small Cell Lung Cancer Cell Lines and 
Tumor Models. Clin Cancer Res 23: 2556-2564 
Darling NJ, Cook SJ (2014) The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. 
Biochim Biophys Acta 1843: 2150-63 
Dassler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert 
R, Tuting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C (2016) RIG-I activation induces the 
release of extracellular vesicles with antitumor activity. Oncoimmunology 5: e1219827 
Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado 
MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD (2016) 
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 126: 3447-52 
Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, 
O'Brien JP, Pierce KA, Gui DY, Sullivan LB, Wasylenko TM, Subbaraj L, Chin CR, Stephanopolous G, Mott BT, 
Jacks T, Clish CB, Vander Heiden MG (2016) Environment Impacts the Metabolic Dependencies of Ras-Driven Non-
Small Cell Lung Cancer. Cell Metab 23: 517-28 
128 
 
de Almeida SF, Fleming JV, Azevedo JE, Carmo-Fonseca M, de Sousa M (2007) Stimulation of an unfolded protein 
response impairs MHC class I expression. J Immunol 178: 3612-9 
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, 
Nortier JW, Pijl H, Kroep JR (2015) The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in 
HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer 15: 652 
Dejeans N, Barroso K, Fernandez-Zapico ME, Samali A, Chevet E (2015) Novel roles of the unfolded protein response 
in the control of tumor development and aggressiveness. Semin Cancer Biol 33: 67-73 
Dejeans N, Manie S, Hetz C, Bard F, Hupp T, Agostinis P, Samali A, Chevet E (2014) Addicted to secrete - novel 
concepts and targets in cancer therapy. Trends Mol Med 20: 242-50 
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 
5: 930-42 
Dey S, Sayers CM, Verginadis, II, Lehman SL, Cheng Y, Cerniglia GJ, Tuttle SW, Feldman MD, Zhang PJ, Fuchs 
SY, Diehl JA, Koumenis C (2015) ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes 
metastasis. J Clin Invest 125: 2592-608 
Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei 
M, Morgan TE, Longo VD (2016) Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor 
Cytotoxicity. Cancer Cell 30: 136-146 
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, 
Kalinke U, Murphy KM, Schreiber RD (2011) Type I interferon is selectively required by dendritic cells for immune 
rejection of tumors. J Exp Med 208: 1989-2003 
Dirx MJ, van den Brandt PA, Goldbohm RA, Lumey LH (2003) Energy restriction early in life and colon carcinoma 
risk: results of The Netherlands Cohort Study after 7.3 years of follow-up. Cancer 97: 46-55 
Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States 
today. J Natl Cancer Inst 66: 1191-308 
Dosset M, Vargas TR, Lagrange A, Boidot R, Vegran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-
Joseph E, Martin F, Ryffel B, Borg C, Adotevi O, Ghiringhelli F, Apetoh L (2018) PD-1/PD-L1 pathway: an adaptive 
immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology 7: e1433981 
Druesne-Pecollo N, Latino-Martel P, Norat T, Barrandon E, Bertrais S, Galan P, Hercberg S (2010) Beta-carotene 
supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 
127: 172-84 
Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, 
Endres S, Schnurr M (2014) RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and 
sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ 21: 1825-37 
Dumbrava MD, Rothschild BM, Weishampel DB, Csiki-Sava Z, Andrei RA, Acheson KA, Codrea VA (2016) A 
dinosaurian facial deformity and the first occurrence of ameloblastoma in the fossil record. Sci Rep 6: 29271 
Eckard SC, Rice GI, Fabre A, Badens C, Gray EE, Hartley JL, Crow YJ, Stetson DB (2014) The SKIV2L RNA 
exosome limits activation of the RIG-I-like receptors. Nat Immunol 15: 839-45 
Edinger AL (2005) Growth factors regulate cell survival by controlling nutrient transporter expression. Biochem Soc 
Trans 33: 225-7 
129 
 
Edinger AL, Thompson CB (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient 
uptake. Mol Biol Cell 13: 2276-88 
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H (2015) Immune-mediated antitumor effect 
by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 112: 1809-14 
Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, 
Antonacci L, Fussi H, Deszcz L, Hartl R, Schraml E, Criollo A, Megalou E, Weiskopf D, Laun P, Heeren G, 
Breitenbach M et al. (2009) Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 11: 1305-14 
Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM (2017) 
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81: 116-
129 
Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, Jin G, Myers J, Abraham RT, Unsal-Kacmaz 
K (2017) Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep 19: 2665-
2680 
Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like 
growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 
prospective studies. Lancet Oncol 11: 530-42 
Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, Wang F, Javors MA, Chen J, Sun LY, Bartke A (2013) 
Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab 17: 456-62 
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, 
Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG (2013) AMPK is a negative regulator of the Warburg effect and 
suppresses tumor growth in vivo. Cell Metab 17: 113-24 
Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, Proia TA, Jin DX, Reinhardt F, Ploegh HL, Wang Q, 
Gupta PB (2014) Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic 
reticulum stress. Cancer Discov 4: 702-15 
Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, 
Fuchs C, Hahn WC, Guarente LP, Sinclair DA (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and 
colon cancer growth. PLoS One 3: e2020 
Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R (2013) 
Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget 4: 2451-61 
Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, Allory Y, de la Taille A, Culine S, Blancou H, 
Cristol JP, Michel F, Sardet C, Fajas L (2010) Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 
inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 9: 
1740-54 
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (2011) Host type I IFN signals are 
required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208: 2005-16 
Fulda S (2010) Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010: 370835 
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological Effects of Conventional Chemotherapy 
and Targeted Anticancer Agents. Cancer Cell 28: 690-714 
130 
 
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017a) Immunogenic cell death in cancer and infectious 
disease. Nat Rev Immunol 17: 97-111 
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017b) Reply: Immunosuppressive cell death in cancer. Nat 
Rev Immunol 17: 402 
Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, 
Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, 
Rubinsztein DC, Simon HU, Simonsen A et al. (2015) Autophagy in malignant transformation and cancer progression. 
EMBO J 34: 856-80 
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews 
DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, 
Bertrand MJM, Bianchi K, Blagosklonny MV et al. (2018) Molecular mechanisms of cell death: recommendations of 
the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25: 486-541 
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW (2014) Radiation-induced immunogenic 
modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. 
Oncotarget 5: 403-16 
Garg AD, Agostinis P (2014) ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced 
anti-cancer immune responses. Photochem Photobiol Sci 13: 474-87 
Garg AD, Maes H, van Vliet AR, Agostinis P (2015) Targeting the hallmarks of cancer with therapy-induced 
endoplasmic reticulum (ER) stress. Mol Cell Oncol 2: e975089 
Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I 
in cancers for effective immunotherapy. Curr Opin Immunol 39: 44-51 
Gavilan MP, Pintado C, Gavilan E, Jimenez S, Rios RM, Vitorica J, Castano A, Ruano D (2009) Dysfunction of the 
unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition. 
Aging Cell 8: 654-65 
Ghosh AP, Klocke BJ, Ballestas ME, Roth KA (2012) CHOP potentially co-operates with FOXO3a in neuronal cells 
to regulate PUMA and BIM expression in response to ER stress. PLoS One 7: e39586 
Gomez-Bougie P, Halliez M, Moreau P, Pellat-Deceunynck C, Amiot M (2016) Repression of Mcl-1 and disruption 
of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis. Cancer Lett 383: 204-211 
Gonzalez CA, Riboli E (2010) Diet and cancer prevention: Contributions from the European Prospective Investigation 
into Cancer and Nutrition (EPIC) study. Eur J Cancer 46: 2555-62 
Goubau D, Deddouche S, Reis e Sousa C (2013) Cytosolic sensing of viruses. Immunity 38: 855-69 
Granados DP, Tanguay PL, Hardy MP, Caron E, de Verteuil D, Meloche S, Perreault C (2009) ER stress affects 
processing of MHC class I-associated peptides. BMC Immunol 10: 10 
Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306-13 
Green DR, Galluzzi L, Kroemer G (2014) Cell biology. Metabolic control of cell death. Science 345: 1250256 
Gronich N, Rennert G (2013) Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev 
Clin Oncol 10: 625-42 
131 
 
Grootjans J, Kaser A, Kaufman RJ, Blumberg RS (2016) The unfolded protein response in immunity and inflammation. 
Nat Rev Immunol 16: 469-84 
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, 
Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett 
MK (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 
13: 890-901 
Guarente L (2013) Calorie restriction and sirtuins revisited. Genes Dev 27: 2072-85 
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-
Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD (2011) Growth hormone receptor deficiency is 
associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3: 70ra13 
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK 
phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-26 
Halama A, Kulinski M, Dib SS, Zaghlool SB, Siveen KS, Iskandarani A, Zierer J, Prabhu KS, Satheesh NJ, Bhagwat 
AM, Uddin S, Kastenmuller G, Elemento O, Gross SS, Suhre K (2018) Accelerated lipid catabolism and autophagy 
are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett 430: 133-147 
Halbleib K, Pesek K, Covino R, Hofbauer HF, Wunnicke D, Hanelt I, Hummer G, Ernst R (2017) Activation of the 
Unfolded Protein Response by Lipid Bilayer Stress. Mol Cell 67: 673-684 e8 
Hall DT, Griss T, Ma JF, Sanchez BJ, Sadek J, Tremblay AMK, Mubaid S, Omer A, Ford RJ, Bedard N, Pause A, 
Wing SS, Di Marco S, Steinberg GR, Jones RG, Gallouzi IE (2018) The AMPK agonist 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. 
EMBO Mol Med 10 
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial 
breast cancer to chromosome 17q21. Science 250: 1684-9 
Han D, Lerner AG, Vande Walle L, Upton JP, Xu W, Hagen A, Backes BJ, Oakes SA, Papa FR (2009) IRE1alpha 
kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138: 562-75 
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70 
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-74 
Handschin C (2016) Caloric restriction and exercise "mimetics'': Ready for prime time? Pharmacol Res 103: 158-66 
Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell 
Biol 8: 774-85 
Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, 
Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA et al. (2012) ER stress-mediated 
autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest 122: 4621-34 
Harvey AE, Lashinger LM, Otto G, Nunez NP, Hursting SD (2013) Decreased systemic IGF-1 in response to calorie 
restriction modulates murine tumor cell growth, nuclear factor-kappaB activation, and inflammation-related gene 
expression. Mol Carcinog 52: 997-1006 
Harwood KR, Hanover JA (2014) Nutrient-driven O-GlcNAc cycling - think globally but act locally. J Cell Sci 127: 
1857-67 
132 
 
Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
Science 253: 905-9 
Henis-Korenblit S, Zhang P, Hansen M, McCormick M, Lee SJ, Cary M, Kenyon C (2010) Insulin/IGF-1 signaling 
mutants reprogram ER stress response regulators to promote longevity. Proc Natl Acad Sci U S A 107: 9730-5 
Herranz D, Iglesias G, Munoz-Martin M, Serrano M (2011) Limited role of Sirt1 in cancer protection by dietary 
restriction. Cell Cycle 10: 2215-7 
Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M (2010) 
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1: 3 
Hetz C, Chevet E, Harding HP (2013) Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12: 
703-19 
Hetz C, Chevet E, Oakes SA (2015) Proteostasis control by the unfolded protein response. Nat Cell Biol 17: 829-38 
Horn H, Bohme B, Dietrich L, Koch M (2018) Endocannabinoids in Body Weight Control. Pharmaceuticals (Basel) 
11 
Horton BL, Gajewski TF (2018) Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer 118: 309-
311 
Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF (2018) Intratumoral CD8(+) T-cell Apoptosis Is a 
Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res 6: 14-24 
Hosios AM, Vander Heiden MG (2014) Acetate metabolism in cancer cells. Cancer Metab 2: 27 
Hou J, Greten TF, Xia Q (2017) Immunosuppressive cell death in cancer. Nat Rev Immunol 17: 401 
Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, 
Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G et al. (2014) Hepatic RIG-I predicts survival and interferon-alpha 
therapeutic response in hepatocellular carcinoma. Cancer Cell 25: 49-63 
Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD (2013) A growing role for mTOR in promoting anabolic metabolism. 
Biochem Soc Trans 41: 906-12 
Hoxhaj G, Hughes-Hallett J, Timson RC, Ilagan E, Yuan M, Asara JM, Ben-Sahra I, Manning BD (2017) The 
mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. Cell Rep 21: 1331-1346 
Hu F, Yu X, Wang H, Zuo D, Guo C, Yi H, Tirosh B, Subjeck JR, Qiu X, Wang XY (2011) ER stress and its regulator 
X-box-binding protein-1 enhance polyIC-induced innate immune response in dendritic cells. Eur J Immunol 41: 1086-
97 
Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB, Clarke R (2015) NF-kappaB signaling is required for XBP1 
(unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Mol 
Cell Biol 35: 379-90 
Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc 
Trans 37: 217-22 
Hur KY, So JS, Ruda V, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Iwawaki T, Glimcher LH, Lee AH (2012) 
IRE1alpha activation protects mice against acetaminophen-induced hepatotoxicity. J Exp Med 209: 307-18 
133 
 
Imamura F, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, Mozaffarian D, Global Burden of Diseases N, Chronic 
Diseases Expert G (2015) Dietary quality among men and women in 187 countries in 1990 and 2010: a systematic 
assessment. Lancet Glob Health 3: e132-42 
Ingram DK, Roth GS (2011) Glycolytic inhibition as a strategy for developing calorie restriction mimetics. Exp 
Gerontol 46: 148-54 
Ingram DK, Roth GS (2015) Calorie restriction mimetics: can you have your cake and eat it, too? Ageing Res Rev 20: 
46-62 
Jeon SM, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during 
energy stress. Nature 485: 661-5 
Jin L, Alesi GN, Kang S (2016) Glutaminolysis as a target for cancer therapy. Oncogene 35: 3619-25 
Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of ageing and age-related disease. Nature 
493: 338-45 
Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, 
Irvine DJ, Walker BD (2014) Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic 
T-lymphocytes. PLoS Pathog 10: e1004287 
Jones RG, Bui T, White C, Madesh M, Krawczyk CM, Lindsten T, Hawkins BJ, Kubek S, Frauwirth KA, Wang YL, 
Conway SJ, Roderick HL, Bootman MD, Shen H, Foskett JK, Thompson CB (2007) The proapoptotic factors Bax and 
Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity 27: 268-80 
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348: 74-
80 
Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH (2017) PD-
L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp 
Med 214: 895-904 
Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH (2012) RAE-1 ligands for the NKG2D receptor are regulated by 
E2F transcription factors, which control cell cycle entry. J Exp Med 209: 2409-22 
Kalaany NY, Sabatini DM (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-
31 
Kalyanaraman B (2017) Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the 
differences between normal and cancer cell metabolism. Redox Biol 12: 833-842 
Kamphorst JJ, Chung MK, Fan J, Rabinowitz JD (2014) Quantitative analysis of acetyl-CoA production in hypoxic 
cancer cells reveals substantial contribution from acetate. Cancer Metab 2: 23 
Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu 
X, Koumenis C, Diehl JA, Fuchs SY (2016) Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced 
Senescence and Mediates Melanoma Development and Progression. Cell Rep 15: 171-180 
Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, 
Peck AR, Pure E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY (2017) Inactivation of Interferon 
Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 31: 194-207 
134 
 
Kawashima M, Ozawa Y, Shinmura K, Inaba T, Nakamura S, Kawakita T, Watanabe M, Tsubota K (2013) Calorie 
restriction (CR) and CR mimetics for the prevention and treatment of age-related eye disorders. Exp Gerontol 48: 
1096-100 
Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA (1982) Fasting: the history, pathophysiology and 
complications. West J Med 137: 379-99 
Kharazi AI, James SJ, Taylor JM, Lubinski JM, Nakamura LT, Makinodan T (1994) Combined chronic low dose 
radiation-caloric restriction: a model for regression of spontaneous mammary tumor. Int J Radiat Oncol Biol Phys 28: 
641-7 
Kim H, Bhattacharya A, Qi L (2015) Endoplasmic reticulum quality control in cancer: Friend or foe. Semin Cancer 
Biol 33: 25-33 
Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic 
opportunities. Nat Rev Drug Discov 7: 1013-30 
Kim J, Yang G, Kim Y, Kim J, Ha J (2016) AMPK activators: mechanisms of action and physiological activities. Exp 
Mol Med 48: e224 
Kim JY, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, Kaufman RJ, Saltiel AR, Karin M (2018) ER 
Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell 175: 133-145 e15 
Kim M, Nitschke M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, 
Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM (2018) Amplification of 
Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res 78: 
922-937 
Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, 
Takamori S, Kuwano M, Ono M (2007) Inflammatory stimuli from macrophages and cancer cells synergistically 
promote tumor growth and angiogenesis. Cancer Sci 98: 2009-18 
Kitai Y, Ariyama H, Kono N, Oikawa D, Iwawaki T, Arai H (2013) Membrane lipid saturation activates IRE1alpha 
without inducing clustering. Genes Cells 18: 798-809 
Kitajima S, Takahashi C (2017) Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and 
inflammation. Cancer Sci 108: 1726-1731 
Kitajima S, Yoshida A, Kohno S, Li F, Suzuki S, Nagatani N, Nishimoto Y, Sasaki N, Muranaka H, Wan Y, Thai TC, 
Okahashi N, Matsuda F, Shimizu H, Nishiuchi T, Suzuki Y, Tominaga K, Gotoh N, Suzuki M, Ewen ME et al. (2017) 
The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. 
Oncogene 36: 5145-5157 
Klinke DJ, 2nd (2012) An evolutionary perspective on anti-tumor immunity. Front Oncol 2: 202 
Krebs-Smith SM, Guenther PM, Subar AF, Kirkpatrick SI, Dodd KW (2010) Americans do not meet federal dietary 
recommendations. J Nutr 140: 1832-8 
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P (2012) Immunogenic cell death and 
DAMPs in cancer therapy. Nat Rev Cancer 12: 860-75 
Kumar SP, Roy SJ, Tokumo K, Reddy BS (1990) Effect of different levels of calorie restriction on azoxymethane-
induced colon carcinogenesis in male F344 rats. Cancer Res 50: 5761-6 
135 
 
Labunskyy VM, Gerashchenko MV, Delaney JR, Kaya A, Kennedy BK, Kaeberlein M, Gladyshev VN (2014) 
Lifespan extension conferred by endoplasmic reticulum secretory pathway deficiency requires induction of the 
unfolded protein response. PLoS Genet 10: e1004019 
Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, 
Ahima RS, Guertin DA, Sabatini DM, Baur JA (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 
loss and uncoupled from longevity. Science 335: 1638-43 
Lancaster GI, Langley KG, Berglund NA, Kammoun HL, Reibe S, Estevez E, Weir J, Mellett NA, Pernes G, Conway 
JRW, Lee MKS, Timpson P, Murphy AJ, Masters SL, Gerondakis S, Bartonicek N, Kaczorowski DC, Dinger ME, 
Meikle PJ, Bond PJ et al. (2018) Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-
Induced Inflammation by Reprogramming Macrophage Metabolism. Cell Metab 27: 1096-1110 e5 
Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ (2010) Metformin associated with lower 
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-6 
Lane N, Martin W (2010) The energetics of genome complexity. Nature 467: 929-34 
Lashinger LM, Malone LM, McArthur MJ, Goldberg JA, Daniels EA, Pavone A, Colby JK, Smith NC, Perkins SN, 
Fischer SM, Hursting SD (2011) Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of 
calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia. Cancer Prev Res (Phila) 4: 1030-40 
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino 
A, Emionite L, de Cabo R, Longo VD (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer 
cell types to chemotherapy. Sci Transl Med 4: 124ra27 
Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD (2010) 
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve 
chemotherapeutic index. Cancer Res 70: 1564-72 
Lee EB, Ahn D, Kim BJ, Lee SY, Seo HW, Cha YS, Jeon H, Eun JS, Cha DS, Kim DK (2015) Genistein from Vigna 
angularis Extends Lifespan in Caenorhabditis elegans. Biomol Ther (Seoul) 23: 77-83 
Lee KP, Simpson SJ, Clissold FJ, Brooks R, Ballard JW, Taylor PW, Soran N, Raubenheimer D (2008) Lifespan and 
reproduction in Drosophila: New insights from nutritional geometry. Proc Natl Acad Sci U S A 105: 2498-503 
Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers (Basel) 3: 3856-93 
Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, 
Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S et al. (2013) 
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153: 1064-79 
Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-
Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, Cohen P, Crimmins EM, Longo VD (2014) Low protein intake 
is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older 
population. Cell Metab 19: 407-17 
Li H, Chen X, Gao Y, Wu J, Zeng F, Song F (2015) XBP1 induces snail expression to promote epithelial- to-
mesenchymal transition and invasion of breast cancer cells. Cell Signal 27: 82-9 
Li HW, Zhao W, Sarkar NH (1994) Dietary regulation of mammary tumorigenesis in RIII/Sa mice: investigation of a 
possible mechanism. Cancer Lett 79: 199-211 
136 
 
Li J, Zhang CX, Liu YM, Chen KL, Chen G (2017a) A comparative study of anti-aging properties and mechanism: 
resveratrol and caloric restriction. Oncotarget 8: 65717-65729 
Li K, Qu S, Chen X, Wu Q, Shi M (2017b) Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-
Mediated Innate Immune Pathways. Int J Mol Sci 18 
Li XX, Zhang HS, Xu YM, Zhang RJ, Chen Y, Fan L, Qin YQ, Liu Y, Li M, Fang J (2017c) Knockdown of IRE1alpha 
inhibits colonic tumorigenesis through decreasing beta-catenin and IRE1alpha targeting suppresses colon cancer cells. 
Oncogene  
Liberti MV, Locasale JW (2016) The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 41: 
211-218 
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K 
(2000) Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, 
Denmark, and Finland. N Engl J Med 343: 78-85 
Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, Tan M (2017) Interplay between Immune 
Checkpoint Proteins and Cellular Metabolism. Cancer Res 77: 1245-1249 
Lippens C, Duraes FV, Dubrot J, Brighouse D, Lacroix M, Irla M, Aubry-Lachainaye JP, Reith W, Mandl JN, Hugues 
S (2016) IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun 75: 39-49 
Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H 
(2012) Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer 
Immunol Immunother 61: 789-801 
Llambi F, Wang YM, Victor B, Yang M, Schneider DM, Gingras S, Parsons MJ, Zheng JH, Brown SA, Pelletier S, 
Moldoveanu T, Chen T, Green DR (2016) BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated 
by ER-Associated Degradation. Cell 165: 421-33 
Lo Presti E, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, Meraviglia S (2018) gammadelta T Cells and 
Tumor Microenvironment: From Immunosurveillance to Tumor Evasion. Front Immunol 9: 1395 
Logue SE, McGrath EP, Cleary P, Greene S, Mnich K, Almanza A, Chevet E, Dwyer RM, Oommen A, Legembre P, 
Godey F, Madden EC, Leuzzi B, Obacz J, Zeng Q, Patterson JB, Jager R, Gorman AM, Samali A (2018) Inhibition of 
IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun 9: 
3267 
Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, Mainolfi N, Suri V, Guak H, Balmer ML, Verway 
MJ, Raissi TC, Tsui H, Boukhaled G, Henriques da Costa S, Frezza C, Krawczyk CM, Friedman A, Manfredi M, 
Richer MJ et al. (2017) Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab 25: 345-357 
Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat 
Rev Cancer 4: 966-77 
Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay 
D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH (2017) Modulating 
the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544: 372-376 
Madeo F, Pietrocola F, Eisenberg T, Kroemer G (2014) Caloric restriction mimetics: towards a molecular definition. 
Nat Rev Drug Discov 13: 727-40 
137 
 
Mahnke YD, Devevre E, Baumgaertner P, Matter M, Rufer N, Romero P, Speiser DE (2012) Human melanoma-
specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. 
Oncoimmunology 1: 467-530 
Mai V, Colbert LH, Berrigan D, Perkins SN, Pfeiffer R, Lavigne JA, Lanza E, Haines DC, Schatzkin A, Hursting SD 
(2003) Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice 
through different mechanisms. Cancer Res 63: 1752-5 
Malamas AS, Gameiro SR, Knudson KM, Hodge JW (2016) Sublethal exposure to alpha radiation (223Ra dichloride) 
enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-
mediated immunogenic modulation. Oncotarget 7: 86937-86947 
Manning BD (2017) Game of TOR - The Target of Rapamycin Rules Four Kingdoms. N Engl J Med 377: 1297-9 
Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin 
Immunol 22: 231-7 
Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L (2006) Curcumin is an inhibitor of p300 histone 
acetylatransferase. Med Chem 2: 169-74 
Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH (2014) 
Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122: 91-128 
Marino G, Pietrocola F, Madeo F, Kroemer G (2014) Caloric restriction mimetics: natural/physiological 
pharmacological autophagy inducers. Autophagy 10: 1879-82 
Mark KA, Dumas KJ, Bhaumik D, Schilling B, Davis S, Oron TR, Sorensen DJ, Lucanic M, Brem RB, Melov S, 
Ramanathan A, Gibson BW, Lithgow GJ (2016) Vitamin D Promotes Protein Homeostasis and Longevity via the 
Stress Response Pathway Genes skn-1, ire-1, and xbp-1. Cell Rep 17: 1227-1237 
Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, 
Minor RK, Blouin MJ, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf 
NS, Spindler SR et al. (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192 
Martinon F, Chen X, Lee AH, Glimcher LH (2010) TLR activation of the transcription factor XBP1 regulates innate 
immune responses in macrophages. Nat Immunol 11: 411-8 
Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, 
Tesniere A, Zitvogel L, Kroemer G (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death 
by endoplasmic reticulum stress. Oncogene 30: 1147-58 
Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ (2011) Pivotal role of innate and adaptive immunity in 
anthracycline chemotherapy of established tumors. Cancer Res 71: 4809-20 
Maurel M, Chevet E, Tavernier J, Gerlo S (2014) Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem 
Sci 39: 245-54 
McCarty MF, Block KI (2006) Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may 
increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer 
Ther 5: 252-68 
McCay CM, Crowell MF, Maynard LA (1989) The effect of retarded growth upon the length of life span and upon the 
ultimate body size. 1935. Nutrition 5: 155-71; discussion 172 
138 
 
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan 
J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, 
Orchard SG et al. (2018) Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med  
Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, 
Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, Andre F, Zitvogel L, Kepp O 
et al. (2012) Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 4: 
143ra99 
Meynet O, Beneteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M, Ricci JE (2012) Glycolysis inhibition targets 
Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26: 1145-7 
Meynet O, Ricci JE (2014) Caloric restriction and cancer: molecular mechanisms and clinical implications. Trends 
Mol Med 20: 419-27 
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding 
W, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71 
Minor RK, Smith DL, Jr., Sossong AM, Kaushik S, Poosala S, Spangler EL, Roth GS, Lane M, Allison DB, de Cabo 
R, Ingram DK, Mattison JA (2010) Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and 
increases mortality in rats. Toxicol Appl Pharmacol 243: 332-9 
Mitchell SJ, Bernier M, Mattison JA, Aon MA, Kaiser TA, Anson RM, Ikeno Y, Anderson RM, Ingram DK, de Cabo 
R (2018) Daily Fasting Improves Health and Survival in Male Mice Independent of Diet Composition and Calories. 
Cell Metab  
Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three 
component phases--elimination, equilibrium and escape. Curr Opin Immunol 27: 16-25 
Monge J, Kricun M, Radovcic J, Radovcic D, Mann A, Frayer DW (2013) Fibrous dysplasia in a 120,000+ year old 
Neandertal from Krapina, Croatia. PLoS One 8: e64539 
Monu NR, Frey AB (2012) Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol 
Invest 41: 595-613 
Moore LV, Dodd KW, Thompson FE, Grimm KA, Kim SA, Scanlon KS (2015) Using Behavioral Risk Factor 
Surveillance System Data to Estimate the Percentage of the Population Meeting US Department of Agriculture Food 
Patterns Fruit and Vegetable Intake Recommendations. Am J Epidemiol 181: 979-88 
Moyer JD, Oliver JT, Handschumacher RE (1981) Salvage of circulating pyrimidine nucleosides in the rat. Cancer 
Res 41: 3010-7 
Mujcic H, Nagelkerke A, Rouschop KM, Chung S, Chaudary N, Span PN, Clarke B, Milosevic M, Sykes J, Hill RP, 
Koritzinsky M, Wouters BG (2013) Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response 
promotes metastasis through induction of LAMP3. Clin Cancer Res 19: 6126-37 
Munoz JP, Ivanova S, Sanchez-Wandelmer J, Martinez-Cristobal P, Noguera E, Sancho A, Diaz-Ramos A, Hernandez-
Alvarez MI, Sebastian D, Mauvezin C, Palacin M, Zorzano A (2013) Mfn2 modulates the UPR and mitochondrial 
function via repression of PERK. EMBO J 32: 2348-61 
Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, Benci JL, DeMichele AM, Tchou J, Marcotrigiano J, Minn 
AJ (2017) Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in 
Cancer. Cell 170: 352-366 e13 
139 
 
Naidoo N, Ferber M, Master M, Zhu Y, Pack AI (2008) Aging impairs the unfolded protein response to sleep 
deprivation and leads to proapoptotic signaling. J Neurosci 28: 6539-48 
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer 
cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-4 
Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo 
J, Koike K, Kaufman RJ, Karin M (2014) ER stress cooperates with hypernutrition to trigger TNF-dependent 
spontaneous HCC development. Cancer Cell 26: 331-343 
Nakamura A, Nambu T, Ebara S, Hasegawa Y, Toyoshima K, Tsuchiya Y, Tomita D, Fujimoto J, Kurasawa O, 
Takahara C, Ando A, Nishigaki R, Satomi Y, Hata A, Hara T (2018) Inhibition of GCN2 sensitizes ASNS-low cancer 
cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci U S A 115: E7776-E7785 
Namba T, Chu K, Kodama R, Byun S, Yoon KW, Hiraki M, Mandinova A, Lee SW (2015) Loss of p53 enhances the 
function of the endoplasmic reticulum through activation of the IRE1alpha/XBP1 pathway. Oncotarget 6: 19990-20001 
Niederreiter L, Fritz TM, Adolph TE, Krismer AM, Offner FA, Tschurtschenthaler M, Flak MB, Hosomi S, Tomczak 
MF, Kaneider NC, Sarcevic E, Kempster SL, Raine T, Esser D, Rosenstiel P, Kohno K, Iwawaki T, Tilg H, Blumberg 
RS, Kaser A (2013) ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem 
cells. J Exp Med 210: 2041-56 
Nikolai S, Pallauf K, Huebbe P, Rimbach G (2015) Energy restriction and potential energy restriction mimetics. Nutr 
Res Rev 28: 100-120 
Niu Z, Wang M, Zhou L, Yao L, Liao Q, Zhao Y (2015) Elevated GRP78 expression is associated with poor prognosis 
in patients with pancreatic cancer. Sci Rep 5: 16067 
Norman C, Howell KA, Millar AH, Whelan JM, Day DA (2004) Salicylic acid is an uncoupler and inhibitor of 
mitochondrial electron transport. Plant Physiol 134: 492-501 
Nowarski R, Gagliani N, Huber S, Flavell RA (2013) Innate immune cells in inflammation and cancer. Cancer 
Immunol Res 1: 77-84 
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41: 49-61 
O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, 
Teng MW, Smyth MJ, Schreiber RD, Bui JD (2012) Cancer immunoediting by the innate immune system in the 
absence of adaptive immunity. J Exp Med 209: 1869-82 
Obacz J, Avril T, Le Reste PJ, Urra H, Quillien V, Hetz C, Chevet E (2017) Endoplasmic reticulum proteostasis in 
glioblastoma-From molecular mechanisms to therapeutic perspectives. Sci Signal 10 
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares 
N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin 
exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61 
Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana 
L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, Pili R (2018) Dietary protein restriction 
reprograms tumor associated macrophages and enhances immunotherapy. Clin Cancer Res  
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte 
D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early 
metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-66 
140 
Pallauf K, Rimbach G (2013) Autophagy, polyphenols and healthy ageing. Ageing Res Rev 12: 237-52 
Pallavi R, Giorgio M, Pelicci PG (2012) Insights into the beneficial effect of caloric/ dietary restriction for a healthy 
and prolonged life. Front Physiol 3: 318 
Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, 
van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G (2009) Mechanisms of pre-apoptotic calreticulin 
exposure in immunogenic cell death. EMBO J 28: 578-90 
Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P (2016) Harnessing the immune system to improve 
cancer therapy. Ann Transl Med 4: 261 
Park IA, Heo SH, Song IH, Kim YA, Park HS, Bang WS, Park SY, Jo JH, Lee HJ, Gong G (2016) Endoplasmic 
reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating 
lymphocytes in triple-negative breast cancer. Oncotarget 7: 59957-59964 
Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW (2004) 15-epi-lipoxin A4-mediated induction 
of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200: 69-78 
Pavlova NN, Thompson CB (2016) The Emerging Hallmarks of Cancer Metabolism. Cell Metab 23: 27-47 
Pereira ER, Frudd K, Awad W, Hendershot LM (2014) Endoplasmic reticulum (ER) stress and hypoxia response 
pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular 
endothelial growth factor (VEGF). J Biol Chem 289: 3352-64 
Perez-Escuredo J, Dadhich RK, Dhup S, Cacace A, Van Hee VF, De Saedeleer CJ, Sboarina M, Rodriguez F, 
Fontenille MJ, Brisson L, Porporato PE, Sonveaux P (2016) Lactate promotes glutamine uptake and metabolism in 
oxidative cancer cells. Cell Cycle 15: 72-83 
Pernicova I, Korbonits M (2014) Metformin--mode of action and clinical implications for diabetes and cancer. Nat 
Rev Endocrinol 10: 143-56 
Peterson LW, Artis D (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat 
Rev Immunol 14: 141-53 
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton 
A, Redouane Y, Lin YJ, Wojtkiewicz G, Iwamoto Y, Mino-Kenudson M, Huynh TG, Hynes RO, Freeman GJ, 
Kroemer G, Zitvogel L, Weissleder R et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint 
Blockade Therapy. Immunity 44: 343-54 
Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP (2010) Dietary energy availability affects primary and 
metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123: 333-44 
Pietrocola F, Castoldi F, Maiuri MC, Kroemer G (2018a) Aspirin-another caloric-restriction mimetic. Autophagy: 1-2 
Pietrocola F, Castoldi F, Markaki M, Lachkar S, Chen G, Enot DP, Durand S, Bossut N, Tong M, Malik SA, Loos F, 
Dupont N, Marino G, Abdelkader N, Madeo F, Maiuri MC, Kroemer R, Codogno P, Sadoshima J, Tavernarakis N et 
al. (2018b) Aspirin Recapitulates Features of Caloric Restriction. Cell Rep 22: 2395-2407 
Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, 
Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A et al. (2016) 
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell 30: 147-160 
141 
 
Piperi C, Samaras V, Levidou G, Kavantzas N, Boviatsis E, Petraki K, Grivas A, Barbatis C, Varsos V, Patsouris E, 
Korkolopoulou P (2011) Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, 
VEGF and microvessel morphometry. Cytokine 55: 387-95 
Ploeger JM, Manivel JC, Boatner LN, Mashek DG (2017) Caloric Restriction Prevents Carcinogen-Initiated Liver 
Tumorigenesis in Mice. Cancer Prev Res (Phila) 10: 660-670 
Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, 
Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S et al. 
(2008) 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14: 1256-63 
Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-
Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P, Strasser A (2007) ER stress triggers apoptosis by activating 
BH3-only protein Bim. Cell 129: 1337-49 
Pytel D, Majsterek I, Diehl JA (2016) Tumor progression and the different faces of the PERK kinase. Oncogene 35: 
1207-15 
Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N (2013) Calreticulin in the immune system: ins and outs. Trends 
Immunol 34: 13-21 
Ramadori G, Konstantinidou G, Venkateswaran N, Biscotti T, Morlock L, Galie M, Williams NS, Luchetti M, 
Santinelli A, Scaglioni PP, Coppari R (2015) Diet-induced unresolved ER stress hinders KRAS-driven lung 
tumorigenesis. Cell Metab 21: 117-25 
Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Zhang LM, Klein-
Seetharaman J, Celis E, Kagan VE, Gabrilovich DI (2014) Oxidized lipids block antigen cross-presentation by 
dendritic cells in cancer. J Immunol 192: 2920-31 
Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA (2006) Functional coupling of p38-induced up-regulation of 
BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant 
carcinoma cells. Cancer Res 66: 1702-11 
Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60: 1577-1585 
Reyes R, Wani NA, Ghoshal K, Jacob ST, Motiwala T (2017) Sorafenib and 2-Deoxyglucose Synergistically Inhibit 
Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. Gene Expr 17: 129-
140 
Richter M, Vidovic N, Honrath B, Mahavadi P, Dodel R, Dolga AM, Culmsee C (2016) Activation of SK2 channels 
preserves ER Ca(2)(+) homeostasis and protects against ER stress-induced cell death. Cell Death Differ 23: 814-27 
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, 
Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C et 
al. (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. 
Cancer Cell 25: 846-59 
Robien K, Demark-Wahnefried W, Rock CL (2011) Evidence-based nutrition guidelines for cancer survivors: current 
guidelines, knowledge gaps, and future research directions. J Am Diet Assoc 111: 368-75 
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor 
EM, Antonia S, Ochoa JB, Ochoa AC (2004) Arginase I production in the tumor microenvironment by mature myeloid 
cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64: 5839-49 
142 
 
Roebuck BD, Baumgartner KJ, MacMillan DL (1993) Caloric restriction and intervention in pancreatic carcinogenesis 
in the rat. Cancer Res 53: 46-52 
Rothschild BM, Witzke BJ, Hershkovitz I (1999) Metastatic cancer in the Jurassic. Lancet 354: 398 
Rubio-Patino C, Bossowski JP, Chevet E, Ricci JE (2018a) Reshaping the Immune Tumor Microenvironment Through 
IRE1 Signaling. Trends Mol Med 24: 607-614 
Rubio-Patino C, Bossowski JP, De Donatis GM, Mondragon L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, 
Marchetti S, Voutetakis K, Chatziioannou A, Castelli FA, Lamourette P, Chu-Van E, Fenaille F, Avril T, Passeron T, 
Patterson JB, Verhoeyen E et al. (2018b) Low-Protein Diet Induces IRE1alpha-Dependent Anticancer 
Immunosurveillance. Cell Metab 27: 828-842 e7 
Rubio-Patino C, Bossowski JP, Villa E, Mondragon L, Zunino B, Proics E, Chiche J, Bost F, Verhoeyen E, Ricci JE 
(2016) Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics. Oncotarget 7: 73270-73279 
Ruegsegger GN, Sevage JA, Childs TE, Grigsby KB, Booth FW (2017) 5-Aminoimidazole-4-carboxamide 
ribonucleotide prevents fat gain following the cessation of voluntary physical activity. Exp Physiol 102: 1474-1485 
Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW (1989) Caloric restriction and 7,12-
dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like 
growth factors I and II, and epidermal growth factor. Cancer Res 49: 4130-4 
Sabatini DM (2017) Twenty-five years of mTOR: Uncovering the link from nutrients to growth. Proc Natl Acad Sci 
U S A 114: 11818-11825 
Sahu N, Dela Cruz D, Gao M, Sandoval W, Haverty PM, Liu J, Stephan JP, Haley B, Classon M, Hatzivassiliou G, 
Settleman J (2016) Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent 
Tumorigenesis. Cell Metab 24: 753-761 
Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping 
Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba, II, Hong WK et al. (2013) 
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung 
adenocarcinoma. Cancer Res 73: 571-82 
Sakatani T, Maemura K, Hiyama N, Amano Y, Watanabe K, Kage H, Fukayama M, Nakajima J, Yatomi Y, Nagase 
T, Takai D (2017) High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence. Jpn 
J Clin Oncol 47: 543-550 
Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM (2010) Ragulator-Rag complex targets 
mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290-303 
Sanmamed MF, Chen L (2014) Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune 
modulation. Cancer J 20: 256-61 
Sarker MR, Franks S, Sumien N, Thangthaeng N, Filipetto F, Forster M (2015) Curcumin Mimics the Neurocognitive 
and Anti-Inflammatory Effects of Caloric Restriction in a Mouse Model of Midlife Obesity. PLoS One 10: e0140431 
Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, 
Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG, 
Papagiannakopoulos T (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon 
metabolism in cancer. Elife 6 
143 
 
Schewe DM, Aguirre-Ghiso JA (2008) ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells 
in vivo. Proc Natl Acad Sci U S A 105: 10519-24 
Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-62 
Schonthal AH (2012) Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica 
(Cairo) 2012: 857516 
Scortegagna M, Kim H, Li JL, Yao H, Brill LM, Han J, Lau E, Bowtell D, Haddad G, Kaufman RJ, Ronai ZA (2014) 
Fine tuning of the UPR by the ubiquitin ligases Siah1/2. PLoS Genet 10: e1004348 
Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol 
Today 21: 455-64 
Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano 
M, Shen S, Marino G, Criollo A, Boileve A, Job B, Ladoire S, Ghiringhelli F, Sistigu A, Yamazaki T, Rello-Varona 
S et al. (2012) An immunosurveillance mechanism controls cancer cell ploidy. Science 337: 1678-84 
Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin 
Invest 125: 3347-55 
Shanware NP, Bray K, Eng CH, Wang F, Follettie M, Myers J, Fantin VR, Abraham RT (2014) Glutamine deprivation 
stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun 5: 4900 
Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA (2012) Starvation-induced activation of 
ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer 12: 571 
Shin CS, Mishra P, Watrous JD, Carelli V, D'Aurelio M, Jain M, Chan DC (2017) The glutamate/cystine xCT 
antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun 8: 15074 
Simpson SJ, Le Couteur DG, James DE, George J, Gunton JE, Solon-Biet SM, Raubenheimer D (2017) The Geometric 
Framework for Nutrition as a tool in precision medicine. Nutr Healthy Aging 4: 217-226 
Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA (2013) Control of amino-acid transport by antigen 
receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol 14: 500-8 
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend 
L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L et al. (2014) 
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20: 1301-
9 
Smith DL, Jr., Elam CF, Jr., Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB (2010) Metformin 
supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 65: 468-74 
Smith JA (2014) A new paradigm: innate immune sensing of viruses via the unfolded protein response. Front Microbiol 
5: 222 
Smith JA, Turner MJ, DeLay ML, Klenk EI, Sowders DP, Colbert RA (2008) Endoplasmic reticulum stress and the 
unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur J Immunol 38: 
1194-203 
Solon-Biet SM, McMahon AC, Ballard JW, Ruohonen K, Wu LE, Cogger VC, Warren A, Huang X, Pichaud N, 
Melvin RG, Gokarn R, Khalil M, Turner N, Cooney GJ, Sinclair DA, Raubenheimer D, Le Couteur DG, Simpson SJ 
144 
 
(2014) The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad 
libitum-fed mice. Cell Metab 19: 418-30 
Solon-Biet SM, Mitchell SJ, Coogan SC, Cogger VC, Gokarn R, McMahon AC, Raubenheimer D, de Cabo R, Simpson 
SJ, Le Couteur DG (2015) Dietary Protein to Carbohydrate Ratio and Caloric Restriction: Comparing Metabolic 
Outcomes in Mice. Cell Rep 11: 1529-34 
Song M, Giovannucci EL (2015a) Cancer risk: many factors contribute. Science 347: 728-9 
Song M, Giovannucci EL (2015b) RE: Doll and Peto's Quantitative Estimates of Cancer Risks: Holding Generally 
True for 35 Years. J Natl Cancer Inst 107 
Speakman JR, Mitchell SE, Mazidi M (2016) Calories or protein? The effect of dietary restriction on lifespan in rodents 
is explained by calories alone. Exp Gerontol 86: 28-38 
Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV (2007) Bortezomib enhances 
dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 
90 on dying tumor cells: therapeutic implications. Blood 109: 4839-45 
Spranger S (2016) Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed 
tumor microenvironment. Int Immunol 28: 383-91 
Sriburi R, Bommiasamy H, Buldak GL, Robbins GR, Frank M, Jackowski S, Brewer JW (2007) Coordinate regulation 
of phospholipid biosynthesis and secretory pathway gene expression in XBP-1(S)-induced endoplasmic reticulum 
biogenesis. J Biol Chem 282: 7024-34 
Stemmermann GN, Nomura AM, Chyou PH, Kato I, Kuroishi T (1991) Cancer incidence in Hawaiian Japanese: 
migrants from Okinawa compared with those from other prefectures. Jpn J Cancer Res 82: 1366-70 
Stowell SR, Ju T, Cummings RD (2015) Protein glycosylation in cancer. Annu Rev Pathol 10: 473-510 
Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu 
A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G (2014) Immunogenic 
calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. 
Cell Death Differ 21: 59-68 
Sullivan MR, Vander Heiden MG (2017) When cancer needs what's non-essential. Nat Cell Biol 19: 418-420 
Swamy M, Pathak S, Grzes KM, Damerow S, Sinclair LV, van Aalten DM, Cantrell DA (2016) Glucose and glutamine 
fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol 17: 712-20 
Swindell WR (2009) Heat shock proteins in long-lived worms and mice with insulin/insulin-like signaling mutations. 
Aging (Albany NY) 1: 573-7 
Talapatra S, Thompson CB (2001) Growth factor signaling in cell survival: implications for cancer treatment. J 
Pharmacol Exp Ther 298: 873-8 
Tam AB, Koong AC, Niwa M (2014) Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. Cell 
Rep 9: 850-8 
Tang J, Guo YS, Zhang Y, Yu XL, Li L, Huang W, Li Y, Chen B, Jiang JL, Chen ZN (2012) CD147 induces UPR to 
inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma. Cell Death 
Differ 19: 1779-90 
145 
 
Tannenbaum A, Silverstone H (1953) Effect of limited food intake on survival of mice bearing spontaneous mammary 
carcinoma and on the incidence of lung metastases. Cancer Res 13: 532-6 
Tauxe W (2015) A tumour through time. Nature 527: S102-3 
Taylor RC, Dillin A (2013) XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity. Cell 153: 
1435-47 
Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN 
(2017) HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget 8: 114156-114172 
Thompson CB (2011) Rethinking the regulation of cellular metabolism. Cold Spring Harb Symp Quant Biol 76: 23-9 
Tsuru A, Imai Y, Saito M, Kohno K (2016) Novel mechanism of enhancing IRE1alpha-XBP1 signalling via the PERK-
ATF4 pathway. Sci Rep 6: 24217 
Tyrakis PA, Palazon A, Macias D, Lee KL, Phan AT, Velica P, You J, Chia GS, Sim J, Doedens A, Abelanet A, Evans 
CE, Griffiths JR, Poellinger L, Goldrath AW, Johnson RS (2016) S-2-hydroxyglutarate regulates CD8(+) T-
lymphocyte fate. Nature 540: 236-241 
Ulianich L, Terrazzano G, Annunziatella M, Ruggiero G, Beguinot F, Di Jeso B (2011) ER stress impairs MHC Class 
I surface expression and increases susceptibility of thyroid cells to NK-mediated cytotoxicity. Biochim Biophys Acta 
1812: 431-8 
Urra H, Dufey E, Avril T, Chevet E, Hetz C (2016) Endoplasmic Reticulum Stress and the Hallmarks of Cancer. 
Trends Cancer 2: 252-262 
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence 
for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat 
Med 9: 1269-74 
Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-92 
Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, 
Kwiatkowski DJ, Asara JM, Henske EP, Manning BD (2017) mTORC1 Couples Nucleotide Synthesis to Nucleotide 
Demand Resulting in a Targetable Metabolic Vulnerability. Cancer Cell 32: 624-638 e5 
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements 
of cell proliferation. Science 324: 1029-33 
Vervliet T, Parys JB, Bultynck G (2016) Bcl-2 proteins and calcium signaling: complexity beneath the surface. 
Oncogene 35: 5079-92 
Vieira AR, Abar L, Chan DSM, Vingeliene S, Polemiti E, Stevens C, Greenwood D, Norat T (2017) Foods and 
beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence 
of the WCRF-AICR Continuous Update Project. Ann Oncol 28: 1788-1802 
Volmer R, van der Ploeg K, Ron D (2013) Membrane lipid saturation activates endoplasmic reticulum unfolded protein 
response transducers through their transmembrane domains. Proc Natl Acad Sci U S A 110: 4628-33 
Walker GA, White TM, McColl G, Jenkins NL, Babich S, Candido EP, Johnson TE, Lithgow GJ (2001) Heat shock 
protein accumulation is upregulated in a long-lived mutant of Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci 
56: B281-7 
146 
 
Wang M, Kaufman RJ (2014) The impact of the endoplasmic reticulum protein-folding environment on cancer 
development. Nat Rev Cancer 14: 581-97 
Wang W, Xie Q, Zhou X, Yao J, Zhu X, Huang P, Zhang L, Wei J, Xie H, Zhou L, Zheng S (2015) Mitofusin-2 
triggers mitochondria Ca2+ influx from the endoplasmic reticulum to induce apoptosis in hepatocellular carcinoma 
cells. Cancer Lett 358: 47-58 
Wang Y, Swiecki M, McCartney SA, Colonna M (2011) dsRNA sensors and plasmacytoid dendritic cells in host 
defense and autoimmunity. Immunol Rev 243: 74-90 
Wei M, Fabrizio P, Hu J, Ge H, Cheng C, Li L, Longo VD (2008) Life span extension by calorie restriction depends 
on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet 4: e13 
Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, Merry TL, Dubuis S, Laube B, Pfeiffer AF, Schulz TJ, 
Guthke R, Platzer M, Zamboni N, Zarse K, Ristow M (2014) D-Glucosamine supplementation extends life span of 
nematodes and of ageing mice. Nat Commun 5: 3563 
Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF (2017) The EGR2 targets LAG-3 and 4-1BB 
describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med 214: 
381-400 
Wolfert MA, Boons GJ (2013) Adaptive immune activation: glycosylation does matter. Nat Chem Biol 9: 776-84 
Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J (2015) HDAC Inhibition Upregulates PD-1 
Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res 3: 1375-85 
Xia X, Lei L, Qin W, Wang L, Zhang G, Hu J (2018) GCN2 controls the cellular checkpoint: potential target for 
regulating inflammation. Cell Death Discov 4: 20 
Xia XJ, Gao YY, Zhang J, Wang L, Zhao S, Che YY, Ao CJ, Yang HJ, Wang JQ, Lei LC (2016) Autophagy mediated 
by arginine depletion activation of the nutrient sensor GCN2 contributes to interferon-gamma-induced malignant 
transformation of primary bovine mammary epithelial cells. Cell Death Discov 2: 15065 
Xie H, Tang CH, Song JH, Mancuso A, Del Valle JR, Cao J, Xiang Y, Dang CV, Lan R, Sanchez DJ, Keith B, Hu 
CC, Simon MC (2018) IRE1alpha RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers. 
J Clin Invest 128: 1300-1316 
Yamamori T, Meike S, Nagane M, Yasui H, Inanami O (2013) ER stress suppresses DNA double-strand break repair 
and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett 587: 
3348-53 
Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, 
Kepp O, Kroemer G (2016) Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer 
chemotherapy. Oncoimmunology 5: e1149673 
Yang M, Kenfield SA, Van Blarigan EL, Batista JL, Sesso HD, Ma J, Stampfer MJ, Chavarro JE (2015) Dietary 
patterns after prostate cancer diagnosis in relation to disease-specific and total mortality. Cancer Prev Res (Phila) 8: 
545-51 
Yang X, Qian K (2017) Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol 18: 
452-465 
Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX (2014) Targeting the tumor 
microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25: 37-48 
147 
 
Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN, Bobrovnikova-Marjon E, Diehl JA, Ron D, Koumenis 
C (2010) The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient 
deprivation. EMBO J 29: 2082-96 
Yecies JL, Manning BD (2011) Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 71: 
2815-20 
York A (2018) Microbiome: Gut microbiota sways response to cancer immunotherapy. Nat Rev Microbiol 16: 121 
Yoshida K, Hirabayashi Y, Watanabe F, Sado T, Inoue T (2006) Caloric restriction prevents radiation-induced myeloid 
leukemia in C3H/HeMs mice and inversely increases incidence of tumor-free death: implications in changes in number 
of hemopoietic progenitor cells. Exp Hematol 34: 274-83 
Yoshida K, Inoue T, Hirabayashi Y, Matsumura T, Nemoto K, Sado T (1997) Radiation-induced myeloid leukemia in 
mice under calorie restriction. Leukemia 11 Suppl 3: 410-2 
Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, 
Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD (2015) The ketone 
metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21: 263-9 
Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC, Chen YY, Liu YC, Hong TH, Yu SL, Chen JJ, Yang PC (2015) 
Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression. Sci Rep 5: 14273 
Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, Wu M, Wainwright DA (2018) IDO1 in cancer: a 
Gemini of immune checkpoints. Cell Mol Immunol 15: 447-457 
Zhang J, Pavlova NN, Thompson CB (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, 
glutamine. EMBO J 36: 1302-1315 
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, 
Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial 
ovarian cancer. N Engl J Med 348: 203-13 
Zhang L, Li Z, Ding G, La X, Yang P, Li Z (2017) GRP78 plays an integral role in tumor cell inflammation-related 
migration induced by M2 macrophages. Cell Signal 37: 136-148 
Zhao Y, Wu T, Shao S, Shi B, Zhao Y (2016) Phenotype, development, and biological function of myeloid-derived 
suppressor cells. Oncoimmunology 5: e1004983 
Zhou J, Mao B, Zhou Q, Ding D, Wang M, Guo P, Gao Y, Shay JW, Yuan Z, Cong YS (2014) Endoplasmic reticulum 
stress activates telomerase. Aging Cell 13: 197-200 
Zhu L, Ploessl K, Zhou R, Mankoff D, Kung HF (2017) Metabolic Imaging of Glutamine in Cancer. J Nucl Med 58: 
533-537 
Zhu X, Pattenden S, Bremner R (1999) pRB is required for interferon-gamma-induction of the MHC class II abeta 
gene. Oncogene 18: 4940-7 
Zink A, Rohrbach H, Szeimies U, Hagedorn HG, Haas CJ, Weyss C, Bachmeier B, Nerlich AG (1999) Malignant 
tumors in an ancient Egyptian population. Anticancer Res 19: 4273-7 
Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF (2018) The microbiome in cancer immunotherapy: Diagnostic 
tools and therapeutic strategies. Science 359: 1366-1370 
148 
 
 


151 
 
Anexes 
2. Article 2 : 
Rubio-Patino, C., Bossowski, J. P., Villa, E., Mondragon, L., Zunino, B., Proics, E., Chiche, J., 
Bost, F., Verhoeyen, E. & Ricci, J. E. (2016) Low carbohydrate diet prevents Mcl-1-mediated 
resistance to BH3-mimetics, Oncotarget. 7, 73270-73279. 
  










152 
 
3. Article 3:  
Rubio-Patino, C., J. P. Bossowski, E. Chevet and J. E. Ricci (2018). "Reshaping the Immune 
Tumor Microenvironment Through IRE1 Signaling." Trends Mol Med 24(7): 607-614. 
  
Opinion
Reshaping the Immune Tumor
Microenvironment Through IRE1 Signaling
Camila Rubio-Patiño,1 Jozef P. Bossowski,1 Eric Chevet,2,3 and Jean-Ehrland Ricci1,*
The ability of a tumor cell to cope with environmental and intracellular stress
depends on its capacity to activate appropriate adaptive pathways. As such,
the endoplasmic reticulum (ER) adjusts the adaptive capacity of tumor cells by
engaging the unfolded protein response (UPR). The UPR maintains the func-
tionality of the secretory pathway, thereby allowing tumor cells to shape their
microenvironment, thus likely determining the nature of the tumor immune
response. Consequently, this makes the UPR very relevant in the context of
cancer therapeutics. We focus here on inositol-requiring enzyme 1a (IRE1) and
compile novel molecular mechanisms demonstrating that tumoral UPR con-
trols the tumor microenvironment (TME) and the immune response, therefore
opening potential novel therapeutic avenues.
The UPR: Controlling the Brake of Cancer
The ability of cancer cells to respond to extrinsic and intrinsic stress depends on their capacity
to successfully activate appropriate adaptive pathways [1,2]. In the course of carcinogenesis,
intrinsic (e.g., oncogene-driven protein synthesis, reactive oxygen species) or extrinsic (e.g.,
hypoxia, nutrient shortage, chemotherapy) challenges impinge on cellular protein homeostasis
(proteostasis; see Glossary) [3]. In the endoplasmic reticulum (ER), an imbalance in
proteostasis leads to a situation known as ER stress [2,4]. To restore ER proteostasis an
adaptive signaling pathway, the UPR, is triggered [3] that is mainly controlled by three ER-
resident sensors: IRE1, protein kinase RNA-like endoplasmic reticulum kinase (PERK), and
activating transcription factor 6 (ATF6) (Figure 1 and Box 1). The UPR attenuates protein
translation, enhances protein folding and quality control, and increases ER clearance capacity.
As such, UPR-mediated adaptation has been proposed to contribute to cancer development
[5]. This was later conﬁrmed in various cancers and was found to play either protumorigenic [6]
or antitumorigenic roles [7,8].
The Dual Role of the IRE1 Signaling in Cancer Cell Fate: Life or Death
The UPR can affect tumor cell biology either as a barrier to tumor development or by
promoting established tumors (Figure 1). The IRE1 branch of the UPR has been so far
the best-documented in its ability to control cell death or survival in tumors [9,10]. IRE1 signals
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Box 1. The ER and the UPR
The UPR is predominantly an adaptive pathway, but when ER stress cannot be resolved the terminal UPR is triggered to
promote cell death, typically by apoptosis [12]. Notably, cancer cells generally display higher basal ER stress than their
non-tumoral counterparts, and they modulate the UPR to fuel growth and survival [39]. The different UPR branches not
only determine cell fate but can also shape the TME in part by controlling the secretory pathway [29]. By reprogramming
the cells and adjusting the secretory pathway, UPR-dependent extracellular signals can modulate the host stroma,
including immune cells. This makes the UPR an appealing candidate mechanism by which one could harness the host
immune system to combat cancer.
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are predominantly mediated by its RNase activity through either the non-conventional splicing
of X-box binding protein 1 (sXBP1) mRNA or regulated IRE1-dependent decay of RNA
(RIDD). IRE1 adaptive signals are mainly mediated by the transcription factor sXBP1 [9].
Alternatively, RIDD can either promote survival through the degradation of RNA coding for
secretory or transmembrane proteins, thereby reducing the ER load [11], or can promote cell
death through the degradation of mRNA encoding antiapoptotic proteins and secretory
proteins involved in protein folding [1]. Interestingly, it has been shown that IRE1 can recruit
TNF receptor-associated factor-2 (TRAF2) and activate c-Jun N-terminal kinase (JNK) which
regulates apoptotic pathways by, for example, phosphorylating the pro-apoptotic protein
BIM and inhibiting BCL-2 [12,13]. IRE1 has also been shown to facilitate tumor growth in vivo
by promoting the expression of the cancer-driver b-catenin, and its inhibition or knockdown
impairs colonic tumorigenesis in an immunodeﬁcient mouse model [14]. Altogether, IRE1
controls life and death decision mechanisms under stressful conditions.
IRE1 Signaling Host Immune Cells
In vivo, tumor progression or regression not only depends on activation of the UPR in
tumor cells but can also be controlled by UPR induction in stromal cells, including immune
cells [2,15]. Tumor-associated dendritic cells (DCs) isolated from mice and human ovarian
tumors exhibit robust sXBP1 activation compared to DCs from naive hosts. This turns out
to be immunosuppressive because it promotes tumor progression and metastasis by
impairing T cell activation [15]. Moreover, XBP1 depletion leads to hyperactivation of IRE1
and downstream RIDD, as shown in mice deﬁcient for XBP1 in DCs [16]. This compen-
satory RIDD induction results in defects in cross-presentation of dead cell-derived anti-
gens by CD8a+ DCs [11,16]. Nevertheless, RIDD activity in DCs has only been reported in
the context of experimental XBP1 deletion, and a physiological role for RIDD has yet to be
demonstrated in the different DC populations. Another example is observed in polymor-
phonuclear myeloid-derived suppressor cells (PMN-MDSCs), which are regulators of the
immune response in cancer patients and have been shown to promote tumor progression.
Indeed, in these cells IRE1 controls the conversion of neutrophils into PMN-MDSCs. PMN-
MDSCs isolated from non-small cell lung cancer, head and neck cancer, colon cancer,
and multiple myeloma patients expressed high levels of lectin-type oxidized LDL receptor-
1 (LOX-1) compared to neutrophils isolated from the same patients. LOX-1 expression
depends on sXBP1 [17]. sXBP1 induction by thapsigargin in neutrophils from healthy
patients increased LOX-1 expression, which converted these cells to immunosuppressive
PMN-MDSCs [17]. In addition to its immunosuppressive functions, the IRE1/XBP1 path-
way was also shown in several mouse models to be important for the differentiation of
immature progenitors into plasma B cells, DCs, and antigen-speciﬁc effector CD8+ T cells
[16,18–20].
What happens when cancer cells are immune cells? Do the same dualistic pathways govern
cell fate? In this case, XBP1-dependent naïve cell differentiation into plasma B cells and
effector T cells induced by fasting can block the development of acute lymphoblastic
leukemia in a human xenograft model in sublethally irradiated severe combined immunodeﬁ-
ciency (SCID) recipient mice [20]. Alternatively, impairment of the IRE1/XBP1 pathway was
identiﬁed as a hallmark of germinal center B cell diffuse large B cell lymphoma, and doxycy-
cline-induced XBP1 protein expression reduced tumor growth in an immunocompromised
AGR129 mouse xenograft model [21]. Notably, constitutive expression of sXBP1 in murine B
cells promotes a disease in mice that resembles multiple myeloma [22], indicating that the
IRE1 pathway can be tumor-promoting for some immune cancer cell types but can negatively
impact on tumor growth in others. Once again, this raises the question of whether the effect of
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transmission of ER stress between
cancer cells and from cancer cells to
cells of TME.
Tumor microenvironment (TME):
the unique environment consisting of
cancer and non-cancer (stromal,
immune) cells present in tumors that
is characterized by hypoxia, nutrient
deprivation, and reduced pH.
activation of the pathway on tumor progression depends on the balance between the
activation of pathways downstream from IRE1.
When Tumor Cells Use IRE1 Signals To Communicate with the Immune
System
Modulation of ER stress in immune cells is not the only way for the UPR to regulate the immune
response. The induction of the different arms of the UPR in tumor cells can result in crosstalk
between the tumor and the immune system. The UPR-dependent regulation of damage-
associated molecular patterns (DAMPs), cytokines (Box 2), and transmissible ER stress
(TERS, Box 3), among other signals, can result in immunosurveillance or immune system
evasion (Figure 1). However, the notion that the UPR can regulate the anticancer immune
response is recent because previous cancer research has mostly been carried out in vitro or in
immunodeﬁcient mouse models. Notably, new evidence supports the concept of a dual role of
the UPR in tumor–immune system crosstalk, thereby yielding either immunosuppressive or
immunogenic outcomes. This makes the interaction between tumor cells and the tumor
microenvironment (TME) even more complex.
Tumor IRE1 downstream pathways can carry different messages when communicating with
the immune system, and a dual role for sXBP1 and RIDD has been established. In glioblas-
toma, high and low IRE1 activity tumor classiﬁcation revealed that patients bearing tumors
with a sXBP1low/RIDDhigh signature showed better survival than those with a sXBP1high/
RIDDlow signature [23]. In the same study, sXBP1 was found to control protumorigenic signals
that promote macrophage recruitment to the tumor and angiogenesis, while RIDD damp-
ened angiogenesis and cell migration. The ﬁnding that RIDD may exert antitumoral effects is
supported by recent results obtained in conditions of macronutrient modulation. In cancer
mouse models of lymphoma, and in xenograft models of colorectal cancer and melanoma, a
moderate reduction of protein intake resulted in the induction of the IRE1/RIDD–RIG-I
pathway in tumor cells. When IRE1 is activated, it cleaves mRNAs targeted to the ER
and produces fragments that resemble those of pathogens (lack of 50 caps or 30 polyA
tails), thus activating retinoic acid-inducible gene I (RIG-I) [24,25]. This gives rise to an
anticancer CD8-dependent immune response that was not observed when mice were fed
a control diet [25]. Using a gene signature reﬂecting IRE1 activation, tumor stratiﬁcation into
high and low IRE1 activity groups showed an association between an increase in IRE1
signaling and an increase in mRNA expression of key antitumor T cell markers in tumors from
colorectal cancer, glioblastoma, and melanoma patients. Accordingly, RIG-I was previously
proposed to be a tumor suppressor in patients with hepatocellular carcinoma [26], and its
activation induces the secretion of extracellular vesicles by human and mouse melanoma
cells in vitro that can induce natural killer (NK) cell-mediated lysis of melanoma cells ex vivo
[27]. Furthermore, murine pancreatic cancer cells treated with RIG-I-like helicase ligands
undergo immunogenic cell death (ICD) associated with calreticulin (CRT) exposure and the
release of HMGB1 (high mobility group box 1). This results in activation of DCs in ex vivo
coculture experiments [28].
Another way of regulating tumor/immune system crosstalk is to modulate the tumor cell
secretome through the direct control of cytokine production by the UPR at the transcriptional
and post-transcriptional levels (Box 2) [29,30] or through TERS [31]. TERS molecules are
released by cancer cells undergoing ER stress and UPR activation (Box 3). Proinﬂammatory
and anti-inﬂammatory cytokines have a direct impact on tumor progression because they
control and alter the TME. There is autocrine and endocrine regulatory feedback between the
UPR and cytokines, meaning that the UPR can induce cytokine production and vice versa.
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Figure 1. Unfolded Protein Response (UPR) Signaling. The UPR is primarily an adaptive response that is transduced by three endoplasmic reticulum (ER)-
resident transmembrane stress sensors, namely inositol-requiring enzyme 1a (hereafter referred to as IRE1), PKR-like ER kinase (PERK), and activating transcription
factor 6 (ATF6). These stress sensors are kept inactive through binding to the ER-resident HSP70 family chaperone GRP78 (also known as BiP). Upon stress (hypoxia,
nutrient shortage, macronutrient modulation, chemotherapy, reactive oxygen species, oncogene-driven protein synthesis, among others) and accumulation of
misfolded proteins in the ER, GRP78 dissociates from the sensors, thereby allowing their activation [1]. IRE1 is the most evolutionarily conserved UPR sensor and
harbors both serine/threonine kinase and endoRNase catalytic domains in its cytosolic portion. Upon GRP78 dissociation, IRE1 undergoes oligomerization and trans-
autophosphorylation, enabling its RNase activity. IRE1 RNase catalyzes the non-conventional splicing of XBP1 mRNA, thus yielding an open reading frame shift. The
spliced XBP1 translation product, sXBP1, is a potent transcription factor that targets genes encoding proteins participating in protein folding, ER-associated protein
degradation (ERAD), protein trafﬁcking, and lipid biosynthesis. In addition, IRE1 RNase activity is involved in the degradation of other RNAs (including mRNAs and
microRNAs) in a process termed regulated IRE1-dependent decay (RIDD) that promotes both pro-survival or pro-death features [8]. PERK is a serine/threonine kinase
that is activated through oligomerization and trans-autophosphorylation upon release of GRP78. Activated PERK phosphorylates its main substrate, the eukaryotic
translation initiation factor 2a (eIF2a), on Ser51. This results in global protein synthesis attenuation and in the selective translation of ATF4, a transcription factor that
regulates speciﬁc metabolic programs such as glucose homeostasis and amino acid synthesis. ATF6 is a membrane-anchored transcription factor. Upon ER stress, the
coordinated dissociation of GRP78 induces ATF6 export to the Golgi complex where it is cleaved by site-1 and site-2 proteases (S1P and S2P). The released cytosolic
domain is a transcription factor that translocates to the nucleus where it triggers the expression of genes encoding chaperones, components of the ERAD machinery,
and proteins involved in lipid metabolism [1,12]. Abbreviations: CRT, calreticulin; DAMP, danger-associated molecular pattern; HMGB1, high mobility group box 1; ICD,
immunogenic cell death; P, phosphorylation; sXBP1 mRNA, spliced XBP1 mRNA; TERS, transmissible ER stress; uXBP1 mRNA, unspliced XBP1 mRNA.
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Altogether, understanding the regulation of ER stress and the UPR in the context of cancer is
vital to ﬁnd new ways to restore cell immunogenicity and potentiate the immune system to
improve the response to therapies.
Nutritional Stress, IRE1 Signaling, and the Immune Response: Deeper into
the Rabbit Hole
It has been shown that a decrease in calorie or food intake can induce autophagy-dependent
anticancer immunosurveillance [32]. Unfortunately, the use of dietary restriction (DR) to reduce
tumor growth can be very hard on cancer patients owing to the risk of cachexia and DR-related
weight loss. For this reason, effort is being put into the development of different ways to mimic
the beneﬁts of DR on tumor growth, but without impacting on calorie or food intake. Previous
studies have shown that changes in amino acid availability can induce ER stress. For example,
proline deprivation induces ER stress and the IRE1 arm of the UPR, impairing the clonogenic
and tumorigenic potential of a vast panel of breast, cervix, esophagus, lung, skin, ovary,
pancreas, and stomach proline-dependent tumor cells both in vitro and in immunodeﬁcient
mice [33]. These results indicate that the effect of a strong reduction in amino acid availability is
Box 2. The UPR and Cytokine Regulation
In response to ER stress, CCAAT-enhancer-binding protein homologous protein (CHOP) acts as a transcription factors
to control the production of interleukin (IL)-23 in DCs, and sXBP1 induces tumor necrosis factor (TNF-a) in macrophages
[40,41]. IRE1 is implicated in inﬂammation by activating c-Jun N-terminal kinase (JNK), inducing IL-8 production under
glutamine deprivation conditions [42] and IL-1b through the activation of glycogen synthase kinase 3b (GSK3b) [43].
Cytokines can also trigger ER stress. For example, IkB kinase (IKKb) phosphorylates sXBP1 in response to TNF-a,
increasing its activity [44]. In addition, IL-10-mediated p38 signaling can block ER stress by inhibiting the TNF-
dependent translocation of the cleaved fragment of activating transcription factor 6 (ATF6) into the nucleus and its
recruitment to the 78 kDa glucose-regulated protein (GRP78) promoter [45]. IL-1, 6, 8, and TNF activate the UPR
and initiate a systemic acute inﬂammatory response by modulating acute-phase response genes in mouse hepatocytes
in the liver in vivo through increased cleavage of the ER-localized transcription factor, cAMP response element-binding
protein (CREBH) [46]. Moreover, type 2 T helper cell (Th2)-associated cytokines (IL-4, IL-6, and IL-10) activate the IRE1
pathway through STAT3 and STAT6, thus upregulating cathepsin secretion by macrophages. Pharmacological
inhibition of IRE1 blocks cathepsin secretion and macrophage-mediated cancer cell invasion [47]. Altogether, the
feedback between ER stress, UPR induction, and cytokine production results in enhanced inﬂammatory responses.
Box 3. Transmissible ER Stress
Another way by which ER stress can modulate the immune system is known as TERS. Upon UPR induction cells release
TERS molecules that can transmit ER stress to other recipient cells either through proteinaceous signals or membrane-
containing structures (extracellular vesicles). TERS is a new phenomenon and its nature remains to be fully character-
ized. When human and murine prostate cancer cell lines were cultured in the presence of conditioned media generated
from cells treated with the ER stress- and UPR-inducer thapsigargin, their survival was increased relative to cells
cultured in control media in the face of stress insults such as chemotherapy and glucose deprivation through the
activation of the PERK branch of the UPR [48]. This is thought to be linked to the production of TERS molecules by
cancer cells treated with UPR inducers; however, the exact nature of such structures remains to be clariﬁed. TERS has
also been observed between lung tumor murine cancer cells and immune system cells. TLR4-dependent TERS was
described in macrophages cultured in conditioned media of cancer cells treated with staurosporine. These macro-
phages were driven towards a proinﬂammatory phenotype, facilitating cancer progression [49,50]. Tumor ER stress has
also been shown to be transmitted to bone marrow-derived dendritic cells (BMDCs). Conditioned media of prostate,
melanoma, and Lewis lung carcinoma cells treated with thapsigargin induced ER stress and the UPR in BMDCs, leading
to the production of proinﬂammatory cytokines by these cells. In these settings there was impaired antigen cross-
presentation by TERS-imprinted BMDCs. CD8+ T cells cross-primed by TERS-imprinted BMDCs showed very high
splicing of XBP1 compared to other UPR elements and very little proliferation capacity. The role of the activation of the
IRE1–XBP1 axis on the cell function of the CD8+ T cells remains to be elucidated [50]. However, most studies aiming to
analyze TERS were carried out in response to pharmacological ER stressors in cancer cells, and these studies suggest a
protumoral role for TERS. Conversely, some types of chemotherapy that induce ER stress in cancer cells have been
described to have antitumoral immune effects [30]. The question remains as to whether non-pharmacological/more
physiologically relevant stimuli such as those occurring in the TME induce the same type of TERS? Do they have the
same effect on cancer progression, or is there an antitumoral type of TERS? Further studies to ﬁll this gap are needed.
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not related to the immune response but directly affects the ability of tumor cells to proliferate.
Mice bearing proline-dependent tumors showed decreased glutamine and ornithine plasma
concentrations compared to mice bearing proline-independent tumors, thus suggesting
increased conversion of glutamine or ornithine into proline to compensate for the lack of
dietary proline [33]. Alternatively, macronutrient modulation through a mild reduction in protein
intake reduced the relative levels of all amino acids, except for glutamine, and induced the IRE1
pathway in tumor cells in a xenograft model of colorectal cancer. This IRE1-speciﬁc activation of
the UPR in tumor cells triggered the immune system and led to increased immunosurveillance
[25]. Nevertheless, the exact mechanism linking a low-protein diet to IRE1 activation remains to
be elucidated. One can speculate that the reduction in speciﬁc amino acids may slow down
protein folding in highly dividing cells, therefore inducing IRE1 activation. In line with this, it has
been shown in E. coli and in human cells that silent mutations in EgFABP1 (Echinococcus
granulosus fatty acid-binding protein 1) [34] and in MDR1 (multidrug resistance 1) [35],
respectively, resulted in changed translation rates, therefore altering protein folding leading
to the UPR. Interestingly, the percentage of protein reduction in the diet determines if its effect is
increased immunosurveillance or immune system evasion. Notably, the protective effect of the
low-protein diet (Low PROT 12.5% – CHO 72.2%, PROT 17%, FAT 10.8%; Low PROT 25% –
CHO 73.7%, PROT 14.9%, FAT 11.5%) compared to the control diet (control – CHO 70.9%,
PROT 19.5%, FAT 9.6%) was lost when mice were fed with a very low protein diet (Low PROT
40% – CHO 76.4%, PROT 12.2%, FAT 11.4%) [25]. We hypothesize that such a massive
reduction in protein may prevent the induction of the anticancer immune response by activating
additional signaling pathways that remain to be identiﬁed.
These results are appealing because they suggest that there is a threshold for the decrease in
dietary protein that determines the nature of the immune response. They also reﬂect the need
for consensus on what to consider as a low-protein diet, which is one of the reasons why
obtaining human data from trials testing low protein intake can be difﬁcult. An additional reason
why translating these studies into the clinic is highly speculative lies in the fact that rodent
metabolism is very different from that of humans. Only a careful and multicentric clinical
investigation will determine the potential beneﬁcial effect of such a low-protein diet on patients.
Conversely, other studies have shown a detrimental effect of the activation of IRE1 on mouse
survival, conﬁrming the pro-survival effect of the pathway on cancer cells. Pharmacological
inhibition of the IRE1/XBP1 pathway suppresses the growth of patient-derived MYC-over-
expressing breast tumors in immunodeﬁcient SCID beige mice compared to vehicle treatment
[36]. Similarly, XBP1 has been shown to negatively regulate ICD in colorectal CT26 tumors
expressing human EGFR growing in immunocompetent BALB/c mice [37]. ICD induction
depended on the mutational status of the EGFR signaling pathway and was restored upon
the inhibition of XBP1. Similarly, the IRE1/XBP1 pathway is induced in MYC-overexpressing
Burkitt lymphoma, neuroblastoma, and hepatocellular carcinoma cells, leading to sustained
growth and survival in vitro and in immunocompetent mice, and pharmacological and genetic
inhibition of sXBP1 induced MYC-dependent apoptosis [38].
A low-protein diet, which induces IRE1 signaling, also had a detrimental effect on Em–Myc
lymphoma progression in immunodeﬁcient NSG mice. It led to a decrease in mouse survival
compared to mice fed with a control diet, conﬁrming the pro-survival role of IRE1 in MYC-
positive tumor cells in the absence of the immune system. Conversely, when the same
experiments on Em–Myc lymphoma progression were performed in immunocompetent
C57BL/6 mice, the immune system changed the outcome because the low-protein diet-
dependent induction of IRE1 resulted in an anticancer immune response [25]. Altogether,
not only the cell type nor the stimulus inducing the pathway (e.g., ER stress, nutritional stress,
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oncogenic mutations, etc.) but also the integrity and status of the immune system can
determine and explain the differences observed in these studies regarding the effect of
IRE1 induction on tumor progression. Supporting the hypothesis of its dual role, pharmaco-
logical and genetic inhibition of the IRE1/RIDD/RIG-I pathway reverted the effect of a low-
protein diet, resulting in sustained tumor growth [25]. This shows the potential power of tumor/
immune system crosstalk in determining disease outcome. These studies highlight the capacity
of the IRE1 branch of the UPR to control tumor cell crosstalk with the immune system, and
indicate that understanding the underlying mechanisms may open new potential ways of
treating cancer.
Concluding Remarks
The TME plays an important role in tumor development because it conditions drug resistance
and cell survival. Chemotherapy, poor vascularization, oxygen and nutrient availability can
induce stress pathways, including the UPR, that counteract these stressors at the same time
impacting on TME. The UPR regulates the crosstalk between tumor cells and the immune
system, potentially opening a new area of research (see Outstanding Questions and Box 4).
IRE1 can either play pro- or antitumoral roles but what determines which role it takes still
remains an open question. It could depend on the stimulus (e.g., oncogene driven protein
synthesis, reactive oxygen species, hypoxia, nutrient shortage, chemotherapy, among others),
on the complex balance of expression of the proteins induced downstream of the UPR sensors
and/or on the intrinsic nature of the cells within the context of their environment. Understanding
speciﬁc IRE1 activation and ER stress dynamics in the TME could offer new possibilities for
improved and effective anticancer therapies.
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SUMMARY
Mitophagy is an evolutionarily conserved process
that selectively targets impaired mitochondria for
degradation. Defects in mitophagy are often associ-
ated with diverse pathologies, including cancer.
Because the main known regulators of mitophagy
are frequently inactivated in cancer cells, the mecha-
nisms that regulate mitophagy in cancer cells are not
fully understood. Here, we identified an E3 ubiquitin
ligase (ARIH1/HHARI) that triggersmitophagy in can-
cer cells in a PINK1-dependent manner. We found
that ARIH1/HHARI polyubiquitinates damaged mito-
chondria, leading to their removal via autophagy.
Importantly, ARIH1 is widely expressed in cancer
cells, notably in breast and lung adenocarcinomas;
ARIH1 expression protects against chemotherapy-
induced death. These data challenge the view that
the main regulators of mitophagy are tumor suppres-
sors, arguing instead that ARIH1-mediated mitoph-
agy promotes therapeutic resistance.
INTRODUCTION
Mitochondria are essential for energy production, reactive
oxygen species (ROS) production, calcium buffering, and regu-
lation of several forms of cell death (Villa and Ricci, 2016;
Wallace, 2005). Over time, or in response to various stresses,
mitochondria will accumulate damage. Therefore, cells have
adopted several quality-control processes, including cycles of
mitochondrial fusion and fission and the selective elimination
of dysfunctional mitochondria by mitophagy, an organelle-spe-
cific type of macroautophagy, to maintain a functional network
of healthy mitochondria (Wei et al., 2015).
The ubiquitin (Ub) E3 ligase Parkin, which is mutated in reces-
sive familial forms of Parkinson’s disease, is a key mediator of
mitochondrial quality control processes (Kitada et al., 1998; Shi-
mura et al., 2000). Phosphatase and tensin homolog deleted on
chromosome 10-induced kinase 1 (PINK1) is a serine/threonine
kinase that shuttles between the cytosol and mitochondria in
healthy cells. Normally, it is rapidly degraded by mitochondrial
proteases, but PINK1 can stabilize on the outer membrane of
depolarized mitochondria and recruit Parkin, which is initially
inactive (Clark et al., 2006; Narendra et al., 2008; Park et al.,
2006). PINK1 will phosphorylate Parkin on the Ub-like (UBL)
domain on the Ser65 in a DJm-dependent process, resulting in
an increase of its Ub ligase activity and the formation of polyubi-
quitin chains on the surface of depolarized mitochondrial mem-
branes. PINK1 will also phosphorylate the conserved Ser65 site
of Ub molecule (Kane et al., 2014; Kazlauskaite et al., 2015;
Koyano et al., 2014; Wauer et al., 2015). It has been proposed
that the phosphorylated Ub could act as a Parkin activator by
overcoming the autoinhibitory mechanism of Parkin. Both events
are needed to fully activate Parkin, which will, in turn, polyubiqui-
tinate numerous mitochondrial outer membrane proteins, lead-
ing to the recruitment of the Ub- and LC3-binding adaptor p62
to these damaged organelles (Herhaus and Dikic, 2015). While
p62 was initially shown to be critical for removing depolarized
mitochondria by transporting them to autophagosomes, later
studies suggested a possible redundancy with the related
Ub- and Atg8/LC3II-binding protein NBR1 (Narendra et al.,
2010; Okatsu et al., 2010), NDP52 (nuclear domain 10 protein
52, also known as CALCOCO2), or optineurin (Lazarou et al.,
2015). In particular, NDP52 and optineurin recognize phospho-
Ub, leading to the recruitment of the autophagy machinery to
initiate mitophagy (Lazarou et al., 2015).
Loss of either PINK1 or Parkin leads to accumulation of
damaged mitochondria in several models (fly, mouse, and hu-
man), further supporting their central and conserved role in mito-
chondrial quality-control pathways (Herhaus and Dikic, 2015).
A growing body of evidence has shown the involvement of
somatic Parkin inactivation in a broad panel of human cancers.
Indeed, Parkin has been shown to be downregulated in multiple
cancer cell lines and primary tumors (Gong et al., 2014; Veeriah
et al., 2010a, 2010b). Parkin-deficient mice show increased
susceptibility to tumorigenesis, while ectopic Parkin expression
reduces the in vitro or in vivo growth of cancer cells of various
origins, strongly suggesting a tumor-suppressive role for Parkin
(for review, see Xu et al., 2014). Therefore, as Parkin is often
downregulated in tumors, the molecular events that promote
mitophagy in these cells remain to be determined.
Ub and Ub-like modifications occur in a three-step enzymatic
process. E1 is an activating enzyme that forms a thioester bond
with the Ub protein. Then, the charged Ub monomer is trans-
ferred to an E2 enzyme that conjugates the Ub molecule to its
target protein, with the help of an E3 Ub ligase (Kerscher
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et al., 2006; Nagy and Dikic, 2010). While there are few E1 and
E2 ligases, there are many diverse E3 Ub ligases that control
substrate specificity and are responsible for the enormous
diversity of the Ub system. Several different classes of E3 Ub
ligases have been identified. The RING ubiquitinases function
as a scaffold between the E2 ligase and the substrate, allowing
the transfer of the Ub moiety to the target protein. In contrast,
homologous to the E6-AP carboxyl terminus (HECT) ubiquiti-
nases play a direct role in substrate ubiquitination by forming
a catalytic intermediate thioester between the C-lobe cysteine
residue and the C terminus of Ub (Spratt et al., 2014). Recently,
E3 ligases from the Parkin family were classified as hybrids
between RING and HECT and were therefore referred to as
RING-between-RING (RBR) E3 ligases (Wenzel et al., 2011).
They are composed of a canonical RING domain, an in-be-
tween ring fingers (IBR) domain, and a RING2 domain. This fam-
ily has 14 members, including Parkin and Ariadne RBR E3 Ub
protein ligase 1 (ARIH1), also known as HHARI. For these
ligases, the first RING domain of the RBR module does not
directly transfer an E2-bound Ub onto a substrate but instead
transfers it to a Cys residue in the RING2 domain (Kulathu
and Komander, 2012).
Here, we explored the mechanism controlling mitophagy in
cancer cells. As Parkin is not expressed in most cancer cells,
we investigated how mitophagy could occur in these cells.
RESULTS
ARIH1 Expression Promotes Elimination of Depolarized
Mitochondria
Parkin is a member of the RBR family of E3 ligases that is
composed of 14 complex multidomain enzymes. As it is
frequently downregulated in cancer cells, we investigated
whether other E3 ligases could control mitophagy in these cells.
We hypothesized that another member of the RBR family could
possibly fulfill this function. A survey of the different family mem-
bers led us to focus on ARIH1, as it shares the same E2 ligase as
Parkin (UbcH7, also known asUBE2L3) (Wenzel et al., 2011), and
because an elegant study using a small interfering RNA (siRNA)-
based screen recently determined that this E3 ligase is involved
in the protection of cancer cells against genotoxic stress (von
Stechow et al., 2015).
Depolarization of the mitochondria in HeLa cells using the
protonophore carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) promoted mitophagy of damaged mitochondria only
upon expression of Parkin (Figure 1A). Importantly, removal
of damaged mitochondria was also observed following
ARIH1 overexpression (Figure 1A). Indeed, after 6 hr of
CCCP treatment, we observed mitochondrial network
collapse around the perinuclear region in HeLa cells express-
ing ARIH1, as determined by TOM20 staining (Figure S1A),
while after 24 hr of CCCP treatment, we observed a complete
loss of the mitochondrial marker TOM20 (Figures 1A–1C) and
a strong reduction in COX IV, succinate dehydrogenase
iron-sulfur subunit (SDHB), and NDUFB8 expression,
mitochondrial proteins that are typically degraded during
mitophagy (Figures 1D and 1E). We observed that ARIH1-
dependent mitophagy occurred to the same extent as
Parkin-dependent mitophagy (Figures 1D and 1E). Impor-
tantly, as described for Parkin, ARIH1 was recruited to mito-
chondria upon CCCP treatment (Figure S1A). Thus, we
concluded that ARIH1 overexpression led to the removal of
depolarized mitochondria.
ARIH1-Mediated Removal of Damaged Mitochondria
Occurs via Mitophagy
We addressed whether the ARIH1-mediated removal of
damaged mitochondria involved mitophagy. To establish this
point, we measured mitophagy using m-Keima fluorophore, a
biosensor of mitochondrial degradation by the lysosomes
(Katayama et al., 2011). m-Keima is a variant of RFP that is tar-
geted to the mitochondrial matrix. This cellular biomarker
changes its fluorescence profile in response to pH and is resis-
tant to degradation within lysosomes. As presented in Figures
2A and 2B, we measured m-Keima conversion from green
(488 nm) to red (561 nm) fluorescence during treatment with
several mitochondria-damaging agents, such as CCCP, oligo-
mycin/antimycin (O/A), and valinomycin, using fluorescence-
activated cell sorting (FACS) (Lazarou et al., 2015). We observed
that ARIH1 could mediate mitophagy upon mitochondrial
damage to the same extent as Parkin overexpression. ARIH1-
mediated mitophagy upon mitochondrial damage was
confirmed by the strong reduction of several mitochondrial
markers, such as SDHB and NDUFB8, at the protein level (Fig-
ure 2C). Interestingly, we observed that basal mitophagy that
removes damaged mitochondria produced over time was also
dependent on ARIH1 expression (Figures S1B and S1C).
To further characterize ARIH1-dependent mitophagy induc-
tion, wemeasured autophagic flux in ARIH1- and Parkin-overex-
pressing HeLa cells following CCCP treatment. We observed an
increase of the autophagic flux as determined by the increased
conversion of LC3B-I to LC3B-II and increased degradation of
the autophagy receptor SQSTM1/p62 and the mitochondrial
protein COX IV (Figures S2B and S2C) in the presence of
ARIH1 or Parkin overexpression. Importantly, treatment with
the lysosomal inhibitor bafilomycin A1 (BafA1) further increased
LC3B-II accumulation and reduced p62 and COX IV degrada-
tion, indicating a complete autophagic response (Figures S2B
and S2C). We verified that CCCP had no effect on the expression
of those proteins in the absence of ARIH1 or Parkin expression
(Figure S2A). We also observed that LC3, ARIH1 (or Parkin
used as a positive control), and the mitochondrial marker cyto-
chrome c were co-localized on mitochondria upon CCCP treat-
ment (Figures S2D and S2E), suggesting that ARIH1 mediates
mitophagy upon mitochondrial damage. To strengthen this
point, we observed that in HeLa cells transfected with an empty
vector, LC3 was not co-localized on mitochondria upon CCCP
treatment (Figure S2F), confirming that HeLa cells cannot
perform mitophagy to a significant extent in the absence of
one of those E3 ligases.
To further investigate the role macroautophagy in ARIH1-
dependent mitophagy, we used ATG7 knockout (KO) mouse
embryonic fibroblasts (MEFs) and KO MEFs reconstituted with
ATG7-GFP (R-ATG7 MEFs; Figures 2D, 2E, and S3) (Taherbhoy
et al., 2011). Importantly, MEFs (KO and reconstituted)
expressed equivalent endogenous levels of ARIH1 but did not
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express Parkin (Figures 2D and S3). We observed that endoge-
nous expression of ARIH1 in MEFs was sufficient to decrease
SDHB expression (Figures 2D and 2E) following CCCP treat-
ment in reconstituted MEFs. However, this effect was not
observed in ATG7 KO MEFs. We also verified that knockdown
of endogenous ARIH1 expression using siRNA prevented
ARIH1-dependent mitophagy upon CCCP treatment in
R-ATG7 MEFs.
Collectively, these data demonstrate that ARIH1 mediates the
removal of depolarized mitochondria through mitophagy.
ARIH1-Mediated Mitophagy Is Dependent on Its Ub
Ligase Activity and PINK1 Stabilization
To further investigate the molecular mechanisms underlying
ARIH1-mediated autophagy, we evaluated the contribution of
PINK1. To accomplish this, we first knocked down PINK1
expression using siRNAs in ARIH1-overexpressing HeLa cells.
As shown in Figures 3A and 3B, silencing of PINK1 prevented
the COX IV decrease following CCCP treatment in HeLa cells
overexpressing ARIH1. The involvement of PINK1 was further
tested by knocking out PINK1 using CRISPR/Cas9 (Figures 3C
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Figure 1. ARIH1 Promotes the Removal of Damaged Mitochondria
HeLa cells were transfected to transiently overexpress the control vector (pcDNA3), ARIH1, or Parkin and then treated with the mitochondrial uncoupling agent
CCCP (10 mM) for 24 hr.
(A–C) Mitochondria were immunostained for TOM20 (green), and the absence of the mitochondrial marker TOM20 was assessed in ARIH1+ cells (B) or in Parkin+
cells (C) using confocal microscopy (scale bar, 10 mm). Quantification of mitophagywas estimated by counting aminimumof 100 cells for each condition. Data are
shown as the mean of 3 independent experiments.
(D) Whole-cell lysates were analyzed for indicated protein expression by immunoblotting (actin was used as a loading control).
(E) Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001 and ****p < 0.0001 according to a two-way ANOVA.
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Figure 2. ARIH1 Removes Damaged Mitochondria via Autophagy
(A) HeLa cells overexpressing pcDNA3, ARIH1, or Parkin were transfected with m-Keima; treated with CCCP (10 mM), oligomycin/antimycin A (O/A; 25 nM and
250 nM, respectively), or valinomycin (10 nM) for 24 hr; and analyzed by flow cytometry. Green fluorescence of m-Keima reflects mitochondria in the cytosol
(FLmito, green), while red fluorescence reflects mitochondria in lysosomes (FLlyso, red). The ratio of mitophagy is reflected by the percentage of cells in the top
panel.
(B) Data are shown as the mean ± SEM of 3 independent experiments performed as in (A).
(legend continued on next page)
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and 3E) in HeLa cells overexpressing ARIH1. Indeed, while
ARIH1 decreased COX IV (Figures 3C and 3D) and increased
conversion from green to red m-Keima following CCCP treat-
ment (Figure 3E), both effects were blunted upon PINK1 KO.
Equivalent results were obtained upon treatment with othermito-
chondria-damaging agents (Figure 3E).
It has been shown that during mitophagy, PINK1 phosphory-
lates Parkin and Ub on Ser65. We established here that in
response to CCCP treatment, ARIH1 was phosphorylated on a
Ser/Thr residue (Figure 3F), suggesting that phosphorylation by
PINK1 is the first step in ARIH1-mediated mitophagy. Thus,
ARIH1-dependent mitophagy requires PINK1 expression.
We then verified that the mitochondria of ARIH1-expressing
HeLa cells were polyubiquitinated upon CCCP treatment as
determined by the increase in Ub staining that co-localized
with TOM20 staining on the mitochondria (Figure 4A). We also
established that upon relocalization to the mitochondria, ARIH1
expression leads to TOM20 and MFN2 (mitofusin 2) degradation
in a proteasomal-dependent manner, as MG132 could prevent it
(Figure 4B).
We then used a mutant of ARIH1 with deletions in the RING
type 1, IBR type, and RING type 2 domain (referred to as
DARIH1). As previously shown, overexpression of full-length
ARIH1 or Parkin resulted in mitophagy upon CCCP treatment,
as determined by the conversion of m-Keima from green to
red (Figure 4C) and the decrease in COX IV and SDHB expres-
sion (Figures 4D and 4E). In contrast, while DARIH1 was
overexpressed to the same extent as full-length ARIH1, it
did not lead to mitophagy (Figures 4C–4E) upon CCCP
treatment.
We could therefore conclude that ARIH1 induces mitophagy
by polyubiquitination of the damaged mitochondria, leading to
its removal by the autophagic machinery.
ARIH1 Is Overexpressed in Cancer Cells and Is the Main
Regulator of Mitophagy in These Cells
After establishing ARIH1 as a regulator of mitophagy, we as-
sessed its expression in various cell lines and tissues (Figures
5A, 5B, and S4). ARIH1 mRNA was widely expressed in human
cancer tissues and cancer cell lines, with strong expression in
lung adenocarcinoma samples (Figures S4A and S4B). We
then investigated ARIH1 protein expression in a panel of
9 different human cancer cell lines (Figure 5A). In contrast to
Parkin, which was not expressed in any of the tumor cell lines
tested (either at the protein or mRNA level; Figures 5A, 5B, and
S4C), ARIH1 was endogenously expressed in several of them
(Figures 5A and 5B), with the highest expression in lung cancer
cell lines (A549 and H1975).
We then determined whether endogenous expression of
ARIH1 could activate mitophagy upon mitochondrial depolariza-
tion. To accomplish this, A549 and H1975 cells were incubated
with increasing amounts of a decoupling agent, and mitophagy
was assessed by measuring COX IV expression. As shown in
Figures 5C and 5D, COX IV expression was reduced upon
decoupling of the mitochondria. This removal of damaged mito-
chondria was associated with an increase in autophagic markers
(LC3 conversion and decrease in p62 expression; Figure 5E),
altogether indicating that endogenous ARIH1 expression in
lung cancer cell lines induced the removal of damaged mito-
chondria through mitophagy.
Importantly, we then demonstrated using three independent
siRNAs that ARIH1 knockdown was sufficient to prevent
CCCP-induced mitophagy as determined by the absence of
the decrease in COX IV expression (Figure 6A). Equivalent
results were obtained in H1975 cells following CCCP treatment
(Figure S5A). To further support our observations, we per-
formed a rescue experiment by knocking down endogenous
ARIH1 expression in A549 cells, and we re-expressed an
siRNA-resistant ARIH1-FLAG. As presented in Figures 6B, 6C,
and S5B, mitophagy was not observed upon ARIH1 knockdown
in the presence of CCCP or O/A, while ARIH1-FLAG expression
restored it. We then measured mitophagy using m-Keima (as
done previously) using a mitochondrial-damaging treatment
(O/A). Mitophagy was blunted upon ARIH1 knockdown (Fig-
ure 6C), while it was observed when ARIH1-FLAG was
expressed (Figure 6D).
We then deleted PINK1 expression using a CRISPR/Cas9
interference technique to validate the implication of this kinase
in ARIH1-mediated mitophagy upon endogenous expression of
this E3 ligase (Figures 6E and 6F). While mitochondrial network
collapse around the perinuclear region and PINK1 induction
(two early signs of mitophagy) could be observed in control cells,
these markers were absent in A549 cells lacking PINK1. Simi-
larly, COX IV reduction following CCCP treatment was not
observed in cells lacking PINK1 (Figure 6F). We confirmed that
the removal of damaged mitochondria in A549 cells was indeed
mediated through mitophagy, as a cellular invalidation of ATG12
or ATG7 using the CRISPR/Cas9 technique (Wang et al., 2014)
prevented CCCP-induced COX IV degradation and m-Keima
conversion (Figures 6G–6I).
It was recently suggested that optineurin and NDP52 are key
cargo adaptors for Parkin-mediated mitophagy (Heo et al.,
2015; Lazarou et al., 2015; Richter et al., 2016). We therefore
knocked down their expression using specific siRNA (Figures
S5C and S5D) to evaluate their implication in ARIH1-mediated
mitophagy. While respective protein expression was massively
reduced in A549 cells, it did not prevent the COX IV decrease
observed upon CCCP treatment, altogether indicating that
neither optineurin nor NDP52 acts as a cargo adaptor for
ARIH1-mediated mitophagy. MFN2 was recently suggested to
be a mitochondrial receptor for Parkin that is required for
mitophagy (Chen and Dorn, 2013). Using two independent
(C) Whole-cell lysates were treated as in (A) and analyzed for SDHB, NDUFB8, PINK1, Parkin, and ARIH1 expression by immunoblotting (actin was used as a
loading control).
(D) Mitophagy was analyzed in MEF KO ATG7 cells and MEF KO cells reconstituted with ATG7-GFP (R-ATG7 MEFs) transfected with an siRNA control or an
siRNA targeting ARIH1 by immunoblotting for SDHB or PINK1.
(E) Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001, ****p < 0.0001 according to a two-way ANOVA.
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siRNAs, we established that MNF2 knockdown does not impair
ARIH1-mediated mitophagy or sensitivity to cisplatin (Figures
S5E–S5H).
Overall, we detected endogenous expression of ARIH1 in
several cancer cell lines, including lung cancer cells, and estab-
lished that ARIH1 is the main regulator of PINK1-dependent
mitophagy upon mitochondrial damage.
ARIH1-Mediated Mitophagy Controls the Sensitivity of
Lung Cancer Cells to Chemotherapy-Induced Death
After we identified ARIH1 as an endogenous regulator of mitoph-
agy in lung cancer cells, we then decided to investigate its role in
cell sensitivity or resistance to chemotherapy. We first investi-
gated whether modulation of ARIH1 expression had an impact
on cell survival. To accomplish this, HeLa cells expressing
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Figure 3. ARIH1-Dependent Mitophagy Requires PINK1
HeLa cells overexpressing ARIH1 were transfected with an siRNA control or an siRNA targeting PINK1 and treated with CCCP (10 mM) for the indicated times.
(A) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(B) Data are shown as the mean ± SEM of 3 independent experiments.
(C–E) HeLa-expressing ARIH1 were transfected with a control construct (CRISPR CTL) or CRISPR/Cas9 construct in order to delete PINK1 and then treated with
CCCP (10 mM) for the indicated times.
(C) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(D) Data are shown as the mean ± SEM of 3 independent experiments.
(E) HeLa cells CRISPR CTL or CRISPR PINK1 ARIH1 were transfected with m-Keima; treated with CCCP (10 mM), oligomycin/antimycin A (O/A; 25 nM and
250 nM, respectively), or valinomycin (10 nM) for 24 hr; and analyzed by flow cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3
independent experiments.
(F) HeLa cells were transfected with pcDNA3 or FLAG-ARIH1 plasmids. Cells were left untreated (left) or treated with CCCP (10 mM) for 4 hr (right). ARIH1 was
immunoprecipitated (IP) with an anti-FLAG antibody followed by immunoblotting for phospho-Ser/Thr antibody. Actin was used as a loading control.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 according to a two-way ANOVA. N.S: non-significant.
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ARIH1 were treated with CCCP, and wemonitored their ability to
grow as clones (clonogenic test). We observed that while only a
few control HeLa cells could grow after CCCP treatment, the
number of clones was significantly increased in cells expressing
ARIH1 (Figure 7A), suggesting a protective effect of ARIH1
following mitochondrial damage.
We then verified that ARIH1 knockdown in A549 cells did not
affect CCCP-induced mitochondrial depolarization (Figure S6A)
or the ability of these cells to form colonies (Figure 7B). In
contrast, knockdown of endogenous ARIH1 was sufficient to
reduce the ability of A549 cells to survive following treatment
with CCCP (Figure 7B). Indeed, two independent siRNAs target-
ing ARIH1 sensitized A549 cells to CCCP-induced apoptosis, as
shown by an increase in PARP cleavage (Figure 7C), an increase
in DEVDase activity (Figure 7D), and an increase in sub-G1 DNA
content (Figure 7H), typical hallmarks of apoptosis. This
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Figure 4. ARIH1-Dependent Mitophagy Requires Its Ub Ligase Activity
(A) ARIH1-overexpressing HeLa cells were treated with CCCP (10 mM) and co-immunostained for TOM20 (pink), Ub (green), and ARIH1 (red). Co-localization was
analyzed by confocal microscopy (scale bar, 10 mm).
(B) HeLa cells were transiently transfected with a control vector (pcDNA3), ARIH1, or Parkin and were treated with the mitochondrial uncoupling agent CCCP
(10 mM) for 24 hr alone or with MG132 (10 mM). Whole-cell lysates were analyzed for TOM20, MFN2, PINK1, ARIH1, and Parkin expression by immunoblotting
(ERK2 was used as a loading control).
(C) HeLa cells overexpressing pcDNA3, ARIH1, Parkin, or a truncated form of ARIH1 (DARIH1-FLAG) were transfected with m-Keima and treated with CCCP
(10 mM) for 24 hr and analyzed by flow cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3 independent experiments.
(D and E) HeLa cells were transiently transfected with a control vector (pcDNA3), ARIH1-FLAG, Parkin, or a truncated form of ARIH1 (DARIH1-FLAG) and treated
with the mitochondrial uncoupling agent CCCP (10 mM) for 24 hr.
(D) Whole-cell lysates were analyzed for COX IV, SDHB, PINK1, ARIH1, Parkin, and FLAG expression by immunoblotting (actin was used as a loading control).
(E) Data are shown as the mean ± SEM of 3 independent experiments.
**p < 0.01 and ****p < 0.0001 according to a two-way ANOVA.
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Figure 5. ARIH1 Is Overexpressed in Breast and Lung Cancer Cells
(A) Immunoblots of ARIH1 and Parkin in the indicated cancer cell lines and healthy skin sample (used as a positive control for endogenous Parkin expression).
ERK2 was used as a loading control.
(B) The ratio of ARIH1 or Parkin to ERK2 expression (average of 2 independent experiments).
(C) A549 and H1975 lung cancer cell lines were treated with CCCP (from 1 to 10 mM) for 24 hr. The decrease in mitochondrial mass was analyzed by immu-
noblotting COX IV.
(legend continued on next page)
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sensitization to CCCP-induced apoptosis following ARIH1
knockdown was also observed in H1975 cells (Figures S6B
and S6C).
The alkylating agent cisplatin is a standard treatment for
several cancers, including lung carcinomas. We therefore inves-
tigated whether endogenous ARIH1 expression could affect
cisplatin-induced cell death. We selected a dose of cisplatin
with a limited ability to prevent control A549 cell growth (trans-
fected with a scramble siRNA). Strikingly, the same treatment
substantially impaired the growth of ARIH1 knockdown A549
cells (Figure 7E) and sensitized these cells to apoptosis, as
shown by the increase in PARP cleavage (Figure 7F), DEVDase
activity (Figure 7G), and sub-G1 DNA content (Figure 7H). We
confirmed that the decrease in mitochondrial potential (DJm)
upon cisplatin treatment was not altered in ARIH1 knockdown
cells, indicating that this E3 ligase acts downstream of the mito-
chondrial dysfunction (Figure S6D).
We demonstrated that ARIH1 functions both in mitophagy and
in resistance to cisplatin. To determine whether ARIH1 promotes
resistance to chemotherapy throughmitophagy, we knocked out
the molecular actors implicated in ARIH1-mediated mitophagy
(PINK1, ATG7, and ATG12) in A549 cells. KO of those key
proteins sensitized cells to various types of chemotherapy-
induced death (Figures 7I, 7J, and S7A), suggesting that lung
cancer cells use mitophagy as a defense mechanism against
chemotherapy-induced cell death.
Finally, Parkin was recently suggested to regulate Bax levels
and promote resistance to apoptosis independently of mitoph-
agy (Cakir et al., 2017; Johnson et al., 2012). We did not observe
any regulation of Bax or Bak levels upon ARIH1 modulation or
PINK1 KO, suggesting that ARIH1-dependent control of cell
death was not mediated by the regulation of the level of expres-
sion of those Bcl-2 members (Figures S6E–S6G). These results
suggest that ARIH1-dependent mitophagy is protective in can-
cer cells.
DISCUSSION
The removal of dysfunctional mitochondria is required to main-
tain a healthy mitochondrial network and promote cell survival
in response to certain stresses. How mitophagy promotes the
turnover of damaged mitochondria that would otherwise injure
the cell has not been fully elucidated. The most extensively char-
acterized mitophagy regulators are Parkin/PINK1, BNIP3, and
NIX (known as BNIP3L), which have non-overlapping roles in
promoting autophagy (for review, see Chourasia et al., 2015).
Importantly, in most cancers, BNIP3, NIX, and Parkin expression
has been shown to be downregulated, indicating their role as
tumor suppressors. Indeed, significant deletions of the BNIP3
locus at 10q26.3 were observed in half of the human tumor
types, including lung carcinomas (Beroukhim et al., 2010). In
addition, epigenetic silencing of BNIP3 expression as tumors
progress to invasion and metastasis has been reported (Calvisi
et al., 2007; Erkan et al., 2005). Similarly, Parkin (PARK2) maps
to a common fragile site on human chromosome 6q25-q26
that is frequently deleted in cancers (Cesari et al., 2003). There-
fore, until now themain regulators ofmitophagywere considered
as tumor suppressors and, therefore, the vast majority of the
studies suggesting that the removal of damaged mitochondria
could play a role in the survival of cancer cells following chemo-
therapeutic treatment could only be obtained after ectopic
expression of those genes.
In sharp contrast, we identify here that the E3 ligase ARIH1 is
regulator of PINK1-dependent mitophagy (Figures 1, 2, 3, and 4)
that is overexpressed in several cancers, including lung adeno-
carcinomas (Figures 5, 6, and S4). We established that ARIH1-
dependent control of mitophagy was indeed dependent on its
Ub ligase activity (Figure 4). Importantly, we showed that
ARIH1 overexpression is associated with resistance to chemo-
therapeutic-induced apoptosis (Figure 7).We also demonstrated
that removal of ARIH1 or of key mitophagy or autophagy regula-
tors sensitized tumor cells to chemotherapy-induced death (Fig-
ure 7), suggesting that mitophagy is protective in those cells,
although we cannot formally exclude at this stage that other
cellular functions of those proteins (which remain to be identified)
are partially involved in the described effect.
Our results also suggest that ARIH1, as opposed to Parkin,
BNIP3, or NIX, could be a predictive marker of chemotherapy.
This notion is supported by the observation that lung adenocar-
cinoma patients with high levels of ARIH1 showed decreased
survival after treatment (Figure S7B).
ARIH1 is a 557-amino-acid protein (64 kDa) distributed in the
cytoplasm and the nuclei of cells (Figure 1A; Elmehdawi et al.,
2013) that shares many structural and functional properties
with Parkin (Parelkar et al., 2012). It is highly conserved, sharing
72% and 98% amino acid sequence identity with the Drosophila
and mouse genes, respectively (Tan et al., 2000). Despite the
widespread distribution of ARIH1 transcripts (Moynihan et al.,
1999) and the lethality of KOs (Aguilera et al., 2000), its cellular
functions are not well characterized. It was previously reported
that ARIH1 levels were higher in cancer tissues than in normal tis-
sues of the same origin (Elmehdawi et al., 2013), as opposed to
the other known regulators of mitophagy. The same study
reported that increased ARIH1 expression was associated with
enhanced cell proliferation (Elmehdawi et al., 2013). Mechanisti-
cally, a yeast two-hybrid screen suggested an interaction be-
tween ARIH1 and the protein translation initiation factor eIF4E2
(Tan et al., 2003), suggesting a role in protein translation or
RNA processing. It was later shown that this interaction with
eIF4E2 was required for the protection of embryonic stem cells
(ESCs) from DNA damage (von Stechow et al., 2015). However,
whether this ARIH1-dependent control of mRNA translation
arrest is required for the control of mitophagy in cancer cells is
not known and will be the subject of further studies.
At the molecular level, it will be important to uncover how
PINK1 activates ARIH1. Recently, ARIH1 was shown to be a
(D) Data are shown as the mean ± SEM of 3 independent experiments.
(E) A549 and H1975 lung cancer cell lines were treated with 10 mMCCCP for the indicated times, and autophagy induction was assessed by immunoblotting LC3
and P62. ERK2 was used as a loading control.
**p < 0.01 according to a two-way ANOVA.
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Figure 6. ARIH1 Induces Mitophagy in Lung Cancer Cells
A549 cells were transfected with the indicated siRNAs and treated with increasing amounts of CCCP (from 1 to 10 mM) for 24 hr.
(A) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(B and C) A549 cells were transfected with the indicated siRNAs and then transfected with either an empty vector or FLAG-ARIH1 in order to rescue the
knockdown of ARIH1 expression.
(B) Cells were treatedwith increasing amounts of CCCP (from 1 to 10 mM).Whole-cell lysates were analyzed for SDHB, NDUFB8, PINK1, and ARIH1 expression by
immunoblotting (actin was used as a loading control).
(legend continued on next page)
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new component of the cullin-RING E3 ligases (CRLs), which spe-
cifically mediate monoubiquitylation of several substrates (Scott
et al., 2016). We therefore speculate that this novel role of ARIH1
could at least in part be involved in PINK1-mediated mitophagy,
possibly through direct interaction with PINK1. PINK1 is a Ser/
Thr kinase stabilized at the outer membrane of depolarized mito-
chondria, and it can phosphorylate Parkin in its UBL domain in
order to overcome its autoinhibitory mechanism. Here, we
show that ARIH1, after a brief exposure to CCCP, can also be
phosphorylated on a Ser/Thr residue (Figure 3F). It is important
to note that, like Parkin, ARIH1 also has an inhibitory (Ariadne)
domain masking the RING type 2 domain containing catalytic
activity. Furthermore, this Ariadne domain contains eight serine
residues and two threonine residues that could potentially be
phosphorylated by PINK1, leading to the unmasking of the
ARIH1 catalytic site. Also, we established that ARIH1-mediated
mitophagy and protection from chemotherapy-induced death
was dependent on PINK1 expression, but not on NDP52, opti-
neurin, MFN2, Bax, or Bak expression (Figure S5), suggesting
that ARIH1 has a different set of targets than Parkin that remains
to be identified.
Another open question is how ARIH1 is overexpressed in
cancer cells. A screen of different public databases indicated
that ARIH1 mRNA expression is upregulated in a wide variety
of cancer tissues. As an example, a survey of Tumorscape
(Broad Institute, Cambridge, MA, USA) (Beroukhim et al.,
2010) indicated that ARIH1 was overexpressed in colorectal
and medulloblastoma as well as in 21 out of 40 lung squamous
carcinoma samples (tissues/cell lines) present in the database.
These data suggest that transcriptional regulation of ARIH1 may
be involved. However, the transcription factors involved have
not been identified. Therefore, in addition to gene expression,
the regulation of ARIH1 protein stability cannot be excluded at
this stage.
The role of Parkin in the regulation of cell death is debated.
While it is widely assumed to inhibit cell death, it was recently
shown that several anti-apoptotic members of the Bcl-2 family
could prevent Parkin translocation to the depolarized mitochon-
dria and therefore regulate the onset of Parkin-dependent mito-
chondrial clearance (Hollville et al., 2014). It was then suggested
that Parkin activation in response to mitochondrial dysfunction
resulted in apoptosis by promoting the degradation of Mcl-1, a
pro-survival gene of the Bcl-2 family (Carroll et al., 2014). These
results suggest a close link between Parkin and the Bcl-2 family.
However, as Parkin is rarely expressed in cancer cells, it would
be interesting to investigate whether ARIH1 can interact with
and control these pro-survival factors, as (1) ARIH1 was reported
to limit protein translation, and (2) Mcl-1 has a short half-life and
is strongly affected by a block in translation (Meynet et al., 2012,
2013; Pradelli et al., 2010).
Finally, it was recently suggested that PINK1 could induce
mitophagy directly through phospho-Ub-mediated recruitment
of autophagy receptors (Lazarou et al., 2015). While this inter-
esting observation might be relevant to cells that do not express
significant levels of Parkin or ARIH1, these results should be
interpreted with caution in cells expressing ARIH1 (such as
breast or lung cancer cell lines).
In conclusion, we show here that ARIH1 is a regulator of
mitophagy in cancer cells that is involved in the protection of
these cells from chemotherapy-induced death. This report chal-
lenges the view that the main regulators of mitophagy are tumor
suppressors and suggests that ARIH1 may facilitate the removal
of damaged mitochondria to promote tumor resistance to
chemotherapy. While the association between Parkin genotype
and cancer susceptibility is still under debate (Alcalay et al.,
2012), our work indicates that ARIH1 is a potential therapeutic
target and potentially a predictive marker of lung cancer sensi-
tivity to chemotherapy.
EXPERIMENTAL PROCEDURES
Cell Death Measurement
To induce cell death, cells were treated with CCCP, cisplatin, or etoposide or
irradiated with a UV lamp (254 nm) with the indicated doses. Cell death was
analyzed either by DEVDase activity or DAPI staining. To assess DEVDase ac-
tivity, cells were lysed in buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 5 mM
EDTA, 1%NP40, 10 mg/mL aprotinin, 1 mM PMSF, and 10 mM leupeptin) 16 hr
after treatment. Lysates were standardized for protein content and loaded into
a black 96-well plate (CellStar) in the presence of 0.2 mmol/L of the caspase-3
substrate Ac-DEVD-AMCdiluted in the following buffer: 50mmol/L HEPES (pH
7.5), 150 mmol/L NaCl, 20 mmol/L EDTA, and 10 mmol/L DTT. Caspase activ-
ity was determined both with and without the presence of 1 mmol/L Ac-DEVD-
CHO using a fluoroscan at 460 nm, and specific activity was expressed as the
change in absorbance per minute per milligram protein.
In parallel, cell viability of the treated cells was assessed by looking at the
plasma membrane permeabilization using DAPI staining and then analyzed
by flow cytometry (Miltenyi Biotec).
For the cell cycle experiments, cells treated for 16 hr were permeabilized in
70% ethanol overnight at 20C and washed with PBS. Cells were incubated
with PBS, RNase (20 mg/mL), and propidium iodide (50 mg /mL, Sigma Aldrich)
for 30 min at 4C and then analyzed by flow cytometry (Miltenyi Biotec).
(C) Cells were treated with oligomycin/antimycin A (O/A; 25 nM and 250 nM, respectively) for 24 hr. Whole-cell lysates were analyzed for SDHB, NDUFB8, PINK1,
and ARIH1 expression by immunoblotting (actin was used as a loading control).
(D) A549 were transfected with the indicated siRNAs and m-Keima, treated with O/A (25 nM and 250 nM, respectively) for 24 hr, and then analyzed by flow
cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3 independent experiments.
(E) A549 control cells (CRISPRCTL) and A549 cells invalidated for PINK1 (CRISPRPINK1) by the CRISPR/Cas9 technique were treated for 6 hr with CCCP (10 mM)
and co-immunostained for TOM20 (green), PINK1 (pink), and ARIH1 (red). Co-localization was analyzed by confocal microscopy (scale bar, 10 mm).
(F) A549 CRISPR CTL and CRISPR PINK1 cells were treated for 24 hr with CCCP (10 mM). Whole-cell lysates were analyzed for COXIV, PINK1, and ARIH1
expression by immunoblotting (ERK2 was used as a loading control).
(G) A549 CRISPR CTL and CRISPR ATG12 cells were treated as described in (F).
(H) A549 CRISPR CTL and CRISPR ATG7 cells were treated for 24 hr with increasing amounts of CCCP (from 1 to 10 mM). Whole-cell lysates were analyzed for
COX IV, PINK1, ATG7, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(I) A549 CRISPR CTL and CRISPR ATG7 were transfected with m-Keima, treated with CCCP (10 mM) for 24 hr, and analyzed by flow cytometry as in Figures 2A
and 2B. Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001 according to a two-way ANOVA.
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Figure 7. ARIH1 Protects Lung Cancer Cells from Cell Death
(A) Clonogenic assay of HeLa control cells (pcDNA3) or cells overexpressing ARIH1, which were treated with CCCP (10 mM) for 6 hr. Pictures were taken 10 days
after treatment.
(B) Clonogenic assay of A549 control cells (siCont) or ARIH1-silenced cells (siARIH1), which were treated with CCCP (10 mM) for 6 hr. Pictures were taken 5 days
after treatment.
(C and D) A549 cells silenced for ARIH1with two different siRNAswere treatedwith increasing concentrations of CCCP (from 1 to 10 mM). Apoptosis was analyzed
by immunoblotting for PARP cleavage (C) and DEVDase activity (D).
(legend continued on next page)
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Mito Keima Mitophagy Analysis
HeLa cells and A549 cells were transfected with m-Keima and then analyzed
by flow cytometry (Miltenyi Biotec) as previously reported (Lazarou et al.,
2015). Excitation 458 nm and emission >650 nm were used to detect m-Keima
in mitochondria in the cytosol (FLmito, green). Excitation 561 nm and emission
>650 nm were used to detect mitochondria in lysosomes (FLlyso, red).
Statistical Methods
Data are expressed as mean ± SEM. Differences in the calculated means
between groups were assessed by two-way ANOVA.
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Summary 
Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) is emerging as a key player in T-cell 
development, function and cancer. Here we investigated the role of GAPDH in T-cell 
development/function by overexpressing GAPDH in the T-cell lineage. Aged mice developed: 1) 
splenomegaly, 2) enlarged lymph nodes, 3) lymphocyte-infiltrations in the liver and bone marrow. 
All showed an increase of strongly proliferating and clonal Tfh CXCR5+PD1highCD4+-T cells 
associated with germinal center B cells and inflammatory cytokine-release. Gene-set-expression-
analysis confirmed that this lymphoma was equivalent to human angioimmunoblastic T-cell 
lymphoma (AITL). Mechanistically, GAPDH induced NF-κB pathway in the murine AITL in vivo 
inhibition of NF-κB combined with anti-PD1 increased mice survival and cancer immune response. 
GAPDH-dependent modulation of NF-κB in T-cells allowed to model AITL-disease and evaluate 
treatments. 
This article is under revision in Cancer Cell. 
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The unfolded protein response (UPR) is a conserved adaptive pathway
that helps cells cope with the protein misfolding burden within the endo-
plasmic reticulum (ER). Imbalance between protein folding demand and
capacity in the ER leads to a situation called ER stress that is often
observed in highly proliferative and secretory tumor cells. As such, activa-
tion of the UPR signaling has emerged as a key adaptive mechanism pro-
moting cancer progression. It is becoming widely acknowledged that, in
addition to its intrinsic effect on tumor biology, the UPR can also regu-
late tumor microenvironment. In this review, we discuss how the UPR
coordinates the crosstalk between tumor and stromal cells, such as
endothelial cells, normal parenchymal cells, and immune cells. In addi-
tion, we further describe the involvement of ER stress signaling in the
response to current treatments as well as its impact on antitumor immu-
nity mainly driven by immunogenic cell death. Finally, in this context, we
discuss the relevance of targeting ER stress/UPR signaling as a potential
anticancer approach.
The UPR is an adaptive mechanism in
cancer cells
Excessive endoplasmic reticulum (ER) stress is emerg-
ing as a hallmark of solid tumors. Cancer cells due to
their high proliferative and secretory demands are at
risk of the accumulation of improperly folded proteins
in the ER lumen, which perturb the protein homeosta-
sis (referred to as proteostasis) [1]. In addition, tumor
cells are constantly exposed to the microenvironmental
pressure such as hypoxia, glucose shortage, oxidative
Abbreviations
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stress, or low pH, all known to cause ER stress [2]. To
cope with those challenges and restore proteostasis,
cells activate the evolutionary conserved adaptive path-
way known as unfolded protein response (UPR) by
the coordinated action of three ER transmembrane
proteins, namely the activating transcription factor 6
(ATF6), the protein kinase PKR-like ER kinase
(PERK), and the inositol requiring enzyme 1 alpha
(IRE1a, referred to as IRE1 hereafter) [2–4]. The cur-
rent dogma in mammalian cells indicates that under
non-stressed conditions, the ER chaperone glucose-
regulated protein 78 (GRP78, also known as BiP) con-
stitutively binds to the luminal domain of the three
sensors precluding their activation. However, upon
accumulation of unfolded/misfolded proteins in the
ER, GRP78 dissociates from those complexes conse-
quently triggering the UPR cascade [4]. It was also
proposed that direct association of unfolded proteins
to yeast and mammalian IRE1 could induce its activa-
tion through conformational change [5,6]. Upon ER
stress, ATF6 is exported from the ER to the Golgi
apparatus, where it is activated by the SP1- and SP2-
medited proteolytic cleavage, which releases the
cytosolic fragment of the protein, ATF6f [7,8]. The lat-
ter is further translocated to the nucleus to regulate
the transcription of genes involved in ER-associated
degradation (ERAD) and protein folding [9]. To
reduce the protein misfolding burden in the ER, acti-
vated PERK phosphorylates the eukaryotic translation
initiation factor eIF2a at serine 51, hence attenuating
global protein synthesis [7,10]. This mechanism also
allows the translational activation of the transcription
factor ATF4, which controls the expression of genes
impacting on amino acid metabolism, antioxidant
response, autophagy, apoptosis, and protein folding
[2,7,11]. Finally, in response to ER stress, IRE1, which
harbors serine/threonine kinase and endoribonuclease
(RNase) activities, dimerizes/oligomerizes and auto-
transphosphorylates. Active IRE1 catalyzes the uncon-
ventional splicing of X-box binding protein-1 (XBP1)
mRNA and together with RTCB ligase yields an active
transcription factor XBP1s. Consequently, XBP1 mod-
ulates the expression of genes involved in glycosyla-
tion, ERAD, protein folding, and lipid synthesis [4,12].
IRE1 endoribonuclease activity also targets other
mRNAs and micro-RNAs in a process called regulated
IRE1-dependent decay (RIDD), which controls cell
fate under ER stress conditions [13]. Finally, IRE1
activates the ASK1/JNK1 signaling pathway through
the recruitment of TRAF2 to IRE1 [14]. Depending
on the time and duration of the ER stress, each arm
of the UPR can either trigger the adaptive response to
alleviate the ER stress or activate the pro-death signals
when ER stress cannot be resolved (terminal UPR;
reviewed in [15]). Briefly, the adaptive UPR relies on
the activation of among others p58IPK, chaperones,
foldases, and antioxidant enzymes as well as inhibition
of the pro-apoptotic CHOP [15]. Pro-death UPR,
however, engages JNK- and NFjB-dependent activa-
tion of pro-apoptotic BCL-2 family proteins, induction
of CHOP, and inhibition of anti-apoptotic miR-106b-
25 [15].
Activation of the UPR in cancer
The overexpression of UPR sensors has been reported
in a large number of human cancers including that of
breast, brain, gastrointestinal tract, liver, kidney, pan-
creas, lung, and prostate [8]. In addition, elevated level
of the main UPR regulator GRP78 is often found in
tumor tissues [16] and is associated with metastasis,
poor prognosis, and resistance to treatment [17–19].
The UPR involvement in cancer initiation and cell
transformation is particularly well documented in gas-
trointestinal and blood cancers (reviewed in [10]). For
instance, the PERK/eIF2a axis is shown to trigger the
loss of stemness in intestinal stem cells, from which
most of the colorectal cancers evolve [20,21]. Similarly,
XBP1 deficiency in epithelial cells of the intestine leads
to the higher incidence of colorectal cancer and colitis-
associated cancer [22]. The IRE1/XBP1 pathway is
also necessary for the terminal differentiation of B
cells into plasma cells and is frequently upregulated in
multiple myeloma (MM) [10]. Moreover, high levels of
XBP1s correlate with advanced MM stages and predict
poor outcome [23]. The importance of UPR signaling
in cancer development is also supported by the num-
ber of cancer-associated mutations identified in the
three UPR sensor-encoding genes [4]. Interestingly, the
somatic mutation profiles of the UPR arms are dis-
tinct, with majority of IRE1 and ATF6 mutations
reported in gastrointestinal cancers, PERK, and ATF6
in urologic and lung cancers, while ATF6 mutations
were predominantly found in genital cancers [4].
Finally, elevated ER stress has been also observed in
RAS-, BRAF-, MYC-, RET-, and HER2-driven
tumorigenesis [24].
UPR and cancer hallmarks
Mounting evidence suggests that UPR signals support
tumor progression by modulating almost all of the
cancer hallmarks (as reviewed elsewhere [7,10,25,26])
(Fig. 1). Genetic ablation of IRE1/XBP1, ATF6, and
PERK as well as usage of the specific inhibitors target-
ing the UPR arms lead to the significant reduction of
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tumor growth both in vitro and in vivo [27–29].
PERK/eIF2a signaling is also required for tumor cells
to overcome apoptosis under hypoxia, oxidative stress,
or glucose deprivation [30], which involves various
downstream signaling cascades, such as AKT activa-
tion, induction of glutathione synthesis, or mTOR
inhibition [31–33]. In contrast, disseminated or circu-
lating cancer cells are often exposed to the inhos-
pitable conditions which prime them to enter a
dormancy. Dormant cells are quiescent, arrested in
G0/G1 cell cycle phase, and show decreased metabolic
rate in order to reactivate when more favorable envi-
ronmental conditions occur [34]. Interestingly, ATF6
that is constitutively activated in quiescent squamous
carcinoma cells promotes cell survival in a RHEB- and
mTOR-dependent manner [35]. Moreover, inhibition
of ATF6 or RHEB reverts dormant tumor cell resis-
tance to rapamycin and triggers cell death in vivo [35].
Similarly, both GRP78 and PERK/eIF2a are associ-
ated with increased survival and drug resistance of
dormant cells [36]. Activation of the UPR also pro-
motes cancer progression by impacting on various
steps in the metastatic cascade. For instance, PERK
activation is required for breast cancer cells to invade
and metastasize [37]. Further, by mediating the activa-
tion of heme oxygenase 1, PERK protects fibrosar-
coma cells from anoikis, thereby facilitating lung
colonization [38]. PERK also promotes cancer cell
migration through ATF4-dependent induction of the
metastasis-associated gene LAMP3 [39]. In gastric can-
cer, PERK, ATF4, and ATF6 induce epithelial-to-
mesenchymal transition (EMT) under severe hypoxia,
which triggers TGF-b release and the concomitant
activation of Smad2/3 and PI3K/AKT signaling [40].
Moreover, IRE1 contributes to the migration and
adhesion of glioma cells [41], whereas XBP1 activation
promotes lung metastasis in triple negative breast can-
cer [27]. IRE1 controls glioma cell migration partially
through the degradation of SPARC mRNA and conse-
quently inhibition of FAK and RhoA signaling [42].
In addition to its aforementioned cell intrinsic effects
on tumor progression, the UPR is now becoming
widely explored for its impact on tumor microenviron-
ment, which will be further discussed in the following
sections.
The UPR in the regulation of tumor
microenvironment
Tumor microenvironment (TME) that comprises can-
cer-associated fibroblasts (CAFs), endothelial cells,
and immune cells plays a key role in cancer progres-
sion. Activated CAFs fuel highly proliferating tumors
with glucose, lactate, fatty acids, and amino acids and
modulate signaling of adjacent cancer cells by secreting
various growth factors and cytokines [43]. They can
also support cancer invasion and metastasis by releas-
ing a large number of EMT-inducing soluble factors
and by remodeling the extracellular matrix [44].
Endothelial cells, which line tumor blood vessels, are
educated by cancer cells to produce pro-angiogenic
factors but also to promote migration, metastasis, and
evade anoikis [45]. Finally, tumor-infiltrating leuko-
cytes that include both effectors of adaptive immunity
Fig. 1. Cell intrinsic effects of the UPR on cancer progression. Activation of the UPR arms—IRE1, PERK, and ATF6 activate the
downstream signaling cascade driven by transcription factors XBP1s, ATF4, and ATF6f, respectively. In addition, IRE1 controls degradation
of target mRNAs through RIDD and activates NFjB signaling, whereas PERK activation leads to the phosphorylation of NRF2. The
integration of these outputs trigger a large number of biological effects supporting tumor progression in auto- and paracrine manner.
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such as T lymphocytes, dendritic cells (DCs), and B
cells, as well as mediators of innate immunity, includ-
ing macrophages, polymorphonuclear leukocytes, and
natural killers (NK) cells, are well known to have a
dual function in cancer [46]. They can eliminate cancer
cells by presenting tumor-associated antigens on the
MHC I and MHC II molecules, which consequently
activate CD4 helper and CD8 cytotoxic T lympho-
cytes; however, infiltrating leukocytes can also
promote tumor growth, metastasis, and chronic
inflammation leading to the unfavorable patient’s out-
come [47]. Interestingly, a large body of evidence
suggests that the UPR regulates the crosstalk between
tumor and non-tumoral cells by impacting on angio-
genesis, on inflammation, and on the host immune
response (Fig. 2).
Transmissible UPR
The crosstalk between cancer cells and their environ-
ment depends on a variety of chemical and mechanical
signals mediated by small molecules, ions, proteins,
and nucleic acids. This intercellular communication
occurs either through physical interactions mediated
Fig. 2. UPR-mediated crosstalk between tumoral and non-tumoral cells. The UPR activation in cancer cells shapes tumor microenvironment
by impacting on neighboring cancer, stromal, and immune cells. This reciprocal communication is mediated by secretion of various soluble
factors including ROS, pro-angiogenetic, and pro-inflammatory molecules or by transmitting the ER stress from one cell to another (known
as TERS). In that manner, TERS-imprinted juxtaposed cancer cells are resistant to apoptosis and chemotherapy. However, the non-tumoral
cells, such as endothelial cells, macrophages, and dendritic cells, support cancer progression by inducing angiogenesis, inflammation, and
escape from immune surveillance. However, UPR in dying cancer cells can also control the induction and/or secretion of DAMPs, which
trigger the anticancer immune response through the activation of dendritic cells and consequently T cells. DAMPs, damage-associated
molecular patterns; DCs, dendritic cells; NK, natural killers; pl DCs, plasmacytoid dendritic cells; ROS, reactive oxygen species; TERS,
transmissible ER stress.
4 The FEBS Journal (2017) ª 2017 Federation of European Biochemical Societies
Regulation of tumor–stroma interactions J. Obacz et al.
by gap junctions (Gap Junctional Intercellular Com-
munication, GJIC) or remotely through the secretion
of signaling molecules such as growth factors, cytoki-
nes, and exosomes. GJIC is crucial for the mainte-
nance of tissue homeostasis by controlling growth,
differentiation, and apoptosis [48,49]. In contrast, loss
of direct cell–cell interaction and the lack of electrical
coupling in cells are common features in many tumors.
While tumor-promoting chemicals and oncogenes inhi-
bit GJIC, antitumor chemicals and anti-oncogene
drugs were associated with growth control and loss of
tumorigenicity by re-gaining GJIC activity [50–58].
Moreover, the key proteins involved in GJIC, connex-
ins are emerging as tumor suppressors [59]. For
instance, the loss of connexin 32 (CX32) leads to a sig-
nificant increase in liver and lung tumors in mouse
models which was reversed by CX32 re-expression
[60,61]. In glioma, CX43 expression was inversely cor-
related with tumor grade, proliferation, and migration
capacities, while CX43 downregulation promotes
tumor growth [62,63]. In addition to gene transcription
regulation, connexin levels can be regulated by traf-
ficking and degradation mechanisms [64]. Perturbation
of protein folding in the ER has been shown to pro-
mote CX43 translocation to the cytosol and its subse-
quent degradation [65–69]. Moreover, CX43 mRNA
and protein levels are found to be downregulated dur-
ing ER stress in numerous human and mouse tumor
cell lines, which reduced cell-to-extracellular matrix
adhesion and increased migration [50].
Exosomes are small endosome-derived extracellular
vesicles of 30- to 100-nm size secreted by a wide range
of mammalian cell types, which act as mediators of
cell–cell communication [70–72]. They contain a con-
served set of proteins, and although they are deprived
of any cellular organelles, they can still transmit vari-
ety of bioactive molecules [73], depending on the cell
and tissue of origin [74,75]. Exosomes secreted by can-
cer cells support disease spread in both autocrine and
paracrine manners by impacting on major tumor-
associated pathways including cancer stemness, angio-
genesis, and metastasis [76]. Exosomes can also play
an important role in drug resistance mechanisms such
as the expulsion of intracellular drugs and their
metabolites, and neutralization of antibody-based ther-
apies [77–82]. Due to their unique stability, selective
cargo and resemblance to the cells of origin, exosomes
have great potential to serve as a reservoir of cancer
biomarkers for disease detection, clinical diagnosis,
and selection of therapy [83–85]. Small amounts of
exosomes collected from non-invasive liquid biopsies
including saliva, urine, and blood [86–90] can provide
multiple dynamic information from different tumors
[91]. For example, exosomes released from human
brain tumors were shown to contain miRNAs, differ-
ent heat-shock proteins, and other tumor-promoting
immunomodulatory agents that drive macrophages
polarization toward pro-tumoral M2 phenotype
in vitro [92–97]. Intriguingly, ER stress and the UPR
activation enhance the exosomes’ secretion. As such,
tunicamycin-induced ER stress increases the multi-
vesicular body formation in cervical cancer cells and
promotes exosomes secretion in IRE1- and PERK-
dependent manner, which is abrogated by PERK and
IRE1 inhibition [98].
The UPR can also enhance the tumor overall fitness
by being transmitted from cancer cells to the cells of
TME. This transmissible ER stress (TERS) has multi-
ple effects on the recipient cells in vitro and in vivo.
For instance, TERS alters the function and cross-
priming of bone marrow–derived DCs by transcrip-
tional upregulation of different tumorigenic and
immunosuppressive molecules, as well as inflammatory
cytokines [99]. This phenomenon is independent of
Toll-Like Receptor 2 (TLR2) or IL-6R but relies on
the TLR4, which senses and potentiates TERS and
conditions macrophages to mirror tumor cells [100].
Moreover, ER stress signaling pathways are triggered
in mice receiving ER stress-conditioned medium that
facilitates pro-tumorigenic characteristics [100,101]. In
prostate cancer cells, TERS promotes survival and
drug resistance to the proteasome inhibition-mediated
toxicity by transmitting a unique UPR signal to the
juxtaposed cancer cells. It induces Wnt signaling in an
IRE1-dependent manner, while the induced enhance-
ment of cell survival is mediated by PERK activation
[102]. TERS secreted from CVB3-infected myocardio-
cytes also promotes the pathogenesis of viral
myocarditis by augmenting the pro-inflammatory
responses of cardiac infiltrating macrophages [103].
In conclusion, activation of the UPR has a broad
range of targets that affects and regulates protein
secretion including those involved in the intercellular
communications. This important role in protein traf-
ficking and the fact that the UPR itself can be trans-
mitted position the UPR to influence cell–cell
communication pathways and to coordinate physiolog-
ical processes between cells and tissues.
UPR and angiogenesis
Angiogenesis, which is a process of remodeling existing
blood vessels, involving sprouting, migration, and pro-
liferation of endothelial cells (ECs), is mediated by sev-
eral factors including PDGF, FGF, IL-8, and VEGF
[104]. A growing evidence suggests that UPR plays a
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key role in angiogenesis induction. It has been
reported that XBP1 and ATF4 can both directly bind
and transactivate VEGFA promoter in response to ER
stress, an event that is even more prominent that
hypoxia-driven VEGFA activation [105]. Moreover,
VEGFA upregulation after oxygen or glucose depriva-
tion is blunted in tumor cells expressing a dominant
negative IRE1 as well as in IRE1-deficient mouse
embryonic fibroblast (MEFs) [106]. Inhibition of IRE1
signaling decreases glioma vascular density and vessel
perfusion in vivo, which are rescued by the expression
of a transgene of IL-6 [41]. Interestingly, in diabetic
bone marrow–derived progenitor cells, loss of IRE1
results in decreased angiopoietin 1 expression and
disrupts angiogenesis, due to inefficient RIDD of
miR-466 and miR-200 families [107]. In line with this
observation, the PERK/ATF4 pathway regulates the
angiogenic switch in human tumors, by increasing the
expression of many proangiogenic modulators, includ-
ing VEGF, FGF-2, and IL-6, with the concomitant
decrease in the expression of the angiogenic inhibitors
THBS1, CXCL14, and CXCL10 mRNA [108]. In vivo,
PERK knockout in j-Ras transformed MEFs leads to
angiogenesis inhibition and reduced tumor mass com-
pared with the wild-type counterparts [109]. More
recently, it has been demonstrated that in response
to acute hypoxic stress, PERK triggers the cap-
independent internal ribosome entry sites-mediated
translation of VEGF and FGF-2 [110]. In addition,
ER stress triggered by tunicamycin, thapsigargin, or
glucose deprivation also increases the expression of the
pro-angiogenic factors FGF-2, IL-1a IL-6, IL-8,
angiopoietin-2 and TGFb2 [105]. Finally, at the post-
translational level, ER stress induces the ER chaper-
one ORP150 which facilitates VEGF processing and
secretion [111].
VEGF itself was shown to induce ER stress in ECs
and consequently activate all three UPR branches,
IRE1, ATF6, and PERK, through a PLCc/mTORC1
pathway [112]. This VEGF-driven UPR activation is
necessary for ECs survival and angiogenesis, and is
mediated by AKT phosphorylation and decrease in
CHOP mRNA level [112]. The UPR can be also trig-
gered in ECs by low pH, and GRP78 has been
reported to play a key role in such activation [113].
Strikingly, targeting the GRP78 in acid-stressed ECs
abrogates sunitinib chemoresistance, partially through
the induction of caspase 7 cleavage [113]. In renal cell
carcinoma, GRP78 knockdown suppresses tumor pro-
gression and enhances the antitumor effects of anti-
angiogenic therapy in vivo [114]. The UPR activation
can be also triggered in ECs by imposing stress from
adjacent cancer cells. As such, breast cancer
cell-stimulated ECs upregulate the chaperone aB-crys-
tallin (CRYAB) that acts downstream of IRE1 and
ATF6 inducing VEGF expression and secretion [115].
Furthermore, by protecting endogenous VEGF from
proteolytic degradation, CRYAB supports ECs prolif-
eration and survival [115]. Taken together, activation
of the UPR in cancer cells promotes angiogenesis by
directly upregulating the expression of pro-angiogenic
factors or transmitting the pro-angiogenic signals to
the surrounding ECs.
UPR activation in immune cells
The UPR is known to control immune cell develop-
ment, function, and survival both in pathological and
physiological conditions. For example, highly secretory
cancer cells, like B cells in multiple myeloma, produce
high levels of immunoglobulins and as a consequence
suffer chronic ER stress [116]. In addition, XBP1s is
among the key regulators required for the activation
of B-cell terminal differentiation [117]. This coincides
with the fact that the upregulation of the leptin recep-
tor upon fasting blocks acute lymphoblastic leukemia
development by activating cell differentiation, which
depends on the increase of the mRNA and protein
levels of key transcription factors like XBP1, BLIMP1,
and IRF4 [118]. In the same line, in the germinal cen-
ter B-cell like (GCB) diffuse large B-cell lymphoma
(DLBCL), characterized by gain-of-function mutations
of EZH2, IRE1 expression levels are reduced by the
binding of high amounts of H3K27me3-repressive
marks to its promoter, impairing the induction of an
effective ER stress response. In result, GCB-DLBCLs
do not induce XBP1 splicing, contributing to acceler-
ate tumor growth [119]. Several other studies have also
suggested the importance of XBP1 during the terminal
differentiation and expansion of antigen-specific CD8
T cells [120].
The IRE1/XBP1 pathway also affects conventional
DCs in a tissue-specific manner. Indeed, intestinal and
splenic conventional DCs survive the loss of XBP1,
although with defects on their ability to cross-present
dead cell-associated antigens [121,122]. This survival
adaptive mechanism involves the induction of the
eIF2a/ATF4/4E-BP1 pathway to avoid excessive pro-
tein loading and the IRE1/RIDD pathway to lower
mRNA abundance and protein folding in the ER.
Conversely, XBP1 loss affects the survival of lung and
other peripheral-tissue-resident conventional DCs in a
CHOP-independent manner [122]. In the context of
cancer, tumor-associated DCs induce XBP1 expression
in response to increased reactive oxygen species
(ROS), thus modulating intracellular lipid homeostasis.
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This increase in XBP1s promotes ovarian tumor
growth by impairing T-cell activation [123]. In macro-
phages, TLR signaling inhibits the translation of
ATF4 mRNA, thereby affecting the expression levels
of its pro-apoptotic target CHOP. As such, macro-
phages can survive during the activation of the
immune response [124]. However, CHOP deficiency in
myeloid-derived suppressor cells shows a decreased
capacity to affect T-cell responses, enhancing T-cell
function and inducing an antitumor response [125]. In
addition, in the MUP-uPA mouse, in which hepato-
cytes express high levels of urokinase plasminogen
activator (uPA), and therefore undergo transient ER
stress, a high fat diet induces hepatocellular carcinoma
(HCC), through an ER stress-mediated mechanism
that includes TNFa production by infiltrating inflam-
matory macrophages. Finally, both macrophage infil-
tration and TNF expression are inhibited by treatment
with the bile acid thought to act as a chemical chaper-
one, tauroursodeoxycholate [126].
UPR and tumor-promoting inflammation
The UPR controls the production of inflammatory
cytokines at the transcriptional and post-transcrip-
tional level, thus having a direct impact on tumor pro-
gression. For example, XBP1s can bind to the
promoter regions of IL-6 and TNFa in response to
ER stress, inducing their expression in macrophages
[124]. Similarly, CHOP directly regulates IL-23p19
expression in DCs [127]. IRE1, via the activation of
GSK3b, induces gene expression of pro-inflammatory
IL-1b, independently of its action on XBP1s signaling
[128]. In addition, mTOR stimulation, also through
IRE1, activates JNK and triggers IL-8 secretion in
response to glutamine deprivation [129]. Interestingly,
cytokines can, in turn, induce ER stress and regulate
the UPR per se, thereby creating a feedback loop that
results in the amplification of the inflammatory
response. For example, in response to TNFa treat-
ment, IKKb phosphorylates and stabilizes XBP1s
[130]. IL-10 blocks TNF-dependent translocation of
cleaved ATF6 (ATF6f) to the nucleus via p38 MAPK
signaling [131]. Pro-inflammatory IL-1b, IL-6, and
TNFa induce the UPR and activate genes involved in
the acute phase response (C-reactive protein and serum
amyloid P-component) through the increased cleavage
of the membrane anchored transcription factor
CREBH [132]. Conversely to the great amount of
studies that describe the inflammatory-dependent acti-
vation of the UPR, it has been recently described that
obesity-related chronic inflammation can induce the
S-nitrosylation of IRE1, thus shutting down its
endoribonuclease activity without affecting its kinase
domain. As a result, this modification of IRE1 con-
tributes to metabolic and inflammatory stress, compro-
mising the adaptive UPR response through the
decrease of XBP1s followed by an increase in JNK
levels [133].
Interestingly, aberrant lipid composition of the ER
membrane (also known as lipid bilayer stress) can acti-
vate IRE1. It has been suggested that IRE1, due to its
localization and mechanistic properties, can sense and
signal lipid changes in the ER membrane indepen-
dently of misfolded protein accumulation in the ER
lumen. This occurs by inducing IRE1 oligomerization
and signaling, hence recognizing IRE1 as a molecular
link between protein and lipid homeostasis [134,135].
IRE1 activation also allows the crosstalk between the
ER and the mitochondria through the ROS-dependent
activation of the NLRP3 inflammasome. This results
in the activation of caspase-2, the cleavage of the pro-
apoptotic factor BID, and the release of mitochondrial
contents [136]. These studies bring new membrane-
based perspectives to the role of lipids in the ER
stress-related pathophysiological conditions.
The UPR crosstalks with numerous other signaling
pathways to regulate tumor–host interactions. The
three branches of the UPR have been shown to induce
the pro-inflammatory NFjB pathway. First, IRE1
interacts with TRAF2, recruiting IKK and inducing
the phosphorylation and degradation of IjB, which
allows NFjB to translocate to the nucleus. Second,
IjB has a shorter half-life than NFjB and for this rea-
son, changes in protein translation under ER stress
stimuli that activate the PERK pathway, induce the
NFjB pathway by decreasing the IjB:NFjB ratio.
Finally, ATF6 can induce NFjB through the phos-
phorylation of AKT [120].
UPR and antitumor immune response
There is a growing evidence that the UPR can also
control the antitumor immune response by acting as
an innate immune machinery. The UPR can regulate
the release of damage-associated molecular patterns
(DAMPs), which can act as ‘eat me’ signals, ‘find me’
signals, or chemoattractants. In summary, DAMPs are
intracellular molecules that are hidden from the
immune system’s recognition under normal conditions.
However, upon cellular stress or death, cells can
induce an immunogenic response by the pre-apoptotic
expression of DAMPs on the cell surface [e.g. calretic-
ulin (CALR) and heat-shock proteins (HSPs)] or by
releasing or secreting them (e.g. ATP and HMGB1)
[120,137]. This type of cell death is known as
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immunogenic cell death (ICD). Interestingly, ICD has
to be preceded by the ER stress in order to induce
CALR and HSPs surface exposure. In the case of
CALR exposure, it occurs through the activation of
the PERK/eIF2a pathway [138]; however, the exact
respective contribution of PERK activation and eIF2a
phosphorylation need to be further explored. Hand,
ATP release depends on premortem autophagy and
the secretion of HMGB1 on secondary necrosis [137].
These DAMPs are recognized by specific receptors:
CALR binds to CD91, ATP binds to purinergic recep-
tors (P2Y2 or P2X7), and HMGB1 binds to TLR4,
respectively [137]. These receptors are found on DCs
and promote engulfment of dying cells, attraction of
DCs into the tumor bed, production of IL-1b, and
tumor antigen presentation. CALR is a highly con-
served calcium-binding ER lectin that has important
functions in the immune response. For example,
CALR chaperones MHC class I molecules, thus regu-
lating antigen presentation hence affecting recognition
by CD8 T cells [139]. It is also associated with the
increased expression of CD86, CD80, and MHC II in
the cell surface of DCs, leading to an efficient anti-
cancer CD8 T-cell response [120]. Furthermore, CALR
exposure at the cell surface plays an important role in
the immunosurveillance mechanism induced by cells
that have increased ploidy [140]. Even though ER
stress induces CALR exposure to the cell surface dur-
ing ICD, the mechanism by which this phenomenon
happens remains elusive.
HMGB1 secretion during cell death can activate the
UPR in DCs by increasing GRP78 expression and
XBP1 splicing [120]. XBP1 silencing leads to the
downregulation of CD86 and CD80 cell surface activa-
tion markers and MHC class II expression. These
events result in the decrease of T-cell proliferation and
differentiation affecting the activation of T cells in
ex vivo co-cultures [120]. In more recent studies,
increased expression of HMGB1, HMGN1, XBP1,
and peIF2a is correlated with a high amount of
tumor-infiltrating lymphocytes in triple negative breast
cancer patients [141]. Besides DAMPs, there are also
‘don’t eat me’ signals that will help cancer cells avoid
the immune system’s recognition. ER stress regulated
proteins also control these signals. For example,
GRP78 inhibition in BALB/c and athymic tumor-
bearing mice increases monocyte chemoattractant pro-
tein-1 (MCP-1) serum levels and regulates CD47, a
glycoprotein of the immunoglobulin superfamily criti-
cal in self-recognition. Normal tissue increases the
CD47 ‘don’t eat me’ signal in response to GRP78
inhibition, while the tumoral tissue decreases its
expression. In this way, GRP78 inhibition stimulates
macrophage infiltration and reduction of estrogen
receptor–positive breast cancers [142].
The similarities between the antigen-specific immune
response triggered by ICD and those induced by
pathogen infection have led scientists to look into
these pathways in order to try to apply this knowledge
in cancer research. This is the case of TLRs, which are
pattern recognition receptors (PRRs) that recognize
pathogen-associated molecular patterns. Activation of
TLRs and the IRE1/XBP1 pathway are interconnected
and result in the induction of the innate immune
surveillance in response to pathogen infection. In
macrophages, TLR activation induces a ROS-
dependent-specific activation of the IRE1a/XBP1 path-
way, but not of the other arms of the UPR. Then,
XBP1 induces IL-6 and IFN-b cytokine production
[124]. This kind of response is not restricted to TLRs,
as there is a clear link between the UPR and retinoic
acid-inducible gene-I (RIG-I)-like receptors (RLRs).
RLRs are RNA helicases that sense pathogenic RNA
and initiate antiviral immunity. Recent studies have
linked IRE1 with the RIG-I pathway upon pathogen
infection [143] and pathological conditions [144]. Upon
the activation of IRE1 RNase activity, the cleavage of
endogenous RNA through RIDD may produce frag-
ments that resemble those of pathogens as they lack
50-caps or 30-polyA-tails that mark mRNA as ‘self’.
These fragments, in turn, activate RIG-I that induces
an innate immune response.
In the context of cancer, endogenous RNAs that
are not shielded by RNA binding proteins have
already been shown to act as DAMPs for PRRs. In
primary human breast cancers, activated stromal cells
present unshielded RNA in exosomes in order to
propagate antiviral signaling to the TME. This
unshielded RNA in stromal exosomes results in an
inflammatory response when transferred to immune
cells and in tumor growth and invasion when trans-
ferred to breast cancer cells [145]. In immunocompe-
tent mice, RIG-I activation induces the secretion of
extracellular vesicles by melanoma cells that act as
immune activating agents favoring the anticancer
immune response [146]. Administration of a BCL-2
siRNA activates RIG-I efficiently and leads to tumor
growth inhibition through an antitumor immune
response. This antitumor response involves myeloid
and plasmacytoid DC activation, NK cells, CD4 and
CD8 T cells and is associated with the secretion of
type I cytokines (IFN-a, IL-12p40, and IFN-c) [147].
Furthermore, RIG-I has been proposed as a tumor
suppressor in HCC as RIG-I deficiency promotes
HCC carcinogenesis [148]. Other studies in highly
immunodeficient mice suggest that RIG-I can inhibit
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tumor growth by inducing apoptosis through the regu-
lation of BH3-only proteins [149]. Additionally, pan-
creatic cancer cells treated with RIG-I–like helicase
ligands die through ICD. This ICD occurs through
the translocation of CALR to the cell surface followed
by the release of HMGB1 that activates DCs and
cytotoxic CD8 T cells [150]. One could speculate that
stimuli activating the IRE1/RIDD pathway in tumor
cells could potentially activate RIG-I, inducing ICD
and an anticancer immune response. Altogether, these
studies highlight the importance of studying the regu-
lation of the UPR in the context of cancer in order to
understand immunogenicity and to improve the anti-
tumor immune responses and therapies.
Impact of UPR activation in tumor-surrounding
parenchyma
Tumors develop in particular tissular environments
that are composed by a multiple of non-tumoral cell
types. Next to ECs and immune cells (presented
above), other stromal/parenchymal cells as such stel-
late cells, epithelial cells, fibroblasts or astrocytes, and
neurons could also be affected by UPR downstream
signals provided by tumor cells. Little if any of such
interactions is up-to-now reported in the context of
neoplasia, and only few indirect evidences are
described so far. For instance, pancreatic stellate cells
are key stromal cells in pancreatic cancer for secreting
extracellular matrix proteins and inflammatory media-
tors. Under metabolic stress, the PERK/CHOP branch
of the UPR is activated in pancreatic stellate cells, thus
protecting them from apoptosis [151]. Furthermore,
under these conditions, stellate cell fibrogenic activity
is reduced and the profile of secreted cytokines is mod-
ulated (i.e. reduction of IL-6 expression and increase
of the immune modulator IL-4), thereby contributing
to the modulation of TME. Several UPR-induced
genes have clear impact on the stromal cells surround-
ing tumors. For instance, Serpin B2 expressed by the
cancer-associated fibroblasts limits metastasis in pan-
creatic ductal adenocarcinoma due to its collagen
remodeling capacity [152]. ATF3, a downstream effec-
tor of the PERK/ATF4 pathway, is a key regulator of
tumor-associated stromal cell reprogramming leading
to increase in their proliferation ability, which in turn
supports tumor growth [153]. The impact of the UPR
on stromal cells is well documented in other pathologic
situations such as neurogenerative diseases [154].
Indeed, instead of improving protein quality control
and protein folding, prolonged ER stress leads to neu-
ronal cell apoptosis, synaptic dysfunction, and axonal
degeneration. One could speculate that brain tumor
transmissible UPR would affect neighboring brain resi-
dent cells such as oligodendrocytes, astrocytes, and
neurons leading to neuronal dysfunctions and tumor
cell bedding. Further studies are required to investigate
such stroma/tumor cell communications through UPR
activation.
Targeting UPR as anticancer approach
As exemplify above, the UPR has a broad impact on
tumor-associated processes such as sustained growth,
resistance to apoptosis, metastasis, inflammation, or
escape from immune recognition, which creates a
rationale for targeting ER stress pathways as a poten-
tial anticancer approach. This can be achieved either
by exploiting the pro-death UPR signaling to effec-
tively kill cancer cells or to impede UPR-mediated
adaptive responses which help tumor cells propagate
in harsh TME conditions and resist the treatment. As
such, ER stress- triggered apoptosis has been observed
in various cancer models both in vitro and in vivo. For
instance, in glioblastoma, a large number of small
molecules including FDA-approved drugs nelfinavir,
quinine, and celecoxib have been reported to induce
cell death by perturbing ER proteostasis, which is
mainly mediated by the upregulation of GRP78 and/
or CHOP mRNA or protein levels [29]. Further, many
natural and chemical agents are shown to promote cell
death by generating ROS and consequently triggering
ER stress in lung, breast, liver, or colon cancer [155].
As discussed above, the UPR has a very important
role in ICD induction and constitutes a promising tar-
get for the development of novel anticancer strategies.
Remarkably, patients can only benefit of checkpoint
blockade immunotherapies if tumors are infiltrated by
tumor-infiltrating lymphocytes (TILs) previous to the
treatment. Importantly, tumors without TILs can be
sensitized to checkpoint blockade immunotherapies
when combined with ICD-inducing drugs [123]. In this
sense, the co-administration of chemotherapies that do
not induce ICD with immunogenic chemotherapies
capable of inducing the UPR should be considered.
Many of the ICD inducers are intensively used in the
clinical practice and are divided into the type I and
type II ICD inducers [156,157]. On one hand, type I
inducers, such as bortezomib, anthracyclines, and
oxaliplatin, trigger apoptosis via non-ER targets (e.g.
through the DNA damage or proteasomal inhibition)
with the parallel ‘off-target’ impact on the ER stress
signaling [157]. On the other hand, type II ICD induc-
ers (involving hypericin-photodynamic therapy and
oncolytic viruses) drive apoptosis through the selective
activation of ROS-mediated ER stress [157].
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Interestingly, it has been recently demonstrated that
cells resistant to ER stress and chemotherapy acquire
a multidrug-resistant phenotype through the activation
of the PERK/NRF2/MRP1 signaling axis. Targeting
this axis restores chemosensitivity in resistant cancer
cells and diminishes tumor growth in vivo [158].
In the past decade, various inhibitors targeting each
of the UPR arm have been developed and have been
shown to yield a promising antitumor response
(Fig. 3). As such, four compounds are reported to
modulate ATF6 signaling: 16F16 (a PDI inhibitor nec-
essary for ATF6 activation), caepins, and two non-
toxic ATF6 activators: compounds 147 and 263 [29].
Interestingly, impairing ATF6 signaling with 16F16
restores imatinib sensitivity in imatinib-resistant leuke-
mia K562 cells [159]. More recently, it has been
showed that melatonin blocks the ATF6 signaling in
HCC leading to a decrease in COX-2 expression and
consequently promoting cell apoptosis under tuni-
camycin-induced ER stress [160]. The IRE1 modula-
tors developed so far include both RNase inhibitors
such as 4l8C, ManKindCorp (MKC) analogs, 3-meth-
oxy-6-bromosalicylaldehyde, and STF-083010, as well
as agents targeting kinase domain—KIRAs and ATP
kinase inhibitor compound 3 [29]. Those inhibitors are
shown to kill cancer cells or sensitize them to common
chemo- or radiotherapies. For instance, STF-083010
significantly inhibits the growth of human multiple
myeloma xenografts [161]. Moreover, it restores
tamoxifen sensitivity in resistant breast cancer cells,
while when administered synergistically with tamox-
ifen, it suppresses breast tumor progression in vivo
[162]. Similarly, MKC-3946 decreases multiple mye-
loma growth and shows therapeutic activity in the
combination with the proteasome inhibitor bortezomib
[163]. Finally, the KIRA6 inhibitor and the optimized
KIRA, KIRA8 which is a mono-selective IRE1
inhibitor with a single digit nanomolar potency, block
IRE1 in vivo and promote cell survival under ER
stress in several mouse models [118,164]. Regarding
PERK inhibitors, GSK2656157, ISRIB, salubrinal,
guanabenz, and sephin 1/IFB-088 are shown to modify
PERK phosphorylation or its downstream signaling
by targeting the eIF2a complexes [29]. GSK2606414
and the related drug GSK2656157 impact on cancer
progression by decreasing tumor growth and reducing
tumor-associated angiogenesis, respectively [165,166].
Moreover, in an orthotopic model of pancreatic ductal
adenocarcinoma, ISRIB enhances the gemcitabine
chemosensitivity by suppressing the integrated stress
response and its downstream anti-apoptotic pathways
[167]. In line, salubrinal, an inhibitor of growth arrest
and DNA damage 34 (GADD34), potentiates the cyto-
toxic effect of doxorubicin in doxorubicin-resistant
breast cancer cells in vitro [168]. Thus, molecules that
generate irremediable ER stress in tumor cells or
specifically target the UPR branches represent interest-
ing therapeutic options alone or in combination with
other commonly used drugs.
Concluding remarks
The UPR signaling has a broad impact on cancer biol-
ogy. It not only provides tumor cells with the selective
advantages to survive and propagate in harsh environ-
mental conditions but also educates the surrounding
non-tumoral cells to even further promote cancer pro-
gression. As discussed herein, signals emerging from the
ER impact on the tumor secretome, which in turn sup-
ports new vessels formation, inflammation, or immune
suppression. Interestingly, a growing evidence suggests
the UPR involvement in the regulation of antitumor
host response. Nevertheless, we still need to uncover
what triggers these opposite outputs. Apparently, the
Fig. 3. Anticancer effects of the UPR-
targeting drugs. Many molecules specifically
targeting each of the UPR branches show
potential anticancer activities either by
inhibiting tumor growth or restoring
chemosensitivity in drug-resistant cells.
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difference lays in a combination of the type of UPR-
inducing stimulus and which pathways are engaged in
response to it. It is tempting to think that it all comes
down to a fine-tuning of the different UPR proteins
downstream of the master sensors. For example, in the
case of IRE1, which has an interesting dual role in both
cell death and immunosurveillance, several pathways
ramify downstream of its activation. Is the outcome the
same if we activate more the XBP1 downstream path-
way than the RIDD pathway and vice versa? Further
studies are needed in order to complete the puzzle that
is the UPR in the TME and its control of cell death and
the immune system response. For these reasons, modu-
lating ER stress in tumor cells and the TME represents
an additional level of therapeutic intervention.
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Résumé 
Plusieurs arguments de la littérature suggèrent l’importance de l’alimentation dans le 
développement tumoral et l’efficacité des traitements anti-cancereux. Dans différents modèles 
animaux, la restriction calorique (CR) supprime la prolifération des cellules tumorales et les 
sensibilise aux thérapies ciblées. Par conséquent, des approches non-pharmacologiques comme la 
restriction calorique ont un intérêt grandissant en clinique. 
Considérant l’addiction des cellules tumorales aux nutriments, nous nous sommes demandé quels 
macronutriments pouvaient avoir des propriétés anticancéreuses. A partir d’un modèle murin de 
lymphomes B (modèle transgénique Eµ-Myc) nous avons testé l’impact de deux régimes 
alimentaires : l’un pauvre en glucides (Low CHO, 25% de réduction en glucides) et l’autre pauvre 
en protéines (Low PROT, 25% de réduction en protéines). Des souris syngéniques C57BL/6 ont 
été injectées par voie intraveineuse avec des cellules primaires Eμ-Myc. Malgré un apport 
alimentaire équivalent entre les groupes, nous avons observé que le régime pauvre en protéines 
augmente la survie globale des souris C57BL/6 développant un lymphome B Eµ-Myc. De manière 
intéressante, nous avons démontré que cet effet pro-survie est dépendant du système immunitaire. 
En effet, la déplétion des cellules T CD8+ ou l’utilisation d’un modèle murin immunodéficient NSG 
(NOD-SCID il2rγ), empêche l’effet bénéfique du régime pauvre en protéines sur le développement 
tumoral. Nous avons reproduit et étendu nos observations en utilisant des lignées modèles de 
cancéreuses colorectaux (CT26) et de mélanome (B16) injectée dans des souris syngéniques, 
immunocompétente. 
Les cellules tumorales étant fortement dépendantes des nutriments, nous avons émis l’hypothèse 
qu’un régime pauvre en protéines pourrait induire un stress du réticulum endoplasmique (RE) dans 
ces dernières. En effet, nous avons observé une augmentation des protéines impliquées dans la 
signalisation du RE : CHOP et sXBP1. Par conséquent, nous avons traité les souris nourries en 
régime pauvre en protéines avec deux inhibiteurs du stress du RE : TUDCA, inhibiteur générique 
et MKC4485 qui cible l’activité ribonucléase d’IRE1. Dans les deux cas, ces inhibiteurs ont bloqué 
l’effet du régime faible en protéines sur le développement tumoral et l’infiltration des T CD8+ au 
sein de la tumeur. Pour s’affranchir, des potentiels effets secondaires des inhibiteurs chimiques, 
nous avons invalidé IRE1 dans la lignée CT26 et nous avons obtenus des résultats similaires, 
démontrant que la voie IRE1 dans les cellules tumorales est une voie centrale dans la réponse 
immunitaire anticancéreuse induite par un régime pauvre en protéines. En outre, nous avons 
découvert que l’activation de RIG-I est un événement en aval de l’activation d’IRE1 et que, par 
analyse bio-informatique nous avons pu corréler une signature IRE1 à une infiltration immunitaire 
élevée et à une immunogénicité accrue du cancer chez les patients atteints de mélanome, 
glioblastome et cancer colorectal. De ce fait, nous avons démontré que la réponse du système 
immunitaire induite par un régime pauvre en protéines est une conséquence de l’activation accrue 
de IRE1 dans les cellules cancéreuses. 
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